<SEC-DOCUMENT>0001104659-25-119341.txt : 20251208
<SEC-HEADER>0001104659-25-119341.hdr.sgml : 20251208
<ACCEPTANCE-DATETIME>20251208165233
ACCESSION NUMBER:		0001104659-25-119341
CONFORMED SUBMISSION TYPE:	N-CSR
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251208
DATE AS OF CHANGE:		20251208
EFFECTIVENESS DATE:		20251208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			abrdn Life Sciences Investors
		CENTRAL INDEX KEY:			0000884121
		ORGANIZATION NAME:           	
		EIN:				043147016
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		N-CSR
		SEC ACT:		1940 Act
		SEC FILE NUMBER:	811-06565
		FILM NUMBER:		251556735

	BUSINESS ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		6177728515

	MAIL ADDRESS:	
		STREET 1:		1900 MARKET STREET
		STREET 2:		SUITE 200
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TEKLA LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	20141015

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	H&Q LIFE SCIENCES INVESTORS
		DATE OF NAME CHANGE:	19920929
</SEC-HEADER>
<DOCUMENT>
<TYPE>N-CSR
<SEQUENCE>1
<FILENAME>tm2527059d12_ncsr.htm
<DESCRIPTION>N-CSR
<TEXT>
<!-- Assembled by CompSci Transform  (tm) - http://www.compsciresources.com - version 1.2 -->
<!-- Created: Fri Dec 05 16:25:00 UTC 2025 -->
<html>
<head>
     <title></title>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_cover.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1" -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>


<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM N-CSR</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTIFIED SHAREHOLDER REPORT OF REGISTERED MANAGEMENT
INVESTMENT COMPANIES</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 4in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Company Act file number:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">811-06565</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exact name of registrant as specified in charter:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Life Sciences Investors</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address of principal executive offices:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900 Market Street, Suite 200</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name and address of agent for service:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon Ferrari</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Inc.</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1900 Market Street Suite 200</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia, PA 19103</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#x2019;s telephone number, including area code:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-800-522-5465</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of fiscal year end:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30</font></td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date of reporting period:</font></td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2025</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#xa0;</div></div><!-- Field: /Rule-Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d12_item1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1" -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#xa0;</b></font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1. Reports to Stockholders.</b></font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a) </font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#xa0;</font></p>


</div><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d12_hqlreport.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1" --><div style="width:100%">
<div style="overflow:hidden; width:100%">
<div style="margin-top:0pt; position:relative; text-align:left; width:100%">
<img src="tm2527059d12hqlreporti001.gif" alt=" ">
<div style="left:43pt; position:absolute; top:44pt"><img src="tm2527059d12hqlreporti002.gif" alt=" ">
</div><div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; left:43pt; line-height:10pt; position:absolute; text-decoration:none; text-transform:none; top:44pt">&#x2009;</div></div>


</div>
<div style="margin-top:29pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:20pt; font-style:Normal; font-weight:bold; line-height:23pt; text-align:left; text-decoration:none; text-transform:none">abrdn Life Sciences Investors (HQL)</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:bold; line-height:17pt; margin-top:14pt; text-align:left; text-decoration:none; text-transform:none">Annual Report</div>
<div style="color:#000000; font-family:Arial; font-size:14pt; font-style:Normal; font-weight:Normal; line-height:17pt; margin-top:2pt; text-align:left; text-decoration:none; text-transform:none">September 30, 2025</div>
</div>
<div style="margin-top:67pt; width:93.96%">
<div style="color:#000000; font-family:Arial; font-size:21.5pt; font-style:Normal; font-weight:bold; line-height:24.5pt; margin-top:2pt; text-align:right; text-decoration:none; text-transform:none">aberdeeninvestments.com</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Managed Distribution Policy
 &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Board of Trustees&#xa0; (the "Board") of
the abrdn Life Sciences Investors&#xa0;(the &#x201c;Fund&#x201d;) has authorized a managed distribution policy (&#x201c;MDP&#x201d;) of paying quarterly distributions at an annual rate, set once a year, that is a
percentage of the rolling average of the Fund&#x2019;s net asset values over the preceding three month period ending on the last day of the month immediately preceding the distribution&#x2019;s declaration date (the
"Distribution Policy"). The Distribution Policy is subject to regular review by the Board. The Distribution Policy seeks to provide investors with a distribution out of current income, supplemented by realized capital
gains and, to the extent necessary, paid-in capital.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">With each distribution, the Fund will issue
a notice to shareholders and an accompanying press release which will provide detailed information regarding the estimated amount and composition of the distribution and other information required by the Fund&#x2019;s
MDP exemptive order. The Board may amend or terminate the MDP at any time without prior notice to shareholders; however, at this time,&#xa0;there are no reasonably foreseeable circumstances that might cause the
termination of the MDP. You should not draw any conclusions about the Fund&#x2019;s investment performance from the amount of distributions or from the terms of the Fund&#x2019;s MDP.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:34.5pt; width:92.99%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Distribution Disclosure
Classification &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)<br>
</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
</div>
<div style="padding-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s policy is to provide
investors with a stable distribution rate. Each quarterly distribution will be paid out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is subject to U.S.
corporate, tax and securities laws. Under U.S. tax rules, the amount applicable to the Fund and character of distributable income for each fiscal period depends on the actual exchange rates during the entire year
between the U.S. Dollar and the currencies in which the Fund's assets are denominated and on the aggregate gains and losses realized by the Fund during the entire year.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">Therefore, the exact amount
of distributable income for each fiscal year can only be determined as of the end of the Fund&#x2019;s fiscal year, September 30. Under Section 19 of the Investment Company Act of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">1940, as amended (the &#x201c;1940
Act&#x201d;), the Fund is required to indicate the sources of certain distributions to shareholders. The estimated distribution composition may vary from quarter to quarter because it may be materially impacted by
future income, expenses and realized gains and losses on securities and fluctuations in the value of the currencies in which the Fund's assets are denominated.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">The&#xa0;distributions&#xa0;
for&#xa0;the&#xa0;fiscal&#xa0;year&#xa0;ended September 30, 2025&#xa0;consisted&#xa0;of&#xa0;95% net investment income and 5% net realized gains.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:justify; text-decoration:none; text-transform:none">In January 2026, a Form
1099-DIV will be sent to shareholders, which will state the final amount and composition of distributions and provide information with respect to their appropriate tax treatment for the 2025 calendar year.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:222.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">abrdn Life Sciences Investors</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Dear Shareholder,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">We present the Annual Report,
which covers the activities of abrdn Life Sciences Investors&#xa0;(the &#x201c;Fund&#x201d;), for the fiscal year ended September 30, 2025. The Fund&#x2019;s investment objective is to seek long-term capital appreciation
by investing primarily in equity and related securities (including securities subject to legal or contractual restrictions on resale) of U.S. and foreign companies principally engaged in the development, production or
distribution of products or services related to scientific advances in life sciences (including biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information
technology and services, devices, supplies and other healthcare-related subsectors), agriculture and environmental management ("Life Sciences Companies").</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return<sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">For the fiscal year ended
September 30, 2025, the total return to shareholders of the Fund based on the net asset value (&#x201c;NAV&#x201d;) and market price of the Fund, respectively, compared to the Fund&#x2019;s benchmark, &#xa0;is as
follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; border-top:0.5pt solid #000000; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:82.60%; background-color: #F0F0F0;">NAV<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:20.89%; background-color: #F0F0F0;">21.06%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:82.60%; background-color: #F0F0F0;">Market Price<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5.84pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:20.89%; background-color: #F0F0F0;">17.62%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:82.60%; background-color: #F0F0F0;">Nasdaq Biotechnology Index<sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:10.08pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:20.89%; background-color: #F0F0F0;">3.19%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">For more information about
Fund performance, please visit the Fund on the web at www.aberdeenhql.com. Here, you can view quarterly commentary on the Fund's performance, monthly fact sheets, distribution and performance information, and other
Fund literature.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">NAV, Market Price and
Premium(+)/Discount(-)</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The below table represents a
comparison between the current fiscal year end and the prior fiscal year end of the&#xa0;Fund's market price to&#xa0;NAV and associated Premium(+) and Discount(-).</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:97.67%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="padding-bottom:1.75pt; padding-right:4pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:42.96%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:center; vertical-align:bottom; width:14.36%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:6pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">&#xa0;
</td><td style="padding-bottom:1.75pt; padding-right:12pt; padding-top:3pt; text-align:right; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:2.5pt; padding-right:4pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:42.96%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.36%; background-color: #D9D9D9;">NAV
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.02%; background-color: #D9D9D9;">Closing<br>
Market<br>
Price
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:24.28%; background-color: #D9D9D9;">Premium(+)/<br>
Discount(-)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:4pt; padding-top:3.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.96%; background-color: #F0F0F0;">9/30/2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.36%; background-color: #F0F0F0;">$<font style="padding-left:2.07pt"></font>17.35
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:16.02%; background-color: #F0F0F0;">$<font style="padding-left:1.90pt"></font>15.51
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:12pt; padding-top:3.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-10.61%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:42.96%; background-color: #F0F0F0;">9/30/2024
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.36%; background-color: #F0F0F0;">$16.38
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.02%; background-color: #F0F0F0;">$15.08
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2.5pt; padding-left:10.22pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:24.28%; background-color: #F0F0F0;">-7.94%
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">During the fiscal year ended September 30,
2025, the Fund&#x2019;s NAV was within a range of $12.00 to $17.34 and the Fund&#x2019;s market price traded within a range of $10.87 to $15.51. During the fiscal year ended September 30, 2025, the Fund&#x2019;s shares
traded within a range of a premium(+)/discount(-) of -12.80% to -6.51%.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Aberdeen Name Change</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">On March 4, 2025, abrdn plc,
the parent company of the Fund's adviser, announced that it would change its name, and from that date, will use `Aberdeen' as the principal trading identity for its Investments business. On March 12, 2025, abrdn plc
completed the steps to legally change its name to Aberdeen Group plc. Aberdeen has retained `abrdn' as an operational abbreviation across its subsidiary legal entities (including the Fund's adviser, fund names and
descriptors).</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Managed Distribution Policy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a managed
distribution policy of paying quarterly distributions at an annual rate, set by the Board of Trustees (the "Board") once a year, as a percentage of the rolling average of the Fund&#x2019;s NAV over the preceding three
month period ending on the last day of the month immediately preceding the distribution&#x2019;s declaration date. On March 11, 2025, the Board determined the rolling distribution rate to be 12% for the 12-month period
commencing with the distribution payable in June 2025. This policy will be subject to regular review by the Board. The distributions will be made from current income, supplemented by realized capital gains and, to the
extent necessary, paid-in capital, which is a nontaxable return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On November 11, 2025, the
Fund announced that it will pay on January 12, 2026, a stock distribution of US $0.50 per share to all shareholders of record as of November 21, 2025. This stock distribution will automatically be paid in newly issued
shares of the Fund unless otherwise instructed by the shareholder. Shares of common stock will be issued at the lower of the NAV per share or the market price per share with a floor for the NAV of not less than 95% of
the market price. Fractional shares will generally be settled in cash, except for registered shareholders with book entry accounts at Computershare Investor Services who will have whole and fractional shares added to
their account.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:23.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be
lower or higher than the performance quoted. NAV return data include investment management fees, custodial charges and administrative fees (such as Trustee and legal fees) and assumes the reinvestment of all
distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:46pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">Assuming the reinvestment of dividends and distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:57pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The Fund&#x2019;s total return is based on the reported NAV for each financial reporting period end and may differ from what is reported on the Financial Highlights due to financial statement rounding or adjustments.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:80pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:2.22%"><sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.78%">The Nasdaq Biotechnology Index contains securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals industry. The Index
is unmanaged and has been provided for comparison purpose only. No fees or expenses are reflected. You cannot invest directly in an index.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:9.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">1
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Shareholders may request to be paid their
quarterly distributions in cash instead of shares of common stock by providing advance notice to the bank, brokerage or nominee who holds their shares if the shares are in &#x201c;street name&#x201d; or by filling out
in advance an election card received from Computershare Investor Services if the shares are in registered form.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is covered under
exemptive relief received by the Fund&#x2019;s investment adviser from the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) that allows the Fund to distribute long-term capital gains as frequently as
quarterly in any one taxable year.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Unclaimed Share Accounts</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Please be advised that
abandoned or unclaimed property laws for certain states require financial organizations to transfer (escheat) unclaimed property (including Fund shares) to the state. Each state has its own definition of unclaimed
property, and Fund shares could be considered &#x201c;unclaimed property&#x201d; due to account inactivity (e.g., no owner-generated activity for a certain period), returned mail (e.g., when mail sent to
a&#xa0;shareholder&#xa0; is returned to the Fund's transfer agent as undeliverable), or a combination of both. If your Fund shares are categorized as unclaimed, your financial advisor or the Fund's transfer agent will
follow the applicable state&#x2019;s statutory requirements to contact you, but if unsuccessful, laws may require that the shares be escheated to the appropriate state. If this happens, you will have to contact the
state to recover your property, which may involve time and expense. For more information on unclaimed property and how to maintain an active account, please contact your financial adviser or the Fund's transfer
agent.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Options Writing</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">In order to further support
the increase in distribution rate for the Fund, the Fund employs a strategy of writing (selling) covered call options on a portion of the common stocks in its portfolio, writing (selling) put options on a portion of
the common stocks in its portfolio and, to a lesser extent, writing (selling) covered call and writing (selling) put options on indices of securities and sectors of securities generally within the healthcare industry.
This option strategy is intended to generate current income from option premiums as a means to enhance distributions payable to the Fund's shareholders. The Fund's investment team does not anticipate any adverse
implications to the Fund's existing total return potential or risk profile as a result of the strategy; however, the investment adviser may choose to decrease or modify its use of the option writing strategy to the
extent that it may negatively impact the Fund's ability to benefit from capital appreciation. The Fund currently expects that it will not write options on more than 10% of its assets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Open Market Repurchase Program</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board has approved an
open market repurchase and discount management policy (the &#x201c;Program&#x201d;). The Program allows the Fund to purchase, in the open market for a one-year period ending</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">September 30, 2026, up to 12% of its
outstanding common shares, with the amount and timing of any repurchase determined at the discretion of the Fund's investment adviser. Such purchases may be made opportunistically at certain discounts to NAV per share
in the reasonable judgment of management based on historical discount levels and current market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis. For the
fiscal year ended September 30, 2025, the Fund did not repurchase any shares through the Program.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">On a quarterly basis, the Board
will receive information on any transactions made pursuant to this policy during the prior quarter.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Holdings Disclosure</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund's complete schedule
of portfolio holdings for the second and fourth quarters of each fiscal year are included in the Fund's semi-annual and annual reports to shareholders. The Fund files its complete schedule of portfolio holdings with
the SEC for the first and third quarters of each fiscal year as an exhibit to its reports on Form N-PORT. These reports are available on the SEC&#x2019;s website at&#xa0;www.sec.gov. The Fund makes the information
available to shareholders upon request and without charge by calling Investor Relations toll-free at 1-800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Proxy Voting</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">A description of the policies
and procedures that the Fund uses to determine how to vote proxies relating to portfolio securities and information regarding how the Fund voted proxies relating to portfolio securities during the most recent 12-month
period ended June 30 is available by August 31 of the relevant year: (1) upon request without charge by calling Investor Relations toll-free at 1-800-522-5465; and (2) on the SEC&#x2019;s website
at&#xa0;www.sec.gov.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations Information</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">As part of Aberdeen's
commitment to shareholders, we invite you to visit the Fund on the web at&#xa0;www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds. Here, you can view monthly fact sheets, quarterly
commentary, distribution and performance information, as well as other Fund literature. Enroll in Aberdeen's email services to receive content related to your fund. In addition, you will receive monthly factsheets
based on your preferences. Sign up today at&#xa0;www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">2
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Letter to Shareholders &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:47.96%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Contact Us:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:5pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:94.19%">Visit:&#xa0;www.aberdeeninvestments.com/en-us/investor/investment-solutions/closed-end-funds
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:1pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Email: Investor.Relations@aberdeenplc.com; or
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:2pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:5.81%">&#x2022;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.19%">Call: 1-800-522-5465 (toll free in the U.S.).
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Yours sincerely,</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">/s/ Alan Goodson<br>
<font style="font-weight:bold">Alan Goodson<br>
</font>President&#xa0;</div>
</div>
<div style="margin-top:501pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:17pt; text-align:center; text-decoration:none; text-transform:none">All amounts are U.S. Dollars
unless otherwise stated.</div>
</div>
<div style="margin-top:21.79pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">3
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of the Investment Adviser &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">Performance Review</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">For the fiscal year ended
September 30, 2025, HQL returned 21.06%<sup style="font-size:85%; font-style:Normal; text-transform:none">1</sup> on a net asset value (NAV)<sup style="font-size:85%; font-style:Normal; text-transform:none">2</sup> basis compared with 3.19% for the Fund&#x2019;s performance target, the NASDAQ Biotechnology Index. On a market&#x2013;price basis, shares returned
17.62%. The fund&#x2019;s performance was driven by a combination of strong stock selection combined with a strong market rally in small to mid-cap biotechnology companies. Unless otherwise noted, performance figures
refer to NAV total return.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Market Review</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:left; text-decoration:none; text-transform:none">U.S. stocks, as measured by the
broad S&amp;P 500 Index, posted strong gains over the 12 months to September 30, 2025.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Global markets fluctuated
over the review period amid monetary policy shifts, trade developments, and geopolitical tensions. The U.S. Federal Reserve cut rates twice in late 2024 and again in mid-2025, supporting sentiment alongside hopes for
a soft landing and easing inflation. President Trump&#x2019;s election initially boosted equities, but optimism faded as tariff concerns and tighter immigration policies weighed on markets, leading to a sharp sell-off
in April before rebounding after most tariffs were paused. Further support came from a U.S.-China tariff truce extension and new trade agreements with the EU and Japan, though optimism was tempered by steep new
tariffs on pharmaceuticals and higher duties on several countries. Geopolitical risks, including Middle East violence, briefly pressured markets, but a U.S.-brokered ceasefire helped stabilize conditions. However, the
partial shutdown of the U.S. government starting in September added to economic and political uncertainty. Inflation eased earlier in the year, but remaining above target, central banks maintained a data-dependent
stance. Global economic growth held up better than expected, with early-2025 fears of a U.S. recession proving to be short-lived.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The performance of the U.S.
healthcare sector notably lagged that of the S&amp;P 500 Index over the period due to the sector&#x2019;s defensive nature. In addition, the nomination of Robert F. Kennedy Jr. to run the Department of Health and Human
Services affected the healthcare sector&#x2019;s returns shortly after the announcement. Subsequently, healthcare stocks faced headwinds from regulatory uncertainty, including proposed Medicaid work requirements and
uncertainty in biotechnology regulation and funding. Although the Trump administration announced high tariffs on branded and patented pharmaceutical imports, the tariff rate implemented was lower than</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">initially feared. Moreover, companies
building manufacturing facilities in the U.S. were exempted, which helped to limit the policy&#x2019;s perceived impact on the healthcare sector.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Review</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">HQL is a fully equity
strategy&#xa0;focused on therapeutics and enabling platforms. During the period we tilted further into SMID&#x2013;cap biotechnology, deliberately leaning into higher&#x2013;risk, smaller&#x2013;cap
opportunities&#xa0;where our analysts&#x2019; deep scientific diligence&#xa0;and clinical&#x2013;regulatory experience try to identify asymmetric opportunities&#xa0;tied to clear milestones (late&#x2013;stage readouts,
label expansions, or partnership paths). As valuations later recovered in parts of biotech, we modestly rebalanced toward larger&#x2013;cap, commercial&#x2013;stage franchises&#xa0;to add stability and cash&#x2013;flow
resilience&#x2014;while retaining a meaningful SMID-cap sleeve for innovation and catalyst exposure. We maintained diversified exposure across therapeutics, tools/diagnostics, and select services, with position sizes
calibrated to event risk and evidence flow.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Positive performance results
were led by stock selection in therapeutics and platforms. uniQure&#xa0;advanced on renewed gene&#x2013;therapy optimism, reflecting progress across key programs. Vigil Neuroscience&#xa0;rose following Sanofi&#x2019;s
announced acquisition (upfront plus potential milestones), and Alnylam&#xa0;gained on strong Amvuttra&#xa0;uptake and cardiovascular RNA&#x2013;platform updates with reaffirmed growth targets. These names were material
contributors&#xa0;and exemplify our focus on pipeline visibility and high&#x2013;quality science translating to products.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As in any portfolio, some
investments did not perform as anticipated and detracted from overall results, including Regeneron Pharmaceuticals, Sarepta Therapeutics, and Vaxcyte&#x2014;reflecting manufacturing&#x2013;cost/competition pressures,
clinical/regulatory headlines, and mixed pediatric vaccine data amid broader policy uncertainty, respectively. We maintained measured exposure&#xa0;where we see durable competitive positions, significant unmet need,
and milestone&#x2013;rich pipelines&#xa0;that can close valuation gaps over time. Several positions derated, improving forward risk&#x2013;reward&#xa0;as we await clarity on utilization, reimbursement, or regulatory
pathways. Sizing reflects near&#x2013;term uncertainty; we reassess around defined catalysts and maintain diversification so that fundamentals&#x2014;not headlines&#x2014;drive outcomes&#xa0;over a full cycle.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">We used
call&#x2013;option<sup style="font-size:85%; font-style:Normal; text-transform:none">3</sup>&#xa0; writing/overwriting<sup style="font-size:85%; font-style:Normal; text-transform:none">4</sup>,<sup style="font-size:85%; font-style:Normal; text-transform:none">5</sup> selectively to generate incremental income&#x2014;particularly around clinical&#x2013;event</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:3.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">1
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Past performance is no guarantee of future results. Investment returns and principal value will fluctuate and shares, when sold, may be worth more or less than original cost. Current performance may be
lower or higher than the performance quoted. Net asset value return data include investment management fees, custodial charges and administrative fees (such as Director and legal fees) and assumes the reinvestment of
all distributions.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:57pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">2
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Net asset value (&#x201c;NAV&#x201d;) &#x2013; A key measure of the value of a company, fund or trust &#x2013; the total value of assets less liabilities, divided by the number of shares.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:80pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Call option &#x2013; A contract that gives the buyer the right, but not the obligation, to buy an asset at a specified price within a set period.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:20.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">4
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of the Investment Adviser &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">volatility&#x2014;which was additive to
returns. As always, options can cap upside in strong rallies and introduce assignment risk if positions are called away; we calibrate use to the catalyst calendar and valuation.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture is a differentiating
feature&#xa0;of HQL and a deliberate source of long&#x2013;duration optionality. Our philosophy: deploy modest, milestone&#x2013;driven capital&#xa0;into differentiated science nearing clinical validation, with
disciplined pacing, syndicate quality, and valuation awareness. Venture outcomes are expected to be episodic; the goal is to compound selectively&#xa0;through cycles without allowing single assets to dominate risk.
During the year, activity was measured&#xa0;and not a material driver&#xa0;of overall performance. We invested in Crystalys Therapeutics&#xa0;(Dotinurad for gout/hyperuricemia) and participated in Third Arc
Bio&#xa0;(multi&#x2013;specific antibodies for oncology/immunology), and we added venture stakes in Nuvig Therapeutics&#xa0;and Aviceda Therapeutics, as well as a new investment in Abcuro&#x2014;each sized to risk with
clear paths to value via data, partnering, or regulatory progress.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Activity</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">We introduced several new
holdings in late 2024, including Halozyme Therapeutics, Syndax Pharmaceuticals, Allogene Therapeutics, Personalis, Vir Biotechnology, Travere, Dyne Therapeutics, and Cargo Therapeutics. These positions were
established for a variety of reasons, including near-term clinical data events and commercial opportunities.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Moving into 2025, we made
several changes to the portfolio. The portfolio management team identified relative value differentials favoring smaller-cap equities over large-cap pharmaceutical and biotechnology companies. Additionally, concerns
over pending tariffs led us to adopt a more cautious stance toward the large-cap pharmaceutical and biotechnology sector. Examples of new initiations included Incyte, Arbutus Biopharma, Immunic, Cidara Therapeutics,
ARS Pharmaceuticals, Centessa Pharmaceuticals, Mereo BioPharma, NewAmsterdam Pharma, Tempus AI, Korro Bio, and Sionna Therapeutics.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Subsequently, we initiated
Vericel Corporation to gain exposure to the company&#x2019;s niche in regenerative medicine. The company&#x2019;s cell therapy franchise, focused on cartilage repair and burn care, has delivered accelerating revenue
growth, with upcoming product developments such as expanded indications for pediatric populations. We also initiated Twist Bioscience Corporation to gain exposure to innovation in deoxyribonucleic acid (DNA)
production. The company provides gene synthesis and genomics tools for research and development. We introduced Disc Medicine Inc to gain exposure to a</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">biotechnology company with a pipeline
focused on haematology. Disc Medicine is advancing therapies for rare blood disorders, including positive mid-stage data in erythropoietic disorders.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Later in the period, the fund
added positions in Jazz Pharmaceuticals, Arcus Biosciences, Aquestive Therapeutics, Equillium, Shattuck Labs, and Apogee Therapeutics, targeting firms with strong balance sheets.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As part of the fund&#x2019;s
venture activities, we made two new investments into two pre-public, venture-backed drug companies: Nuvig Therapeutics and Aviceda Therapeutics. We also made a new investment in a pre-public, venture-backed company,
Abcuro.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Conversely, we sold several
positions. These disposals included Exelixis after the company won a patent lawsuit, Apellis Pharmaceuticals on concerns about the ultimate market opportunity for its drug in geographic atrophy, and both Illumina and
Arcellx after strong share-price performance.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Some sales were motivated by
a lack of confidence in the companies' prospects, while others resulted from failed clinical trials. Also, in line with increasing the fund&#x2019;s allocation to smaller-cap equities and decreasing its allocation to
large-cap equities; we sold some positions, including Biogen, Eli Lilly, Thermo Fisher Scientific, Intra-Cellular Therapies, Natera, BeiGene, Avantor, 89bio, Moderna, AstraZeneca, and Marinus Pharmaceuticals.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Meanwhile, we sold Incyte
Corporation, reallocating capital given the appearance of a maturing growth profile and increased competitive pressures in its core business. We also disposed of Medpace Holdings, a clinical research organization,
after a period of strong share-price performance. We sold our holding in Arvinas after a reassessment of the company&#x2019;s risk and competitive position in the targeted protein degradation field.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">We also sold smaller
biotechnology positions with matured theses or liquidity concerns, increasing exposure to late-stage pipelines and diversifying the therapeutic mix.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The monthly distribution<sup style="font-size:85%; font-style:Normal; text-transform:none">6</sup> reflects the Fund&#x2019;s current policy to provide shareholders with a relatively stable cash flow per share. During the 12-month period ended
September 30, 2025, the distributions comprised ordinary income, capital gains, and a return of capital.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Outlook and Strategy</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">Uncertainty continues to
cloud the macroeconomic, geopolitical, and market outlook. A combination of shifting fiscal and monetary policies along with structural changes in global trade dynamics has created an increasingly volatile market
environment. Much of the focus remains on the Trump administration&#x2019;s tariff strategy and its</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:0.5pt; width:94%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">4
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Call-option writing &#x2013; Selling a call option, which obligates the seller to sell the asset at the strike price if the option is exercised.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:23pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">5
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Overwriting &#x2013; Selling a call option on an asset the seller does not expect to reach the strike price before expiration, aiming to collect the premium without exercise.
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; text-align:left; text-decoration:none; text-transform:none">{foots1}</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:46pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.20%">6
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.80%">Distribution &#x2013; The payment of any income, capital gains, or return of capital by a fund.
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:21.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">5
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of the Investment Adviser &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">potential implications for economic growth
and inflation. However, the broader macroeconomic backdrop is further complicated by labor market data revisions, proposed tax cuts, widening budget deficits, evolving interest-rate policy, healthcare reform, and a
range of other policy initiatives that may have both intended and unintended consequences. Given the rapidly evolving landscape, market participants are struggling to build meaningful conviction around the trajectory
of both domestic and international economies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">With policy and macro
variables still in play, we believe relative valuation&#xa0;across many parts of biotech remains attractive&#xa0;versus the broader equity market after a multi&#x2013;year de&#x2013;rating&#x2014;particularly within
innovation&#x2013;rich SMID caps&#xa0;where milestones can unlock disproportionate value. As conditions evolve and valuations for select cohorts recover, we expect to modestly balance&#xa0;that SMID-cap exposure with
larger&#x2013;cap, commercial&#x2013;stage&#xa0;franchises to enhance stability and cash&#x2013;flow durability. Over our horizon, fundamentals&#x2014;advancing pipelines, scalable platforms in RNA/cell &amp; gene
therapy/radiopharma, and productivity&#x2013;enhancing diagnostics/tools&#x2014;should be the primary driver of share appreciation. We also anticipate a continued cadence of mergers and acquisitions (M&amp;A) as
large&#x2013;caps address loss&#x2013;of&#x2013;exclusivity (LOE)&#xa0;and pipeline gaps, a supportive backdrop for SMID-cap innovators and platform companies alike. For HQL specifically, we will continue to use our deep
scientific diligence to target asymmetric opportunities in smaller caps, pace position sizes to milestones, and opportunistically add commercial&#x2013;stage stability as price discovery improves&#x2014;aiming to let
fundamental progress, not headlines, lead returns over the cycle.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:italic; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Risk Considerations</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:left; text-decoration:none; text-transform:none">Past performance is not an
indication of future results.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Life sciences companies are likely to be
more sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the life sciences industries. Life sciences companies have, in the past, been characterized
by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a disproportionate share of a
company&#x2019;s revenue, obsolete. Obtaining governmental approval from U.S. governmental agencies and from non-U.S. governmental agencies for new products can be lengthy, expensive and uncertain as to the outcome.
Such delays in product development may result in the need to seek additional capital, potentially diluting the interests of existing investors such as the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection upon which life sciences companies can be highly dependent for maintenance of profit
margins and market exclusivity. The complex nature of the technologies involved can lead to patent disputes, including litigation, that may be costly and that could result in a company losing an exclusive right to a
patent. Additionally, certain life sciences companies may be exposed to potential product liability risks that are inherent to the life sciences industry. A product liability claim may have a material adverse effect
on a company in which the Fund has invested.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">All of these factors, as well as
others may cause the value of the Fund&#x2019;s shares to fluctuate significantly over relatively short periods of time.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:239.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">6
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Total Investment Return &#xa0;<font style="font-size:11pt; line-height:14pt">(unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:33.5pt; width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the average annual Fund performance compared to the Fund&#x2019;s primary benchmark&#xa0;for the 1-year, 3-year, 5-year and 10-year periods ended September 30, 2025.</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:10pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3.5pt; padding-right:12pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:60.04%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.80%; background-color: #D9D9D9;">1 Year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.86%; background-color: #D9D9D9;">3 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.72%; background-color: #D9D9D9;">5 Years
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:12pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.58%; background-color: #D9D9D9;">10 Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:2.12pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:60.04%; background-color: #F0F0F0;">Net Asset Value (NAV)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.80%; background-color: #F0F0F0;">21.06%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.86%; background-color: #F0F0F0;">16.44%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.80pt; padding-right:12pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">7.53%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.67pt; padding-right:6pt; padding-top:2.12pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">7.22%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:60.04%; background-color: #F0F0F0;">Market Price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.38pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.80%; background-color: #F0F0F0;">17.62%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:13.67pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.86%; background-color: #F0F0F0;">17.02%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">8.17%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1pt; padding-left:12pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">6.49%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:12pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:60.04%; background-color: #F0F0F0;">Nasdaq Biotechnology Index
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:15.68pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.80%; background-color: #F0F0F0;">3.19%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:15.95pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.86%; background-color: #F0F0F0;">9.90%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.21pt; padding-right:12pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.72%; background-color: #F0F0F0;">3.58%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:4.5pt; padding-left:12.26pt; padding-right:6pt; padding-top:1pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.58%; background-color: #F0F0F0;">5.09%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:13pt; text-align:left; text-decoration:none; text-transform:none">Performance of a $10,000
Investment<font style="font-weight:Normal"> (as of September 30, 2025)</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:7pt; text-align:left; text-decoration:none; text-transform:none">This graph shows the change in
value of a hypothetical investment of $10,000 in the Fund for the periods indicated. For comparison, the same investment is shown in the indicated&#xa0;index.</div>
<div style="margin-left:26.48%; margin-top:5pt; text-align:Center; width:47.22%">
<img src="tm2527059d12hqlreporti003.jpg" alt=" ">
</div>


<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:justify; text-decoration:none; text-transform:none">Returns represent past
performance. Total investment return at NAV is based on changes in the NAV of Fund shares and assumes reinvestment of dividends and distributions, if any, at market prices pursuant to the dividend reinvestment program
sponsored by the Fund&#x2019;s transfer agent. All return data at NAV includes fees charged to the Fund, which are listed in the Fund&#x2019;s Statement of Operations under &#x201c;Expenses.&#x201d; Total investment
return at market value is based on changes in the market price at which the Fund&#x2019;s shares traded on the NYSE during the period and assumes reinvestment of dividends and distributions, if any, at market prices
pursuant to the dividend reinvestment program sponsored by the Fund&#x2019;s transfer agent. The Fund&#x2019;s total investment return is based on the reported NAV as of the financial reporting period end date of
September 30, 2025. Because the Fund&#x2019;s shares trade in the stock market based on investor demand, the Fund may trade at a price higher or lower than its NAV. Therefore, returns are calculated based on both
market price and NAV. <font style="font-weight:bold">Past performance is no guarantee of future results</font>. The performance information provided does not reflect the deduction of taxes that a shareholder would pay on distributions received
from the Fund or the sale of Fund shares. The current performance of the Fund may be lower or higher than the figures shown. The Fund&#x2019;s yield, return, market price and NAV will fluctuate. Performance information
current to the most recent month-end is available at www.aberdeenhql.com&#xa0;or by calling 800-522-5465.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The gross operating expense
ratio based on the fiscal year ended September 30, 2025 was 1.24%.&#xa0;</div>
</div>
<div style="margin-top:159pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">7
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio Summary &#xa0;<font style="font-size:11pt; line-height:14pt"> (as a percentage of net assets) (unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the composition of the Fund&#x2019;s portfolio by asset allocation.</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #D9D9D9;">Asset Allocation
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:6.96%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.21pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">88.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.74pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">6.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.38pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">2.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.30pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.18pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.65pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">1.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Call Options Written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:9.53pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">(0.1%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.13pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:18pt; text-align:left; text-decoration:none; text-transform:none">The following table summarizes
the industry composition of the Fund&#x2019;s portfolio, in S&amp;P Global Inc.&#x2019;s Global Industry Classification Standard (&#x201c;GICS&#x201d;) Industries.&#xa0;</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #D9D9D9;">Industries
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:6.96%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:8.38pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">80.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:91.18%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:9.94pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">12.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Life Sciences Tools &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.00pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">5.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Health Care Providers &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.57pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:13.13pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Short-Term Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:14.65pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">1.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">Liabilities in Excess of Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:9.53pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">(0.1%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:91.18%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.96%; background-color: #F0F0F0;">100.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:18pt; text-align:left; text-decoration:none; text-transform:none">The following were the
Fund&#x2019;s top ten holdings as of September 30, 2025:</div>
<div style="text-align:left">
<table style="border-bottom:0.5pt solid #000000; border-collapse:collapse; empty-cells:show; margin-top:6pt; width:99.81%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #D9D9D9;">Top Ten Holdings
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:9pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:5.22%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">uniQure NV
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6.03pt; padding-right:9pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">7.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Vertex Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.25pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">3.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Amgen, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">3.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Alnylam Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">3.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Insmed, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.24pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">2.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Argenx SE, ADR
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:5.00pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">2.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.38pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">2.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:4.25pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">2.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Cytokinetics, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.25pt; padding-left:6.54pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">2.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:92.92%; background-color: #F0F0F0;">Ultragenyx Pharmaceutical, Inc.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.21pt; padding-right:9pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:5.22%; background-color: #F0F0F0;">2.0%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;</div>
</div>
<div style="margin-top:204pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">8
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:58.07%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.23%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Convertible Preferred Stocks<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;6.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;3.8%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Abcuro, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;232,252
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">$<font style="padding-left:1.29pt"></font>&#x2002;&#x2007;&#x2007;1,274,994
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Abcuro, Inc. Series C1
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;51,403
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.46pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;310,407
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.49pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;38,624
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.38pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;640,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;389,294
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.11pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,599,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc. Series A, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,008,829
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.08pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;406,659
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc. Series B, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.31pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;447,566
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.76pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;160,721
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Atalanta Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;777,778
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,400,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Aviceda Therapeutics Series C
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;38,906
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.58pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;224,091
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Flamingo Therapeutics, Inc. Series A3
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.87pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;107,120
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.41pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;144,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Glycomine, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.06pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,655,105
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,593,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. Series B, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.82pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,291,668
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,100,003
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. Series C, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.60pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;284,119
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.93pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;920,801
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.34pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;832,650
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.44pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,599,995
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Priothera Co. Ltd. Series A, 6.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.54pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;152,534
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.89pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;18
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Quell Therapeutics Ltd. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;846,561
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.00pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,760,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Recode Therapeutics, Inc. Series B, 5.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.66pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;155,959
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,440,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Seismic Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.85pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">282,340
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.23pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,274,991
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Third Arc Bio, Inc. Series A, 8.00%
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">807,908
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,700,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:14.38pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">19,549,743
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">IO Light Holdings, Inc. Series A2
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.75pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">421,634
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:43.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">42
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;2.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Biotheryx, Inc. Series E, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">609,524
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.03pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">346,453
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Crystalys Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,020,512
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,022,400
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Curasen Therapeutics, Inc. Series A
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.27pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">9,049,182
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.76pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,339,083
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Curasen Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,379,821
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">661,624
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series B, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">296,855
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,399,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc. Series C, 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.15pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">54,815
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.46pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">357,646
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Engrail Therapeutics, Inc., 8.00%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.82pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,124,646
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,250,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">HiberCell, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,305,163
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.19pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">519,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">HiberCell, Inc. Series C
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.69pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">719,652
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">333,631
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Nuvig Therapeutics, Inc. Series B
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.01pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">739,010
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.73pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">775,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Qlaris Bio, Inc. Series B
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.60pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,974,522
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.74pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,550,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.60pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">13,554,898
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Total Convertible Preferred Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:13.78pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">33,104,683
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Convertible Notes<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;0.4%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:58.07%; background-color: #F0F0F0;">Biotechnology&#x2014;0.3%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., 6.00%, 04/10/26
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:2.99%; background-color: #F0F0F0;">$&#x2002;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.50pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">323,870
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.71pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">323,870
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., 8.00%, 04/18/26
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.90pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">738,460
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.11pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">738,460
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., 10.00%, 09/09/26
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.63pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">257,586
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">257,586
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:20.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,319,916
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Health Care Providers &amp; Services&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Recode Therapeutics, Inc., 8.00%, 03/23/27
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">75,939
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:30.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">75,939
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:58.07%; background-color: #F0F0F0;">Pharmaceuticals&#x2014;0.1%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">HiberCell, Inc., 10.00%, 12/31/25
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.91pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">206,589
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">206,589
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., 8.00%, 03/31/26
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.26pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">441,083
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.47pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">441,083
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:25.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">647,672
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Total Convertible Notes
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:17.89pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,043,527
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Common Stocks&#x2014;88.3%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;75.2%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Abivax SA, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.44pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">49,000
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.61pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,160,100
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Akero Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.97pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">178,163
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">8,459,179
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Alkermes PLC<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">63,294
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,898,820
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Allogene Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.47pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,582,265
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.92pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,962,009
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Alnylam Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:10.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">33,645
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:17.75pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">15,342,120
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:58.07%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.23%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:4pt; padding-top:1.5pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">
</td><td style="padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">
</td><td style="padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">
</td><td style="padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; text-align:left; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Amgen, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.74pt; padding-right:4pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;54,622
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">$<font style="padding-left:1.16pt"></font>&#x2002;&#x2007;15,414,328
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Apogee Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.89pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;54,760
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.88pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;2,175,615
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arbutus Biopharma Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.31pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;799,979
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.28pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,631,905
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arcus Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;62,906
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.09pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;855,522
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arcutis Biotherapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;218,107
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.12pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;4,111,317
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Ardelyx, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.24pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;493,320
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.21pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;2,718,193
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Argenx SE, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.36pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;18,929
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.73pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;13,961,273
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Arrowhead Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:3.04pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;213,011
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;7,346,749
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">ARS Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.26pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;507,686
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;5,102,244
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Ascendis Pharma AS, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.98pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;20,185
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;4,012,980
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Avalo Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.61pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;72,800
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.58pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;&#x2007;925,288
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Avidity Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.41pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;146,245
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;6,371,895
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">BioMarin Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.40pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;225,446
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.97pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;12,210,155
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">BioNTech SE, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.94pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;78,339
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.11pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;7,725,792
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Caribou Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.62pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,388,905
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.76pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,236,149
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Centessa Pharmaceuticals PLC, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.69pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;53,574
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,299,169
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Chinook Therapeutics, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">59,063
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.79pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">18,900
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Cidara Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">56,305
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.51pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,391,767
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Corbus Pharmaceuticals Holdings, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.93pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">188,231
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,381,122
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Cytokinetics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.05pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">197,644
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">10,862,514
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Denali Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.23pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">477,567
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">6,934,273
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Disc Medicine, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.48pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">32,061
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.89pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,118,591
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Dyne Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.77pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">556,733
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.13pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">7,042,672
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Equillium, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.89pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">379,526
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">542,722
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Geron Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.02pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,042,059
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.48pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,797,621
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Gilead Sciences, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">47,677
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,292,147
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">GRAIL, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">87,974
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,201,903
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Ideaya Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.57pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">213,524
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.71pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,809,988
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Immatics NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.26pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">240,137
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.67pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,045,967
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Immunic, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.75pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">3,028,916
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.05pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,670,292
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Immunovant, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.99pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">330,935
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.99pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,334,672
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Insmed, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">101,010
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">14,546,450
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Ionis Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.01pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">43,865
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.84pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,869,648
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Iovance Biotherapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">607,210
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,317,646
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Janux Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">93,315
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.36pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,280,619
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Korro Bio, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">57,983
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,776,806
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Krystal Biotech, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.78pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">20,154
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.40pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,557,786
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Mereo Biopharma Group PLC, ADR<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.17pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,076,408
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.55pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,277,400
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Merus NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.38pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">51,779
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,874,993
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Neurocrine Biosciences, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.42pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">27,165
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.09pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,813,423
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Newamsterdam Pharma Co. NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.92pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">122,441
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,482,222
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Nuvalent, Inc., Class A<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.18pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">33,821
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,924,840
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Oruka Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">75,680
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,455,326
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Palvella Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.63pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">16,225
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,017,145
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Regeneron Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">23,930
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:18.87pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">13,455,121
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Rhythm Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.45pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">11,667
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.44pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,178,250
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Sarepta Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(d)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.55pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">338,517
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">6,523,223
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Shattuck Labs, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.85pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">94,504
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:25.69pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">225,865
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Sionna Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.13pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">289,277
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">8,507,637
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Summit Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.95pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">393,856
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">8,137,065
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Syndax Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">372,792
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.89pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,735,405
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Tectonic Therapeutic, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.94pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">115,501
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:23.22pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,812,211
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Tenaya Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.64pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">600,700
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:27.27pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">973,134
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Travere Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.72pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">301,778
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.58pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">7,212,494
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">TScan Therapeutics, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">795,606
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.33pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,448,003
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Twist Bioscience Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.39pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">110,740
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.20pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,116,224
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Ultragenyx Pharmaceutical, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.30pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">349,116
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:16.33pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">10,501,409
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">uniQure NV<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.03pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">658,737
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:15.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">38,450,479
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Vaxcyte, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">230,213
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.39pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">8,292,272
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Vericel Corp.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:11.21pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">76,592
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:20.01pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,410,350
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:20pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">9
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:22.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:58.07%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.23%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Common Stocks (continued)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology (continued)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Vertex Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;43,829
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">$<font style="padding-left:4.57pt"></font>&#x2002;&#x2007;17,165,190
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Vir Biotechnology, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.56pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;553,092
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,158,155
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Xencor, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:-0.15pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;258,080
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.23pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,027,278
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Xenon Pharmaceuticals, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.77pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;211,804
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.16pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;8,503,931
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:8.36pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">386,393,953
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Equipment &amp; Supplies&#x2014;0.0%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Willow Laboratories, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.39pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;130,000
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.07pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;13
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Health Care Providers &amp; Services&#x2014;0.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Guardant Health, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:-0.11pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;40,398
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;2,524,067
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Life Sciences Tools &amp; Services<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>&#x2014;5.5%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Adaptive Biotechnologies Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;374,318
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.62pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;5,599,797
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Codexis, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,587,334
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,873,095
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Illumina, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;42,377
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.97pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;4,024,544
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Personalis, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.43pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1,074,416
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.06pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;7,005,192
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Quanterix Corp.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.12pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;564,581
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.72pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;3,065,675
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Tempus AI, Inc.<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;&#x2007;60,205
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.40pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;4,859,146
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:13.50pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">28,427,449
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>&#x2014;7.1%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Aquestive Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">196,160
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,096,534
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Axsome Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.32pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">39,219
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.03pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,763,148
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Crinetics Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:8.91pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">131,752
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.70pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,487,471
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Edgewise Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">263,291
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.39pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,270,580
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">EyePoint Pharmaceuticals, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6.65pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">276,280
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.96pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,934,227
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Fulcrum Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.50pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">137,961
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:21.54pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,269,241
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14.73pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">3,256
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:33.32pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">4,493
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Jazz Pharmaceuticals PLC
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.90pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">14,506
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.83pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,911,891
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">LENZ Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:10.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">39,337
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.03pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,832,317
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Oculis Holding AG<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:7.59pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">170,667
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.55pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,025,926
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Spectrum Pharmaceuticals, Inc. CVR<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:9.53pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">34,880
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:47.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Structure Therapeutics, Inc., ADR
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:5.28pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">204,880
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:19.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">5,736,640
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Tarsus Pharmaceuticals, Inc.
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:11.89pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">51,678
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.95pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,071,224
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:12.45pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">36,403,692
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Total Common Stocks
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:11.32pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">453,749,174
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Warrants<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>&#x2014;0.6%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:58.07%; background-color: #F0F0F0;">Biotechnology&#x2014;0.6%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Immunic, Inc., Series A(expiration date 12/31/2025)<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,311,826
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.18pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">453,281
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Immunic, Inc.
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,311,826
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.42pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">2,038,106
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Immunic, Inc., Series B(expiration date 6/30/2030)<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.29pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,311,826
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:26.26pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">607,633
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:17.02pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,099,020
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Health Care Providers &amp; Services&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Recode Therapeutics, Inc.(expiration date 9/23/2035, exercise price $0.01)<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>
</td><td style="line-height:0pt; padding-bottom:2.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:10.84pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">75,939
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:2.5pt; padding-left:47.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">0
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.48%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-right:4pt; padding-top:4pt; text-align:left; vertical-align:top; width:58.07%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:4pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.23%; background-color: #CCCCCC;" colspan="2">Shares or<br>
Principal<br>
Amount
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:0pt; padding-right:6pt; padding-top:4pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:4pt; padding-top:1.5pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">
</td><td style="padding-top:1.5pt; text-align:left; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">
</td><td style="padding-right:4pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">
</td><td style="padding-right:6pt; padding-top:1.5pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Pharmaceuticals<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;0.0%
</td><td style="line-height:0pt; padding-bottom:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-right:6pt; text-align:center; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">HiberCell, Inc.(expiration date 09/15/28, exercise price $0.46)
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:1.93pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2007;719,652
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">$<font style="padding-left:1.47pt"></font>&#x2002;&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">HiberCell, Inc.(expiration date 09/13/34, exercise price $0.08)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:0.56pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">2,582,362
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;2
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:47.78pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Total Warrants
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:17.14pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">3,099,023
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Short-Term Investment&#x2014;1.6%
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">State Street Institutional U.S. Government Money Market Fund, Premier Class, 4.09%<sup style="font-size:85%; font-style:Normal; text-transform:none">(f)</sup>
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.19pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">8,417,353
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.34pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;8,417,353
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Total Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:19.28pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">8,417,353
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Total Investments Before Milestone Interests&#x2014;97.4%<br>
(Cost $387,182,739)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:9.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">500,413,760
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:4pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #CCCCCC;">Interests
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #CCCCCC;">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.92%; background-color: #F0F0F0;" colspan="4">Milestone Interests<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(b)</sup><sup style="font-size:85%; font-style:Normal; text-transform:none">,(c)</sup>&#x2014;2.7%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Biotechnology&#x2014;0.3%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Amphivena Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">$<font style="padding-left:0.33pt"></font>&#x2002;&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Invetx, Inc. Milestone Interest
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:13.43pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2007;&#x2007;1,455,577
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.5pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:1.5pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:19.49pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,455,577
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:96.92%; background-color: #F0F0F0;" colspan="4">Pharmaceuticals&#x2014;2.4%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Afferent Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:2.09pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:12.11pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">&#x2009;&#x2009;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;&#x2007;0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Amolyt Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.74pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.68pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">1,078,585
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Ethismos Research Milestone Interest
</td><td style="line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.74pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:47.82pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:58.07%; background-color: #F0F0F0;">Neurovance Milestone Interest
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:29.74pt; padding-right:4pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.23%; background-color: #F0F0F0;">1
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:20.22pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">11,172,421
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:left; vertical-align:top; width:58.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:8pt; padding-bottom:1.25pt; padding-top:1.25pt; text-align:right; vertical-align:bottom; width:2.99%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:1.25pt; padding-right:4pt; padding-top:1.25pt; text-align:center; vertical-align:bottom; width:14.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.86pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">12,251,006
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Total Milestone Interests
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.25pt; padding-left:14.15pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">13,706,583
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Total Investments (Cost $390,703,166)<sup style="font-size:85%; font-style:Normal; text-transform:none">(g)</sup>&#x2014;100.1%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:10.59pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">514,120,343
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Liabilities in Excess of Other Assets&#x2014;(0.1%)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.25pt; padding-left:22.97pt; padding-right:6pt; padding-top:1.5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:21.63%; background-color: #F0F0F0;">(464,397)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:6pt; padding-right:4pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:75.29%; background-color: #F0F0F0;" colspan="3">Net Assets&#x2014;100.0%
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:0.25pt; padding-left:4pt; padding-right:6pt; padding-top:1.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:21.63%; background-color: #F0F0F0;">$<font style="padding-left:1.21pt"></font>513,655,946
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:10pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Level 3 security. See Note 2(a) of the accompanying Notes to&#xa0;Financial Statements.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Non-income producing security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Restricted security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">A portion of security is pledged as collateral for call options written.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Foreign security.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(f)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">Registered investment company advised by State Street Investment Management. The rate shown is the 7 day yield as of&#xa0;September 30, 2025.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:4.00%">(g)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:96.57%">See accompanying Notes to Financial Statements for tax unrealized appreciation/(depreciation) of securities.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">ADR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:6pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">American Depositary Receipt
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">CVR
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Contingent Value Right
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:0pt; padding-right:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:5.94%">PLC
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:6pt; padding-left:1.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:94.63%">Public Limited Company
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; width:100%">
</div>
</div>
<div style="padding-top:133pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">10
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Portfolio of Investments&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(concluded)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:13.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.91%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:8pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:33.67%; background-color: #CCCCCC;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:25.78%; background-color: #CCCCCC;">Number of Contracts<br>
(100 shares each)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:25.66%; background-color: #CCCCCC;">Notional Amount ($)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.02%; background-color: #CCCCCC;">Value ($)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Option Contracts Written&#x2014;(0.1)%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%; background-color: #E6E6E6;" colspan="4">Call Options Written&#x2014;(0.1)%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Argenx SE Oct25 770 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">12
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(924,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(10,380)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Arrowhead Pharmaceuticals, Inc. Oct25 35 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">262
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(917,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(43,230)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Ascendis Pharma AS Oct25 210 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">33
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(693,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(11,121)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">BioMarin Pharmaceutical, Inc. Oct25 57.5 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">199
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(1,144,250)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(11,940)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">BioNTech SE Oct25 105 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">65
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(682,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(6,500)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Cidara Therapeutics, Inc. Oct25 80 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">86
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(688,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(163,830)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Cytokinetics, Inc. Oct25 55 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">125
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(687,500)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(33,125)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">GRAIL, Inc. Oct25 50 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">100
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(500,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(103,700)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">GRAIL, Inc. Oct25 70 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">50
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(350,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(24,000)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Sarepta Therapeutics, Inc. Oct25 20 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">343
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(686,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(12,005)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:33.67%; background-color: #E6E6E6;">Tempus AI, Inc. Oct25 90 Call
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.78%; background-color: #E6E6E6;">75
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:25.66%; background-color: #E6E6E6;">(675,000)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:1.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(14,625)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:14pt; padding-right:6pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-indent:-8pt; text-transform:none; vertical-align:bottom; width:85.11%; background-color: #E6E6E6;" colspan="3">Total Call Options Written<br>
(Premiums received $(204,596))
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.02%; background-color: #E6E6E6;">(434,456)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to Financial
Statements.</div>
</div>
<div style="margin-top:448pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">11
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Assets and Liabilities<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.46%">Assets
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.72%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Investments, at value (cost $378,765,386)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">$&#x2003;491,996,407
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Short-term investment, at value (cost $8,417,353)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:24.04pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#x2003;8,417,353
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Milestone interests, at value (cost $3,520,427)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:17.93pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#x2003;13,706,583
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.46%">Cash
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:41.94pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">75,538
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Receivable for investments sold
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:29.95pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">1,036,393
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Interest and dividends receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:38.45pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">101,706
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Tax reclaim receivable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:46.51pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">8,970
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:40.94pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">38,862
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Other assets (Note 2j)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:54.14pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">189
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Total assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:18.59pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">515,382,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:85.46%">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Payable for investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:37.69pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">720,901
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Written options, at value (premiums received $204,596)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:35.74pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">434,456
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Investment advisory fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:38.53pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">379,103
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Trustee fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:43.62pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">35,187
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Investor relations fees payable (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:41.91pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">24,952
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Administration fees payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:48.05pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">9,154
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Other accrued expenses
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:37.71pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">122,302
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Total liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:28.86pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.72%; background-color: #F0F0F0;">1,726,055
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Commitments and Contingencies (Notes 7 &amp; 9)
</td><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">$<font style="padding-left:4.91pt"></font>513,655,946
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Composition of Net Assets
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Common stock (par value $0.010 per share) (Note 5)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">$<font style="padding-left:16.86pt"></font>&#x2003;295,987
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Paid-in capital in excess of par
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:13.93pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#x2003;435,755,727
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Distributable earnings
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.81pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">&#x2003;77,604,232
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Net Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">$<font style="padding-left:4.91pt"></font>513,655,946
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.46%">Net asset value per share based on 29,598,692 shares issued and outstanding
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.72%; background-color: #F0F0F0;">$<font style="padding-left:31.22pt"></font>17.35<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.12%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.43%">The NAV shown above differs from the traded NAV on September 30, 2025 due to financial statement rounding and/or financial statement adjustments.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:215pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">12
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Operations<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Year Ended September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Net Investment Income
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:12.20%">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Investment Income:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.99%">Dividends
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">$<font style="padding-left:2.12pt"></font>&#x2003;1,588,555
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Interest and other income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.95pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;349,835
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Total investment income
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.36pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">1,938,390
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.99%">Expenses:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Investment advisory fee (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:15.20pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;4,521,763
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Independent auditors&#x2019; fees and tax expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:21.16pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;150,628
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Trustees' fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:22.76pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;144,128
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Investor relations fees and expenses (Note 3)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:26.07pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;98,412
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Legal fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:27.79pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;91,221
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Reports to shareholders and proxy solicitation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.03pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;86,887
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Transfer agent&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:24.54pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;48,402
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Custodian&#x2019;s fees and expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.59pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;46,267
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Insurance expense
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:25.43pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;26,635
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Administration fee
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:26.64pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;24,831
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:86.99%">Miscellaneous
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:28.25pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#x2003;74,162
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Total expenses
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.21pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">5,313,336
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:2.5pt; text-align:left; vertical-align:bottom; white-space:nowrap; width:99.18%" colspan="2">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Net Investment Loss
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.70pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">(3,374,946)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Net Realized/Unrealized Gain/(Loss):
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Net realized gain/(loss) from:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:1.5pt; text-align:right; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:16.94pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">26,766,592
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.23pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">1,127,357
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:86.99%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.07pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">27,893,949
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Net change in unrealized appreciation/depreciation on:
</td><td style="line-height:9.5pt; padding-bottom:1.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.20%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Investments in unaffiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:17.16pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">61,295,039
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Investments in affiliated issuers
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:35.19pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">14,261
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Milestone interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.5pt; padding-left:32.50pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">38,862
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.78pt; padding-right:12pt; padding-top:1.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">(272,819)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; vertical-align:bottom; width:86.99%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.34pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">61,075,343
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Net realized and unrealized gain from investments, milestone interests and written options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.62pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">88,969,292
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:86.99%">Change in Net Assets Resulting from Operations
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.20%; background-color: #F0F0F0;">$85,594,346
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:168pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">13
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statements of Changes in Net Assets<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:7.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:64.00%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.56%">For the<br>
Year Ended<br>
September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%">For the<br>
Year Ended<br>
September 30, 2024
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Increase/(Decrease) in Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:64.00%">Operations:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">$<font style="padding-left:9.76pt"></font>(3,374,946)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">$<font style="padding-left:12.42pt"></font>(1,920,347)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net realized gain from investments and written options
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.60pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">27,893,949
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.97pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">31,957,173
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:64.00%">Net change in unrealized appreciation on investments, milestone interests and written
options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.86pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">61,075,343
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.15pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">55,259,633
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net increase in net assets resulting from operations
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.95pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">85,594,346
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:21.53pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">85,296,459
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Distributions to Shareholders From:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.33pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(52,118,605)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.47pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(39,686,734)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:59.07pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.35pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(5,606,991)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net decrease in net assets from distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.33pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">(52,118,605)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.74pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">(45,293,725)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:10pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:64.00%">Reinvestment of dividends resulting in the issuance of 1,537,293 and 1,270,202 shares
of common stock, respectively
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.17pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">20,485,599
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.05pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">17,758,355
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Change in net assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:20.30pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">53,961,340
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.88pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">57,761,089
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Net Assets:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.56%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:17.62%; background-color: #D9D9D9;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">Beginning of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:13.56pt; padding-right:7.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">459,694,606
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:19.11pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">401,933,517
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.00%">End of year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.56%; background-color: #F0F0F0;">$513,655,946
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.62%; background-color: #D9D9D9;">$459,694,606
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:318pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">14
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Statement of Cash Flows&#xa0;<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">For the Year Ended &#xa0;September 30, 2025</div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Cash flows from operating activities:
</td><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:12pt; padding-top:5pt; text-align:right; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net increase/(decrease) in net assets resulting from operations
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">$<font style="padding-left:4.59pt"></font>&#x2003;85,594,346
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:85.32%">Adjustments to reconcile net increase in net assets resulting<br>
from operations to net cash provided by operating activities:
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Investments purchased
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.68pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;(314,126,692)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Investments sold and principal repayments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.45pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;339,341,545
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Proceeds from option contracts written
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.76pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;1,258,070
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net change in short-term investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.97pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;8,813,975
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Decrease in interest, dividends and other receivables
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:34.80pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;59,233
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Decrease in prepaid expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:39.46pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;2,669
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Decrease in accrued investment advisory fee payable
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:31.07pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;(26,009)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Decrease in other accrued expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.61pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;(239,302)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net change in unrealized appreciation of investments
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.0pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;(61,075,343)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net realized gain on investments transactions and options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:15.73pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#x2003;(27,893,949)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net cash provided by operating activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:23.88pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.87%; background-color: #F0F0F0;">31,708,543
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Cash flows from financing activities:
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:12pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Distributions paid to shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:22.72pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.87%; background-color: #F0F0F0;">(31,633,006)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net cash used in financing activities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:19.84pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.87%; background-color: #F0F0F0;">(31,633,006)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Net change in cash
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.65pt; padding-right:12pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.87%; background-color: #F0F0F0;">75,537
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:9.5pt; padding-right:7.5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Unrestricted and restricted cash, beginning of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:65.16pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:13.87%; background-color: #F0F0F0;">1
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:7.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:85.32%">Unrestricted and restricted cash, end of year
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:7.5pt; padding-right:12pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.87%; background-color: #F0F0F0;">$<font style="padding-left:28.60pt"></font>75,538
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:19pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:335pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">15
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Financial Highlights<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:14.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.07%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9.5pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:5pt; text-align:left; vertical-align:bottom; width:52.30%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:46.48%; background-color: #D9D9D9;" colspan="5">For the Fiscal Years Ended September 30,
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6.5pt; padding-top:1.75pt; text-align:left; vertical-align:bottom; width:52.30%; background-color: #D9D9D9;">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #D9D9D9;">2025<br>


</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #D9D9D9;">2024<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #D9D9D9;">2023<br>


</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #D9D9D9;">2022<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #D9D9D9;">2021<br>
<sup style="font-size:85%; font-style:Normal; text-transform:none">(b)</sup>
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">PER SHARE OPERATING PERFORMANCE:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.62pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net asset value per common share, beginning of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.71pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">$16.38
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.23pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$15.00
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.12pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$15.49
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.81pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$21.22
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.10pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$20.25
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net investment loss<sup style="font-size:85%; font-style:Normal; text-transform:none">(c)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.93pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">(0.12)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.47pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.07)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.34pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(0.08)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.12pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(0.12)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:26.12pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(0.17)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net realized and unrealized gains/(losses) on investments, written
options and foreign currency transactions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:27.14pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">2.91
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:29.58pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">3.11
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.11pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">0.87
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.76pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(4.14)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.70pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">2.83
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Total from investment operations applicable to common shareholders
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.59pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">2.79
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.94pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">3.04
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.30pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">0.79
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.01pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(4.26)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.76pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">2.66
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Distributions to common shareholders from:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net investment income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.86pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">(1.72)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.08pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.69)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.76pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(0.02)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:22.58pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(0.03)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.49pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(0.42)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net realized gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.48pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">(0.10)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.93pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.76)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:24.28pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(1.26)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:23.78pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(1.44)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:25.59pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(1.27)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Return of capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.48pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.21)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.78pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:38.81pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:39.47pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Total distributions
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:23.98pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">(1.82)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.37pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(1.66)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.14pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(1.28)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.53pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(1.47)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:24.74pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(1.69)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net asset value per common share, end of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.78pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">$17.35
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.25pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$16.38
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.85pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$15.00
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.16pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$15.49
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.47pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$21.22
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Market price, end of year
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:18.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">$15.51
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.26pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$15.08
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.71pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$12.47
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:17.04pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$13.66
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:16.25pt; padding-right:12pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$20.80
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Total Investment Return Based on<sup style="font-size:85%; font-style:Normal; text-transform:none">(d)</sup>:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Market price
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.83pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">17.62%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:13.51pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">35.94%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.12pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">0.23%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:12.74pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(27.97%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.26pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">28.32%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net asset value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:10.97pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">21.13%<sup style="font-size:85%; font-style:Normal; text-transform:none">(e)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.69pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">22.75%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:18.49pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">6.32%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:10.89pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(19.88%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.07pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">13.65%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Ratio to Average Net Assets Applicable to Common Shareholders/Supplementary Data:
</td><td style="line-height:9.5pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.33%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.26%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.27%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.62pt; padding-right:12pt; padding-top:1.62pt; text-align:right; vertical-align:bottom; width:9.39%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:16pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net assets applicable to common shareholders, end of year (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.38pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">$513,656
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$459,695
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$401,934
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.78pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$397,902
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$523,440
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Average net assets applicable to common shareholders (000 omitted)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">$429,010
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:8.11pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">$433,142
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.15pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">$421,289
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6.5pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">$436,937
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:7.72pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">$519,380
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Gross operating expenses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.41pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">1.24%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.56pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">1.36%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.45pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">1.35%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:19.09pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">1.38%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:20.26pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">1.24%
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Net Investment loss
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.31pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">(0.79%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.91pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">(0.44%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.34pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">(0.52%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:14.69pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">(0.68%)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.62pt; padding-left:15.17pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">(0.80%)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6.5pt; padding-top:1.62pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:52.30%; background-color: #F0F0F0;">Portfolio turnover
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.59pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.23%; background-color: #F0F0F0;">73%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.30pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.33%; background-color: #F0F0F0;">46%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.39pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.26%; background-color: #F0F0F0;">35%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:25.24pt; padding-right:6.5pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.27%; background-color: #F0F0F0;">42%
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:26.03pt; padding-right:12pt; padding-top:1.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.39%; background-color: #F0F0F0;">62%
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Effective October 27, 2023, abrdn Inc. became the investment adviser of the Fund. Prior to October 27, 2023, the Fund was managed by Tekla Capital Management, LLC. Members of the portfolio management
team from&#xa0;Tekla joined abrdn Inc., and continue to manage the Fund.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(b)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Beginning with the year ended September 30, 2023, the Fund&#x2019;s financial statements were audited by KPMG LLP. Previous years were audited by a different independent registered public accounting
firm.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(c)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Based on average shares outstanding.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(d)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">Total investment return based on market value is calculated assuming that shares of the Fund&#x2019;s common stock were purchased at the closing market price as of the beginning of the period, dividends,
capital gains and other distributions were reinvested as provided for in the Fund&#x2019;s dividend reinvestment plan and then sold at the closing market price per share on the last day of the period. The computation
does not reflect any sales commission investors may incur in purchasing or selling shares of the Fund. The total investment return based on the net asset value is similarly computed except that the Fund&#x2019;s net
asset value is substituted for the closing market value.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.23%">(e)
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.32%">The total return shown above includes the impact of financial statement rounding of the NAV per share and/or financial statement adjustments.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">See accompanying Notes to
Financial Statements.</div>
</div>
<div style="margin-top:118pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">16
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">1.&#xa0;&#xa0;Organization</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">abrdn Life Sciences
Investors (the "Fund") is a Massachusetts business trust formed on February 20, 1992, and registered under the Investment Company Act of 1940 as a non-diversified closed-end management investment company. The Fund
commenced operations on May 8, 1992. The Fund&#x2019;s investment objective is to seek long-term capital appreciation by investing primarily in equity and related securities (including securities subject to legal or
contractual restrictions on resale) of U.S. and foreign companies principally engaged in the development, production or distribution of products or services related to scientific advances in life sciences (including
biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices, supplies and other healthcare-related subsectors), agriculture
and environmental management ("Life Sciences Companies"). The Fund invests primarily in securities of public and private companies that are believed by the Fund&#x2019;s investment adviser, abrdn Inc. (the "Investment
Adviser," the "Adviser" or "Aberdeen") to have significant potential for above-average growth. The Fund may invest up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in
Western Europe, Canada and Japan, and securities of U.S. issuers that are traded primarily in foreign markets.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">2.&#xa0;&#xa0;Summary of Significant
Accounting Policies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund is an investment
company and accordingly follows the investment company accounting and reporting guidance of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification Topic 946 Financial Services-Investment
Companies. The following is a summary of significant accounting policies followed by the Fund in the preparation of its financial statements. The policies conform to generally accepted accounting principles in the
United States of America ("U.S.&#xa0;GAAP"). The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of
contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses for the period. Actual results could differ from those estimates. The accounting records of
the Fund are maintained in U.S. Dollars and the U.S. Dollar is used as both the functional and reporting currency.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Security Valuation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund values its
securities at fair value, consistent with regulatory requirements. "Fair value" is defined in the Fund's Valuation and Liquidity Procedures as the price that could be received to sell an asset or paid to transfer a
liability in an orderly transaction between willing market participants without a compulsion to transact at the measurement date, also referred to as market value. Pursuant to Rule 2a-5 under the 1940 Act, the Board
designated Aberdeen as the</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">valuation designee ("Valuation Designee")
for the Fund to perform the fair value determinations relating to Fund investments for which market quotations are not readily available or deemed&#xa0;unreliable and the Fund's investments in securities of early
and/or later stage financing of a privately held companies ("Venture Capital Securities").</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In accordance with the
authoritative guidance on fair value measurements and disclosures under U.S. GAAP, the Fund discloses the fair value of its investments using a three-level hierarchy that classifies the inputs to valuation techniques
used to measure the fair value. The hierarchy assigns Level 1, the highest level, measurements to valuations based upon unadjusted quoted prices in active markets for identical assets, Level 2 measurements to
valuations based upon other significant observable inputs, including adjusted quoted prices in active markets for similar assets, and Level 3, the lowest level, measurements to valuations based upon unobservable
inputs that are significant to the valuation. Inputs refer broadly to the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk, for example, the risk
inherent in a particular valuation technique used to measure fair value including a pricing model and/or the risk inherent in the inputs to the valuation technique. Inputs may be observable or unobservable. Observable
inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability, which are based on market data obtained from sources independent of the reporting entity. Unobservable
inputs are inputs that reflect the reporting entity&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in
the circumstances. A financial instrument&#x2019;s level within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Open-end mutual funds are
valued at the respective NAV as reported by such company. The prospectuses for the registered open-end management investment companies in which the Fund invests explain the circumstances under which those companies
will use fair value pricing and the effects of using fair value pricing. Closed-end funds and exchange-traded funds ("ETFs") are valued at the market price of the security at the Valuation Time (defined below). A
security using any of these pricing methodologies is generally determined to be a Level 1 investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Long-term debt and other
fixed-income securities are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service provider. If there are no current day bids, the security is valued at the
previously applied bid. Pricing services generally price debt securities assuming orderly transactions of an institutional &#x201c;round lot&#x201d; size and the strategies employed by the Valuation Designee generally
trade in round lot sizes. In certain circumstances, some trades may occur in smaller &#x201c;odd lot&#x201d; sizes which may be effected at lower, or higher, prices than institutional round lot</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:24.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">17
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">trades. Short-term debt securities (such as
commercial paper and U.S. treasury bills) having a remaining maturity of 60 days or less are valued at the last quoted or evaluated bid price on the valuation date provided by an independent pricing service, or on the
basis of amortized cost, if it represents the best approximation of fair value. Debt and other fixed-income securities are generally determined to be Level 2 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Equity securities that are
traded on an exchange are valued at the last quoted sale price or the official close price on the principal exchange on which the security is traded at the &#x201c;Valuation Time&#x201d; subject to application, when
appropriate, of the valuation factors described in the paragraph below. Under normal circumstances, the Valuation Time is as of the close of regular trading on the New York Stock Exchange ("NYSE") (usually 4:00 p.m.
Eastern Time). In the absence of a sale price, the security is valued at the mean of the bid/ask price quoted at the close on the principal exchange on which the security is traded. Securities traded on NASDAQ are
valued at the NASDAQ official closing price.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Convertible preferred shares,
warrants or convertible note interests in Venture Capital Securities, milestone interests, and other restricted securities are typically valued in good faith, based upon the recommendations made by&#xa0;the Valuation
Designee pursuant to fair valuation policies and procedures approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Derivative instruments are
valued at fair value. Exchange-traded futures are generally Level 1 investments and centrally cleared swaps and forwards are generally Level 2 investments. Forward foreign currency contracts are generally valued based
on the bid price of the forward rates and the current spot rate. Forward exchange rate quotations are available for scheduled settlement dates, such as 1-, 3-, 6-, 9- and 12-month periods. An interpolated valuation is
derived based on the actual settlement dates of the forward contracts held. Futures contracts are valued at the settlement price or at the last bid price if no settlement price is available. Swap agreements are
generally valued by an approved pricing agent based on the terms of the swap agreement (including future cash flows). When market quotations or exchange rates are not readily available, or if the Adviser concludes
that such market quotations do not accurately reflect fair value, the fair value of the Fund&#x2019;s assets are determined in good faith in accordance with the Valuation Procedures.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign equity securities
that are traded on foreign exchanges that close prior to the Valuation Time are valued by applying valuation factors to the last sale price or the mean price as noted above. Valuation factors are provided by an
independent pricing service provider. These valuation factors are used when pricing the Fund's portfolio holdings to estimate market movements between the time foreign markets close and the time the Fund values such
foreign securities. These valuation factors are based on inputs such as depositary receipts, indices, futures, sector indices/ETFs, exchange</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">rates, and local exchange opening and
closing prices of each security. When prices with the application of valuation factors are utilized, the value assigned to the foreign securities may not be the same as quoted or published prices of the securities on
their primary markets. A security that applies a valuation factor is generally determined to be a Level 2 investment because the exchange-traded price has been adjusted. Valuation factors are not utilized if the
independent pricing service provider is unable to provide a valuation factor or if the valuation factor falls below a predetermined threshold; in such case, the security is determined to be a Level 1 investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Short-term investments are
comprised of cash and cash equivalents invested in short-term investment funds which are redeemable daily. The Fund sweeps available cash into the State Street Institutional&#xa0;U.S. Government Money Market Fund,
which has elected to qualify as a &#x201c;government money market fund&#x201d; pursuant to Rule 2a-7 under the 1940 Act, and has an objective, which is not guaranteed, to maintain a&#xa0;$1.00 per share NAV. Generally,
these investment types are&#xa0;categorized as Level 1 investments.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the event that a
security&#x2019;s, other than a Venture Capital Security, market quotations are not readily available or are deemed unreliable (for reasons other than because the foreign exchange on which it trades closes before the
Valuation Time), the security is valued at fair value as determined by the Valuation Designee, taking into account the relevant factors and surrounding circumstances using valuation policies and procedures approved by
the Board. A security that has been fair valued by the Valuation Designee&#xa0;may be classified as Level 2 or Level 3 depending on the nature of the inputs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture Capital Securities
are valued based on a consideration of relevant factors, including both observable and&#xa0;unobservable inputs. Observable and unobservable inputs considered may include (i) the existence of any contractual
restrictions on the disposition of securities; (ii) information obtained from the company, which may include an analysis of the company's financial statements, products, intended markets or technologies; (iii) the
price of the same or similar security negotiated at arm's length in an issuer's completed subsequent round of financing; (iv) the price and extent of public trading in similar securities of the issuer or of comparable
companies; or (v) a probability and time value adjusted analysis of contractual terms. Where available and appropriate, multiple valuation methodologies are applied to confirm fair value.&#xa0;Significant unobservable
inputs are often used in the fair value determination. A significant change in any of these inputs may result in a significant change in the fair value measurement. Additionally, changes in the market environment and
other events that may occur over the life of the investments may cause the gains or losses ultimately realized on these investments to be different from the valuations used at the date of these
financial&#xa0;statements.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:20.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">18
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">The three-level hierarchy of inputs is
summarized below:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Level 1 - quoted prices
(unadjusted) in active markets for identical investments;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Level 2 - other significant observable
inputs (including valuation factors, quoted prices for similar securities, interest rates, prepayment speeds, and credit risk, etc.); or</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">Level 3 - significant unobservable inputs
(including the Fund&#x2019;s own assumptions in determining the fair value of investments).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Level 3 investments are
valued using significant unobservable inputs. The derived value of a Level 3 investment may not represent the value which is received upon disposition and this could impact the results of operations.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a
summary of the inputs used as of September 30, 2025 in valuing the Fund's investments and other financial instruments at fair value. The inputs or methodology used for valuing securities are not necessarily an
indication of the risk associated with investing in those securities. Please refer to the Portfolio of Investments for a detailed breakout of the security types:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:35.62%">Investments, at Value
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%">Level 1 &#x2013; Quoted<br>
Prices
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%">Level 2 &#x2013; Other Significant<br>
Observable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%">Level 3 &#x2013; Significant<br>
Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:70.49%; background-color: #F0F0F0;" colspan="3">Assets
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.75pt; text-align:right; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:49.63%; background-color: #F0F0F0;" colspan="2">Investments in Securities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:0.44pt"></font>453,725,768
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:35.99pt"></font>&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:19.91pt"></font>23,406
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">$<font style="padding-left:4.56pt"></font>453,749,174
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:54.60pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.95pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.29pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">33,104,683
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.68pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%; background-color: #F0F0F0;">33,104,683
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:54.60pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.95pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15.49pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">13,706,583
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.89pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%; background-color: #F0F0F0;">13,706,583
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:35.62%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:54.60pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.45pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">2,038,106
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:21.32pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">1,060,917
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:21.22pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%; background-color: #F0F0F0;">3,099,023
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:54.60pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:46.95pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:19.86pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">2,043,527
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:22.25pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%; background-color: #F0F0F0;">2,043,527
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Short-Term Investment
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:22.26pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">8,417,353
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:46.95pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:53.95pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:24.00pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%; background-color: #F0F0F0;">8,417,353
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Total Investments
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$462,143,121
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$2,038,106
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:2.67pt"></font>49,939,116
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.47%; background-color: #F0F0F0;">$514,120,343
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:43.63pt"></font><font style="font-weight:bold">&#x2013;</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:35.99pt"></font><font style="font-weight:bold">&#x2013;</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:32.26pt"></font><font style="font-weight:bold">189</font>
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">$<font style="padding-left:34.66pt"></font><font style="font-weight:bold">189</font>
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Total Investment Assets
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.01%; background-color: #F0F0F0;">$462,143,121
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:20.87%; background-color: #F0F0F0;">$2,038,106
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:17.03%; background-color: #F0F0F0;">$49,939,305
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">$<font style="padding-left:0.95pt"></font>514,120,532
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:70.49%; background-color: #F0F0F0;" colspan="3">Liabilities
</td><td style="line-height:9.5pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.38pt; text-align:right; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:49.63%; background-color: #F0F0F0;" colspan="2">Other Financial Instruments
</td><td style="line-height:9.5pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:12.42pt"></font>(434,456)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:35.99pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.98pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">$<font style="padding-left:14.16pt"></font>(434,456)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.62%; background-color: #F0F0F0;">Total Investment Liabilities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.01%; background-color: #F0F0F0;">$<font style="padding-left:9.72pt"></font>(434,456)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:20.87%; background-color: #F0F0F0;">$<font style="padding-left:35.78pt"></font>&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.03%; background-color: #F0F0F0;">$<font style="padding-left:42.77pt"></font>&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.47%; background-color: #F0F0F0;">$<font style="padding-left:11.46pt"></font>(434,456)
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
</div>
</div>
<div style="padding-top:297pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">19
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.26%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:100.00%" colspan="7">Rollforward of Level 3 Fair Value Measurements<br>
For the Year Ended September 30, 2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%">Investments<br>
in Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Balance<br>
as of<br>
September 30,<br>
2024
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%">Net Realized<br>
Gain (Loss)<br>
and Change<br>
in Unrealized<br>
Appreciation/<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.10%">Net<br>
Purchases<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%">Net<br>
Sales<br>
and<br>
conversions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Balance<br>
as of<br>
September 30,<br>
2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Net Change in<br>
Unrealized<br>
Appreciation/<br>
Depreciation<br>
from<br>
Investments<br>
Held at<br>
September 30,<br>
2025
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Common Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:3.5pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.39pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$133,482
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.44pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$3,544
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:40.93pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">$&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10.15pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$(118,126)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:24.61pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$18,900
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.88pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$(91,548)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.59pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">13
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:47.33pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">13
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:33.35pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">5,346
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:29.67pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(853)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:33.77pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">4,493
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:29pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,191
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Convertible Notes
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.15pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,062,330
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.02pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">257,586
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:20.59pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,319,916
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Health Care Providers &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:51.20pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">75,939
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:29.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">75,939
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:23.30pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">206,589
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.39pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">441,083
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:26.29pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">647,672
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.46pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">15,621,446
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.37pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">770,712
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.21pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">3,936,282
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">(778,697)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.28pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">19,549,743
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.70pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">770,712
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Health Care Equipment &amp; Supplies
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.49pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:46.24pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">42
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:11.66pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">12,030,060
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.37pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(605,193)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.02pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">2,130,031
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.00pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">13,554,898
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.70pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">(605,193)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Milestone Interests
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.18pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,399,863
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:17.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">150,337
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.03pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">(94,623)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:19.72pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,455,577
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">150,337
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:12.20pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">12,362,480
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">(111,474)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:14.55pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">12,251,006
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.17pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">(111,474)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Warrants
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Biotechnology
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:51.20pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:10pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">1,060,914
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:18.57pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,060,914
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:9.33pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">1,060,914
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Health Care Providers &amp; Services
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:51.20pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:51.95pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Pharmaceuticals
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:50.48pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:51.22pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:4pt; padding-right:4pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:32.86%; background-color: #F0F0F0;">Other Assets
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.36pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">189
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:43.38pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.23%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:45.89pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.10%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:41.84pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.91%; background-color: #F0F0F0;">&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:42.11pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">189
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:42.71pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">&#x2013;
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:32.86%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$42,821,843
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.23%; background-color: #F0F0F0;">$1,267,987
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.10%; background-color: #F0F0F0;">$6,840,921
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.91%; background-color: #F0F0F0;">$(991,446)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$49,939,305
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">$1,174,939
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:right; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.85%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%">Fair Value at<br>
September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.07%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.15%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if Input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:14pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:10.85%; background-color: #F0F0F0;">Common Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$13
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.07%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.15%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increases
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:10.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$23,393
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.07%; background-color: #F0F0F0;">0.00% - 46.00%<br>
0.25 - 4.25 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.15%; background-color: #F0F0F0;">21.76%<br>
4.19 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Increases<br>
Decreases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:14pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:10.85%; background-color: #F0F0F0;">Convertible Notes
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$2,043,527
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.07%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.15%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:14pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:10.85%; background-color: #F0F0F0;">Convertible Preferred Stocks
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$31,684,609
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.07%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.15%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increases
</td></tr></table>
</div>
</div>
<div style="margin-top:50.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">20
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:85.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4pt; padding-right:5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.85%">Description
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%">Fair Value at<br>
September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.44%">Valuation Technique (s)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.05%">Unobservable Inputs
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:14.07%">Range
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.15%">Weighted<br>
Average
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:5pt; padding-right:4pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%">Relationship<br>
Between<br>
Fair Value<br>
and Input;<br>
if Input value<br>
increases then<br>
Fair Value:
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:9.5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; vertical-align:top; width:10.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$852,694
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Timing of events<br>
Implied market volatility<br>
Risk free rate<br>
Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.07%; background-color: #F0F0F0;">3.00 years<br>
111.65%<br>
3.72%<br>
N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.15%; background-color: #F0F0F0;">3.00 years<br>
111.65%<br>
3.72%<br>
N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decreases<br>
Decreases<br>
Decreases<br>
Increases
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:10.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$567,380
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.07%; background-color: #F0F0F0;">3.84% - 4.27%<br>
1.84% - 90.00%<br>
1.00 - 11.50 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.15%; background-color: #F0F0F0;">3.98%<br>
24.28%<br>
5.42 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decreases<br>
Increases<br>
Decreases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:14pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:10.85%; background-color: #F0F0F0;">Milestone Interests
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$13,706,583
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.07%; background-color: #F0F0F0;">3.70% - 10.00%<br>
0.00% - 81.00%<br>
0.00 - 8.00 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.15%; background-color: #F0F0F0;">4.48%<br>
6.87%<br>
3.09 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decreases<br>
Increases<br>
Decreases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:10.85%; background-color: #F0F0F0;">Warrants
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$3
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Market approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Transaction Price<sup style="font-size:85%; font-style:Normal; text-transform:none">(a)</sup>
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:14.07%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:9.15%; background-color: #F0F0F0;">N/A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.96%; background-color: #F0F0F0;">Increases
</td></tr>
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:10.85%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$1,060,914
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income Approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount Rate<br>
Implied market volatility<br>
Timing of events<br>
Marketability Discount
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:14.07%; background-color: #F0F0F0;">3.74% - 3.93%<br>
0.48%<br>
0.25 - 4.68 years<br>
0.75%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:9.15%; background-color: #F0F0F0;">3.82%<br>
0.48%<br>
2.79 years<br>
0.75%
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; width:11.96%; background-color: #F0F0F0;">Decreases<br>
Decreases<br>
Decreases<br>
Decreases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:10.85%; background-color: #F0F0F0;">Other Assets
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$189
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.44%; background-color: #F0F0F0;">Income approach
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:19.05%; background-color: #F0F0F0;">Discount rate<br>
Probability of events<br>
Timing of events
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:14.07%; background-color: #F0F0F0;">4.04%<br>
5.00%<br>
6.25 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.15%; background-color: #F0F0F0;">4.04%<br>
5.00%<br>
6.25 years
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">Decreases<br>
Increases<br>
Decreases
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:10.85%; background-color: #F0F0F0;">Total
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$49,939,305
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:18.44%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:left; vertical-align:top; width:19.05%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:14.07%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:9.15%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4pt; padding-top:1.75pt; text-align:right; vertical-align:bottom; width:11.96%; background-color: #F0F0F0;">&#xa0;
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.47%">(a)
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.09%">The valuation technique used as a basis to approximate fair value of these investments is based on a transaction price or&#xa0;subsequent financing rounds.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Restricted
Securities:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Restricted securities are privately-placed
securities whose resale is restricted under U.S. securities laws. The Fund may invest in restricted securities, including unregistered securities eligible for resale without registration pursuant to Rule 144A and
privately-placed securities of U.S. and non-U.S. issuers offered outside the U.S. without registration pursuant to Regulation S under the Securities Act of 1933, as amended (the "1933 Act"). Rule 144A securities may
be freely traded among certain qualified institutional investors, such as the Fund, but resale of such securities in the U.S. is permitted only in limited circumstances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Foreign Currency
Translation:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Foreign securities,
currencies, and other assets and liabilities denominated in foreign currencies are translated into U.S. Dollars at the exchange rate of said currencies against the U.S. Dollar, as of the Valuation Time, as provided by
an independent pricing service approved by the Board.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Foreign currency amounts are
translated into U.S. Dollars on the following basis:</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">(i) fair value of investment securities, other
assets and liabilities &#x2013; at the current daily rates of exchange at the Valuation Time; and</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">(ii) purchases and sales of
investment securities, income and expenses &#x2013; at the relevant rates of exchange prevailing on the respective dates of such transactions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund does not isolate
that portion of gains and losses on investments in equity securities due to changes in the foreign exchange rates from the portion due to changes in market prices of equity securities. Accordingly, realized and
unrealized foreign currency gains and losses with respect to such securities are included in the reported net realized and unrealized gains and losses on investment transactions balances.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net unrealized currency gains
or losses from valuing foreign currency denominated assets and liabilities at period end exchange rates are reflected as a component of net unrealized appreciation/depreciation</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:15.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">21
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">in value of investments, and translation of
other assets and liabilities denominated in foreign currencies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Net realized foreign exchange
gains or losses represent foreign exchange gains and losses from transactions in foreign currencies and forward foreign currency contracts, exchange gains or losses realized between the trade date and settlement date
on security transactions, and the difference between the amounts of interest and dividends recorded on the Fund&#x2019;s books and the U.S. Dollar equivalent of the amounts actually received.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign security and currency
transactions may involve certain considerations and risks not typically associated with those of domestic origin, including unanticipated movements in the value of the foreign currency relative to the U.S. Dollar.
Generally, when the U.S. Dollar rises in value against foreign currency, the Fund's investments denominated in that foreign currency will lose value because the foreign currency is worth fewer U.S. Dollars; the
opposite effect occurs if the U.S. Dollar falls in relative value.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Rights Issues and
Warrants:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Rights issues give the
right, normally to existing shareholders, to buy a proportional number of additional securities at a given price (generally at a discount) within a fixed period (generally a short-term period) and are offered at the
company&#x2019;s discretion. Warrants are securities that give the holder the right to buy common stock at a specified price for a specified period of time. Rights issues and warrants are speculative and have no value
if they are not exercised before the expiration date. Rights issues and warrants are valued at the last sale price on the exchange on which they are traded.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Options:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">An option contract is a
contract in which the writer (seller) of the option grants the buyer of the option, upon payment of a premium, the right to purchase from (call option) or sell to (put option) the</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">writer a designated instrument at a
specified price within a specified period of time. Certain options, including options on indices, will require cash settlement by the Fund if the option is exercised.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s obligation
under an exchange traded written option or investment in an exchange traded purchased option is valued at the last sale price, or in the absence of a sale, the mean between the closing bid and asked prices. Gain or
loss is recognized when the option contract expires, is exercised or is closed.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the Fund writes a covered
call option, the Fund foregoes, in exchange for the premium, the opportunity to profit during the option period from an increase in the market value of the underlying security above the exercise price. If the Fund
writes a put option it accepts the risk of a decline in the market value of the underlying security below the exercise price. Over-the-counter options have the risk of the potential inability of counterparties to meet
the terms of their contracts. The Fund&#x2019;s maximum exposure to purchased options is limited to the premium initially paid. In addition, certain risks may arise upon entering into option contracts including the
risk that an illiquid secondary market will limit the Fund&#x2019;s ability to close out an option contract prior to the expiration date and that a change in the value of the option contract may not correlate exactly
with changes in the value of the securities or currencies hedged.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">All options on securities and
securities indices written by the Fund are required to be covered. When the Fund writes a call option, this means that during the life of the option the Fund may own or have the contractual right to acquire the
securities subject to the option or may maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the market value of the securities underlying the
option. When the Fund writes a put option, this means that the Fund will maintain with the Fund&#x2019;s custodian in a segregated account appropriate liquid securities in an amount at least equal to the exercise price
of the option.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:8.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Summary of Derivative
Instruments:</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The&#xa0;Fund may
use derivatives for various purposes as noted above. The following is a summary of the fair value of derivative instruments, not accounted for as hedging instruments, as of September 30, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:35.44%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:64.57%" colspan="7">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:35.44%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.71%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%">Other
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.71%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:100.00%; background-color: #F0F0F0;" colspan="8">Liabilities:
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:100.00%; background-color: #F0F0F0;" colspan="8">Unrealized depreciation on:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:35.44%; background-color: #F0F0F0;">Written Options, fair value
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.71%; background-color: #F0F0F0;">$<font style="padding-left:2.38pt"></font>434,456
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:6.55%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.71%; background-color: #F0F0F0;">$<font style="padding-left:2.38pt"></font>434,456
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:35.44%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.71%; background-color: #F0F0F0;">$434,456
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:6.55%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.71%; background-color: #F0F0F0;">$434,456
</td></tr></table>
</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
</div>
<div style="padding-top:26.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">22
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The effect of derivative
instruments on the Statement of Operations for the fiscal year ended September 30, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:9pt; padding-bottom:3pt; padding-right:6pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:41.45%">&#xa0;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:58.56%" colspan="6">Risk Exposure Category
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:0pt; padding-bottom:3pt; padding-right:6pt; padding-top:2.62pt; text-align:left; vertical-align:bottom; width:41.45%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Interest<br>
Rate<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Foreign<br>
Currency<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%">Credit<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%">Equity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%">Commodity<br>
Contracts
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.62pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.98%">Total
</td></tr>
<tr style="page-break-inside:avoid"><td style="padding-right:6pt; padding-top:2.75pt; text-align:left; vertical-align:top; width:100%; background-color: #F0F0F0;" colspan="7">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100%; background-color: #F0F0F0;" colspan="7">Realized Gain/(Loss) on Derivatives Recognized<br>
as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:41.45%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%; background-color: #F0F0F0;">$<font style="padding-left:2.75pt"></font>1,127,357
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%; background-color: #F0F0F0;">$<font style="padding-left:2.75pt"></font>1,127,357
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:41.45%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.98%; background-color: #F0F0F0;">$1,127,357
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.98%; background-color: #F0F0F0;">$1,127,357
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-left:16pt; padding-right:6pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:100%; background-color: #F0F0F0;" colspan="7">Net Change in Unrealized Appreciation/Depreciation on<br>
Derivatives Recognized as a Result of Operations:
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:41.45%; background-color: #F0F0F0;">Written Options
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.28%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%; background-color: #F0F0F0;">$<font style="padding-left:3.29pt"></font>(272,819)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.75%; background-color: #F0F0F0;">$<font style="padding-left:0.21pt"></font>&#x2013;
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%; background-color: #F0F0F0;">$<font style="padding-left:3.29pt"></font>(272,819)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:41.45%; background-color: #F0F0F0;">Total
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:9.28%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%; background-color: #F0F0F0;">$<font style="padding-left:0.67pt"></font>(272,819)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.75%; background-color: #F0F0F0;">$&#x2013;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:2.25pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:9.98%; background-color: #F0F0F0;">$<font style="padding-left:0.67pt"></font>(272,819)
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Information about derivatives reflected as
of the date of this report is generally indicative of the type of activity for the fiscal year ended September 30, 2025. The table below summarizes the weighted average values of derivatives holdings for the Fund
during the fiscal year ended September 30, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:68.10%">Derivative
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.60%">Average Monthly<br>
Notional Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:68.10%; background-color: #F0F0F0;">Written Options Contracts
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:29.60%; background-color: #F0F0F0;">$153,728
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Security Transactions,
Investment Income and Expenses:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Security transactions are
recorded on the trade date. Realized and unrealized gains/(losses) from security and currency transactions are calculated on the identified cost basis. Dividend income and corporate actions are recorded generally on
the ex-date, except for certain dividends and corporate actions which may be recorded after the ex-date, as soon as the Fund acquires information regarding such dividends or corporate actions. Interest income and
expenses are recorded on an accrual basis.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Distributions:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has a managed
distribution policy to pay distributions from net investment income supplemented by net realized capital gains and return of capital distributions, if necessary, on a quarterly basis. The managed distribution policy
is subject to regular review by the Board. The Fund will also declare and pay distributions at least annually from net realized gains on investment transactions and net realized foreign exchange gains, if any.
Dividends and distributions to shareholders are recorded on the ex-dividend date. Dividends and distributions to shareholders are determined in accordance with federal income tax regulations, which may differ from
U.S.&#xa0;GAAP.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Federal Income Taxes:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to
continue to qualify as a &#x201c;regulated investment company&#x201d; ("RIC") by complying with the provisions available to certain investment companies, as defined in Subchapter M of the Internal Revenue Code of 1986,
as amended (the "Code"), and to make distributions of net investment income and net realized capital gains sufficient to relieve the Fund from all federal income taxes. Therefore, no federal income tax provision is
required.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund recognizes the tax
benefits of uncertain tax positions only where the position is &#x201c;more likely than not&#x201d; to be sustained assuming examination by tax authorities. Management of the Fund has concluded that there are no
significant uncertain tax positions that would require recognition in the financial statements. Since tax authorities can examine previously filed tax returns, the Fund's U.S. federal and state tax returns for each of
the most recent four fiscal years up to the most recent fiscal year ended September 30, 2025 are subject to such review.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Milestone Interests</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund holds financial
instruments which reflect the current value of future milestone payments the Fund may receive as a result of contractual obligations from other parties. The value of such payments are adjusted to reflect the estimated
risk based on the relative uncertainty of both the timing and the achievement of individual milestones. A risk to the Fund is that the milestones will not be achieved and no payment will be received by the Fund. The
milestone interests were received as part of the proceeds from the sale of six private companies. Any payments&#xa0;received are treated as a reduction of the cost basis of the milestone interests with payments
received in excess of the cost basis treated as a realized gain. The contractual obligations with respect to the milestone interests provide for</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:28.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">23
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">payments at various stages of the
development of Afferent, Amolyt, Amphivena, Ethismos Research, Invetx and Neurovance principal product candidate as of the date of the sale.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The following is a summary of
the impact of the milestone interests on the financial statements as of and for the fiscal year ended September 30, 2025:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100.00%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:74.83%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Milestone interests, at value
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:22.87%; background-color: #F0F0F0;">$13,706,583
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:74.83%; background-color: #F0F0F0;">Statement of Assets and Liabilities, Total distributable earnings
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.87%; background-color: #F0F0F0;">$<font style="padding-left:3.07pt"></font>10,186,156
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:16pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-indent:-10pt; text-transform:none; vertical-align:top; width:74.83%; background-color: #F0F0F0;">Statement of Operations, Change in unrealized appreciation/depreciation
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.87%; background-color: #F0F0F0;">$<font style="padding-left:15.41pt"></font>38,862
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">j.&#xa0;&#xa0;Other Assets</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Other assets in the
Statement of Assets and Liabilities consists of amounts due to the Fund at various times in the future in connection with the sale of investments in one private company.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">3.&#xa0;&#xa0;Agreements and Transactions
with Affiliates</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Investment Advisory and
Other Affiliated Fees</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Aberdeen serves as the
Fund&#x2019;s Investment Adviser pursuant to an investment advisory agreement (the &#x201c;Advisory Agreement&#x201d;) with the Fund. Aberdeen also provides administration services under the same agreement. The Adviser
is a wholly-owned indirect subsidiary of Aberdeen Group plc. In rendering management services, the Adviser may use the resources of investment advisor subsidiaries of Aberdeen Group plc. These affiliates have entered
into procedures pursuant to which investment professionals from affiliates may render portfolio management and research services as associated persons of the Adviser. As compensation for its services to the Fund, the
Adviser receives an annual investment advisory fee at an annual rate of (i) 2.50% of the average net assets for the month of its venture capital and other restricted securities up to 25% of net assets and (ii) for all
other net assets, 0.98% of the average net assets up to $250 million, 0.88% of the average net assets for the next $250 million, 0.80% of the average net assets for the next $500 million and 0.70% of the average net
assets thereafter. Based on the Portfolio of Investments as of September 30, 2025 the aggregate fee would not exceed a rate when annualized of 1.36%. For the fiscal year ended September 30, 2025, the Fund paid the
Adviser $4,521,763.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Effective upon the close of
business on October 27, 2023, the Adviser as Adviser of the Fund, entered into a written contract with the Fund to limit the total ordinary operating expenses of the Fund (excluding</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">leverage costs, interest, taxes, brokerage
commissions, acquired fund fees and expenses and any non-routine expenses) from exceeding 1.36% of the average daily net assets of the Fund on an annualized basis for two years (the &#x201c;Expense Limitation
Agreement&#x201d;). The Expense Limitation Agreement terminated on October 27, 2025. For the fiscal year ended September 30, 2025 the Adviser did not waive any Fund's expenses pursuant to the Expense Limitation
Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Investor Relations:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Effective March 1, 2024,
under the terms of the Investor Relations Services Agreement, Aberdeen is compensated to provide and may pay third parties to provide investor relations services to the Fund and certain other funds advised by Aberdeen
or its affiliates as part of an Investor Relations Program. Under the Investor Relations Services Agreement, the Fund owes a portion of the fees related to the Investor Relations Program (the "Fund's Portion").
However, investor relations services fees are limited by Aberdeen so that the Fund will only pay up to an annual rate of 0.05% of the Fund's average weekly net assets. Any difference between the capped rate of 0.05%
of the Fund's average weekly net assets and the Fund's Portion is paid for by Aberdeen.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pursuant to the terms of the
Investor Relations Services Agreement, Aberdeen (or third parties engaged by Aberdeen), among other things, provides objective and timely information to shareholders based on publicly-available information; provides
information efficiently through the use of technology while offering shareholders immediate access to knowledgeable investor relations representatives; develops and maintains effective communications with investment
professionals from a wide variety of firms; creates and maintains investor relations communication materials such as fund manager interviews, films and webcasts, publishes white papers, magazine articles and other
relevant materials discussing the Fund's investment results, portfolio positioning and outlook; develops and maintains effective communications with large institutional shareholders; responds to specific shareholder
questions; and reports activities and results to the Board and management detailing insight into general shareholder sentiment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the fiscal year ended
September 30, 2025, the Fund incurred investor relations fees of approximately $98,412. For the fiscal year ended September 30, 2025, Aberdeen did not contribute to the investor relations fees for the Fund because the
Fund&#x2019;s contribution was below 0.05% of the Fund&#x2019;s average weekly net assets on an annual basis.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">4.&#xa0;&#xa0;Investment
Transactions</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">Purchases and sales
of investment securities (excluding short-term securities) for the fiscal year ended September 30, 2025, were $314,113,473 and $339,321,195, respectively.</div>
</div>
</div>
<div style="padding-top:42.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">24
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">5.&#xa0;&#xa0;Capital</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund is authorized to
issue an unlimited number of common shares of beneficial interest at par value $0.01 per common share. As of September 30, 2025, there were 29,598,692 shares of common stock issued and outstanding.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table shows the
shares issued by the Fund as a part of a quarterly distribution to shareholders during the fiscal year ended September 30, 2025.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:88.10%">Payment Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.90%">Shares Issued
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">January 10, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">404,917
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">March 31, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">406,100
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">June 30, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">398,051
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:88.10%; background-color: #F0F0F0;">September 30, 2025
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.90%; background-color: #F0F0F0;">328,225
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">6.&#xa0;&#xa0;Open Market Repurchase
Program</div>
</div>
<div style="margin-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Board has approved an open market
repurchase and discount management policy (the &#x201c;Program&#x201d;). The Program allows the Fund to purchase, in the open market, up to 12% of its outstanding common shares in the fiscal year, with the amount and
timing of any repurchase determined at the discretion of the Fund's investment adviser. Such purchases may be made opportunistically at certain discounts to NAV per share in the reasonable judgment of management based
on</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">historical discount levels and current
market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis. For the fiscal year ended September 30, 2025, the Fund did not repurchase any shares through the
Program.&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">On a quarterly basis, the Board
will receive information on any transactions made pursuant to this policy during the prior quarter.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">7.&#xa0;&#xa0;Private
Companies and Other Restricted Securities</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The Fund may invest
in private companies and other restricted securities if these securities currently comprise 40% or less of net assets. The value of these securities represented 9.52% of the Fund&#x2019;s net assets at September 30,
2025.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">At September 30,
2025, the Fund had a commitment of $4,227,068 relating to additional investments in three private companies.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The following table
details the acquisition date, cost, carrying value per unit, and value of the Fund&#x2019;s private companies and other restricted securities at September 30, 2025. The Fund on its own does not have the right to demand
that such securities be registered.</div>
</div>
</div>
<div style="padding-top:304pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">25
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:10.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.22%">Security
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%">Acquisition<br>
Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%">Cost
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%">Carrying Value<br>
per Unit
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Abcuro, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">12/19/23, 8/10/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.86pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.25%; background-color: #F0F0F0;">$1,278,310
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:9.38pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">$5.49
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.38pt; padding-right:6pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.32%; background-color: #F0F0F0;">$1,274,994
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Abcuro, Inc., Series C1 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">2/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.19pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">310,717
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.04
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.45pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">310,407
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Afferent Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/27/16
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">24,556
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:51.03pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Amolyt Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/12/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.10pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">684,946
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:7.61pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">157.47
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.80pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,078,585
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Amphivena Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/18/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:51.03pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/29/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.58pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">643,721
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">16.57
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:22.99pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">640,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Arbor Biotechnologies, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/27/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.57pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,604,052
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.36pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.11
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.21pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,599,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">1/24/22, 1/23/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.78pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">599,405
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.05pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.36
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.00pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">160,721
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Arkuda Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">05/16/19, 4/2/20,<br>
7/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,819,396
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.68pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.40
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.82pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">406,659
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Atalanta Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/11/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.89pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,400,664
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.02pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.80
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.22pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,400,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Aviceda Therapeutics, Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">12/17/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.12pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">229,091
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.32pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">5.76
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.61pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">224,091
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Biotheryx, Inc., Series E &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/19/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">3,206,642
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.86pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.57
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.96pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">346,453
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Chinook Therapeutics, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/14/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.53pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.32
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.62pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">18,900
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Crystalys Therapeutics, Inc., Series A
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">6/23/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.96pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,022,636
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.98pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.78pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,022,400
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">8/20/24, 1/7/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.09pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">662,599
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.70pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">661,624
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Curasen Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/20/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.79pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">4,359,339
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.72pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.48
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.53pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">4,339,083
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Curasen Therapeutics, Inc.
</td><td style="line-height:0pt; padding-bottom:1.45pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.13pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">441,083
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.49pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">441,083
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">1/21/22
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.45pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,402,998
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.04pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.72
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.02pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,399,998
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Endeavor Biomedicines, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/19/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.97pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">357,879
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.69pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">6.52
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.66pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">357,646
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Engrail Therapeutics, Inc. &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/14/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.52pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">2,251,416
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.15pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.06
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.82pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">2,250,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Ethismos Research Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/31/17
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:51.03pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Flamingo Therapeutics, Inc., Series A3 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/21/20, 10/28/20
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:16.55pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">2,469,343
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.28pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.34
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.21pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">144,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Fusion Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">7/10/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:36.61pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,791
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.27pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.38
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:33.82pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">4,493
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Glycomine, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">7/22/24, 3/26/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.49pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,594,944
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.80pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.60
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.15pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,593,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">HiberCell, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/15/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">334,898
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.85pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.46
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.52pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">333,631
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">HiberCell, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">5/5/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.98pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,607,454
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.68pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.40
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.35pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">519,063
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Warrant
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/15/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:34.97pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,294
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:52.38pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/13/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.73pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">206,589
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.09pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">206,589
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">HiberCell, Inc. &#x2014; Warrant
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/13/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:51.48pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">2
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., Series C &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">11/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.81pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">923,279
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.68pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">3.24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.84pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">920,801
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/22/20, 6/17/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.83pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">3,111,268
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.13pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.40
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.08pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">3,100,003
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Hotspot Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/12/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.41pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">323,870
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.78pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">323,870
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Incendia Therapeutics, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">8/12/21, 5/24/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,608,617
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.92
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.61pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,599,995
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/18/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:23.70pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">738,460
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.07pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">738,460
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Incendia Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/9/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:25.76pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">257,586
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:26.12pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">257,586
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Invetx, Inc. Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/4/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.30pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,305,241
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:5.01pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">103.98
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:19.77pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,455,577
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">IO Light Holdings, Inc., Series A2 &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">4/30/20, 5/17/21,<br>
9/15/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,395,847
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:46.29pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">42
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Neurovance Milestone Interest
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/20/17
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.59pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,505,684
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.88pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">328.07
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.26pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">11,172,421
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Nuvig Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">10/18/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:27.64pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">777,913
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:15.42pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">1.05
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:24.80pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">775,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Priothera Co. Ltd., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">10/07/20, 10/19/21
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.25pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,783,093
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:47.17pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">18
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Qlaris Bio, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">4/11/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.55pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,551,724
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.79
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.70pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,550,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Quell Therapeutics Ltd., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">11/29/21, 3/23/22,<br>
2/18/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:17.14pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,609,803
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.12pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">2.08
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.08pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,760,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Recode Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">1/26/24, 10/21/21,<br>
2/16/22, 9/15/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.34pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,446,891
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.56pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">9.23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:18.27pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,440,001
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Recode Therapeutics, Inc. &#x2014; Convertible Note
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/23/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.58pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">75,939
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">100.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:29.94pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">75,939
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Recode Therapeutics, Inc. &#x2014; Warrant
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">9/23/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:51.03pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">0
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Seismic Therapeutics, Inc., Series B &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/30/24
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:21.89pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">1,277,774
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:14.57pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">4.52
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:20.65pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">1,274,991
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Spectrum Pharmaceuticals, Inc. CVR &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">8/2/23
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:34.37pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">2,790
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:51.03pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">0
</td></tr></table>
</div>
</div>
<div style="margin-top:23.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">26
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:30.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:6pt; padding-right:4.5pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.22%">Security
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%">Acquisition<br>
Date
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%">Cost
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%">Carrying Value<br>
per Unit
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:3pt; padding-left:4.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%">Value
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:3.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Third Arc Bio, Inc., Series A &#x2014; Convertible Preferred Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">7/15/24, 4/24/25
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.82pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.25%; background-color: #F0F0F0;">$1,703,027
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:11.46pt; padding-right:4.5pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">$2.10
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:12.68pt; padding-right:6pt; padding-top:3.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.32%; background-color: #F0F0F0;">$1,700,000
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:49.22%; background-color: #F0F0F0;">Willow Laboratories, Inc. &#x2014; Common Stock
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.30%; background-color: #F0F0F0;">3/31/98
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:50.66pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">0
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:13.63pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:12.08%; background-color: #F0F0F0;">0.00
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.45pt; padding-left:47.38pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">13
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:4.5pt; padding-top:1.45pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:49.22%; background-color: #F0F0F0;">Total
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:15.30%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.25%; background-color: #F0F0F0;">$49,914,569
</td><td style="line-height:0pt; padding-bottom:3.5pt; padding-right:4.5pt; padding-top:1.45pt; text-align:right; vertical-align:bottom; width:12.08%; background-color: #F0F0F0;">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3.5pt; padding-left:4.5pt; padding-right:6pt; padding-top:1.45pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:11.32%; background-color: #F0F0F0;">$48,878,202
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">8.&#xa0;&#xa0;Portfolio Investment
Risks</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">a.&#xa0;&#xa0;Concentration Risk:</div>
</div>
<div style="margin-top:8.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s portfolio may be more
sensitive to, and possibly more adversely affected by, regulatory, economic or political factors or trends relating to the healthcare industries than a portfolio of companies representing a larger number of
industries. This risk is in addition to the risks normally associated with any strategy seeking capital appreciation by investing in a portfolio of equity securities. As a result of its concentration policy, the
Fund&#x2019;s investments may be subject to greater risk than a fund that has securities representing a broader range of investments and may cause the value of the Fund&#x2019;s shares to fluctuate significantly over
relatively short periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">b.&#xa0;&#xa0;Derivatives Risk
(including Options):</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Derivatives are speculative
and may hurt the Fund&#x2019;s performance. The potential benefits to be derived from the Fund&#x2019;s options strategy are dependent upon the portfolio managers&#x2019; ability to discern pricing inefficiencies and
predict trends in these markets, which decisions could prove to be inaccurate.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">c.&#xa0;&#xa0;Equity Securities
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The stock or other security
of a company may not perform as well as expected, and may decrease in value, because of factors related to the company (such as poorer than expected earnings or certain management decisions), to the industry in which
the company is engaged (such as a reduction in the demand for products or services in a particular industry) or to the market as a whole (such as periods of market volatility or instability, or general and prolonged
periods of economic decline). Holders of common stock generally are subject to more risks than holders of preferred stock or debt securities because the right to repayment of common shareholders' claims is
subordinated to that of preferred stock and debt securities upon the bankruptcy of the issuer.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">d.&#xa0;&#xa0;Key Personnel Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">There may be only a limited
number of securities professionals who have comparable experience to that of the Fund&#x2019;s existing portfolio management team in the area of healthcare companies. If one or more of the team members dies, resigns,
retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found immediately.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">e.&#xa0;&#xa0;Restricted Securities and Valuation
Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Some of the Fund&#x2019;s
investments are subject to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity. The valuation process requires an analysis of various
factors. The Fund&#x2019;s fair value methodology includes the examination of, among other things, (i) the existence of any contractual restrictions on the disposition of the securities; (ii) information obtained from
the issuer which may include an analysis of the company&#x2019;s financial statements, the company&#x2019;s products or intended markets, or the company&#x2019;s technologies; and (iii) the price of a security sold at
arm&#x2019;s length in an issuer&#x2019;s subsequent completed round of financing. As there is typically no readily available market&#xa0;value for some of the Restricted Securities in the Fund&#x2019;s portfolio, such
Restricted Securities in the Fund&#x2019;s portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant to the Fund&#x2019;s valuation policy and a consistently applied
valuation process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Fund&#x2019;s investments determined in good
faith by the Board may differ significantly from the values that would have been used had a ready market existed for the investments, and the differences could be material.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">f.&#xa0;&#xa0;Risks Associated with
the Fund&#x2019;s Option Strategy:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The ability of the Fund to
achieve its investment objective is partially dependent on the successful implementation of its option strategy. There are several risks associated with transactions in options on securities used in connection with
the Fund's option strategy. For example, there are significant differences between the securities and options markets that could result in an imperfect correlation between these markets, causing a given transaction
not to achieve its objectives. A decision as to whether, when and how to use options involves the exercise of skill and judgment, and even a well-conceived transaction may be unsuccessful to some degree because of
market behavior or unexpected events.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">As the writer of a call
option covered with a security held by the Fund, the Fund forgoes, during the option's life, the opportunities to profit from increases in the market value of the security covering the call option above the sum of the
premium and the strike price of the call but retains the risk of loss should the price of the underlying security</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">27
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">decline. As the Fund writes such covered
calls over more of its portfolio, its ability to benefit from capital appreciation becomes more limited. To the extent the Fund writes call options that are not fully covered by securities in its portfolio (such as
calls on an index or sector), it will lose money if the portion of the security or securities underlying the option that is not covered by securities in the Fund's portfolio appreciate in value above the exercise
price of the option by an amount that exceeds the premium received on the option plus the exercise price of the option. The amount of this loss theoretically could be unlimited. The writer of an option has no control
over the time when it may be required to fulfill its obligations as a writer of the option.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">When the Fund writes put
options, it bears the risk of loss if the value of the underlying stock declines below the exercise price minus the put premium. If the option is exercised, the Fund could incur a loss if it is required to purchase
the stock underlying the put option at a price greater than the market price of the stock at the time of exercise plus the put premium the Fund received when it wrote the option. While the Fund's potential gain as the
writer of a covered put option is limited to the premium received from the purchaser of the put option, the Fund risks a loss equal to the entire exercise price of the option minus the put premium.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">g.&#xa0;&#xa0;Sector Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">To the extent that the Fund
has a significant portion of its assets invested in securities conducting business in a broadly related group of industries within an economic sector, the Fund may be more vulnerable to unfavorable developments in
that economic sector than funds that invest more broadly.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Biotechnology Industry
Risk.<font style="font-style:Normal"> The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the
development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs, products or technologies and the related
intellectual property rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a
profitable drug, product or technology.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price
discounting. Companies in the biotechnology sector may also be subject to expenses and losses from</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">extensive litigation based on intellectual
property, product liability and similar claims. Companies in the biotechnology sector may be adversely affected by government regulation and changes in reimbursement rates. Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a
portion of the cost of healthcare related products or services. Biotechnology companies will continue to be affected by the efforts of governments and third-party payors to contain or reduce health care costs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pharmaceutical Sector
Risk<font style="font-style:Normal">. The success of companies in the pharmaceutical sector is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights. The research and other costs associated with developing or procuring new drugs and the related intellectual property
rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that those efforts or costs will result in the development of a profitable drug.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The pharmaceutical sector is
also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the
pharmaceutical sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Companies in the pharmaceutical sector may be adversely
affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize and monetize current and any future products depends in part on the extent to which
reimbursement for the cost of such products and related treatments are available from third-party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed Care Sector
Risk.<font style="font-style:Normal"> Companies in the managed care sector often assume the risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies base the premiums they charge and their Medicare bids on estimates of future
medical costs over the fixed contract period; however, many factors may cause actual costs to exceed what was estimated and reflected in premiums or bids.</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:19.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">28
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies are regulated at the
federal, state, local and international levels. The evolution of the ACA and other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their
results of operations, financial position and cash flows. New laws or regulations could drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. A
transformative overhaul of the U.S. healthcare system could impact the financial viability of managed care companies in which the Fund may invest.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Life Science and Tools
Industry Risk.&#xa0; <font style="font-style:Normal">Life science industries are characterized by limited product focus, rapidly changing technology, extensive government regulation, and intense competition.&#xa0; In particular, technological
advances can render an existing product, which may account for a disproportionate share of a company&#x2019;s revenue, obsolete. Extensive regulation can delay cause delays in product development, which may
disadvantage a company in an intensely competitive environment. These various factors may result in abrupt advances and declines in the securities prices of particular companies, and, in some cases, may have a broad
effect on the prices of securities of companies in particular life science industries.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Technology Sector
Risk.<font style="font-style:Normal"> Companies in the healthcare technology sector may incur substantial cost related to product-related liabilities, interruptions at their data centers or client support facilities, claims for
infringement or misappropriation of intellectual property rights of others, or infringement or misappropriation of their intellectual property.&#xa0; Each of these may adversely impact the prices of securities of
companies in the healthcare technology sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Additionally, the success of
healthcare technology companies depends upon the recruitment and retention of key personnel. The failure to attract and retain qualified personnel could have a material adverse effect on healthcare technology
companies&#x2019; prospects for long-term growth.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Services Sector
Risk.<font style="font-style:Normal"> The operations of healthcare services companies are subject to extensive federal, state and local government regulations. A violation or departure from any of these legal requirements may
result in government audits, lower reimbursements, significant fines and penalties, the potential loss of certification, recoupment efforts or voluntary repayments. If healthcare services companies fail to adhere to
all of the complex government regulations that apply to their businesses, such companies could suffer severe consequences that would substantially reduce revenues, earnings, cash flows and stock prices.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A substantial percentage of a
healthcare services company&#x2019;s service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs
(&#x201c;VA&#x201d;), as their primary</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">coverage. As state governments and other
governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates, delays in the receipt of payments, limitations on enrollee eligibility or
other changes to the applicable programs.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Supplies Sector
Risk. <font style="font-style:Normal">If healthcare supplies companies are unable to successfully expand their product lines through internal research and development and acquisitions or are unable to successfully grow their
business through marketing partnerships, their business may be materially and adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Quality is extremely
important to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of their products and
services. If a healthcare supplies company fails to meet these standards or fails to adapt to evolving standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations
could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Facilities Sector
Risk.<font style="font-style:Normal"> A healthcare facility&#x2019;s ability to negotiate favorable contracts significantly affects the revenues and operating results of such healthcare facilities. If a healthcare facility is
unable to enter into and maintain managed care contractual arrangements on acceptable terms, if it experiences material reductions in the contracted rates received from managed care payers, or if it has difficulty
collecting from managed care payers, its results of operations could be adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Further changes in the
Medicare and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility&#x2019;s business. In addition to the changes affected by the ACA, the Medicare and Medicaid
programs are subject to other regulatory changes which could materially increase or decrease payments from government programs in the future, as well as affect the cost of providing services to patients and the timing
of payments to facilities, which could in turn adversely affect a healthcare facility&#x2019;s overall business, financial condition, results of operations or cashflows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Equipment Sector
Risk. <font style="font-style:Normal">The medical device markets are highly competitive and characterized by rapid change, which may affect a company&#x2019;s ability to be competitive. They are also rigorously regulated and it
is anticipated that governmental authorities will continue to scrutinize this industry closely, and that additional regulation may increase compliance and legal costs, exposure to&#xa0;&#xa0;&#xa0; litigation, and
other adverse effects to operations.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare equipment
companies are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may negatively impact the ability of healthcare
equipment companies to sell current or future products.&#xa0; Quality problems with the processes, goods and</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">29
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">services of a healthcare equipment company
could harm the company&#x2019;s reputation for producing high-quality products and erode its competitive advantage, sales and market share. Quality certifications are critical to the marketing success of goods and
services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Distributors
Sector Risk.<font style="font-style:Normal"> Companies in the healthcare distribution sector operate in markets that are highly competitive and in an industry that is highly regulated and often subject to legal proceedings. Due to the
nature of the business of healthcare distribution companies, each of the above may have an adverse impact on the securities prices of companies in the healthcare distribution sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare distribution
companies depend on the availability of various components, compounds, raw materials and energy supplied by others for their operations. Any of these supplier relationships could be interrupted due to events beyond
the control of such companies, including pandemics, epidemics or natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">h.&#xa0;&#xa0;Valuation Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The price that the Fund
could receive upon the sale of any particular portfolio investment may differ from the Fund's valuation of the investment, particularly for securities that trade in thin or volatile markets or that are valued using a
fair valuation methodology or a price provided by an independent pricing service. As a result, the price received upon the sale of an investment may be less than the value ascribed by the Fund, and the Fund could
realize a greater than expected loss or lower than expected gain upon the sale of the investment. The Fund's ability to value its investments may also be impacted by technological issues and/or errors by pricing
services or other third-party service providers.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">i.&#xa0;&#xa0;Venture Capital
Investments Risk:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may occasionally
invest in venture capital opportunities. While these securities offer the opportunity for significant capital</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">gains, such investments also involve a
degree of risk that can result in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in a &#x201c;start-up&#x201d; stage of development, have
little or no operating history, operate at a loss or with substantial variations in operating results from period to period, have limited products, markets, financial resources or management depth, or have the need
for substantial additional &#x201c;follow-on&#x201d; capital to support expansion or to achieve or maintain a competitive position. Such additional investments may dilute the interests of prior investors, such as the
Fund. Some of these companies may be emerging companies at the research and development stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging
growth companies will, in the future, yield returns commensurate with their associated risks.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">These investments, which are
considered Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise
when the Investment Adviser believes that such investments would be consistent with the Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that, in light of the risk characteristics associated with investments in emerging growth companies, if such investments were to be compared with investments rated by S&amp;P or Moody&#x2019;s, they may be rated as low
as &#x201c;C&#x201d; in the rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly
speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">9.&#xa0;&#xa0;Contingencies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In the normal course of
business, the Fund may provide general indemnifications pursuant to certain contracts and organizational documents. The Fund's maximum exposure under these arrangements is dependent on future claims that may be made
against the Fund, and therefore, cannot be estimated; however, the Fund expects the risk of loss from such claims to be remote.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:9.5pt; width:100%">
<div style="clear:both; color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">10.&#xa0;&#xa0;Tax
Information</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:left; text-decoration:none; text-transform:none">The U.S. federal
income tax basis of the Fund's investments (including derivatives, if applicable) and the net unrealized appreciation as of September 30, 2025, were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:6pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.55%">Tax Cost of<br>
Securities
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.04%">Unrealized<br>
Appreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.19%">Unrealized<br>
Depreciation
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.78%">Net<br>
Unrealized<br>
Appreciation/<br>
(Depreciation)
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:0pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.55%; background-color: #F0F0F0;">$447,094,789
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.04%; background-color: #F0F0F0;">$162,149,564
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:10.5pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.19%; background-color: #F0F0F0;">$(95,558,466)
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:10.5pt; padding-right:6pt; padding-top:2.5pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:29.78%; background-color: #F0F0F0;">$66,591,098
</td></tr></table>
</div>
</div>
</div>
<div style="padding-top:48.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">30
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(continued)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:16.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">The tax character of
distributions paid during the fiscal years ended September 30, 2025 and September 30, 2024 was as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.63%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9pt; padding-bottom:2pt; padding-right:5pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:66.43%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:5pt; padding-right:5pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%">September 30, 2025
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; padding-bottom:2pt; padding-left:5pt; padding-right:6pt; padding-top:3pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.35%">September 30, 2024
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:5pt; padding-top:2.5pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Distributions paid from:
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:5pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:16.29%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-bottom:1.75pt; padding-right:6pt; padding-top:2.5pt; text-align:right; vertical-align:bottom; width:16.35%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Ordinary Income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.29%; background-color: #F0F0F0;">$<font style="padding-left:2.40pt"></font>49,327,891
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:5pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:16.35%; background-color: #F0F0F0;">$<font style="padding-left:5.34pt"></font>18,919,190
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Net Long-Term Capital Gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.67pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">2,790,714
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:13.83pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.35%; background-color: #F0F0F0;">20,767,544
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:6pt; padding-right:5pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Return of Capital
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:50.41pt; padding-right:5pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">-
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:17.60pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.35%; background-color: #F0F0F0;">5,606,991
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:5pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:66.43%; background-color: #F0F0F0;">Total tax character of distributions
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:5pt; padding-right:5pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.29%; background-color: #F0F0F0;">$52,118,605
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:5pt; padding-right:6pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:16.35%; background-color: #F0F0F0;">$45,293,725
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">As of September 30, 2025, the
components of accumulated earnings on a tax basis were as follows:</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:98.89%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Undistributed Ordinary Income
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:3pt; padding-right:12pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.46%; background-color: #F0F0F0;">$<font style="padding-left:2.19pt"></font>10,816,469
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Undistributed Long-Term Capital Gains
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:49.46pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.46%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Total undistributed earnings
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:3pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.46%; background-color: #F0F0F0;">$<font style="padding-left:2.19pt"></font>10,816,469
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Accumulated Capital and Other Losses
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:3pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.46%; background-color: #F0F0F0;">$<font style="padding-left:21.18pt"></font>(7,930)
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Capital loss carryforward
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:3pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:10.46%; background-color: #F0F0F0;">$<font style="padding-left:41.49pt"></font>-*
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Other currency gains
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:49.46pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.46%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Other Temporary Differences
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:49.46pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.46%; background-color: #F0F0F0;">-
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Unrealized Appreciation/(Depreciation)
</td><td style="border-bottom:0.5pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:2pt; padding-left:9.25pt; padding-right:12pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.46%; background-color: #F0F0F0;">66,795,693**
</td></tr>
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:6pt; padding-right:3pt; padding-top:2.38pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:87.86%; background-color: #F0F0F0;">Total accumulated earnings/(losses) &#x2013; net
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:2pt; padding-left:3pt; padding-right:12pt; padding-top:2.38pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:10.46%; background-color: #F0F0F0;">$77,604,232
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:16pt; text-align:left; text-decoration:none; text-transform:none">Amounts listed as
 &#x201c;&#x2013;&#x201d; are $0 or round to $0.</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.22%">*
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.33%">During the fiscal year ended September 30, 2025, the Fund did not utilize a capital loss carryforward.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.22%">**
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.33%">The difference between book-basis and tax-basis unrealized appreciation/(depreciation) is attributable to the difference between the tax deferral of wash sales,
the realization for tax purposes of unrealized gains on investments in passive foreign investment companies and Milestone installment sale adjustments.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">11.&#xa0;&#xa0;Segment Reporting</div>
</div>
<div style="margin-top:7pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">In this reporting period, the Fund adopted
FASB Accounting Standards Update 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures ("ASU 2023-07"). Adoption of the new standard impacted disclosures only and did not affect the
Fund&#x2019;s financial position nor the results of its operations. Operating segments are components of a public entity that engage in business activities from which it may recognize revenues and incur expenses, have
discrete financial information available, and have their operating results regularly reviewed by the public entity&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) when assessing segment performance and
making decisions about segment resources. The Chief Financial Officer of the Fund acts as the Fund&#x2019;s CODM. The CODM monitors the operating results of the Fund as a whole, and the Fund&#x2019;s asset allocation is
managed in accordance with its Prospectus. The Fund operates as a single operating and reporting segment pursuant to its investment objective and principal investment strategy. The Fund&#x2019;s portfolio composition,
total returns, expense ratios and changes in net assets used by the CODM to assess segment performance and make resource allocations are consistent with the information presented</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">within the Fund's financial statements.
Segment assets are reflected on the Fund&#x2019;s Statement of Assets and Liabilities as &#x201c;Total Assets&#x201d; and significant segment expenses are listed on the Statement of Operations.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">12.&#xa0;&#xa0;Recent Accounting
Pronouncements</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">In December 2023, the FASB
issued Accounting Standards Update 2023-09 (&#x201c;ASU 2023-09&#x201d;), Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which amends quantitative and qualitative income tax disclosure requirements in
order to increase disclosure consistency, bifurcate income tax information by jurisdiction and remove information that is no longer beneficial. ASU 2023-09 is effective for annual periods beginning after December 15,
2024, and early adoption is permitted. Fund Management is evaluating the impacts of these changes on the Fund&#x2019;s financial statements.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:21.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">31
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Notes to &#xa0;Financial Statements<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;(concluded)<br>
</font><font style="font-size:11pt; font-weight:Normal; line-height:14pt">September 30, 2025</font></div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:17.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">13.&#xa0;&#xa0;Subsequent Events</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1.5pt; text-align:justify; text-decoration:none; text-transform:none">Management has evaluated
the need for disclosures and/or adjustments resulting from subsequent events through the date the financial statements were issued.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48.45%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Based on this evaluation, no disclosures
and/or adjustments were required to the financial statements as of September 30, 2025, other than as noted below.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">On November 11, 2025, the
Fund announced that it will pay on January 12, 2026, a stock distribution of US $0.50 per share to all shareholders of record as of November 21, 2025.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:581pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">32
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Report of Independent Registered Public Accounting
Firm<font style="font-size:11pt; line-height:14pt">&#xa0;&#xa0;</font></div>
</div>
<div style="margin-top:13pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:24.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">To&#xa0;the&#xa0;
Shareholders&#xa0;and&#xa0;Board&#xa0;of&#xa0;Trustees<br>
abrdn Life Sciences Investors:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Opinion on the Financial
Statements</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:justify; text-decoration:none; text-transform:none">We have audited the
accompanying statement of assets and liabilities of abrdn Life Sciences Investors (the Fund), including the portfolio of investments, as of September 30, 2025, the related statements of operations and cash flows for
the year then ended, the statements of changes in net assets for each of the years in the two-year period then ended, and the related notes (collectively, the financial statements) and the financial highlights for
each of the years in the three-year period then ended. In our opinion, the financial statements and financial highlights present fairly, in all material respects, the financial position of the Fund as of September 30,
2025, the results of its operations and its cash flows for the year then ended, the changes in its net assets for each of the years in the two-year period then ended, and the financial highlights for each of the years
in the three-year period then ended, in conformity with U.S. generally accepted accounting principles. The financial highlights for each of the years in the two-year period ended September 30, 2022 were audited by
other independent registered public accountants whose report, dated November 21, 2022, expressed an unqualified opinion on those financial highlights.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Basis for Opinion</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:justify; text-decoration:none; text-transform:none">These financial statements
and financial highlights are the responsibility of the Fund's management. Our responsibility is to express an opinion on these financial statements and financial highlights based on our audits. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:justify; text-decoration:none; text-transform:none">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements and financial highlights are free of
material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements and financial highlights, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements and financial
highlights. Such procedures also included confirmation of securities owned as of September 30, 2025, by correspondence with the custodian, respective portfolio company, and brokers; when replies were not received from
brokers, we performed other auditing procedures. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements and financial highlights. We believe that our audits provide a reasonable basis for our opinion.</div>
<div style="margin-left:40.19%; margin-top:9pt; text-align:Center; width:19.63%">
<img src="tm2527059d12hqlreporti004.jpg" alt=" ">
</div>


<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">We have served as the auditor
of one or more abrdn investment companies since 2009.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Columbus, Ohio<br>
November 28, 2025&#xa0;</div>
</div>
<div style="margin-top:204pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">33
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Federal Tax Information: Dividends and
Distributions&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6.5pt; text-align:left; text-decoration:none; text-transform:none">Designation Requirements</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">Of the distributions paid by the
Fund from ordinary income for the year ended September 30, 2025, the following percentages met the requirements to be treated as qualifying for the corporate dividends received deduction and qualified dividend income,
respectively.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">Dividends Received Deduction
2.44%</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">Qualified Dividend Income
2.61%</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">$2,790,714 from long-term
capital gains, subject to a long-term capital gains tax rate of not greater than 20%..</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">The above amounts are based on
the best available information at this time. In early 2026, the Fund will notify applicable shareholders of final amounts for use in preparing 2025 U.S. federal income tax forms.&#xa0;</div>
</div>
<div style="margin-top:530pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">34
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Supplemental Information&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6.5pt; text-align:left; text-decoration:none; text-transform:none">Results of Annual Meeting of
Shareholders</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">The Annual Meeting of
Shareholders was held on May 28, 2025. The description of each proposal and number of shares voted at the meeting are as follows:</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:left; text-decoration:none; text-transform:none">To elect two Class C Trustees to
the Board of Trustees:</div>
</div>
<div style="margin-top:2.5pt; width:80.26%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="border-bottom:1pt solid #000000; line-height:9.5pt; padding-bottom:3pt; padding-right:15pt; padding-top:3pt; text-align:left; vertical-align:bottom; width:65.35%">&#xa0;
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:15pt; padding-right:15pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:15.75%">Votes For
</td><td style="border-bottom:1pt solid #000000; color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; padding-bottom:3pt; padding-left:15pt; padding-right:6pt; padding-top:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:19.56%">Votes Against/<br>
Withheld
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:6pt; padding-right:15pt; padding-top:2.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:65.35%; background-color: #F0F0F0;">Rose DiMartino
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:15pt; padding-right:15pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.75%; background-color: #F0F0F0;">16,018,555
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:1.75pt; padding-left:16.34pt; padding-right:6pt; padding-top:2.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.56%; background-color: #F0F0F0;">3,906,874
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:6pt; padding-right:15pt; padding-top:1.75pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:65.35%; background-color: #F0F0F0;">Todd Reit
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:15.05pt; padding-right:15pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:15.75%; background-color: #F0F0F0;">16,041,001
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-bottom:3.5pt; padding-left:15pt; padding-right:6pt; padding-top:1.75pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.56%; background-color: #F0F0F0;">3,884,428
</td></tr></table>
</div>
</div>
<div style="margin-top:12.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6.5pt; text-align:left; text-decoration:none; text-transform:none">Summary of Board Considerations in
Approving the Investment Advisory Agreement</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">At a regularly scheduled
meeting (the &#x201c;Meeting&#x201d;) of the Board of Directors (the &#x201c;Board&#x201d;) of abrdn Life Sciences Investors (&#x201c;HQL&#x201d; or the &#x201c;Fund&#x201d;) held on June 10, 2025, the Board, including those
Directors (the &#x201c;Independent Directors&#x201d;) who are not &#x201c;interested persons&#x201d; (as that term is defined in the&#xa0; Investment Company Act of 1940, (the &#x201c;1940 Act&#x201d;)) of the Fund,
approved the continuation of the investment advisory agreement (the &#x201c;Advisory Agreement&#x201d;) between abrdn Inc. (the &#x201c;Adviser&#x201d;) and the Fund. In connection with their consideration of whether to
approve the continuation of the Advisory Agreement, the Board members received and reviewed a variety of information provided by the Adviser relating to the Fund, the Advisory Agreement, and the Adviser. The
information provided to the Board members included (but was not limited to): comparative performance, fee and expense information (as well as information on the limitations of such comparable data) of a peer group of
funds based on the Fund&#x2019;s Morningstar Category (the &#x201c;Peer Funds&#x201d;), as selected by Institutional Shareholder Services Inc. (&#x201c;ISS&#x201d;), an independent third-party provider of investment
company data and other performance information. The Peer Funds presented for fee and expense data comparison consisted of a sub-set of the Morningstar Category as determined independently by ISS, and the Peer Funds
presented for the performance data comparison consisted of the Fund&#x2019;s Morningstar category, as determined by ISS. The Board also received information regarding relevant benchmark indices and information
regarding the nature, extent and quality of services provided by the Adviser under the Advisory Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">The materials provided to the
Board generally included, among other items: (i) information on the investment performance of the Fund, the performance of the Peer Funds, comparable funds, if any, and the Fund&#x2019;s performance benchmark; (ii)
reports prepared by the&#xa0;Adviser in response to requests submitted by the Independent Directors&#x2019; independent legal counsel on behalf of such Directors; (iii) information on the Fund&#x2019;s management fee
and other expenses, including information comparing the Fund&#x2019;s expenses to the Peer Funds, comparable funds, if any, and information about applicable fee &#x201c;breakpoints&#x201d; in the Fund&#x2019;s fee
structure and expense limitations, if any; (iv) information regarding the Adviser&#x2019;s revenues and costs of providing services to the funds and any compensation paid to affiliates of the Adviser; and (v) a
memorandum from the Independent Directors&#x2019; independent legal counsel on the responsibilities of the Board in considering the approval of the investment advisory arrangement under the 1940 Act and Massachusetts
law.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">The Independent Directors met
with representatives of the Adviser and separately in executive session with independent legal counsel on June 10, 2025 to discuss the continuation of the Advisory Agreement. The Independent Directors also met with
representatives of the Adviser and separately in executive session with independent legal counsel on May 29, 2025 to discuss the materials provided to the Board by the Adviser in response to a request for information
sent to them by the Independent Directors&#x2019; independent legal counsel.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">In evaluating whether to
renew the Advisory Agreement for the Fund, the Board considered numerous factors, including: (i) the nature, extent and quality of services provided to the Fund by the Adviser under the Advisory Agreement; (ii) the
costs of services provided to the Fund and the profits realized by the Adviser (and its affiliates) from its relationship with the Fund; (iii) the Fund&#x2019;s total expense ratio as well as the management fee paid by
the Fund pursuant to the Advisory Agreement relative to the total expense ratios of and the management fees charged to the Peer Funds and comparable accounts, if any; (iv) the investment performance of the Fund
relative to that of its benchmark index as well as the performance of the Peer Funds and comparable funds, if any; (v) any additional benefits (such as soft dollars, if any) received by the Adviser or its affiliates;
(vi) the extent to which economies of scale are being realized by shareholders and will be realized as the Fund&#x2019;s assets increase; (vii) the Adviser&#x2019;s compliance program; and (viii) any other
considerations deemed relevant by the Board. The Independent Directors also discussed the Advisory Agreement in an executive session with independent legal counsel at which no representatives of the Adviser were
present.&#xa0; No single factor reviewed by the Board was identified as the principal factor in determining whether to renew the Advisory Agreement, and individual Directors may have given different weight to various
factors.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">The discussion immediately
below outlines in greater detail certain of the materials and information presented to the Board by the Adviser in connection with the Board&#x2019;s consideration and approval of the continuation of the Advisory
Agreement, and the conclusions made by the Board at the Meeting when determining to renew the Advisory Agreement.</div>
</div>
<div style="margin-top:21.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">35
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Supplemental Information&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited)&#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">The Nature, Extent and Quality of
Services Provided to the Fund Under the&#xa0;Advisory Agreement</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Directors considered the
nature, extent and quality of services provided by the Adviser to the Fund. They reviewed information about the resources dedicated to the Fund by the Adviser and its affiliates. Among other things, the Board reviewed
and discussed the background and experience of the Adviser&#x2019;s senior management personnel who serviced the Fund and the qualifications, background and responsibilities of the portfolio managers primarily
responsible for providing day-to-day portfolio management services for the Fund. The Directors also considered the financial condition of the Adviser and the Adviser&#x2019;s ability to provide quality service to the
Fund. Management representatives reported to the Board and responded to questions on, among other things, the Adviser&#x2019;s business plans and any current or proposed organizational changes. The Directors also took
into account the Adviser&#x2019;s experience as an asset manager and considered information regarding the Adviser&#x2019;s compliance with applicable laws and Securities and Exchange Commission (&#x201c;SEC&#x201d;) and
other regulatory agency inquiries or audits of the Fund, the Adviser and/or its affiliates. The Board considered reports from the Adviser on its risk management processes. The Board noted that it received information
on a regular basis from the Fund&#x2019;s Chief Compliance Officer regarding the Adviser&#x2019;s compliance policies and procedures and information concerning the Adviser&#x2019;s brokerage policies and practices. The
Directors also noted that the Adviser had provided information and periodic reporting, including updates on the management of the Fund and the quality of performance, and had discussed these matters with the Directors
at meetings held regularly throughout the preceding year.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">Based on the totality of the
information considered, the Board concluded that the nature, extent and quality of the Adviser&#x2019;s services provided to the Fund were of high quality, and that the Adviser has provided and could reasonably be
expected to continue to provide these services on an ongoing basis based on its experience, operations and resources.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">The Costs of Services Provided
and Profits Realized by the Adviser and its&#xa0;Affiliates from their Relationships with the Fund</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board reviewed
information compiled by ISS that compared the Fund&#x2019;s effective annual management fee rate with the fees paid by its Peer Funds. The Board reviewed with management the effective annual management fee paid by the
Fund to the Adviser for investment management services. The Board considered the Fund&#x2019;s management fee structure. The Directors also considered information from management about the fees charged by the Adviser
to other clients investing primarily in an asset class similar to that of the Fund. The Board considered the fee comparisons in light of the differences in resources and costs required to manage the different types of
accounts. In evaluating the Fund&#x2019;s management fees, the Board took into account the regulatory regimes, fund structure, level of services, complexity and quality of the investment management of the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">In addition to the foregoing,
the Board considered the Fund&#x2019;s fees and expenses relative to the fees and expenses of the Peer Funds, as well as information on the limitations of such comparable data given differences between the Fund and the
Peer Funds presented. This information showed that the Fund&#x2019;s net management fee and total net expenses, exclusive of investment-related expenses, were above the median of the Peer Funds. The Board noted that
the Fund has the ability to utilize leverage and that the Adviser oversees opportunities for leverage, as well as the Fund&#x2019;s structure, including any discount to the Fund&#x2019;s net asset value during market
trading. The Board also reviewed the profitability of the investment advisory relationship with the Fund to the Adviser. The Board concluded that the Fund&#x2019;s fees and expenses, as well as the Investment
Adviser&#x2019;s profitability, were reasonable in light of the nature, extent and quality of services provided.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Investment Performance of the
Fund</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board received and
reviewed with the Fund&#x2019;s management, among other performance data, information that compared the Fund&#x2019;s return over the one-year period to the Peer Funds and discussed this information and other related
performance data with the Adviser. In addition, the Board received and reviewed information regarding the Fund&#x2019;s total return on a gross and net basis and relative to the Fund&#x2019;s benchmark. The Board also
considered information about the Fund&#x2019;s discount/premium ranking relative to its Peer Funds and the Adviser&#x2019;s discussion of the Fund&#x2019;s performance. The Directors noted that the Fund underperformed
the average of the Peer Funds and the benchmark for the 1-year period ended March 31, 2025. The Board noted that the Adviser began managing the strategy in October 2023, and that prior performance is attributed to
another adviser. The Board considered the Adviser&#x2019;s discussion of Fund performance relative to the benchmark and the Peer Funds, including distinguishing features between the benchmark and the Funds and that the
Peer Funds have varying investment objectives, strategies and policies, as well as varying exposures to the healthcare sector which limits the comparability of Peer Fund performance to the Fund. The Board also
considered the Adviser&#x2019;s plans for the Fund, among other factors, in determining to continue the Advisory Agreement.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Direct and Indirect Benefits</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board then considered
whether or the extent to which the Adviser derives any direct, ancillary or indirect benefits, such as reputational benefits, that could accrue to the Adviser from the Fund&#x2019;s operations as a result of the
Adviser&#x2019;s relationship with the Fund. The Board recognized the services provided to the Fund by affiliates of the Adviser and the related compensation paid by the Fund for those services. Based on the totality
of the information considered, the Board concluded that any benefits accruing to the Adviser by virtue of its relationship with the Fund appeared to be reasonable.</div>
</div>
<div style="margin-top:38.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.15%">36
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.41%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Supplemental Information&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:8pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:20.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:bold; line-height:12.5pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Economies of Scale</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Board next considered
management&#x2019;s discussion of the Fund&#x2019;s management fee structure and determined that the management fee structure was reasonable and reflected the sharing of economies of scale between the Fund and the
Adviser as the Fund&#x2019;s assets increased. The Board based its determination on various factors, including how the Fund&#x2019;s management fee compared relative to the Peer Funds at higher asset levels and that the
breakpoints in the Fund&#x2019;s Advisory Agreement would adjust the management fee rate downward to reflect anticipated economies of scale in the event of asset increases, if applicable. The Board also considered that
the Fund had an expense limitation agreement in place until October 27, 2025, pursuant to which the Adviser agreed to waive a portion of its management fee and/or reimburse certain expenses as a means of limiting the
Fund&#x2019;s total annual operating expenses. The Board concluded the economies of scale shared with the Fund were reasonable.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:center; text-decoration:none; text-transform:none">* * *</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:8pt; text-align:justify; text-decoration:none; text-transform:none">Based on the Board&#x2019;s
deliberations and its evaluation of the information described above and other factors and information the Directors deemed relevant in the exercise of their individual reasonable business judgment, the Board,
including the Independent Directors, with the assistance of fund counsel and independent legal counsel to the Independent Directors, unanimously determined that the fees charged pursuant to the Advisory Agreement were
fair and reasonable and approved the continuation of the Advisory Agreement.&#xa0;</div>
</div>
<div style="margin-top:497pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.44%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">37
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">RECENT CHANGES</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:italic; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The following information is
a summary of certain changes during the fiscal year ended September 30, 2025. This information may not reflect all of the changes that have occurred since you purchased the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">During the applicable period,
there have been: (i) no material changes to the Fund&#x2019;s investment objective and policies that constitute its principal portfolio emphasis that have not been approved by the Fund&#x2019;s shareholders (the
 &#x201c;Shareholders&#x201d;), (ii) no material changes to the Fund&#x2019;s principal risks, (iii) no changes to the persons primarily responsible for day-to-day management of the Fund; and (iv) no changes to the
Fund&#x2019;s charter or by-laws that would delay or prevent a change of control that have not been approved by Shareholders.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">INVESTMENT OBJECTIVE, STRATEGIES AND
POLICIES</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund&#x2019;s investment
objective is to seek long-term capital appreciation by investing primarily in securities of life sciences companies. The Fund&#x2019;s investment objective is a fundamental policy and may not be changed without the
affirmative vote of the holders of a majority of the outstanding shares (as that term is defined in Section 2(a)(42) of the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;)).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">In an effort to achieve its
investment objective, the Fund will invest primarily in equity and related securities (including securities subject to legal or contractual restrictions on resale) of U.S. and foreign companies principally engaged in
the development, production or distribution of products or services related to scientific advances in life sciences (including biotechnology, pharmaceuticals, diagnostics, managed healthcare and medical equipment,
hospitals, healthcare information technology and services, devices, supplies and other healthcare-related subsectors), agriculture and environmental management ("Life Sciences Companies"). &#xa0;The Fund invests
primarily in Life Sciences Companies&#xa0;that are generally believed by the Investment Adviser to have significant potential for above-average, long-term growth in revenues and earnings. The Investment Adviser
expects that such companies generally will possess some or all of the following characteristics, in the Investment Adviser&#x2019;s judgment: current or anticipated strong market position for their services or
products, experienced business management, recognized technological expertise and the ability either to generate funds internally to finance growth or to secure outside sources of capital. For companies with earnings,
the Investment Adviser generally will attempt to invest in securities that sell at price-earnings ratios or at multiples of underlying asset or potential values which, have upside potential.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may invest in
securities of emerging growth Life Sciences Companies which may offer limited products or services or which are at the research and development stage with no marketable or approved products or technologies. The Fund
also may invest in</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">securities of large, well-known companies
with existing products in the life sciences industries that are believed by the Investment Adviser to be undervalued in relation to their long-term growth potential or asset value. The Fund also may invest up to 40%
of its net assets in venture capital and other securities that are subject to legal or contractual restrictions on resale (&#x201c;Restricted Securities&#x201d;). The Fund also may invest up to 20% of its net assets in
securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of U.S. issuers traded in foreign markets (&#x201c;Foreign Securities&#x201d;). The Fund may buy and
sell currencies for the purpose of settlement of transactions in Foreign Securities. Under normal market conditions, the Fund expects to invest at least 80% of its net assets in securities of Life Sciences Companies.
This policy may not be changed without 60 days&#x2019; prior notice to Shareholders. The Fund is required, except for temporary defensive purposes, to invest at least 25% of its net assets in such companies. For
purposes of satisfying the foregoing requirements, a company will be deemed to be a Life Sciences Company if, at the time the Fund makes an investment therein, 50% or more of such company&#x2019;s sales, earnings
efforts or assets arise from or are dedicated to, or are expected to arise from or be dedicated to, the application of scientific advances related to healthcare, agriculture or environmental management, as the case
may be. Determinations as to whether a company is a Life Sciences Company will be made by the Investment Adviser in its discretion.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The equity and related
securities in which the Fund may invest consist of common stock of life sciences companies and, to a lesser extent, of preferred stock, convertible debt, limited partnership interests and warrants or other rights to
acquire common or preferred stocks of such companies. The Fund&#x2019;s investments in venture capital opportunities, which are considered Restricted Securities, will be made primarily in convertible preferred stock.
The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise when the Investment Adviser believes that such investments would be consistent with the
Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Investment Adviser believes that, in light of the risk characteristics associated with investments in emerging growth
companies (see &#x201c;Risk Factors&#x201d;), if such investments were to be compared with investments rated by S&amp;P Global Ratings ("S&amp;P") or Moody&#x2019;s, they may be rated as low as &#x201c;C&#x201d; in the
rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:12pt; text-align:left; text-decoration:none; text-transform:none">Put or Call Options</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:1pt; text-align:justify; text-decoration:none; text-transform:none">The Fund may purchase and
sell (or write) put or call options on any security in which it is permitted to invest or on any index of securities or other index, the change in value of which has a high degree of</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">38
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">correlation with the changes in value of the
Fund&#x2019;s portfolio securities,and may purchase and sell (or write) on a covered basis financial futures contracts and options on such futures.</div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">RISK FACTORS</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Investing in any investment
company security involves risk, including the risk that you may receive little or no return on your investment or even that you may lose part or all of your investment. Investors should consider the following Risk
Factors and special considerations associated with investing in the Fund&#x2019;s shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Portfolio Market Risk.<font style="font-weight:Normal"> The Fund is subject to market risk&#x2014;the possibility that the prices of equity securities will decline over short or extended periods of time. The price of an equity security of an
issuer may be particularly sensitive to general movements in the stock market, or a drop in the stock market may depress the price of most or all of the equity securities held by the Fund. In addition, equity
securities held by the Fund may decline in price if the issuer fails to make anticipated distributions or dividend payments because, among other reasons, the issuer experiences a decline in its financial condition. As
a result, the value of an investment in the Fund&#x2019;s shares will fluctuate with the market. You could lose some or all of your investment over short or long periods of time.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Political and economic news
can influence market-wide trends and can cause disruptions int he U.S. or world financial markets. Other factors may be ignored by the market as a whole but may cause movements in the price of one company&#x2019;s
stock or the stock of companies in one or more industries. All of these factors may have a greater impact on initial public offerings and emerging company shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Market Disruption and
Geopolitical Risk.<font style="font-weight:Normal"> The value of your investment in the Fund is based on the market prices of the securities the Fund holds. These prices change daily due to economic and other events that affect markets
generally, as well as those that affect particular regions, countries, industries, companies or governments. These price movements, sometimes called volatility, may be greater or less depending on the types of
securities the Fund owns and the markets in which the securities trade. The increasing interconnectivity between global economies and financial markets increases the likelihood that events or conditions in one region
or financial market may adversely impact issuers in a different country, region or financial market. Securities in the Fund&#x2019;s portfolio may underperform due to inflation (or expectations for inflation), interest
rates, global demand for particular products or resources, natural/ environmental disasters, pandemics, epidemics, cyber-attacks, terrorism, armed conflicts, regulatory events and governmental or quasi-governmental
actions. The occurrence of global events, such as terrorist attacks around the world, natural/environmental disasters-, social and political discord or debt crises and downgrades, among others, may result in
market</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">volatility and may have long term effects on
both the U.S. and global financial markets. A disruption of financial markets or other terrorist attacks could adversely affect Fund service providers and/or the Fund&#x2019;s operations as well as interest rates,
secondary trading, credit risk, inflation and other factors relating to the shares. The Fund cannot predict the effects or likelihood of similar events in the future on the U.S. and world economies, the value of the
shares or the NAV of the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Social, political, economic
and other conditions and events, such as natural disasters, health emergencies (e.g., epidemics and pandemics such as COVID-19, avian influenza or HINI/09), terrorism, actual or threatened wars or other armed
conflicts (such as the Russia/Ukraine war and Middle East conflicts), may occur and could significantly impact issuers, industries, governments and other systems, including the financial markets. These impacts could
negatively affect the Fund&#x2019;s investments in securities and instruments that are economically tied to the applicable region, and include (but are not limited to) declines in value and reductions in liquidity. In
addition, to the extent new sanctions are imposed or previously relaxed sanctions are reimposed, complying with such restrictions may prevent the Fund from pursuing certain investments, cause delays or other
impediments with respect to consummating such investments or divestments, require divestment or freezing of investments on unfavorable terms, render divestment of underperforming investments impracticable, negatively
impact the Fund&#x2019;s ability to achieve its investment objective, prevent the Fund from receiving payments otherwise due it, increase diligence and other similar costs to the Fund, render valuation of affected
investments challenging, or require the Fund to consummate an investment on terms that are less advantageous than would be the case absent such restrictions. As global systems, economies and financial markets are
increasingly interconnected, events that once had only local impact are now more likely to have regional or even global effects. Events that occur in one country, region or financial market will, more frequently,
adversely impact issuers in other countries, regions or markets. These impacts can be exacerbated by failures of governments and societies to adequately respond to an emerging event or threat. These types of events
quickly and significantly impact markets in the U.S. and across the globe leading to extreme market volatility and disruption. The extent and nature of the impact on supply chains or economies and markets from these
events is unknown, particularly if these types of events persist for an extended period of time. These types of events, could reduce consumer demand or economic output, result in market closures, travel restrictions
or quarantines, and generally have a significant impact on the economies and financial markets and the Investment Adviser&#x2019;s investments advisory activities and services of other service providers, which in turn
could adversely affect the Fund&#x2019;s investments and other operations. The value of the Fund&#x2019;s investments impact the operations and effectiveness of the</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:10.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">39
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Investment Adviser or key service providers
or if these events disrupt systems and processes necessary or beneficial to the investment advisory or other activities on behalf the Fund.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Systemic risk events and/or
resulting government actions in the financial markets can negatively impact the Fund, for example, through less credit being available to issuers or uncertainty regarding safety of deposits at other institutions.
These risks also may adversely affect financial intermediaries, such as clearing agencies, clearing houses, banks, securities firms, and exchanges, with which the Fund interacts.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Market Events Risk. <font style="font-weight:Normal">The market values of securities or other assets will fluctuate, sometimes sharply and unpredictably, due to changes in general market conditions, overall economic trends or events,
governmental actions or intervention, actions taken by the US Federal Reserve or foreign central banks, market disruptions caused by trade disputes or other factors, political events within the U.S. and abroad, such
as changes in the U.S. presidential administration and Congress, investor sentiment and other factors that may or may not be related to the issuer of the security or other asset. Economies and financial markets
throughout the world are increasingly interconnected. Economic, financial or political events, imposition of sanctions and other measures, trading and tariff arrangements, actual or threatened war or armed conflicts,
terrorism, social unrest, natural or environmental disasters and other circumstances in one country or region could have profound impacts on global economies or markets. As a result, whether or not the Fund invests in
securities of issuers located in or with significant exposure to the countries directly affected, the value and liquidity of the Fund's investments may be negatively affected. In addition, public health emergencies
(such as the spread of infectious diseases, pandemics and epidemics) or similar issues could reduce consumer demand or economic output, result in market closures, travel restrictions or quarantines, and generally have
a significant impact on the world economy, which in turn could adversely affect the Fund's investments. The impact of the recent U.S. elections on such policies remains uncertain and policies supported by the new
administration (or the reversal of policies supported by the previous administration) could impact U.S. interest rates or inflation or otherwise impact the Fund.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Security Market Risk - Discount
to NAV.<font style="font-weight:Normal"> Shares of closed-end investment companies frequently trade at a discount from NAV. The risk that the Fund&#x2019;s common shares may trade at a discount is separate from the risk of a
decline in the Fund&#x2019;s NAV as a result of investment activities.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Whether shareholders will
realize a gain or loss for federal income tax purposes upon the sale of their common shares depends upon whether the market value of the common shares at the time of sale is above or below the shareholder&#x2019;s
basis in such common shares, taking</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">into account transaction costs, and it is
not directly dependent upon the Fund&#x2019;s NAV. Because the market price of the Fund&#x2019;s common shares will be determined by factors such as the relative demand for and supply of the shares in the market,
general market conditions and other factors beyond the Fund&#x2019;s control, the Fund cannot predict whether its common shares will trade at, below or above the NAV, or at, below or above the public offering price for
the Fund&#x2019;s common shares.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Non-Diversification Risk.<font style="font-weight:Normal"> The Fund is non-diversified, meaning that the Fund is permitted to invest more of its assets in fewer issuers than &#x201c;diversified&#x201d; funds. Thus, the Fund may be more susceptible
to adverse developments affecting any single issuer held in its portfolio, and may be more susceptible to greater losses because of these developments.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Selection Risk.<font style="font-weight:Normal"> Different types of equity securities tend to shift into and out of favor with investors, depending on market and economic conditions. The performance of funds that invest in equity
securities of life sciences companies may at times be better or worse than the performance of funds that focus on other types of securities or that have a broader investment style.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Concentration in the Life
Sciences Industries.<font style="font-weight:Normal"> Under normal market conditions, the Fund expects to invest at least 80% of its net assets in securities of Life Sciences Companies. This policy may not be changed without 60 days&#x2019;
prior written notice to Shareholders. The Fund will not have less than 25% of its net assets invested in Life Sciences Companies. As a result, the Fund&#x2019;s portfolio may be more sensitive to, and possibly more
adversely affected by,regulatory, economic or political factors or trends relating to the life sciences industries than a portfolio of companies representing a larger number of industries. As a result of its
concentration policy, the Fund&#x2019;s investments may be subject to greater risk and market fluctuation than a fund that has securities representing a broader range of investments.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Life sciences companies have
in the past been characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an existing product, which may account for a
disproportionate share of a company&#x2019;s revenue, obsolete. Obtaining governmental approval from agencies such as the Food and Drug Administration (the &#x201c;FDA&#x201d;), U.S. Department of Agriculture and other
U.S. and non-U.S. governmental agencies for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital, potentially
diluting the interests of existing investors such as the Fund. In addition, governmental agencies may, for a variety of reasons, restrict the release of certain innovative technologies of commercial significance, such
as genetically altered material. These various factors may result in abrupt advances and declines in the</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">40
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">securities prices of particular companies
and, in some cases, may have a broad effect on the prices of securities of companies in particular life sciences industries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life sciences companies can be highly dependent on the strength of patents, trademarks
and other intellectual property rights for maintenance of profit margins and market share. Accordingly, such companies may be significantly affected by such things as the expiration of patents or the loss of , or the
inability to enforce, intellectual property rights. The complex nature of the technologies involved can lead to patent disputes, including litigation that could result in a company losing an exclusive right to a
patent. Competitors of life sciences companies may have substantially greater financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified
managerial and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than any that may be developed by life sciences companies in which the
Fund invests and may also prove to be more successful in production and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater availability
of capital for investment in these fields.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">With respect to healthcare
industries, cost containment measures already implemented by national governments, state or provincial governments, international organizations and the private sector have adversely affected certain sectors of these
industries. Increased emphasis on managed care in the United States may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect the sales
and revenues of life sciences companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable clinical trial results, limited effectiveness in treating the specified
condition or illness, harmful side effects, failure to obtain regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those life sciences
companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Certain life sciences
companies in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceuticals, medical devices or other products.
There can be no assurance that a product liability claim would not have a material adverse effect on the</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">business, financial condition or securities
prices of a company in which the Fund has invested.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">All of these factors as well as
others may cause the value of the Fund&#x2019;s shares to fluctuate significantly over relatively short periods of time.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Pharmaceutical Sector
Risk.<font style="font-weight:Normal"> The success of companies in the pharmaceutical sector is highly dependent on the development, procurement and marketing of drugs. The values of pharmaceutical companies are also dependent
on the development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of pharmaceutical companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The research and other costs
associated with developing or procuring new drugs and the related intellectual property rights can be significant, and the results of such research and expenditures are unpredictable. There can be no assurance that
those efforts or costs will result in the development of a profitable drug. Pharmaceutical companies may be susceptible to product obsolescence. Many pharmaceutical companies face intense competition from new products
and less costly generic products. Moreover, the process for obtaining regulatory approval by the FDA or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary
approvals will be obtained or maintained.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The pharmaceutical sector is
also subject to rapid and significant technological change and competitive forces that may make drugs obsolete or make it difficult to raise prices and, in fact, may result in price discounting. Companies in the
pharmaceutical sector may also be subject to expenses and losses from extensive litigation based on intellectual property,product liability and similar claims. Failure of pharmaceutical companies to comply with
applicable laws and regulations can result in the imposition of civil and criminal fines,penalties and, in some instances, exclusion of participation in government sponsored programs such as Medicare and Medicaid.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the
pharmaceutical sector may be adversely affected by government regulation and changes in reimbursement rates. The ability of many pharmaceutical companies to commercialize and monetize current and any future products
depends in part on the extent to which reimbursement for the cost of such products and related treatments are available from third party payors, such as Medicare, Medicaid, private health insurance plans and health
maintenance organizations. Third-party payors are increasingly challenging the price and cost-effectiveness of many medical products.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Significant uncertainty
exists as to the reimbursement status of health care products, and there can be no assurance that adequate</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">41
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">third-party coverage will be available for
pharmaceutical companies to obtain satisfactory price levels for their products.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The international operations
of many pharmaceutical companies expose them to risks associated with instability and changes in economic and political conditions, foreign currency fluctuations, changes in foreign regulations and other risks
inherent to international business. Additionally, a pharmaceutical company&#x2019;s valuation can often be based largely on the potential or actual performance of a limited number of products. A pharmaceutical
company&#x2019;s valuation can also be greatly affected if one of its products proves unsafe, ineffective or unprofitable. Such companies also may be characterized by thin capitalization and limited markets, financial
resources or personnel, as well as dependence on wholesale distributors. The stock prices of companies in the pharmaceutical industry have been and will likely continue to be extremely volatile.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Biotechnology Industry
Risk.<font style="font-weight:Normal"> The success of biotechnology companies is highly dependent on the development, procurement and/or marketing of drugs. The values of biotechnology companies are also dependent on the
development, protection and exploitation of intellectual property rights and other proprietary information, and the profitability of biotechnology companies may be significantly affected by such things as the
expiration of patents or the loss of, or the inability to enforce, intellectual property rights.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The research and other costs
associated with developing or procuring new drugs, products or technologies and the related intellectual property rights can be significant, and the results of such research and expenditures are unpredictable. There
can be no assurance that those efforts or costs will result in the development of a profitable drug, product or technology.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Moreover, the process for
obtaining regulatory approval by the FDA or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The biotechnology sector is
also subject to rapid and significant technological change and competitive forces that may make drugs, products or technologies obsolete or make it difficult to raise prices and, in fact, may result in price
discounting. Companies in the biotechnology sector may also be subject to expenses and losses from extensive litigation based on intellectual property, product liability and similar claims. Failure of biotechnology
companies to comply with applicable laws and regulations can result in the imposition of civil and/or criminal fines, penalties and, in some instances, exclusion of participation in government sponsored programs such
as Medicare and Medicaid.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Companies in the
biotechnology sector may be adversely affected by government regulation and changes in reimbursement rates.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare providers, principally hospitals,
that transact with companies in the biotechnology industry, often rely on third party payors, such as Medicare, Medicaid, private health insurance plans and health maintenance organizations to reimburse all or a
portion of the cost of healthcare related products or services. Biotechnology companies will continue to be affected by the efforts of governments and third party payors to contain or reduce health care costs. For
example, certain foreign markets control pricing or profitability of biotechnology products and technologies. In the United States, there has been,and there will likely continue to be, a number of federal and state
proposals to implement similar controls.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A biotechnology
company&#x2019;s valuation could be based on the potential or actual performance of a limited number of products and could be adversely affected if one of its products proves unsafe, ineffective or unprofitable. Such
companies may also be characterized by thin capitalization and limited markets, financial resources or personnel. The stock prices of companies involved in the biotechnology sector have been and will likely continue
to be extremely volatile.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed Care Sector Risk.<font style="font-weight:Normal"> Companies in the managed care sector often assume the risk of both medical and administrative costs for their customers in return for monthly premiums. The profitability of these products
depends in large part on the ability of such companies to predict, price for, and effectively manage medical costs. Managed care companies base the premiums they charge and their Medicare bids on estimates of future
medical costs over the fixed contract period; however, many factors may cause actual costs to exceed what was estimated and reflected in premiums or bids. These factors may include medical cost inflation,increased use
of services, increased cost of individual services, natural catastrophes or other large-scale medical emergencies, epidemics, the introduction of new or costly treatments and technology, new mandated benefits (such as
the expansion of essential benefits coverage) or other regulatory changes and insured population characteristics. Relatively small differences between predicted and actual medical costs or utilization rates as a
percentage of revenues can result in significant changes in financial results.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies are
regulated at the federal, state, local and international levels. Insurance and Health Maintenance Organizations (&#x201c;HMOs&#x201d;) subsidiaries must be licensed by and are subject to the regulations of the
jurisdictions in which they conduct business. U.S. health plans and insurance companies are also regulated under state insurance holding company regulations, and some of their activities may be subject to other health
care-related regulations. The health care industry is also regularly subject to negative publicity, including as a result of governmental investigations, adverse media coverage and political debate surrounding
industry regulation. Negative publicity may adversely affect stock price, damage the reputation of managed care companies</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">42
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">in various markets or foster an increasingly
active regulatory environment, which, in turn, could further increase the regulatory burdens under which such companies operate and their costs of doing business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The evolution of the ACA and
other regulatory reforms could materially and adversely affect the manner in which U.S. managed care companies conduct business and their results of operations, financial position and cash flows. The ACA includes
guaranteed coverage and expanded benefit requirements, eliminates pre-existing condition exclusions and annual and lifetime maximum limits, restricts the extent to which policies can be rescinded, establishes minimum
medical loss ratios, creates a federal premium review process, imposes new requirements on the format and content of communications (such as explanations of benefits) between health insurers and their members, grants
to members new and additional appeal rights, and imposes new and significant taxes on health insurers and health care benefits.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">New laws or regulations could
drive substantial change to the way healthcare products and services are currently delivered and paid for in the United States. Health plans and insurance companies could face meaningful disruption or
disintermediation if the U.S. migrates to a single payer healthcare system where the government acts as the sole payer of healthcare services for the entire population. A transformative overhaul of the U.S. healthcare
system could impact the financial viability of managed care companies in which the Fund may invest.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Managed care companies
contract with physicians, hospitals, pharmaceutical benefit service providers, pharmaceutical manufacturers, and other health care providers for services. Suchcompanies&#x2019; results of operations and prospects are
substantially dependent on their continued ability to contract for these services at competitive prices. Failure to develop and maintain satisfactory relationships with health care providers, whether in-network or
out-of network,could materially and adversely affect business, results of operations, financial position and cash flows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Life Science and Tools Industry
Risk.<font style="font-weight:Normal"> Life sciences industries are characterized by limited product focus, rapidly changing technology and extensive government regulation. In particular, technological advances can render an
existing product, which may account for a disproportionate share of a company&#x2019;s revenue, obsolete. Obtaining governmental approval from agencies such as the FDA, the U.S. Department of Agriculture and other U.S.
and non-U.S. governmental agencies for new products can be lengthy, expensive and uncertain as to outcome. Such delays in product development may result in the need to seek additional capital, potentially diluting the
interests of existing investors such as the Fund. In addition,governmental agencies may, for a variety of reasons, restrict the release</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">of certain innovative technologies of
commercial significance, such as genetically altered material. These various factors may result in abrupt advances and declines in the securities prices of particular companies and, in some cases, may have a broad
effect on the prices of securities of companies in particular life sciences industries.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Intense competition exists
within and among certain life sciences industries, including competition to obtain and sustain proprietary technology protection. Life sciences companies can be highly dependent on the strength of patents, trademarks
and other intellectual property rights for maintenance of profit margins and market share. Accordingly, such companies may be significantly affected by such things as the expiration of patents or the loss of , or the
inability to enforce, intellectual property rights. The complex nature of the technologies involved can lead to patent disputes, including litigation that could result in a company losing an exclusive right to a
patent. Competitors of life sciences companies may have substantially greater financial resources, more extensive development, manufacturing, marketing and service capabilities, and a larger number of qualified
managerial and technical personnel. Such competitors may succeed in developing technologies and products that are more effective or less costly than any that may be developed by life sciences companies in which the
Fund invests and may also prove to be more successful in production and marketing. Competition may increase further as a result of potential advances in health services and medical technology and greater availability
of capital for investment in these fields.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">With respect to healthcare
industries, cost containment measures already implemented by the federal government, state governments and the private sector have adversely affected certain sectors of these industries. Increased emphasis on managed
care in the United States may put pressure on the price and usage of products sold by life sciences companies in which the Fund may invest and may adversely affect the sales and revenues of life sciences companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Product development efforts
by life sciences companies may not result in commercial products for many reasons, including, but not limited to, failure to achieve acceptable clinical trial results, limited effectiveness in treating the specified
condition or illness, harmful side effects, failure to obtain regulatory approval, and high manufacturing costs. Even after a product is commercially released, governmental agencies may require additional clinical
trials or change the labeling requirements for products if additional product side effects are identified, which could have a material adverse effect on the market price of the securities of those life sciences
companies</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Certain life sciences
companies in which the Fund may invest may be exposed to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of pharmaceuticals, medical devices or other products.
There can be no assurance that a</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">43
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">product liability claim would not have a
material adverse effect on the business, financial condition or securities prices of a company in which the Fund has invested.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Technology Sector
Risk.<font style="font-weight:Normal"> Companies in the healthcare technology sector may incur substantial costs related to product-related liabilities. Many of the software solutions,health care devices or services developed
by such companies are intended for use in collecting, storing and displaying clinical and health care-related information used in the diagnosis and treatment of patients and in related health care settings such as
admissions,billing, etc. The limitations of liability set forth in the companies&#x2019; contracts may not be enforceable or may not otherwise protect these companies from liability for damages. Healthcare technology
companies may also be subject to claims that are not covered by contract, such as a claim directly by a patient. Although such companies may maintain liability insurance coverage, there can be no assurance that such
coverage will cover any particular claim that has been brought or that may be brought in the future, that such coverage will prove to be adequate or that such coverage will continue to remain available on acceptable
terms, if at all.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare technology
companies may experience interruption at their data centers or client support facilities. The business of such companies often relies on the secure electronic transmission, data center storage and hosting of sensitive
information, including protected health information, financial information and other sensitive information relating to clients,company and workforce. In addition, such companies may perform data center and/or hosting
services for certain clients, including the storage of critical patient and administrative data and support services through various client support facilities. If any of these systems are interrupted, damaged or
breached by an unforeseen event or actions of a third party,including a cyber-attack, or fail for any extended period of time, it could have a material adverse impact on the results of operations for such
companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The proprietary technology
developed by healthcare technology companies may be subject to claims for infringement or misappropriation of intellectual property rights of others, or maybe infringed or misappropriated by others. Despite protective
measures and intellectual property rights, such companies may not be able to adequately protect against theft, copying,reverse-engineering, misappropriation, infringement or unauthorized use or disclosure of their
intellectual property, which could have an adverse effect on their competitive position. In addition, these companies are routinely involved in intellectual property infringement or misappropriation claims and it is
expected that this activity will continue or even increase as the number of competitors, patents and patent enforcement organizations in the healthcare technology market increases, the functionality of software
solutions and services</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">expands, the use of open-source software
increases and new markets such as health care device innovation, health care transactions, revenue cycle, population health management and life sciences are entered into. These claims, even if not meritorious, are
expensive to defend and are often incapable of prompt resolution.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The success of healthcare
technology companies depends upon the recruitment and retention of key personnel. To remain competitive, such companies must attract, motivate and retain highly skilled managerial, sales, marketing, consulting and
technical personnel, including executives, consultants, programmers and systems architects skilled in healthcare technology,health care devices, health care transactions, population health management, revenue cycle
and life sciences industries and the technical environments in which solutions, devices and services are needed. Competition for such personnel in the healthcare technology sector is intense in both the United States
and abroad. The failure to attract additional qualified personnel could have a material adverse effect on healthcare technology companies&#x2019; prospects for long-term growth.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Services Sector
Risk.<font style="font-weight:Normal"> The operations of healthcare services companies are subject to extensive federal, state and local government regulations, including Medicare and Medicaid payment rules and regulations,
federal and state anti-kickback laws, the physician self-referral law (&#x201c;Stark Law&#x201d;) and analogous state self-referral prohibition statutes, Federal Acquisition Regulations, the False Claims Act and federal
and state laws regarding the collection, use and disclosure of patient health information and the storage, handling and administration of pharmaceuticals. The Medicare and Medicaid reimbursement rules related to
claims submission, enrollment and licensing requirements, cost reporting, and payment processes impose complex and extensive requirements upon dialysis providers as well. A violation or departure from any of these
legal requirements may result in government audits,lower reimbursements, significant fines and penalties, the potential loss of certification,recoupment efforts or voluntary repayments. If healthcare services
companies fail to adhere to all of the complex government regulations that apply to their businesses, such companies could suffer severe consequences that would substantially reduce revenues, earnings, cash flows and
stock prices.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">A substantial percentage of a
healthcare services company&#x2019;s service revenues may be generated from patients who have state Medicaid or other non-Medicare government-based programs, such as coverage through the Department of Veterans Affairs
(&#x201c;VA&#x201d;), as their primary coverage. As state governments and other governmental organizations face increasing budgetary pressure, healthcare services companies may in turn face reductions in payment rates,
delays in the receipt of payments, limitations on enrollee eligibility or other changes to the applicable programs.</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">44
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Adverse economic conditions could adversely
affect the business and profitability of healthcare services companies. Among other things, the potential decline in federal, non-U.S. government and state revenues that may result from such conditions may create
additional pressures to contain or reduce reimbursements for services from Medicare, Medicaid and other government sponsored programs. Increasing job losses or slow improvement in the unemployment rate in the United
States and elsewhere as a result of adverse or recent economic conditions may result in a smaller percentage of patients being covered by an employer group health plan and a larger percentage being covered by lower
paying Medicare and Medicaid programs. Employers may also select more restrictive commercial plans with lower reimbursement rates. To the extent that payors are negatively impacted by a decline in the economy,
healthcare services companies may experience further pressure on commercial rates, a further slowdown in collections and a reduction in the amounts they expect to collect. In addition, uncertainty in the financial
markets could adversely affect the variable interest rates payable under credit facilities or could make it more difficult to obtain or renew such facilities or to obtain other forms of financing in the future, if at
all. Any or all of these factors, as well as other consequences of the adverse economic conditions which cannot currently be anticipated, could have a material adverse effect on a healthcare services company&#x2019;s
revenues, earnings and cash flows and otherwise adversely affect its financial condition.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Supplies Sector
Risk.<font style="font-weight:Normal"> If healthcare supplies companies are unable to successfully expand their product lines through internal research and development and acquisitions, their business may be materially and
adversely affected. In addition, if these companies are unable to successfully grow their businesses through marketing partnerships and acquisitions, their business may be materially and adversely affected.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Consolidation of healthcare
providers has increased demand for price concessions and caused the exclusion of suppliers from significant market segments. It is expected that market demand, government regulation, third-party reimbursement
policies, government contracting requirements and societal pressures will continue to change the worldwide healthcare industry, resulting in further business consolidations and alliances among customers and
competitors. This may exert further downward pressure on the prices of healthcare suppliescompanies&#x2019; products and adversely impact their businesses, financial conditions or results of operations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Quality is extremely
important to healthcare supplies companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of their products and
services. If a healthcare supplies company fails to meet these standards or fails to adapt to evolving</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">standards, its reputation could be damaged, it
could lose customers, and its revenue and results of operations could decline.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Facilities Sector
Risk.<font style="font-weight:Normal"> A healthcare facility&#x2019;s ability to negotiate favorable contracts with HMOs, insurers offering preferred provider arrangements and other managed care plans significantly affects the
revenues and operating results of such healthcare facilities.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">In addition, private payers
are increasingly attempting to control health care costs through direct contracting with hospitals to provide services on a discounted basis, increased utilization reviews and greater enrollment in managed care
programs, such as HMOs and Preferred Provider Organizations (&#x201c;PPOs&#x201d;). The trend toward consolidation among private managed care payers tends to increase their bargaining power over prices and fee
structures. As various provisions of the ACA evolve, it is not clear what impact, if any, the increased obligations on private payers imposed by the health care reform law will have on a healthcare facility&#x2019;s
ability to negotiate reimbursement increases. Non-government payers may increasingly demand reduced fees. If a healthcare facility is unable to enter into and maintain managed care contractual arrangements on
acceptable terms, if it experiences material reductions in the contracted rates received from managed care payers, or if it has difficulty collecting from managed care payers, its results of operations could be
adversely affected.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Further changes in the
Medicare and Medicaid programs or other government health care programs could have an adverse effect on a healthcare facility&#x2019;s business. In addition to the changes affected by the ACA, the Medicare and Medicaid
programs are subject to other statutory and regulatory changes, administrative rulings, interpretations and determinations concerning patient eligibility requirements, funding levels and the method of calculating
payments or reimbursements, among other things, requirements for utilization review, and federal and state funding restrictions. All of these could materially increase or decrease payments from government programs in
the future, as well as affect the cost of providing services to patients and the timing of payments to facilities, which could in turn adversely affect a healthcare facility&#x2019;s overall business, financial
condition, results of operations or cash flows.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare facilities are
adversely affected by uninsured and underinsured patients, as well as a growing mix of Medicare and Medicaid patients that typically have lower reimbursement rates than commercial managed care patients As a result,
healthcare facilities continue to experience a shift in payer mix and a high level of uncollectible accounts, which could worsen if there is an increase in unemployment. Healthcare facilities may continue to
experience significant levels of bad debt expense and may have to provide uninsured discounts and charity care for undocumented immigrants</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:18.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">45
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">who are not permitted to enroll in a health
insurance exchange or government health care program. The trend of higher co-pays and deductibles and a focus on migrating healthcare utilization to lower cost sites of care, may also pressure volumes and revenue at
certain healthcare facilities which could adversely impact the financial condition of hospitals and facilities with high fixed cost structures.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Equipment
Sector Risk.<font style="font-weight:Normal"> The medical device markets are highly competitive and a healthcare equipment company many be unable to compete effectively. These markets are characterized by rapid change resulting from
technological advances and scientific discoveries.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Development by other
companies of new or improved products, processes, or technologies may make a healthcare equipment company&#x2019;s products or proposed products less competitive. In addition, these companies face competition from
providers of alternative medical therapies such as pharmaceutical companies.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Medical devices and related
business activities are subject to rigorous regulation, including by the FDA, U.S. Department of Justice (&#x201c;DOJ&#x201d;), and numerous other federal, state, and foreign governmental authorities. These authorities
and members of Congress have been increasing their scrutiny of the healthcare equipment industry. In addition, certain states have passed or are considering legislation restricting healthcare equipment
companies&#x2019; interactions with health care providers and requiring disclosure of certain payments to them. It is anticipated that governmental authorities will continue to scrutinize this industry closely,and that
additional regulation may increase compliance and legal costs, exposure to litigation, and other adverse effects to operations.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare equipment
companies are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in the payment of significant
monetary damages and/or royalty payments, may negatively impact the ability of healthcare equipment companies to sell current or future products, or may prohibit such companies from enforcing their patent and other
proprietary rights against others.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Quality problems with the
processes, goods and services of a healthcare equipment company could harm the company&#x2019;s reputation for producing high-quality products and erode its competitive advantage, sales and market share. Quality is
extremely important to healthcare equipment companies and their customers due to the serious and costly consequences of product failure. Quality certifications are critical to the marketing success of goods and
services. If a healthcare equipment company fails to meet these standards, its reputation could be damaged, it could lose customers, and its revenue and results of operations could decline.</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare Distributors Sector Risk.<font style="font-weight:Normal"> Companies in the healthcare distribution sector operate in markets that are highly competitive. Because of competition, many of these companies face pricing pressures from customers and
suppliers. If these companies are unable to offset margin reductions caused by pricing pressures through steps such as effective sourcing and enhanced cost control measures, the financial condition of such companies
could be adversely affected. In addition, the healthcare industry has continued to consolidate. Further consolidation among customers and suppliers (including branded pharmaceutical manufacturers) could give the
resulting enterprises greater bargaining power,which may adversely impact the financial condition of companies in the healthcare distribution sector.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Fewer generic pharmaceutical
launches or launches that are less profitable than those previously experienced may have an adverse effect on the profits of companies in the healthcare distribution sector. Additionally, prices for existing generic
pharmaceuticals generally decline over time, although this may vary. Price deflation on existing generic pharmaceuticals may have an adverse effect on company profits. With respect to branded pharmaceutical price
appreciation, if branded manufacturers increase prices less frequently or by amounts that are smaller than have been experienced historically, healthcare distribution companies may profit less from branded
pharmaceutical agreements.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The healthcare industry is
highly regulated, and healthcare distribution companies are subject to regulation in the United States at both the federal and state level and in foreign countries. If healthcare distribution companies fail to comply
with these regulatory requirements, the financial condition of such companies could be adversely affected.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Due to the nature of the
business of healthcare distribution companies, such companies may from time to time become involved in disputes or legal proceedings. For example, some of the products that these companies distribute may be alleged to
cause personal injury or violate the intellectual property rights of another party, subjecting such companies to product liability or infringement claims. Litigation is inherently unpredictable, and the unfavorable
resolution of one or more of these legal proceedings could adversely affect the cash flows and balance sheets of healthcare distribution companies. Pharmaceutical distributors currently face lawsuits related to the
abuse of opioid medications in the United States. The allegations include that pharmaceutical distributors failed to provide effective controls around the quantities of opioid medications distributed to certain
pharmacies, failed to properly prevent the diversion of medications and failed to report suspicious orders. Pharmaceutical distributors are in discussions with federal, state and local</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:25.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">46
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">jurisdictions related to their role in the
distribution of opioid pharmaceuticals and it is possible that they will be required to pay multi-billion dollar settlements related to the ongoing litigation.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Healthcare distribution
companies depend on the availability of various components,compounds, raw materials and energy supplied by others for their operations. Any of these supplier relationships could be interrupted due to events beyond the
control of such companies, including pandemics, epidemics or natural disasters, or could be terminated. A sustained supply interruption could have an adverse effect on business.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Risks Associated with
Regulatory and Policy Changes.<font style="font-weight:Normal"> At any time after the date hereof, U.S. and non-U.S. governmental agencies and other regulators may implement additional regulations and legislators may pass new laws that affect the
investments held by the Fund, the strategies used by the Fund or the level of regulation or taxation applying to the Fund. These regulations and laws impact the investment strategies, performance, costs and operations
of the Fund, as well as the way investments in, and Shareholders of, the Fund are taxed. In particular, changes to U.S. healthcare policy could affect the Fund and its investments.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Investment in Emerging Growth
Companies. <font style="font-weight:Normal">The Fund may invest in equity securities of emerging growth life sciences companies. While these securities offer the opportunity for significant capital gains, such investments also
involve a degree of risk that can result insubstantial losses. There can be no assurance that securities of start-up or emerging growth companies will, in the future, yield returns commensurate with their associated
risks.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Liquidity of Portfolio
Investments.<font style="font-weight:Normal"> The Fund may invest in securities that are traded in the over-the-counter markets or on regional stock exchanges where the low trading volume of a particular security may result in abrupt
and erratic price movements or that are not traded in any market. An investment in such securities may have limited liquidity, and the Fund may find it necessary to sell at a discount from recent prices or to sell
over extended periods of time when disposing of such securities. In addition, the Fund may invest up to40% of its net assets in Restricted Securities, which by their terms are illiquid. In many cases,&#xa0;Restricted
Securities in which the Fund may invest cannot be sold except in a public offering registered under the Securities Act of 1933, as amended, pursuant to an exemption from the Securities Act or in compliance with
applicable Securities and Exchange Commission regulations.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Venture Capital
Investments Risk.<font style="font-weight:Normal"> The Fund may occasionally invest in venture capital opportunities. While these securities offer the opportunity for significant capital gains, such investments also involve a degree of
risk that can result in substantial losses. Some of the venture capital opportunities in which the Fund may invest are expected to be companies that are in a &#x201c;start-up&#x201d; stage of</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">development, have little or no operating
history, operate at a loss or with substantial variations in operating results from period to period, have limited products, markets, financial resources or management depth, or have the need for substantial
additional &#x201c;follow-on&#x201d; capital to support expansion or to achieve or maintain a competitive position. Such additional investments may dilute the interests of prior investors, such as the Fund. Some of
these companies may be emerging companies at the research and development stage with no marketable or approved products or technology. There can be no assurance that securities of start-up or emerging growth companies
will, in the future, yield returns commensurate with their associated risks.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">These investments, which are
considered Restricted Securities, will be made primarily in convertible preferred stock. The Fund may also purchase non-convertible debt securities in connection with its venture capital investments, and otherwise
when the Investment Adviser believes that such investments would be consistent with the Fund&#x2019;s investment objective. While these debt investments typically will not be rated, the Investment Adviser believes
that,in light of the risk characteristics associated with investments in emerging growth companies,if such investments were to be compared with investments rated by S&amp;P or Moody&#x2019;s, they may be rated as low
as &#x201c;C&#x201d; in the rating categories established by S&amp;P and Moody&#x2019;s. Such securities are commonly referred to as &#x201c;junk bonds&#x201d; and are considered, on balance, as predominantly
speculative.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Restricted Securities and
Valuation Risk.<font style="font-weight:Normal"> Some of the Fund&#x2019;s investments are subject to restrictions on resale and generally have no established trading market or are otherwise illiquid with little or no trading activity.
The valuation process requires an analysis of various factors. The Fund&#x2019;s fair value methodology includes the examination of, among other things,(i) the existence of any contractual restrictions on the
disposition of the securities;(ii) information obtained from the issuer which may include an analysis of the company&#x2019;s financial statements, the company&#x2019;s products or intended markets, or the
company&#x2019;s technologies; and (iii) the price of a security sold at arm&#x2019;s length in an issuer&#x2019;s subsequent completed round of financing. As there is typically no readily available market value for some
of the Restricted Securities in the Fund&#x2019;s portfolio, such Restricted Securities in the Fund&#x2019;s portfolio are valued at fair value as determined in good faith by or under the direction of the Board pursuant
to the Fund&#x2019;s valuation policy and a consistently applied valuation process. Because of the inherent uncertainty of determining the fair value of investments that do not have a readily available market value,
the fair value of the Fund&#x2019;s investments determined in good faith by the Board may differ significantly from the values that would have been used had a ready market existed for the investments, and the
differences could be material. There is no single standard for determining fair value in good faith. As a result, determining fair value</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:12.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">47
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">requires that judgment be applied to the
specific facts and circumstances of each portfolio investment, while employing a consistently applied valuation process for the types of investments the Fund makes.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign Securities Risk.<font style="font-weight:Normal"> The Fund may invest up to 20% of its net assets in Foreign Securities. Foreign Securities involve special risks that are not typically associated with U.S.dollar denominated or quoted
securities of U.S. issuers. Foreign Securities may be affected by changes in currency rates, changes in foreign or U.S. laws or restrictions applicable to such investments and changes in exchange control regulations
(e.g., currency blockage). A decline in the exchange rate of the currency (i.e., weakening of the currency against the U.S. dollar) in which a portfolio security is quoted or denominated relative to the U.S. dollar
would reduce the value of the portfolio security. In addition, if the currency in which the Fund receives dividends, interest or other payments declines in value against the U.S. dollar before such income is
distributed as dividends to Shareholders or converted to U.S. dollars, the Fund may have to sell portfolio securities to obtain sufficient cash to pay such dividends.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Brokerage commissions,
custodial services and other costs relating to investment in international securities markets generally are more expensive than in the United States. In addition, clearance and settlement procedures may be different
in foreign countries and, in certain markets, such procedures have been unable to keep pace with the volume of securities transactions, thus making it difficult to conduct such transactions.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Foreign issuers are not
generally subject to uniform accounting, auditing and financial reporting standards comparable to those applicable to U.S. issuers. There may be less publicly available information about a foreign issuer than about a
U.S. issuer. In addition, there is generally less government regulation of foreign markets, companies and securities dealers than in the United States, and the legal remedies for investors may be more limited than the
remedies available in the United States. Foreign securities markets may have substantially less volume than U.S. securities markets and securities of many foreign issuers are less liquid and more volatile than
securities of comparable domestic issuers. Furthermore, with respect to certain foreign countries, there is a possibility of nationalization, expropriation or confiscatory taxation, imposition of withholding or other
taxes on dividend or interest payments (or, in some cases, capital gains distributions), limitations on the removal of funds or other assets from such countries, and risks of political or social instability or
diplomatic developments which could adversely affect investments in those countries. Adverse diplomatic developments may include the imposition of economic or trade sanctions or other measures by the U.S. or other
governments and supranational organizations or changes in trade policies. These developments may, among other things, limit the ability of the Fund</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:left; text-decoration:none; text-transform:none">to invest in certain securities or require the
disposition of an investment.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Management Risk.<font style="font-weight:Normal"> The Fund&#x2019;s ability to achieve its investment objective is directly related to the Investment Adviser&#x2019;s investment strategies for the Fund. The value of your investment in the
Fund&#x2019;s common shares may vary with the effectiveness of the research and analysis conducted by the Investment Adviser and its ability to identify and take advantage of attractive investment opportunities. If the
investment strategies of the Investment Adviser do not produce the expected results, the value of your investment could be diminished or even lost entirely, and the Fund could underperform the market or other funds
with similar investment objective.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Key Personnel Risk.<font style="font-weight:Normal"> There may be only a limited number of securities professionals who have comparable experience to that of the Fund&#x2019;s existing portfolio management team in the area of healthcare
companies. If one or more of the team members dies, resigns, retires or is otherwise unable to act on behalf of the Investment Adviser, there can be no assurance that a suitable replacement could be found
immediately.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Concentration of
Investments.<font style="font-weight:Normal"> The Fund may from time to time concentrate its investments in a few issuers and take large positions in those issuers. As a result, the Fund may be subject to a greater risk of loss than
an investment company that diversifies its investments more broadly. Taking larger positions is also likely to increase the volatility of the Fund&#x2019;s NAV reflecting fluctuation in the value of its large holdings.
The Fund may make investments in any company with the objective of controlling or influencing the management and policies of that company. Investing for the purpose of controlling or influencing the management and
policies of a company could potentially make the Fund less diversified and more susceptible to declines in the value of the company&#x2019;s stock. The Investment Adviser may seek a control position in private venture
capital investments where the Investment Adviser believes its knowledge and experience will be of significant benefit to the invested company and, therefore, to the Fund&#x2019;s investment. The Investment Adviser
expects to seek control in public companies only occasionally and most often in companies with a small capitalization.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Anti-Takeover Provisions
Risk.<font style="font-weight:Normal"> The Fund&#x2019;s Declaration of Trust (&#x201c;Declaration of Trust&#x201d;),dated February 20, 1992, as amended, has provisions that could have the effect of limiting the ability of other
entities or persons to (1) acquire control of the Fund, (2) cause it to engage in certain transactions, or (3) modify its structure. The By-Laws also contain provisions regarding qualifications for nominees for
Trustee positions, advance notice of Shareholder proposals, and requirements for the call of special Shareholder meetings. These provisions may be considered &#x201c;anti-takeover&#x201d; provisions.</font></div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:11.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">48
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(continued)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">Related Party Transactions Risk.<font style="font-weight:Normal"> The Fund may be subject to certain potential conflicts of interest. Although the Fund has no obligation to do so, it may place brokerage orders with brokers who provide supplemental
investment research and market and statistical information about life sciences companies and the life sciences industries. In addition, other investment companies advised by the Investment Adviser may concurrently
invest with the Fund in Restricted Securities under certain conditions. The Fund also may invest, subject to applicable law, in companies in which the principals of the Investment Adviser or Trustees of the Fund have
invested, or for which they serve as directors or executive officers. The Investment Company Act prohibits the Fund from engaging in certain transactions involving its &#x201c;affiliates,&#x201d; including, among
others, the Fund&#x2019;s Trustees, officers and employees, the Investment Adviser and any &#x201c;affiliates&#x201d; of such affiliates except pursuant to an exemptive order or the provisions of certain rules under the
Investment Company Act. In the view of the staff of the Commission, other investment companies advised by the Investment Adviser may,in some instances, be viewed to be affiliates of the Fund. Such legal restrictions
and delays and costs involved in obtaining necessary regulatory approvals may preclude or discourage the Fund from making certain investments and no assurance can be given that any exemptive order sought by the Fund
will be granted.</font></div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Investment
Adviser&#x2019;s investment team is responsible for managing the Fund as well as three other closed-end investment companies. In the future, the investment team may manage other funds and accounts, including
proprietary accounts, separate accounts and other pooled investment vehicles, such as unregistered hedge funds. In the future, a portfolio manager may manage a separate account or other pooled investment vehicle which
may have materially higher fee arrangements than the Fund and may also have a performance based fee. The side-by-side management of these funds or accounts may raise potential conflicts of interest relating to cross
trading, the allocation of investment opportunities and the aggregation and allocation of trades.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Regulation as a
 &#x201c;Commodity Pool&#x201d;.<font style="font-weight:Normal"> The Investment Adviser has claimed an exclusion from the definition of the term &#x201c;commodity pool operator&#x201d; with respect to the Fund pursuant to Regulation 4.5 promulgated by the
U.S. Commodity Futures Trading Commission (the &#x201c;CFTC&#x201d;). For the Investment Adviser to continue to qualify for the exclusion under CFTC Regulation 4.5 with respect to the Fund, the aggregate initial margin
and premiums required to establish our positions in derivative instruments subject to the jurisdiction of the Commodity Exchange Act of 1936, as amended (&#x201c;CEA&#x201d;) (other than positions entered into for
hedging purposes) may not exceed five percent of the Fund&#x2019;s liquidation value or, alternatively, the net notional value of the Fund&#x2019;s aggregate investments in CEA-regulated derivative instruments (other
than positions entered into for hedging</font></div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">purposes) may not exceed 100% of the
Fund&#x2019;s liquidation value. In the event the Investment Adviser fails to qualify for the exclusion with respect to the Fund and is required to register as a &#x201c;commodity pool operator&#x201d;, it will become
subject to additional disclosure, record keeping and reporting requirements with respect to the Fund, which may increase the Fund&#x2019;s expenses.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:bold; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Special Purpose Acquisition
Company Risk.<font style="font-weight:Normal"> The Fund may invest in SPACs. SPACs are collective investment structures that pool funds in order to seek potential acquisition opportunities. Unless and until an acquisition is completed,
a SPAC generally invests its assets (less an amount to cover expenses) in U.S. government securities, money market fund securities and cash. SPACs and similar entities may be blank check companies with no operating
history or ongoing business other than to seek a potential acquisition. Certain SPACs may seek acquisitions only in limited industries or regions. If an acquisition that meets the requirements for the SPAC is not
completed within a predetermined period of time, the invested funds are returned to the entity&#x2019;s shareholders, unless such shareholders approve alternative arrangements. Investments in SPACs may be illiquid
and/or be subject to restrictions on resale.</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:bold; line-height:14pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">FUNDAMENTAL INVESTMENT
RESTRICTIONS&#xa0;</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The Fund has adopted the
following fundamental restrictions, which, like its investment objective, may not be changed without the approval of the holders of a majority of the Fund's outstanding voting securities (which for this purpose and
under the Investment Company Act, means the lesser of (1) 67% of the voting shares present in person or by proxy at a meeting at which more than 50% of the outstanding voting shares are present in person or by proxy,
or (2) more than 50% of the outstanding voting shares).</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">1.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund may not purchase or sell physical commodities or physical commodities contracts.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">2.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund may not purchase or sell real estate; provided that the Fund may invest in securities secured by real estate or interests therein or issued by companies which invest in real estate or interests
therein.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">3.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund may not underwrite securities of other issuers, except to the extent that, in connection with the disposition of its portfolio securities, the Fund may be deemed an underwriter under federal or
state securities laws.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">4.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund may issue senior securities to the extent permitted under the Investment Company Act and the rules and regulations thereunder.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">5.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund may not make loans of money, which for the purposes of this restriction does not include the purchase of debt obligations in which the Fund may invest consistent with its
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:17.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">49
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Additional Information Regarding the
Fund&#xa0;<font style="font-size:11pt; line-height:14pt">(Unaudited) &#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-left:0pt; padding-right:2pt; text-align:left; vertical-align:top; width:6.98%">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">investment objective and policies. The Fund reserves the authority to enter into repurchase agreements and to make loans of its portfolio securities to qualified institutional investors, brokers,
dealers, banks or other financial institutions, so long as the terms of the loans are not inconsistent with the requirements of the Investment Company Act. Such loans of portfolio securities may not exceed an
aggregate amount of 33 1/3% of the Fund&#x2019;s net assets.
</td></tr></table>
</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:6pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:0pt; padding-right:2pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:6.98%">6.
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">The Fund may not invest less than 25% of its net assets in securities of Life Sciences Companies in the healthcare industry, except that, during periods in which the Investment Adviser
</td></tr></table>
</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="line-height:0pt; padding-left:0pt; padding-right:2pt; text-align:left; vertical-align:top; width:6.98%">&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; padding-left:2pt; text-align:justify; text-decoration:none; text-transform:none; vertical-align:top; width:93.02%">believes the healthcare industry is affected by adverse economic conditions, the Fund may temporarily have less than 25% of the value of its net assets so invested.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Except as otherwise noted,
all percentage limitations set forth above apply immediately after a purchase and a subsequent change in the applicable percentage resulting from market fluctuations does not require elimination of any security from
the portfolio.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:504.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">50
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">The Fund intends to distribute to
shareholders substantially all of its net investment income and to distribute any net realized capital gains at least annually. Net investment income for this purpose is income other than net realized long-term and
short-term capital gains net of expenses. Pursuant to the Dividend Reinvestment and Optional Cash Purchase Plan (the &#x201c;Plan&#x201d;), shareholders whose shares of common stock are registered in their own names
will be deemed to have elected to have all distributions automatically reinvested by Computershare Trust Company N.A. (the &#x201c;Plan Agent&#x201d;) in the Fund shares pursuant to the Plan, unless such shareholders
elect to receive distributions in cash. Shareholders who elect to receive distributions in cash will receive such distributions paid by check in U.S. Dollars mailed directly to the shareholder by the Plan Agent, as
dividend paying agent. In the case of shareholders such as banks, brokers or nominees that hold shares for others who are beneficial owners, the Plan Agent will administer the Plan on the basis of the number of shares
certified from time to time by the shareholders as representing the total amount registered in such shareholders&#x2019; names and held for the account of beneficial owners that have not elected to receive
distributions in cash. Investors that own shares registered in the name of a bank, broker or other nominee should consult with such nominee as to participation in the Plan through such nominee and may be required to
have their shares registered in their own names in order to participate in the Plan. Please note that the Fund does not issue certificates so all shares will be registered in book entry form. The Plan Agent serves as
agent for the shareholders in administering the Plan. If the Trustees of the Fund declare an income dividend or a capital gains distribution payable either in the Fund&#x2019;s common stock or in cash, nonparticipants
in the Plan will receive cash and participants in the Plan will receive common stock, to be issued by the Fund or purchased by the Plan Agent in the open market, as provided below. If the market price per share (plus
expected per share fees) on the valuation date equals or exceeds NAV per share on that date, the Fund will issue new shares to participants at NAV; provided, however, that if the NAV is less than 95% of the market
price on the valuation date, then such shares will be issued at 95% of the market price. The valuation date will be the payable date for such distribution or dividend or, if that date is not a trading day on the NYSE,
the immediately preceding trading date. If NAV exceeds the market price of Fund shares at such time, or if the Fund should declare an income dividend or capital gains distribution payable only in cash, the Plan Agent
will, as agent for the participants, buy Fund shares in the open market, on the NYSE or elsewhere, for the participants&#x2019; accounts on, or shortly after, the payment date. If, before the Plan Agent has completed
its purchases, the market price exceeds the NAV of the Fund's share, the average per share purchase price paid by the Plan Agent may exceed the NAV of the Fund&#x2019;s shares, resulting in the acquisition of fewer
shares than if the distribution had been paid in shares issued by the Fund on the dividend payment date. Because of</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the foregoing difficulty with respect to
open-market purchases, the Plan provides that if the Plan Agent is unable to invest the full dividend amount in open-market purchases during the purchase period or if the market discount shifts to a market premium
during the purchase period, the Plan Agent will cease making open-market purchases and will receive the uninvested portion of the dividend amount in newly issued shares at the close of business on the last purchase
date.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants have the option
of making additional cash payments of a minimum of $50 per investment (by check, one-time online bank debit or recurring automatic monthly ACH debit) to the Plan Agent for investment in the Fund&#x2019;s common stock,
with an annual maximum contribution of $250,000. The Plan Agent will wait up to three business days after receipt of a check or electronic funds transfer to ensure it receives good funds. Following confirmation of
receipt of good funds, the Plan Agent will use all such funds received from participants to purchase Fund shares in the open market on the 25th day of each month or the next trading day if the 25th is not a trading
day.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">If the participant sets up
recurring automatic monthly ACH debits, funds will be withdrawn from his or her U.S. bank account on the 20th of each month or the next business day if the 20th is not a banking business day and invested on the next
investment date. The Plan Agent maintains all shareholder accounts in the Plan and furnishes written confirmations of all transactions in an account, including information needed by shareholders for personal and tax
records. Shares in the account of each Plan participant will be held by the Plan Agent in the name of the participant, and each shareholder&#x2019;s proxy will include those shares purchased pursuant to the Plan. There
will be no brokerage charges with respect to common shares issued directly by the Fund. However, each participant will pay a per share fee of $0.02 incurred with respect to the Plan Agent&#x2019;s open market purchases
in connection with the reinvestment of dividends, capital gains distributions and voluntary cash payments made by the participant. Per share fees include any applicable brokerage commissions the Plan Agent is required
to pay.</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">Participants also have the
option of selling their shares through the Plan. The Plan supports two types of sales orders. Batch order sales are submitted on each market day and will be grouped with other sale requests to be sold. The price will
be the average sale price obtained by Computershare&#x2019;s broker, net of fees, for each batch order and will be sold generally within 2 business days of the request during regular open market hours. Please note that
all written sales requests are always processed by Batch Order. ($10 and $0.12 per share). Market Order sales will sell at the next available trade. The shares are sold real time when they hit the market, however an
available trade must be presented to complete this transaction. Market Order sales may only</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:16.5pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">51
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:92.99%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Dividend Reinvestment and Optional Cash Purchase
Plan&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(concluded)</font></div>
</div>
<div style="margin-top:6pt; width:92.99%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:21.5pt">
<div style="float:left; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">be requested by phone at 1-800-647-0584 or
using Investor Center through www.computershare.com/buyaberdeen. ($25 and $0.12 per share).</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:6pt; text-align:justify; text-decoration:none; text-transform:none">The receipt of dividends and
distributions under the Plan will not relieve participants of any income tax that may be payable on such dividends or distributions. The Fund or the Plan Agent may terminate the Plan as applied to any voluntary cash
payments made and any dividend or distribution paid subsequent to notice of the termination sent to members of the Plan at least 30 days prior to the record date for such dividend or distribution. The Plan also may be
amended by</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:46.98%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; text-align:justify; text-decoration:none; text-transform:none">the Fund or the Plan Agent, but (except when
necessary or appropriate to comply with applicable law or the rules or policies of the Securities and Exchange Commission or any other regulatory authority) only by mailing a written notice at least 30 days prior to
the effective date to the participants in the Plan. All correspondence concerning the Plan should be directed to the Plan Agent by phone at 1-800-647-0584, using Investor Center through <font style="color:#0000FF; text-decoration:underline">www.computershare.com/buyaberdeen</font> or in writing to Computershare Trust Company N.A., P.O. Box 43006, Providence, RI 02940-3078.&#xa0;</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:517.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">52
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:18.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">The names, years of birth and
business addresses of the Board Members and officers of the Fund as of October 31, 2025, their principal occupations during at least the past five years, the number of portfolios each Board Member oversees and other
directorships they hold are provided in the tables below. Board Members that are deemed &#x201c;interested persons&#x201d; (as that term is defined in Section 2(a)(19) of the Investment Company Act of 1940, as amended)
of the Fund or the Fund's Advisers are included in the table below under the heading &#x201c;Interested Board Members.&#x201d; Board Members who are not interested persons, as described above, are referred to in the
table below under the heading &#x201c;Independent Board Members.&#x201d; abrdn Inc., its parent company Aberdeen Group plc, and its advisory affiliates are collectively referred to as &#x201c;Aberdeen&#x201d; in the
tables below.</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.53%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.32%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.06%; background-color: #D9D9D9;">Principal Occupation(s)<br>
During at Least the Past Five Years
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.16%; background-color: #D9D9D9;">Number of Registered<br>
Investment Companies<br>
("Registrants") consisting<br>
of Investment Portfolios<br>
("Portfolios") in<br>
Fund Complex*<br>
Overseen by<br>
Board Members
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.88%; background-color: #D9D9D9;">Other<br>
Directorships<br>
Held by<br>
Board Member**
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;"><font style="text-decoration:underline">Interested Board Member</font>
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:13.32%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:11.31%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:22.06%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:center; vertical-align:top; width:17.16%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:17.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Christian Pittard***<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1973
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class B Trustee and Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2027; Trustee since 2024
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Pittard is Head of Closed End Funds for abrdn and is responsible for the US and UK businesses. Aberdeen is currently the 5th largest listed Closed-End Fund
manager in the world. &#xa0;He is also Managing Director of Corporate Finance, having done a significant number of closed end fund transactions in the US and UK since joining abrdn in 1999. Previously, he was Head of
the Americas and the North American Funds business for Aberdeen based in the US.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">12 Registrants<br>
consisting of<br>
12 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;"><font style="text-decoration:underline">Independent Board Members</font>
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:13.32%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:11.31%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:22.06%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:4pt; padding-top:2.25pt; text-align:center; vertical-align:top; width:17.16%; background-color: #F0F0F0;">&#xa0;
</td><td style="line-height:0pt; padding-right:6pt; padding-top:2.25pt; text-align:left; vertical-align:top; width:17.88%; background-color: #F0F0F0;">&#xa0;
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Jeffrey A. Bailey<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1962
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class B Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2027; Trustee since 2020
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Bailey was the CEO of IllummOss Inc from 2018-2020. He also served as the Board Chairman of Aileron Therapeutics Inc. 2017-2024 and Independent Board Chair of
Tekla Funds&#xa0;2020 - 2023.&#xa0; Most recently he served as the Director and CEO of BioDelivery Systems, Inc. from 2020-2022. He currently also serves on the board of Aurinia Pharmaceuticals.&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">4&#xa0;Registrants<br>
consisting of<br>
4 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.88%; background-color: #F0F0F0;">Aurinia Pharmaceuticals, Director since 2023.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Rose DiMartino<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1952
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class C Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2028; Trustee since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Ms. DiMartino has been retired since 2019. Previously, she was Partner (1991-2017) and Senior Counsel (2017-2019) at the law firm of&#xa0;Willkie
Farr &amp; Gallagher LLP.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">5 Registrants<br>
consisting of<br>
7 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr></table>
</div>
</div>
<div style="margin-top:142pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">53
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:82.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.53%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.32%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.06%; background-color: #D9D9D9;">Principal Occupation(s)<br>
During at Least the Past Five Years
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.16%; background-color: #D9D9D9;">Number of Registered<br>
Investment Companies<br>
("Registrants") consisting<br>
of Investment Portfolios<br>
("Portfolios") in<br>
Fund Complex*<br>
Overseen by<br>
Board Members
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.88%; background-color: #D9D9D9;">Other<br>
Directorships<br>
Held by<br>
Board Member**
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Kathleen Goetz<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1966
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class A Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2026; Trustee since 2021
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Ms. Goetz is a healthcare advisor and biotech consultant since 2020. She brings over 30 years of biotech and pharma industry experience spanning commercial strategy,
business and product development, finance, operational effectiveness, corporate governance, and market access.She most recently served in multiple roles at Novartis Pharmaceuticals, including Vice President of Sales
(2017-2019) and Executive Director and Head of US Strategic Accounts (2014-2017). She currently serves on the board of Aurinia Pharmaceuticals.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">4&#xa0;Registrants<br>
consisting of<br>
4 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.88%; background-color: #F0F0F0;">Aurinia Pharmaceuticals, Director, since &#xa0;2025.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">C. William Maher<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1961
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Class A Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2026; Trustee since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Maher is a Co-founder of Asymmetric Capital Management LLC from May 2018 to September 2020. Formerly Chief Executive Officer of Santa Barbara
Tax Products Group ("SBTPG") from October 2014 to April 2016. Previously, he held senior financial leadership positions as CFO for SBTPG, CFO and Managing Director at LPL Financial, CFO and Managing Director at
Nicholas Applegate Capital Management and CFO at Mitchell Hutchins Asset Management.
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">7 Registrants<br>
consisting of<br>
7 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr></table>
</div>
</div>
<div style="margin-top:256pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">54
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:82.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.53%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:13.32%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:22.06%; background-color: #D9D9D9;">Principal Occupation(s)<br>
During at Least the Past Five Years
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.16%; background-color: #D9D9D9;">Number of Registered<br>
Investment Companies<br>
("Registrants") consisting<br>
of Investment Portfolios<br>
("Portfolios") in<br>
Fund Complex*<br>
Overseen by<br>
Board Members
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:17.88%; background-color: #D9D9D9;">Other<br>
Directorships<br>
Held by<br>
Board Member**
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:17.53%; background-color: #F0F0F0;">Todd Reit<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1968
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:13.32%; background-color: #F0F0F0;">Chair of the Board, Class C Trustee
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Term expires 2028; Trustee since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:22.06%; background-color: #F0F0F0;">Mr. Reit is a Managing Member of Cross Brook Partners LLC, a real estate investment and management company since 2017. Mr. Reit is also Director
and Financial Officer of Shelter Our Soldiers, a charity to support military veterans, since 2016. Mr. Reit was formerly a Managing Director and Global Head of Asset Management Investment Banking for UBS AG, where he
was responsible for overseeing all the bank&#x2019;s asset management client relationships globally, including all corporate security transactions, mergers and acquisitions. Mr. Reit retired from UBS in 2017 after an
over 25-year career at the company and its predecessor company, PaineWebber Incorporated (merged with UBS AG in 2000).
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:17.16%; background-color: #F0F0F0;">10 Registrants<br>
consisting of<br>
10 Portfolios
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:17.88%; background-color: #F0F0F0;">None.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:center; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.61%">*
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.94%">As of October 31, 2025, the Fund Complex has a total of 17 Registrants with each Board member serving on the Boards of the number of Registrants listed. Each Registrant in the Fund Complex has one
Portfolio except for two Registrants that are open-end funds, abrdn Funds and abrdn ETFs, which each have multiple Portfolios. The Registrants in the Fund Complex are as follows: abrdn Asia-Pacific Income Fund, Inc.,
abrdn Global Income Fund, Inc., abrdn Australia Equity Fund, Inc., abrdn Emerging Markets ex-China Fund, Inc., The India Fund, Inc., abrdn Income Credit Strategies Fund, abrdn Global Dynamic Dividend Fund, abrdn
Global Premier Properties Fund, abrdn Total Dynamic Dividend Fund, abrdn Global Infrastructure Income Fund, abrdn National Municipal Income Fund, abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn
Healthcare Opportunities Fund, abrdn World Healthcare Fund, abrdn Funds (17 Portfolios), and abrdn ETFs (3 Portfolios).
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.61%">**
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.94%">Current directorships (excluding Fund Complex) as of the date of this report held in (1) any other investment companies registered under the 1940 Act, (2) any company with a class of securities
registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the &#x201c;1934 Act&#x201d;) or (3) any company subject to the requirements of Section 15(d) of the Exchange Act.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:2.61%">***
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:97.94%">Mr. Pittard is deemed to be an interested person because of his affiliation with the Fund&#x2019;s investment adviser.
</td></tr></table>
</div>
</div>
<div style="margin-top:208pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">55
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(continued)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:19.5pt; width:100%">
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; margin-top:10pt; text-align:left; text-decoration:none; text-transform:none">Officers of the Fund</div>
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.42%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.86%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office*<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:57.68%; background-color: #D9D9D9;">Principal Occupation(s) During at Least the Past Five Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Jason Akus**<br>
c/o&#xa0;abrdn Inc.<br>
28 State Street<br>
17th floor<br>
Boston, MA 02109<br>
Year of Birth: 1974&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Senior Investment Director. Dr. Akus joined abrdn Inc in October 2023 from Tekla Capital Management where he was employed as a Senior Vice President of
Research.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Joshua Duitz**<br>
c/o&#xa0;abrdn Inc.<br>
875 Third Ave<br>
4th Floor, Suite 403<br>
New York, NY 10022<br>
Year of Birth: 1970
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Head of Global Income at abrdn Inc. Mr. Duitz joined abrdn Inc. in 2018 from Alpine Woods Capital Investors LLC where he was a Portfolio Manager.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Sharon Ferrari**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1977
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Treasurer and Chief Financial Officer
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Director,&#xa0;Product Management for abrdn Inc. Ms. Ferrari joined abrdn Inc. as a Senior Fund Administrator in 2008.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Katie Gebauer**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1986
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Chief Compliance Officer and Vice President - Compliance
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Ms. Gebauer is Head of US Registered Fund Compliance. She serves as the Chief Compliance Officer for Aberdeen's US closed end funds, open end funds and
ETFs. Ms. Gebauer joined abrdn Inc. in 2014.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Alan Goodson**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1974
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:11.86%; background-color: #F0F0F0;">President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Executive Director and Head of Product &amp; Client Solutions &#x2013; Americas for abrdn Inc., overseeing Product Management &amp; Governance, Product
Development and Client Solutions for registered and unregistered investment companies in the U.S., Brazil and Canada. Mr. Goodson is Director and Vice President of abrdn Inc. and joined abrdn Inc. in 2000.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Heather Hasson**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1982
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Development Manager. Previously, Senior Product Solutions and Implementation Manager, Product Governance US for abrdn Inc. Ms. Hasson
joined the company in November 2006.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Robert Hepp**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1986
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Governance Manager &#x2013; US for abrdn Inc. Mr. Hepp joined abrdn Inc. as a Senior Paralegal in 2016.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Megan Kennedy**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1974
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Secretary and Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Director, &#xa0;Product Governance for abrdn Inc. Ms. Kennedy joined abrdn Inc. in 2005.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Andrew Kim**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1983
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Governance Manager &#x2013; Attorney for abrdn Inc. Mr. Kim joined abrdn Inc. as a Product Manager in 2013.
</td></tr></table>
</div>
</div>
<div style="margin-top:34pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:3.08%">56
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:bottom; width:97.46%">abrdn Life Sciences Investors
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:Normal; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Management of the Fund&#xa0;<font style="font-size:11pt; line-height:14pt"> (Unaudited)&#xa0;&#xa0;(concluded)</font></div>
<div style="color:#000000; font-family:Arial; font-size:11pt; font-style:Normal; font-weight:Normal; line-height:14pt; text-align:left; text-decoration:none; text-transform:none">As of October 31, 2025<br>
</div>
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:32.5pt; width:100%">
<div style="text-align:left">
<table style="border-collapse:collapse; empty-cells:show; margin-top:0pt; width:99.28%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:6pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:18.42%; background-color: #D9D9D9;">Name, Address and<br>
Year of Birth
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.86%; background-color: #D9D9D9;">Position(s) Held<br>
with the Fund
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:4pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:11.31%; background-color: #D9D9D9;">Term of Office*<br>
and Length of<br>
Time Served
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:bold; line-height:11pt; padding-bottom:2.25pt; padding-left:4pt; padding-right:6pt; padding-top:5pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:bottom; width:57.68%; background-color: #D9D9D9;">Principal Occupation(s) During at Least the Past Five Years
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Michael Marsico**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1980
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2025
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Manager &#x2013; US for abrdn Inc. Mr. Marsico joined abrdn Inc. as a Fund Administrator in 2014.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Ben Ritchie**<br>
c/o abrdn Investments Limited<br>
280 Bishopsgate<br>
London, EC2M 4AG<br>
Year of Birth: 1980&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Head of the Developed Markets Equity team at abrdn.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Kolotioloma Silue**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1977
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2024
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Senior Product Manager for abrdn Inc. Mr. Silue joined abrdn Inc in October 2023 from Tekla Capital Management where he was employed as a Senior Manager
of Fund Administration.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Lucia Sitar**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1971
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Chief Legal Officer and Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Vice President and U.S. Counsel - Head of Product Governance for&#xa0;abrdn Inc. Previously, Ms. Sitar was Head of Product Governance and Management and
Managing U.S. Counsel for abrdn Inc. She joined abrdn Inc. as U.S. Counsel in 2007.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Michael Taggart**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1970&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently, Head of Closed-End Fund Investor Relations at abrdn Inc since 2023. Prior to that, he was Vice President of Investment Research and Operations at Relative
Value Partners, LLC from June 2022. Prior to that, he was self-employed after having left Nuveen in November 2020, where he had served as Vice President of Closed-End Fund Product Strategy since November 2013.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Loretta Tse**<br>
c/o&#xa0;abrdn Inc.<br>
28 State Street<br>
17th floor<br>
Boston, MA 02109<br>
Year of Birth: 1967&#xa0;
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2023
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Investment Director at abrdn. Ms. Tse joined abrdn in October 2023 from Tekla Capital Management LLC where she was a Vice President investing in venture.
Previously, she worked for the Fred Hutchinson Cancer Research Center and Oxford Biosciences Partners.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:6pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:18.42%; background-color: #F0F0F0;">Ashton Wilson**<br>
c\o abrdn Inc.<br>
1900 Market Street<br>
Suite 200<br>
Philadelphia, PA 19103<br>
Year of Birth: 1986
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:11.86%; background-color: #F0F0F0;">Vice President
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:4pt; padding-top:2.25pt; text-align:center; text-decoration:none; text-transform:none; vertical-align:top; width:11.31%; background-color: #F0F0F0;">Since 2024
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:4.5pt; padding-left:4pt; padding-right:6pt; padding-top:2.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:57.68%; background-color: #F0F0F0;">Currently Senior Investment Director in healthcare portfolio management. Mr. Wilson joined abrdn in October 2023 from Tekla Capital Management
where he was a Senior Vice President. Previously, he worked for Goldman Sachs and Co.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; text-align:left; text-decoration:none; text-transform:none">&#xa0;&#xa0;&#xa0;&#xa0;</div>
<div style="text-align:center">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-right:auto; margin-top:11pt; width:100%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:0pt; padding-right:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:1.92%">*
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-left:3pt; padding-top:3pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.62%">Officers hold their positions with the Fund until a successor has been duly elected and qualifies. Officers are elected annually at a meeting of the Fund Board.
</td></tr>
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:0pt; padding-right:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; white-space:nowrap; width:1.92%">**
</td><td style="color:#000000; font-family:Arial; font-size:8pt; font-style:Normal; font-weight:Normal; line-height:11pt; padding-bottom:3pt; padding-left:3pt; padding-top:1.25pt; text-align:left; text-decoration:none; text-transform:none; vertical-align:top; width:98.62%">Each officer may hold officer position(s) in one or more other funds which are part of the Fund Complex.
</td></tr></table>
</div>
<div style="color:#000000; font-family:Arial; font-size:9.5pt; font-style:Normal; font-weight:Normal; line-height:12.5pt; margin-top:5pt; text-align:left; text-decoration:none; text-transform:none">Further information about the
Fund's Board Members and Officers is available in the Fund's Statement of Additional Information, which can be obtained without charge by calling (800) 522-5465.&#xa0;</div>
</div>
<div style="margin-top:131pt; width:100%">
<div style="text-align:right">
<table style="border-collapse:collapse; empty-cells:show; margin-left:auto; margin-top:0pt; width:19.02%; border-spacing: 0px;" cellpadding="0">
<tr style="page-break-inside:avoid"><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:Normal; line-height:10pt; padding-left:0pt; padding-right:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; width:100%">abrdn Life Sciences Investors
</td><td style="color:#000000; font-family:Arial; font-size:7pt; font-style:Normal; font-weight:bold; line-height:10pt; padding-left:3pt; text-align:right; text-decoration:none; text-transform:none; vertical-align:bottom; white-space:nowrap; width:19.05%">57
</td></tr></table>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:10pt; font-style:Normal; font-weight:Normal; line-height:13pt; text-align:center; text-decoration:none; text-transform:none">[THIS PAGE INTENTIONALLY LEFT BLANK]</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:18pt; font-style:Normal; font-weight:bold; line-height:21pt; text-align:left; text-decoration:none; text-transform:none">Corporate Information<font style="font-size:11pt; line-height:14pt">&#xa0;</font></div>
</div>
<div style="margin-top:2pt; width:100%">
<hr style="background-color:#000000; border-bottom:0pt; border-left:0pt; border-right:0pt; border-top:0.5pt solid #000000; height:0.5pt; width:100%; text-align: Left;">
</div>
<div style="margin-top:26.5pt">
<div style="float:left; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Trustees</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Todd Reit, <font style="font-style:italic">Chair<br>
</font>Jeffrey Bailey<br>
Rose DiMartino<br>
Kathleen Goetz<br>
C. William Maher<br>
Christian Pittard</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investment Adviser</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA&#xa0;19103</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Custodian</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">State Street Bank and Trust Company<br>
John Adams Building<br>
1776 Heritage Drive<br>
North Quincy, MA 02171</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Transfer Agent</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Computershare Trust Company, N.A.<br>
P.O. Box 43006<br>
Providence, RI 02940-3078</div>
</div>
<div style="float:right; overflow:hidden; position:relative; width:48%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Independent Registered Public Accounting Firm</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">KPMG LLP<br>
191 West Nationwide Blvd., Suite 500<br>
Columbus, OH 43215</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Legal Counsel</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">Dechert LLP<br>
1900 K Street N.W.<br>
Washington, D.C. 20006</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:bold; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">Investor Relations</div>
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; text-align:left; text-decoration:none; text-transform:none">abrdn Inc.<br>
1900 Market Street, Suite 200<br>
Philadelphia, PA 19103<br>
1-800-522-5465<br>
Investor.Relations@aberdeenplc.com</div>
</div>
</div>
<div style="clear:both">&#xa0;
<div style="clear:both; padding-top:212pt; width:100%">
<div style="margin-left:38.41%; margin-top:5pt; text-align:Center; width:23.19%">
<img src="tm2527059d12hqlreporti005.jpg" alt=" ">
</div>


<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:9pt; text-align:left; text-decoration:none; text-transform:none">Notice is hereby given in
accordance with Section 23(c) of the Investment Company Act of 1940, as amended, that the Fund may purchase, from time to time, shares of its common stock in the open market.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">Shares of abrdn Life
Sciences Investors are traded on the NYSE under the symbol &#x201c;HQL.&#x201d; Information about the Fund&#x2019;s net asset value and market price is available at www.aberdeenhql.com.</div>
<div style="clear:both; color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:6pt; text-align:left; text-decoration:none; text-transform:none">This report, including
the financial information herein, is transmitted to the shareholders of abrdn Life Sciences Investors for their general information only. It does not have regard to the specific investment objectives, financial
situation and the particular needs of any specific person. Past performance is no guarantee of future results.</div>
</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<hr style="margin-bottom:0pt">
<div style="page-break-before:always; margin-top:6pt; margin-bottom:12pt"><p style="margin:0pt">&#xa0;</p></div>
<div style="width:100%">
<div style="width:100%">
<div style="color:#000000; font-family:Arial; font-size:9pt; font-style:Normal; font-weight:Normal; line-height:12pt; margin-top:11pt; text-align:left; text-decoration:none; text-transform:none">HQL-ANNUAL</div>
</div>
</div>
<div style="clear:both; font-size:12pt; height:0pt">
</div>
<div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d12_item2-19.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1" -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(b)&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 2. Code of Ethics.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="text-align: justify; padding-left: 0in; width: 95%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of September 30, 2025, abrdn Life Sciences Investors (the &#x201c;Fund&#x201d; or the &#x201c;Registrant&#x201d;) had adopted a Code of Ethics that applies to the Registrant&#x2019;s principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, regardless of whether these individuals are employed by the Registrant or a third party (the &#x201c;Code of Ethics&#x201d;).&#xa0;</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="width: 95%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Definitional.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></td>
    <td style="width: 95%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There have been no amendments, during the period covered by this report, to a provision of the Code of Ethics.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></td>
    <td style="width: 95%; font-size: 10pt">During the period covered by this report, there were no waivers to the provisions of
the Code of Ethics.&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</font></td>
    <td style="width: 95%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</font></td>
    <td style="width: 95%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A copy of the Code
of Ethics has been filed as an exhibit to this Form N-CSR.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3. Audit Committee Financial Expert.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Registrant's Board of Trustees has determined
that C. William Maher, a member of the Board of Trustees&#x2019; Audit Committee, possesses the attributes, and has acquired such attributes
through means, identified in instruction 2 of Item 3 to Form N-CSR to qualify as an &#x201c;audit committee financial expert,&#x201d; and
has designated Mr. Maher as the Audit Committee&#x2019;s financial expert. Mr. Maher is considered to be an &#x201c;independent&#x201d; trustee,
as such term is defined in paragraph (a)(2) of Item 3 to Form N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 4. Principal Accountant Fees and Services.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.55pt; text-align: justify; text-indent: -6.55pt">(a) &#x2013; (d)
Below is a table reflecting the fee information requested in Items 4(a) through (d):</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fiscal Year <br>
Ended</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(a)<br> Audit Fees<sup>1</sup></b></font></td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b)<br> Audit-Related Fees<sup>2</sup></b></font></td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(c)<br> Tax Fees<sup>3</sup></b></font></td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)<br> All Other Fees<sup>4</sup></b></font></td><td style="white-space: nowrap; padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: center; padding-bottom: 1pt">September 30, 2025</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">126,900</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right">0</td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage approved pursuant to pre-approval exception<b><sup>5</sup></b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">September 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">123,200</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage approved pursuant to pre-approval exception<b><sup>5</sup></b></font></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><sup>1</sup></font>
 &#x201c;Audit Fees&#x201d; are the aggregate fees billed for professional services for the audit of the Fund&#x2019;s annual financial statements
and services provided in connection with statutory and regulatory filings or engagements.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><sup>2</sup></font>
 &#x201c;Audit Related Fees&#x201d; are the aggregate fees billed for assurance and related services reasonably related to the performance
of the audit or review of financial statements that are not reported under &#x201c;Audit Fees&#x201d;. These fees include offerings related
to the Fund&#x2019;s common shares.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><sup>3</sup></font>
 &#x201c;Tax Fees&#x201d; are the aggregate fees billed for professional services for tax advice, tax compliance, and tax planning. These
fees include: federal and state income tax returns, review of excise tax distribution calculations and federal excise tax return.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><sup>4</sup></font>
 &#x201c;All Other Fees&#x201d; are the aggregate fees billed for products and services other than &#x201c;Audit Fees&#x201d;, &#x201c;Audit-Related
Fees&#x201d; and &#x201c;Tax Fees&#x201d;.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-family: Times New Roman, Times, Serif"><sup>5</sup></font>
Pre-approval exception under Rule 2-01 of Regulation S-X. The pre-approval exception for services provided directly to the Fund waives
the pre-approval requirement for services other than audit, review or attest services if: (A) the aggregate amount of all such services
provided constitutes no more than 5% of the total amount of revenues paid by the Fund to its accountant during the fiscal year in which
the services are provided; (B) the Fund did not recognize the services as non-audit services at the time of the engagement; and (C) the
services are promptly brought to the Audit Committee&#x2019;s attention, and the Committee (or its delegate) approves the services before
the audit is completed.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)(1)</font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&#x2019;s Audit Committee (the &#x201c;Committee&#x201d;) has adopted a Charter that provides that the Committee shall annually select, retain or terminate, and recommend to the Independent Directors for their ratification, the selection, retention or termination, the Registrant&#x2019;s independent auditor and, in connection therewith, to evaluate the terms of the engagement (including compensation of the independent auditor) and the qualifications and independence of the independent auditor, including whether the independent auditor provides any consulting, auditing or tax services to the Registrant&#x2019;s investment adviser (the &#x201c;Adviser&#x201d;) or any sub-adviser, and to receive the independent auditor&#x2019;s specific representations as to their independence, delineating all relationships that may affect the independent auditor&#x2019;s independence, including the disclosures required by PCAOB Rule 3526 or any other applicable auditing standard. PCAOB Rule 3526 requires that, at least annually, the auditor: (1) disclose to the Committee in writing all relationships between the auditor and its related entities and the Registrant and its related entities that in the auditor&#x2019;s professional judgment may reasonably be thought to bear on independence; (2) confirm in the letter that, in its professional judgment, it is independent of the Registrant within the meaning of the Securities Acts administered by the SEC; and (3) discuss the auditor&#x2019;s independence with the audit committee. The Committee is responsible for actively engaging in a dialogue with the independent auditor with respect to any disclosed relationships or services that may impact the objectivity and independence of the independent auditor and for taking, or recommending that the full Board take, appropriate action to oversee the independence of the independent auditor. The Committee Charter also provides that the Committee shall review in advance, and consider approval of, any and all proposals by Management or the Adviser that the Registrant, the Adviser or their affiliated persons, employ the independent auditor to render &#x201c;permissible non-audit services&#x201d; to the Registrant and to consider whether such services are consistent with the independent auditor&#x2019;s independence. &#x201c;Permissible non-audit services&#x201d; include any professional services, including tax services, provided to the Registrant by the independent auditor, other than those provided to the Registrant in connection with an audit or a review of the financial statements of the Registrant. Permissible non-audit services may not include: (i) bookkeeping or other services related to the accounting records or financial statements of the Registrant; (ii) financial information systems design and implementation; (iii) appraisal or valuation services, fairness opinions or contribution-in-kind reports; (iv) actuarial services; (v) internal audit outsourcing services; (vi) management functions or human resources; (vii) broker or dealer, investment adviser or investment banking services; (viii) legal services and expert services unrelated to the audit; and (ix) any other service the PCAOB determines, by regulation, is impermissible.&#xa0;&#xa0;Pre-approval by the Committee of any permissible non-audit services is not required so long as: (i) the aggregate amount of all such permissible non-audit services provided to the Registrant constitutes not more than 5% of the total amount of revenues paid by the Registrant to its auditor during the fiscal year in which the permissible non-audit services are provided; (ii) the permissible non-audit services were not recognized by the Registrant at the time of the engagement to be non-audit services; and (iii) such services are promptly brought to the attention of the Committee and approved by the Committee or its Delegate(s) prior to the completion of the audit. The Committee may delegate to one or more of its members (&#x201c;Delegates&#x201d;) authority
to pre-approve permissible non-audit services to be provided to the Registrant. Any pre-approval determination of a Delegate shall be presented to the full Committee at its next meeting. Any pre-approval determination of a Delegate shall be presented to the full Committee at its next meeting. Pursuant to this authority, the Registrant&#x2019;s Committee delegates to the Committee Chair, subject to subsequent ratification by the full Committee, up to a maximum amount of $25,000, which includes any professional services, including tax services, provided to the Registrant by its independent registered public accounting firm other than those provided to the Registrant in connection with an audit or a review of the financial statements of the Registrant.&#xa0;&#xa0;The Committee shall communicate any pre-approval made by it or a Delegate to the Adviser, who will ensure that the appropriate disclosure is made in the Registrant&#x2019;s periodic reports required by Section 30 of the Investment Company Act of 1940, as amended, and other documents as required under the federal securities laws.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)(2)</font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of the services described in each of paragraphs (b) through (d) of this Item involved a waiver of the pre-approval requirement by the Audit Committee pursuant to Rule 2-01 (c)(7)(i)(C) of Regulation S-X.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42.2pt; text-align: justify; text-indent: -35.65pt">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 6%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</font></td>
    <td style="width: 94%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-Audit Fees</font></td></tr>
  </table>
<p style="margin-top: 0; margin-bottom: 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 6%; text-align: left"></td><td style="text-align: justify; width: 94%">The following table shows the amount of fees that KPMG LLP billed during the Fund&#x2019;s last two
                                                                                fiscal years for non-audit services to the Registrant, and to the Adviser, and any entity controlling, controlled by or under common
                                                                                control with the Adviser that provides ongoing services to the Fund (&#x201c;Affiliated Fund Service Provider&#x201d;):</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif">Fiscal Year Ended</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#xa0;Non-Audit&#xa0;Fees<br> Billed to Fund</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#xa0;Non-Audit&#xa0;Fees<br> billed to Adviser and<br> Affiliated&#xa0;Fund&#xa0;Service<br> Providers&#xa0;(engagements<br> related directly to the<br> operations and&#xa0;financial<br> reporting of the Fund)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total&#xa0;Non-Audit&#xa0;Fees<br> billed to Adviser and<br> Affiliated&#xa0;Fund&#xa0;Service<br> Providers (all other<br> engagements)</td><td style="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#xa0;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 19%; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2025</font></td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,253,744</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="width: 17%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,253,744</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30, 2024</font></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">629,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">629,124</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#x201c;Non-Audit Fees billed to Fund&#x201d; for both fiscal years represent
 &#x201c;Tax Fees&#x201d; and &#x201c;All Other Fees&#x201d; billed to Fund in their respective amounts from the previous table.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 5%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</font></td>
    <td style="width: 95%; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left">(i)</td><td style="text-align: justify; width: 95%">Not applicable.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left">(j)</td><td style="text-align: justify; width: 95%">Not applicable.</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5. Audit Committee of Listed Registrants.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant has a separately-designated standing Audit Committee established in accordance with Section 3(a)(58)(A) of the Exchange Act (15 U.S.C. 78c(a)(58)(A)).</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of the fiscal year ended September
30, 2025, the Audit Committee members were:</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48.6pt; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">Jeffrey Bailey</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">Rose DiMartino</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">Kathleen Goetz</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">C. William Maher</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">Todd Reit</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not applicable.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 6. Schedule of Investments.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(a) Included as part of the Report to Shareholders
filed under Item 1 of this Form N-CSR.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 29.25pt; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(b) Not applicable. &#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7. Financial Statements and Financial Highlights for Open-End
Management Investment Companies. </b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8. Changes in and Disagreements with Accountants for Open-End
Management Investment Companies. </b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9. Proxy Disclosures for Open-End Management Investment Companies.
</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 10. Remuneration Paid to Directors, Officers, and Others of
Open-End Management Investment Companies. </b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 11. Statement Regarding Basis for Approval of Investment Advisory
Contract. </b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statement regarding the basis for approval of the investment advisory
contract is included in the response to Item 1, above.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 12. Disclosure of Proxy Voting Policies and Procedures for
Closed-End Management Investment Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Registrant's Proxy Voting
Policy and Procedures, the Registrant has delegated responsibility for its proxy voting to its Adviser, provided that the
Registrant's Board of Trustees has the opportunity to periodically review the Adviser's proxy voting policies and material
amendments thereto.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The proxy voting policies of the Registrant are
included herewith as Exhibit (d) and policies of the Adviser are included as Exhibit (e).</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 13. Portfolio Managers of Closed-End Management Investment
Companies.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">(a)(1) PORTFOLIO MANAGER BIOGRAPHIES</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">As of the date of filing this report, Jason Akus, M.D./M.B.A.,
Ashton L. Wilson, Christopher Abbott, Robert Benson, Kelly Girskis, Ph.D., Richard Goss, and Loretta Tse, Ph.D. are members of a team
that analyzes investments on behalf of the Fund. Dr. Akus exercises ultimate decision-making authority with respect to investments.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 22%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual&#xa0;&amp; Position</font></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 66%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Past Business Experience&#xa0;&#xa0;</font></td>
    <td style="padding-right: 5.4pt; width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Served on the Fund Since</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jason Akus, M.D./M.B.A</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Head of Healthcare Investments</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Healthcare Investments of the investment adviser and is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas. He joined the predecessor investment adviser in 2001, where he was Senior Vice President, Research. Dr.&#xa0;Akus joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-right: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2001</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ashton Wilson</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Senior Investments Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Investments Director of the investment adviser. He joined the predecessor investment adviser in 2018, where he was Senior Vice President. He was previously a Vice President in equity derivative trading at Goldman Sachs and Co. and was an equity derivative trader at Bank of America Merrill Lynch. He joined abrdn Inc. in October&#xa0;2023</font></td>
    <td style="padding-right: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christopher Abbott</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. He joined the predecessor investment adviser in 2016, where he was Vice President, Research. Previously, Mr.&#xa0;Abbott was at Leerink Partners where he was a Vice President on the Equity Research Team. He joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-right: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</font></td></tr>


<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 22%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robert Benson</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; width: 66%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. He joined the predecessor investment adviser in 2016, where he was Vice President. Previously, Mr.&#xa0;Benson was at State Street Global Advisors (SSgA) where he performed quantitative research for asset allocation, equities, and alternatives teams. He joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt; width: 12%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2016</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kelly Girskis, Ph.D.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. She joined the predecessor investment adviser in 2021, where she was Vice President, Research. Previously, Dr.&#xa0;Girskis was an Equity Research Associate at SVB Leerink. She joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-right: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Richard Goss</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. He joined the predecessor investment adviser in 2018, where he was Vice President, Research. Previously, Mr.&#xa0;Goss was at Leerink Partners where he was a Vice President on the Large Pharma and Biotech Equity Research Teams and a Healthcare Analyst at Datamonitor. He joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-right: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018</font></td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Loretta Tse, Ph.D.&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investment Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Director of the investment adviser. She joined the predecessor investment adviser in 2015, where she was Vice President. She previously ran a biotech consulting business and worked at various venture funds and start-up companies and was Managing Director at Fred Hutchinson Cancer Research Center. She joined abrdn Inc. in October&#xa0;2023.</font></td>
    <td style="padding-right: 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-bottom: 10pt; text-align: center; padding-left: 5.4pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2015</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)(2) OTHER ACCOUNTS MANAGED
BY PORTFOLIO MANAGERS.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following chart summarizes information regarding
other accounts for which each portfolio manager has day-to-day management responsibilities. Accounts are grouped into the following three
categories: (1) registered investment companies; (2) other pooled investment vehicles; and (3) other accounts. To the extent that any
of these accounts pay advisory fees that are based on account performance (&#x201c;performance-based fees&#x201d;), information on those
accounts is provided separately. The figures in the chart below for the category of &#x201c;registered investment companies&#x201d; include
the Fund. The &#x201c;Other Accounts Managed&#x201d; represents the accounts managed by the teams of which the portfolio manager is a member.
The information in the table below is as of September 30, 2025.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Name of<br> Portfolio Manager</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">Type&#xa0;of&#xa0;Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">Other<br>
 Accounts <br>
Managed</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">Total Assets ($M)</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">Number of<br> Accounts<br> Managed&#xa0;for<br> Which<br> Advisory<br> Fee is Based<br> on<br> Performance</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td>
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif">Total&#xa0;Assets&#xa0;for<br> Which<br> Advisory&#xa0;Fee&#xa0;is<br> Based&#xa0; on<br> Performance ($M)</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 19%; text-align: left">Jason Akus</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 16%; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 14%; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 14%; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 14%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 13%; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Ashton Wilson</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Christopher Abbot</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Robert Benson</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Kelly Girskis</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Richard Goss</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt">&#xa0;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: right">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Loretta Tse</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Registered Investment Companies</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">4</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">3,209.00</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Pooled Investment Vehicles</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">Other Accounts</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: right">0</td><td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: left">&#xa0;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>


<!-- Field: Page; Sequence: 6 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">POTENTIAL CONFLICTS OF INTEREST</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.7pt; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Adviser and its affiliates (collectively referred
to herein as &#x201c;Aberdeen&#x201d;) serve as investment advisers for multiple clients, including the Registrant and other investment
companies registered under the 1940 Act and private funds (such clients are also referred to below as &#x201c;accounts&#x201d;). The portfolio
managers&#x2019; management of &#x201c;other accounts&#x201d; may give rise to potential conflicts of interest in connection with their management
of the Registrant&#x2019;s investments, on the one hand, and the investments of the other accounts, on the other. The other accounts may
have the same investment objective as the Registrant. Therefore, a potential conflict of interest may arise as a result of the identical
investment objectives, whereby the portfolio manager could favor one account over another. However, the Adviser believes that these risks
are mitigated by the fact that: (i) accounts with like investment strategies managed by a particular portfolio manager are generally managed
in a similar fashion, subject to exceptions to account for particular investment restrictions or policies applicable only to certain accounts,
differences in cash flows and account sizes, and similar factors; and (ii) portfolio manager personal trading is monitored to avoid potential
conflicts. In addition, the Adviser has adopted trade allocation procedures that require equitable allocation of trade orders for a particular
security among participating accounts.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In some cases, another account managed by the
same portfolio manager may compensate Aberdeen based on the performance-based fees with qualified clients. The existence of such a performance-based
fee may create additional conflicts of interest for the portfolio manager in the allocation of management time, resources and investment
opportunities.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Another potential conflict could include instances
in which securities considered as investments for the Registrant also may be appropriate for other investment accounts managed by the
Adviser or its affiliates. Whenever decisions are made to buy or sell securities for the Registrant and one or more of the other accounts
simultaneously, the Adviser may aggregate the purchases and sales of the securities and will allocate the securities transactions in a
manner that it believes to be equitable under the circumstances. As a result of the allocations, there may be instances where the Registrant
will not participate in a transaction that is allocated among other accounts. While these aggregation and allocation policies could have
a detrimental effect on the price or amount of the securities available to the Registrant from time to time, it is the opinion of the
Adviser that the benefits from the policies outweigh any disadvantage that may arise from exposure to simultaneous transactions. The Registrant
has adopted policies that are designed to eliminate or minimize conflicts of interest, although there is no guarantee that procedures
adopted under such policies will detect each and every situation in which a conflict arises.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With respect to non-discretionary model delivery
accounts (including UMA accounts) and discretionary SMA accounts, abrdn Inc. will utilize a third party service provider to deliver model
portfolio recommendations and model changes to the Sponsors. abrdn Inc. seeks to treat clients fairly and equitably over time, by delivering
model changes to our service provider and investment instructions for our other discretionary accounts to our trading desk, simultaneously
or approximately at the same time. The service provider will then deliver the model changes to each Sponsor on a when-traded, randomized
full rotation schedule. All Sponsors will be included in the rotation schedule, including SMA and UMA.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">UMA Sponsors will be responsible for determining
how and whether to implement the model portfolio or model changes and implementation of any client specific investment restrictions. The
Sponsors are solely responsible for determining the suitability of the model portfolio for each model delivery client, executing trades
and seeking best execution for such clients.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>


<!-- Field: Page; Sequence: 7 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As it relates to SMA accounts, abrdn Inc. will
be responsible for managing the account on the basis of each client&#x2019;s financial situation and objectives, the day to day investment
decisions, best execution, accepting or rejecting client specific investment restrictions and performance. The SMA Sponsors will collect
suitability information and will provide a summary questionnaire for our review and approval or rejection. For dual contract SMAs, abrdn
Inc. will collect a suitability assessment from the client, along with the Sponsor suitability assessment. Our third party service provider
will monitor client specific investment restrictions on a day to day basis. For SMA accounts, model trades will be traded by the Sponsor
or may be executed through a &#x201c;step-out transaction,&#x201d;- or traded away- from the client&#x2019;s Sponsor if doing so is consistent
with Aberdeen&#x2019;s obligation to obtain best execution. When placing trades through Sponsor Firms (instead of stepping them out), we
will generally aggregate orders where it is possible and in the client&#x2019;s best interests. In the event we are not comfortable that
a Sponsor can obtain best execution for a specific security and trading away is infeasible, we may exclude the security from the model.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trading costs are not covered by the Wrap Program
fee and may result in additional costs to the client. In some instances, step-out trades are executed without any additional commission,
mark-up, or mark-down, but in many instances, the executing broker-dealer may impose a commission or a mark-up or mark-down on the trade.
Typically, the executing broker will embed the added costs into the price of the trade execution, making it difficult to determine and
disclose the exact added cost to clients. In this instance, these additional trading costs will be reflected in the price received for
the security, not as a separate commission, on trade confirmations or on account statements. In determining best execution for SMA accounts,
abrdn Inc. takes into consideration that the client will not pay additional trading costs or commission if executing with the Sponsor.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While UMA accounts are invested in the same strategies
as and may perform similarly to SMA accounts, there are expected to be performance differences between them. There will be performance
dispersions between UMAs and other types of accounts because Aberdeen does not have discretion over trading and there may be client specific
restrictions for SMA accounts.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aberdeen may have already commenced trading for
its discretionary client accounts before the model delivery accounts have executed Aberdeen&#x2019;s recommendations. In this event, trades
placed by the model delivery clients may be subject to price movements, particularly with large orders or where securities are thinly
traded, that may result in model delivery clients receiving less favorable prices than our discretionary clients. Aberdeen has no discretion
over transactions executed by model delivery clients and is unable to control the market impact of those transactions.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Timing delays or other operational factors associated
with the implementation of trades may result in non-discretionary and model delivery clients receiving materially different prices relative
to other client accounts. In addition, the constitution and weights of stocks within model portfolios may not always be exactly aligned
with similar discretionary accounts. This may create performance dispersions within accounts with the same or similar investment mandate.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt">(a)(3)</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-indent: -45pt">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #212529"><font style="text-decoration:underline">DESCRIPTION OF COMPENSATION STRUCTURE</font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Aberdeen&#x2019;s remuneration policies are designed
to support its business strategy as a leading international asset manager.&#xa0; The objective is to attract, retain and reward talented
individuals for the delivery of sustained, superior returns for Aberdeen&#x2019;s clients and shareholders.&#xa0; Aberdeen operates in
a highly competitive international employment market, and aims to maintain its strong track record of success in developing and retaining
talent.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Aberdeen&#x2019;s policy is to recognize corporate
and individual achievements each year through an appropriate annual bonus scheme. The bonus is a single, fully discretionary variable
pay award. The aggregate value of awards in any year is dependent on the group&#x2019;s overall performance and profitability.&#xa0; Consideration
is also given to the levels of bonuses paid in the market.&#xa0; Individual awards, which are payable to all members of staff, are determined
by a rigorous assessment of achievement against defined objectives.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The variable pay award is composed of a mixture
of cash and a deferred award, the portion of which varies based on the size of the award.&#xa0; Deferred awards are by default Aberdeen
Group plc shares, with an option to put up to 50% of the deferred award into funds managed by Aberdeen. Overall compensation packages
are designed to be competitive relative to the investment management industry.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><font style="text-decoration:underline">Base Salary</font></b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">Aberdeen&#x2019;s policy is to pay a fair salary
commensurate with the individual&#x2019;s role, responsibilities and experience, and having regard to the market rates being offered for
similar roles in the asset management sector and other comparable companies. Any increase is generally to reflect inflation and is applied
in a manner consistent with other Aberdeen employees; any other increases must be justified by reference to promotion or changes in responsibilities.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><font style="text-decoration:underline">Annual Bonus</font></b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.25in">The Remuneration Committee determines the key performance
indicators that will be applied in considering the overall size of the bonus pool.&#xa0; In line with practices amongst other asset management
companies, individual bonuses are not subject to an absolute cap.&#xa0; However, the aggregate size of the bonus pool is dependent on
the group&#x2019;s overall performance and profitability.&#xa0; Consideration is also given to the levels of bonuses paid in the market.&#xa0;
Individual awards are determined by a rigorous assessment of achievement against defined objectives, and are reviewed and approved by
the Remuneration Committee.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Aberdeen has a deferral policy which is intended
to assist in the retention of talent and to create additional alignment of executives&#x2019; interests with Aberdeen&#x2019;s sustained
performance and, in respect of the deferral into funds managed by Aberdeen, to align the interest of portfolio managers with our clients.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Staff performance is reviewed formally at least
once a year. The review process evaluates the various aspects that the individual has contributed to Aberdeen, and specifically, in the
case of portfolio managers, to the relevant investment team. Discretionary bonuses are based on client service, asset growth and the performance
of the respective portfolio manager. Overall participation in team meetings, generation of original research ideas and contribution to
presenting the team externally are also evaluated.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In the calculation of a portfolio management team&#x2019;s
bonus, Aberdeen takes into consideration investment matters (which include the performance of funds, adherence to the company investment
process, and quality of company meetings) as well as more subjective issues such as team participation and effectiveness at client presentations
through key performance indicator scorecards.&#xa0; To the extent performance is factored in, such performance is not judged against any
specific benchmark and is evaluated over the period of a year - January&#xa0;to December. The pre- or after-tax performance of an individual
account is not considered in the determination of a portfolio manager&#x2019;s discretionary bonus; rather the review process evaluates
the overall performance of the team for all of the accounts the team manages.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Portfolio manager performance on investment matters
is judged over all of the accounts the portfolio manager contributes to and is documented in the appraisal process.&#xa0; A combination
of the team&#x2019;s and individual&#x2019;s performance is considered and evaluated.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although performance is not a substantial portion
of a portfolio manager&#x2019;s compensation, Aberdeen also recognizes that fund performance can often be driven by factors outside one&#x2019;s
control, such as (irrational) markets, and as such pays attention to the effort by portfolio managers to ensure integrity of our core
process by sticking to disciplines and processes set, regardless of momentum and &#x2018;hot&#x2019; themes.&#xa0; Short-terming is thus
discouraged and trading-oriented managers will thus find it difficult to thrive in the Aberdeen environment.&#xa0; Additionally, if any
of the aforementioned undue risks were to be taken by a portfolio manager, such trend would be identified via Aberdeen&#x2019;s dynamic
compliance monitoring system.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 9 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In rendering investment management services, the
Adviser may use the resources of additional investment adviser subsidiaries of Aberdeen Group plc. These affiliates have entered into
a memorandum of understanding (&#x201c;MOU&#x201d;) pursuant to which investment professionals from each affiliate may render portfolio
management, research or trading services to Abrdeen clients. Each investment professional who renders portfolio management, research or
trading services under a MOU or personnel sharing arrangement (&#x201c;Participating Affiliate&#x201d;) must comply with the provisions
of the Advisers Act, the 1940 Act, the Securities Act of 1933, the Exchange Act, and the Employee Retirement Income Security Act of 1974,
and the laws of states or countries in which the Adviser does business or has clients. No remuneration is paid by the Fund with respect
to the MOU/personnel sharing arrangements.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0.25in; text-indent: 0.25in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0.25in; text-indent: 0.25in">(a)(4)</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0.25in; text-indent: 0.25in">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-right: 0.75in; margin-left: 0.5in; border-spacing: 0px;">
  <tr>
    <td style="padding-top: 2pt; white-space: nowrap; vertical-align: bottom; border-bottom: black 1pt solid; text-align: center; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dollar Range of Equity Securities in the <br>
Registrant Beneficially Owned by the Portfolio<br>
Manager as of September 30, 2025</b></font></td>
    <td colspan="2" style="padding-top: 2pt; padding-bottom: 2pt">&#xa0;</td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; width: 60%; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jason Akus</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; width: 3%; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; width: 37%; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ashton Wilson</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher Abbot</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Benson</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kelly Girkskis</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard Goss</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  <tr>
    <td style="padding-top: 2pt; vertical-align: top; text-align: justify; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loretta Tse</font></td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt">&#xa0;</td>
    <td style="padding-top: 2pt; vertical-align: bottom; padding-bottom: 2pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</font></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 0.25in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0.25in; text-indent: 0.25in">(b) Not applicable.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0.25in; text-indent: 0.5in">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 14. Purchases of Equity Securities by Closed-End Management
Investment Company and Affiliated Purchasers.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Period</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(a) Total <br> No.<br> of Shares<br> Purchased (1)</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(b) <br> Average<br> Price Paid<br> per<br> Share</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(c) Total No.<br> of Shares<br> Purchased as<br> Part of<br> Publicly<br> Announced Plans<br> or Programs</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">(d) Maximum No.<br> of Shares that<br> May Yet Be<br> Purchased Under<br> the Plans or<br> Programs</td><td style="font: bold 10pt Times New Roman, Times, Serif">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 48%">Month #1 (Oct.&#xa0;1, 2024-Oct.&#xa0;31, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #2 (Nov.&#xa0;1, 2024 &#x2013; Nov.&#xa0;30, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #3 (Dec.&#xa0;1, 2024&#x2013; Dec.&#xa0;31, 2024)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #4 (Jan.&#xa0;1, 2025 &#x2013; Jan.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #5 (Feb.&#xa0;1, 2025 &#x2013; Feb.&#xa0;28, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #6 (Mar.&#xa0;1, 2025 &#x2013; Mar.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #7 (Apr.&#xa0;1, 2025 &#x2013; Apr.&#xa0;30, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #8 (May&#xa0;1, 2025 &#x2013; May&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #9 (June&#xa0;1, 2025 &#x2013; June&#xa0;30, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,326,419</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #10 (Jul.&#xa0;1, 2025 &#x2013; Jul.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,512,456</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #11 (Aug.&#xa0;1, 2025 &#x2013; Aug.&#xa0;31, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,512,456</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Month #12 (Sep.&#xa0;1, 2025&#x2013; Sep.&#xa0;30, 2025)</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif">&#xa0;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">3,512,456</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#xa0;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif">Total</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">&#xa0;</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#xa0;</td>
    <td style="width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June&#xa0;30, 2011, the share repurchase program (the &#x201c;Program&#x201d;) was announced, which has been subsequently reviewed and approved by the Board of Trustees. In March&#xa0;2025, the Board approved the renewal of the repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares in the open market for a one-year period ending July&#xa0;14, 2026. Prior to this renewal, in March&#xa0;2024, the Trustees approved the renewal of the share repurchase program to allow the Fund to repurchase up to 12% of its outstanding shares for a one-year period ending July&#xa0;14, 2025. In September 2025, the Board approved a change to the Program allowing the Fund to purchase, in the open market for a one-year period from October 1, 2025 to September 30, 2026, up to 12% of its outstanding common shares as of September 30, 2025, with the amount and timing of any repurchase determined at the discretion of the Fund's investment adviser.&#xa0;&#xa0;Such purchases may be made opportunistically at certain discounts to NAV per share in the reasonable judgment of management based on historical discount levels and current market conditions. If shares are repurchased, the Fund reports repurchase activity on its website on a monthly basis. For the fiscal year ended September 30, 2025, the Fund did not repurchase any shares through the Program.&#xa0;&#xa0;</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 10 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 15. Submission of Matters to a Vote of Security Holders.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the year ended September 30, 2025, there were no material changes
to the procedures by which shareholders may recommend nominees to the Registrant&#x2019;s Board of Trustees.&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 16. Controls and Procedures.</b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#xa0;</td>
    <td style="text-align: justify; width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Registrant&#x2019;s principal executive and principal financial officers, or persons performing similar functions, have concluded that the Registrant&#x2019;s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the &#x201c;Act&#x201d;) (17 CFR 270.30a-3(c)) are effective, as of a date within 90 days of the filing date of the report that includes the disclosure required by this paragraph, based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the Act (17 CFR 270.30a3(b)) and Rule 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934, as amended (17 CFR 240.13a-15(b) or 240.15d15(b)).</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#xa0;</td>
    <td style="text-align: justify; width: 24px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were no changes in the Registrant&#x2019;s internal control over financial reporting (as defined in Rule&#xa0;30a-3(d)&#xa0;under the Act (17 CFR 270.30a-3(d))) that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Registrant&#x2019;s internal control over financial reporting.</font></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 17. Disclosure of Securities Lending Activities for Closed-End
Management Investment Companies</b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 18. Recovery of Erroneously Awarded Compensation. </b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#xa0;</b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 19. Exhibits.</b></p>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 12%; padding-left: 35pt"><a href="tm2527059d12_ex99-codeeth.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(1)</font></a></td>
    <td style="text-align: justify; width: 88%"><a href="tm2527059d12_ex99-codeeth.htm" style="-sec-extract: exhibit">Code of Ethics of the Registrant for the period covered by this report as required pursuant to Item 2 of this Form <font style="font-family: Times New Roman, Times, Serif">N-CSR.</font>&#xa0;</a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(2)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any policy required by the listing standards adopted pursuant to Rule 10D-1 under the Exchange Act (17 CFR 240.10D-1) by the registered national securities exchange or registered national securities association upon which the registrant&#x2019;s securities are listed. Not applicable.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d12_ex99-cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(3)</font></a></td>
    <td style="text-align: justify"><a href="tm2527059d12_ex99-cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certifications of the registrant as required by Rule 30a-2(a) under the Act are exhibits to this Form N</font><font style="font-size: 10pt">&#xa0;<font style="font-family: Times New Roman, Times, Serif">-CSR.</font></font></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(4)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any written solicitation to purchase securities under Rule 23c-1 under the 1940 Act (17 CFR 270.23c-1) sent or given during the period covered by the report by or on behalf of the registrant to 10 or more persons. Not applicable.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)(5)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in Registrant&#x2019;s independent public accountant.&#xa0;&#xa0;Not applicable.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d12_ex99-906cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></a></td>
    <td style="text-align: justify"><a href="tm2527059d12_ex99-906cert.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The certifications of the registrant as required by Rule 30a-2(b) under the Act are exhibits to this Form N-CSR.</font><font style="font-size: 10pt">&#xa0;</font></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></td>
    <td style="text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A copy of the Registrant&#x2019;s notices to stockholders, which accompanied distributions paid, pursuant to the Registrant&#x2019;s Managed Distribution Policy since the Registrant&#x2019;s last filed N-CSR, are filed herewith as <a href="tm2527059d12_ex99-xcx1.htm" style="-sec-extract: exhibit">Exhibits (c)(1)</a> and <a href="tm2527059d12_ex99-xcx2.htm" style="-sec-extract: exhibit">(c)(2)</a> as required by the terms of the Registrant&#x2019;s SEC exemptive order.</font></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d12_ex99-xd.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></a></td>
    <td style="text-align: justify"><a href="tm2527059d12_ex99-xd.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Voting Policy of Registrant</font><font style="font-size: 10pt">&#xa0;</font></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 42pt">&#xa0;</td>
    <td style="text-align: justify">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; padding-left: 35pt"><a href="tm2527059d12_ex99-xe.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</font></a></td>
    <td style="text-align: justify"><a href="tm2527059d12_ex99-xe.htm" style="-sec-extract: exhibit"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy Voting Policies and Procedures of Adviser.</font><font style="font-size: 10pt">&#xa0;</font></a></td></tr>
  </table>


<p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 11; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>




















































</div><div style="font: 10pt Times New Roman, Times, Serif"><div style="Page-Break-Before: Always"></div><!-- BannerFile="tm2527059d12_sigpage.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1" -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase"><b><font style="text-decoration:underline">SIGNATURES</font></b></font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><font style="text-transform: uppercase"><b>&#xa0;</b></font></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, the Registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Life Sciences Investors</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 47%; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Alan Goodson</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Goodson,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Life Sciences Investors</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;December 8, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 47%; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Alan Goodson</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan Goodson,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Executive Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Life Sciences Investors</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;December 8, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;&#xa0;</p>


<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
    <td style="width: 47%; border-bottom: black 1pt solid"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Sharon Ferrari</i></font></td>
    <td style="width: 50%">&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon Ferrari,</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Financial Officer of</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td>&#xa0;</td>
    <td><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">abrdn Life Sciences Investors</font></td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2">&#xa0;</td>
    <td>&#xa0;</td></tr>
  <tr style="vertical-align: top">
    <td colspan="2"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&#xa0;December 8, 2025</font></td>
    <td>&#xa0;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><p style="margin: 0pt">&#xa0;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#xa0;</p>


</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CODEETH
<SEQUENCE>2
<FILENAME>tm2527059d12_ex99-codeeth.htm
<DESCRIPTION>EXHIBIT 99.CODEETH
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_codeeth.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.CODEETH&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CODE OF ETHICS (PERSONAL TRADING)</U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>I.</B></TD><TD><B>Introduction</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rule&nbsp;17j-1(b)&nbsp;under
the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;), makes it unlawful for any affiliated person, officer or Board
member of the Funds in connection with the purchase or sale by such person of a Security (as defined below) &ldquo;held or to be acquired&rdquo;
by the Funds:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify">To employ any device, scheme or artifice to defraud the Funds;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">To make to the Funds any untrue statement of a material fact or omit to state to the Funds a material
fact necessary in order to make the statement made, in light of the circumstances under which they are made, not misleading;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit
upon the Funds; or</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">To engage in any manipulative practice with respect to the Funds&rsquo; investment portfolios.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>II.</B></TD><TD><B>Purpose of the Code of Ethics</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Funds expect that the
officers and Fund Board members will conduct their personal investment activities in accordance with (1)&nbsp;the duty at all times to
place the interests of the Funds&rsquo; shareholders first; (2)&nbsp;the requirement that all personal Securities transactions be conducted
consistent with this Code of Ethics and in such a manner as to avoid any actual or potential conflict of interest or any abuse of an individual&rsquo;s
position of trust and responsibility; and (3)&nbsp;the fundamental standard that investment company personnel should not take inappropriate
advantage of their positions.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In view of the foregoing,
the provisions of Section&nbsp;17(j)&nbsp;of the 1940 Act, Rule&nbsp;17j-1 under the 1940 Act, and various pronouncements by the Securities
and Exchange Commission (&ldquo;SEC&rdquo;) and the Investment Company Institute on personal investing by investment company personnel,
<SUP>1</SUP> the Funds have adopted this Code of Ethics to specify a code of conduct for certain types of personal Securities transactions
that might involve conflicts of interest or an appearance of impropriety, and to establish reporting requirements and enforcement procedures.
This Code does not attempt to identify all possible conflicts of interest, and literal compliance with each of its specific provisions
will not shield Fund personnel from liability for personal trading or other conduct that violates a fiduciary duty to Fund shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Code of Ethics does not
apply to any officer, Board member or employee of the Funds who is also an Access Person or Investment Personnel (as defined under Rule&nbsp;17j-1
under the 1940 Act) employed by the Funds&rsquo; investment adviser, investment sub-advisers or principal underwriter (&ldquo;Excluded
Advisory Personnel&rdquo;). Those individuals are covered by the Codes of Ethics that have been adopted by their respective entities and
approved by the Board of each of the Funds in accordance with the provisions of Rule&nbsp;17j-1 of the 1940 Act.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">See Investment Adviser Code of Ethics, SEC Release No. IC-26492 (July 9, 2004); Personal Investment
                                                                                   Activities of Investment Company Personnel, SEC Release No. IC-23958 (August 24, 1999); Personal Investment Activities of Investment
                                                                                   Company Personnel, Report by the Securities and Exchange Commission (September 1994); and Report of the Advisory Group on Personal
                                                                                   Investing, Investment Company Institute (May 9, 1994).</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>III.</B></TD><TD><B>Definitions</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Access Person</U></B>&rdquo; means (1)&nbsp;each Board member or officer of the Funds; and
(2)&nbsp;any Advisory Person of the Funds except Excluded Advisory Personnel.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Advisory Person</U></B>&rdquo; means (1)&nbsp;each Board member, officer, general partner
or employee of the Funds (or of any company in a control relationship to the Funds) who in connection with his or her regular functions
or duties, makes, participates in, or obtains information regarding the purchase or sale of a Reportable Security (as defined below) by
the Funds or whose functions relate to the making of any recommendations with respect to such purchases or sales; and (2)&nbsp;any natural
person in a control relationship to the Funds who obtains information concerning recommendations made to the Funds with regard to the
purchase or sale of a Reportable Security by the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">C.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Automatic Investment Plan</U></B>&rdquo; means a program in which regular periodic purchases
(or withdrawals) are made automatically in (or from) investment accounts in accordance with a predetermined schedule and allocation. An
Automatic Investment Plan includes a dividend reinvestment plan.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">D.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Beneficial Ownership</U></B>&rdquo; shall be interpreted in the same manner as it would be
in determining whether a person is considered a &ldquo;beneficial owner&rdquo; as defined in Rule&nbsp;16a-1(a)(2)&nbsp;under the Securities
Exchange Act of 1934, as amended (&ldquo;1934 Act&rdquo;), which generally speaking, encompasses those situations where the beneficial
owner has the right to enjoy some economic benefit from the ownership of the Reportable Security. You will be treated as a &ldquo;beneficial
owner&rdquo; of a Security under this Code only if you have a direct or indirect pecuniary interest in the Security. A direct pecuniary
interest is the opportunity, directly or indirectly, to profit, or to share the profit, from the transaction. An indirect pecuniary interest
is any nondirect financial interest, but is specifically defined in the rules&nbsp;to include, among other things, Securities held by
members of your immediate family sharing the same household; Securities held by a partnership of which you are a general partner; Securities
held by a trust of which you are the settlor if you can revoke the trust without the consent of another person, or a beneficiary if you
have or share investment control with the trustee; and equity Securities which may be acquired upon exercise of an option or other right,
or through conversion. For interpretive guidance on this test, you should consult your counsel. A person is normally regarded as the beneficial
owner of Reportable Securities held in the name of his or her spouse or minor children and adults living in his or her household.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">E.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Control</U></B>&rdquo; shall have the same meaning as set forth in Section&nbsp;2(a)(9)&nbsp;of
the 1940 Act. Generally, control is the power to exercise a controlling influence over the management or policies of a company unless
such power is solely the result of an official position with such company.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">F.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Exempt Transactions</U></B>&rdquo; means: (1)&nbsp;purchases or sales effected in any account
over which an Access Person or Investment Personnel has no direct or indirect influence or control; (2)&nbsp;purchases or sales which
are non-volitional<SUP>2</SUP> on the part of the Access Person, Investment Personnel or the Funds; (3)&nbsp;purchases which are
part of an Automatic Investment Plan; or (4)&nbsp;purchases effected upon the exercise of rights issued by an issuer pro-rata to all holders
of a class of its Reportable Securities, to the extent such rights were acquired from such issuer, and sales of such rights so acquired.</TD></TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><SUP>2</SUP></TD><TD STYLE="text-align: justify">Non-volitional purchases or sales include those transactions,
which do not involve a willing act or conscious decision on the part of the Board Member, officer or employee. For example, shares received
or disposed of by Access Persons or Investment Personnel in a merger, recapitalization or similar transaction are considered non-volitional.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">G.</TD><TD STYLE="text-align: justify">A Security is &ldquo;<B><U>held or to be acquired</U></B>&rdquo; if within the most recent 15 days it
(1)&nbsp;is or has been held by the Funds, (2)&nbsp;is being or has been considered by the Funds or the investment adviser or investment
sub-adviser for purchase by the Funds or (3)&nbsp;any option to purchase or sell and any Security convertible into or exchangeable for
a Reportable Security that is described in (1)&nbsp;or (2)&nbsp;of this definition.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">H.</TD><TD STYLE="text-align: justify">An Access Person&rsquo;s &ldquo;<B><U>immediate family</U></B>&rdquo; means a spouse, minor children and
adults living in the same household as the Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">I.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Independent Board Member</U></B>&rdquo; means each Board member who is not an &ldquo;interested
person&rdquo; of the Funds (as defined in Section&nbsp;2(a)(19) of the 1940 Act) and who would be required to make a report under Section&nbsp;V
of this Code solely by reason of being a Board member of the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">J.</TD><TD STYLE="text-align: justify">An &ldquo;<B><U>Initial Public Offering</U></B>&rdquo; means an offering of Securities registered under
the Securities Act of 1933, the issuer of which, immediately before the registration, was not subject to the reporting requirements of
Sections 13 or 15(d)&nbsp;of the 1934 Act.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">K.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Investment Personnel</U></B>&rdquo; of the Funds means (1)&nbsp;any employee of the Funds
(or of any company in a control relationship to the Funds) who, in connection with his or her regular functions or duties, makes or participates
in making recommendations regarding the purchase or sale of Securities by the Funds or (2)&nbsp;any natural person who controls the Funds
and who obtains information concerning recommendations made to the Funds regarding the purchase or sale of Securities by the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">L.</TD><TD STYLE="text-align: justify">A &ldquo;<B><U>Limited Offering</U></B>&rdquo; means an offering that is exempt from registration under
the Securities Act of 1933 pursuant to Section&nbsp;4(2)&nbsp;or Section&nbsp;4(6)&nbsp;or pursuant to Rule&nbsp;504, Rule&nbsp;505, or
Rule&nbsp;506 under the Securities Act of 1933.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">M.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Purchase or sale of a Reportable Security</U></B>&rdquo; includes, among other things, the
writing of an option to purchase or sell a Reportable Security.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">N.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Reportable Security</U></B>&rdquo; means a Security excluding (1)&nbsp;direct obligations
of the Government of the United States; (2)&nbsp;banker&rsquo;s acceptances; (3)&nbsp;bank certificates of deposit; (4)&nbsp;commercial
paper; (5)&nbsp;high quality short-term debt instruments (any instrument having a maturity at issuance of less than 366 days and that
is rated in one of the two highest rating categories by a nationally recognized statistical rating organization), including repurchase
agreements; and (6)&nbsp;shares of registered open-end investment companies other than those advised by an Aberdeen Adviser.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">O.</TD><TD STYLE="text-align: justify">&ldquo;<B><U>Security</U></B>&rdquo; means a security as defined in Section&nbsp;2(a)(36)of the 1940 Act
which is defined as any note, stock, treasury stock, security future, bond, debenture, evidence of indebtedness, certificate of interest
or participation in any profit-sharing agreement, collateral-trust certificate, preorganization certificate or subscription, transferable
share, investment contract, voting-trust certificate, certificate of deposit for a security, fractional undivided interest in oil, gas,
or other mineral rights, any put, call, straddle, option, or privilege on any security (including a certificate of deposit) or on any
group or index of securities (including any interest therein or based on the value thereof), or any put, call, straddle, option, or privilege
entered into on a national securities exchange relating to foreign currency, or, in general, any interest or instrument commonly known
as a &ldquo;security,&rdquo; or any certificate of interest or participation in, temporary or interim certificate for, receipt for, guarantee
of, or warrant or right to subscribe to or purchase, any of the foregoing.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>IV.</B></TD><TD><B>Policies of the Funds Regarding Personal Securities Transactions</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">General Policy</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No Access Person of the Funds
shall engage in any act, practice or course of business that would violate the provisions of Rule&nbsp;17j-1(b)&nbsp;set forth above,
or in connection with any personal investment activity, engage in conduct inconsistent with this Code of Ethics.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">B.</TD><TD STYLE="text-align: justify">Specific Policies</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Restrictions on Personal Securities Transactions by Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">The Funds recognize that an Independent
Board Member does not have on-going, day-to-day interaction with the operations of the Funds. In addition, it has been the practice of
the Funds to give information about Securities purchased or sold by the Funds or considered for purchase or sale by the Funds to Independent
Board Members in materials circulated more than 15 days after such Securities are purchased or sold by the Funds or are considered for
purchase or sale by the Funds. Accordingly, the Funds believe the following controls are appropriate for Independent Board Members:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Personal Account Dealing in Fund Shares.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25in"></TD><TD STYLE="width: 0.5in">i.</TD><TD STYLE="text-align: justify">Independent Board Members are prohibited from buying or selling any Aberdeen-advised U.S. Registered Fund
(closed-end, open-end, and ETFs) shares during the two week period prior to or following Board meetings of which they are aware.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25in"></TD><TD STYLE="width: 0.5in">ii.</TD><TD STYLE="text-align: justify">Independent Board Members are required to pre-clear with the Fund CCO or his/her designee all Aberdeen-advised
U.S. Registered Fund buys or sells including funds for which an Independent Board Member does not serve as a director/trustee.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.25in"></TD><TD STYLE="width: 0.5in">iii.</TD><TD STYLE="text-align: justify">The Fund CCO may waive this prohibition in exceptional circumstances and upon a determination that the
transaction does not violate any applicable laws or regulations. The Fund CCO will document any such waivers.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Limited Pre-clearance. The Securities pre-clearance requirement contained in IV.B.2. below shall only
apply to an Independent Board Member if he or she knew that during the fifteen day period before the proposed transaction in a Reportable
Security (other than Exempt Transactions) or at the time of the transaction that the Reportable Security to be purchased or sold by him
or her (other than Exempt Transactions) was also purchased or sold by the Fund(s)&nbsp;or considered for the purchase or sale by the Fund(s)&nbsp;(i)&nbsp;for
which such Independent Board Member acts as a Director or Trustee or (ii)&nbsp;any Aberdeen-advised U.S. Registered Fund (closed-end,
open-end, and ETFs).<SUP>3</SUP></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Pre-clearance Not Granted. When the securities pre-clearance requirement applies to an Independent Board
Member, no clearance will be given to the Independent Board Member to purchase or sell any Reportable Security (1)&nbsp;on a day when
any Fund has a pending &ldquo;buy&rdquo; or &ldquo;sell&rdquo; order in that same Reportable Security until that order is executed or
withdrawn or (2)&nbsp;when the Funds&rsquo; Chief Compliance Officer has been advised by the Funds&rsquo; investment adviser or investment
sub-adviser that the same Reportable Security is being considered for purchase or sale for any Fund.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Restrictions on Initial Public Offering or Limited Offering Personal Securities Transactions by Access
Persons Who Are Not Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Pre-clearance. An Access Person who is not an Independent Board Member is prohibited from buying or selling
any Security through an Initial Public Offering or a Limited Offering for his or her personal portfolio or the portfolio of a member of
his or her immediate family without obtaining (i)&nbsp;email or other written authorization or (ii)&nbsp;oral authorization from a Funds
Chief Compliance Officer prior to effecting such Reportable Security transaction.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">A written authorization for such Security
transaction will be provided by the Funds&rsquo; Chief Compliance Officer or his/her delegate to the person receiving the oral authorization
(if granted). The written authorization will also be provided to the Funds&rsquo; administrator to memorialize the email and oral authorization
that was granted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify"><U>Note</U>: If an Access Person has questions
as to whether purchasing or selling a Reportable Security for his or her personal portfolio or the portfolio of a member of his or her
immediate family requires prior oral authorization, the Access Person should consult the Funds&rsquo; Chief Compliance Officer for clearance
or denial of clearance to trade prior to effecting any Reportable Securities transition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>3</SUP></TD><TD STYLE="text-align: justify">Because monitoring the publication of the portfolio holdings
of series of abrdn ETFs and abrdn Funds that operate as ETFs is not construed to be within the ordinary course of fulfilling the duties
of a board member, the publication or availability of such portfolio holdings shall not be construed to impart actual or constructive
knowledge of such series&rsquo; portfolio transactions on an Independent Board Member.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Pre-clearance Expiration. Pre-clearance approval will expire at the close of business on the trading day
after the date on which written or oral authorization is received, and the Access Person is required to renew clearance for the transaction
if the trade is not completed before the authority expires.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Pre-clearance Not Granted. No pre-clearance will be given to purchase or sell any Reportable Security
(1)&nbsp;on a day when any Fund has a pending &ldquo;buy&rdquo; or &ldquo;sell&rdquo; order in that same Reportable Security until that
order is executed or withdrawn or (2)&nbsp;when the Funds&rsquo; Chief Compliance Officer has been advised by the Funds&rsquo; investment
adviser or investment sub-adviser that the same Reportable Security is being considered for purchase or sale for any Fund.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Additional Restrictions on Investment Personnel</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Gifts. No investment personnel shall receive any gift or other thing of more than <I>de minimis</I> value
from any person or entity that does business with or on behalf of the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Board Service. Investment Personnel shall not serve on the boards of directors of publicly traded companies
absent prior authorization by the Funds&rsquo; Chief Compliance Officer.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>V.</B></TD><TD><B>Procedures &ndash; Initial Holdings Reports, Annual Holdings Reports and Quarterly Transaction Reports</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">A.</TD><TD STYLE="text-align: justify">In order to provide the Funds with information to enable it to determine with reasonable assurance whether
the provisions of this Code of Ethics are being observed by its Access Persons:</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify"><B>Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Holdings Reports Not Required &ndash; Each Independent Board Member need not make initial or annual holdings
reports.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Limited Quarterly Transaction Reporting &ndash; An Independent Board Member must submit the same quarterly
transaction report as required under paragraph V.A.2.d below to the Chief Compliance Officer of the Funds, but only for a transaction
in a Reportable Security where he or she knew at the time of the transaction or, in the ordinary course of fulfilling his or her official
duties as an Independent Board Member, should have known that during the 15-day period immediately preceding or after the date of the
transaction, such Reportable Security is or was purchased or sold, or considered by the Funds, its investment adviser or investment sub-adviser
for purchase or sale by the Fund (i)&nbsp;for which such Independent Board Member acts as a Director or Trustee or (ii)&nbsp;any Aberdeen-advised
U.S. Registered Fund (closed-end, open-end, and ETFs).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><B>Access Persons Who Are Not Independent Board Members</B></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">Initial Holdings Reports &ndash; Each Access Person who is not an Independent Board Member will submit
to the Chief Compliance Officer or his/her designee of the Funds an Initial Holdings Report in the form attached hereto as <B>Exhibit&nbsp;A</B>
that lists all Reportable Securities in which the Access Person has Beneficial Ownership.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Initial Holdings Report must be submitted within ten days of becoming an Access Person and must contain
information current as of a date no more than 45 days prior to becoming an Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Initial Holdings Report must include the title of each Reportable Security, the number of shares held
(for equity securities), the principal amount (for debt securities) of each Reportable Security, the date the report is submitted as well
as a list of any Securities accounts maintained with any broker, dealer or bank in which any Securities were held for the direct or indirect
benefit of the Access Person as of the date the person became an Access Person of the Funds.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">An Access Person need not include in the report transactions effected for, and Reportable Securities held
in, any account over which the Access Person has no direct or indirect influence or control.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The report may contain a statement that the report shall not be construed as an admission by the person
making such report that he or she has any direct or indirect beneficial ownership in the Reportable Security to which the report relates.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">Annual Holdings Reports &ndash; Each Access Person of the Funds who is not an Independent Board Member
will also submit to the Chief Compliance Officer or his/her designee of the Funds an Annual Holdings Report attached hereto as <B>Exhibit&nbsp;A</B>
no later than 30 days after the end of the calendar year.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The information contained in the Annual Holdings Report must be current as of a date no more than 45 days
before the report is submitted.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The Annual Holdings Report must list all Reportable Securities in which the Access Person has Beneficial
Ownership, the title of each Reportable Security, the number of shares held (for equity securities), the principal amount (for debt securities)
of the Reportable Security, and the date the report is submitted. The Report must also list any Securities accounts maintained with any
broker, dealer or bank in which any Securities were held for the direct or indirect benefit of the Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">An Access Person need not include in the report transactions effected for, and Reportable Securities held
in, any account over which the Access Person has no direct or indirect influence or control.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The report may contain a statement that the report shall not be construed as an admission by the person
making such report that he or she has any direct or indirect beneficial ownership in the Reportable Security to which the report relates.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">c.</TD><TD STYLE="text-align: justify">Securities Confirmations &ndash; Each Access Person of the Funds who is not an Independent Board Member
shall direct his or her broker to supply to a Chief Compliance Officer or his/her designee of the Funds, on a timely basis, duplicate
copies of confirmation of all personal Securities transactions and copies of periodic statements for all Securities accounts in which
the Access Person has Beneficial Ownership.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">d.</TD><TD STYLE="text-align: justify">Quarterly Transaction Reports &ndash; Each Access Person of the Funds who is not an Independent Board
Member shall submit reports in the form attached hereto as <B>Exhibit&nbsp;B</B> to the Chief Compliance Officer or his/her designee of
the Funds, showing all transactions in Reportable Securities in which the person has, or by reason of such transaction acquires, any direct
or indirect Beneficial Ownership, as well as all accounts established with brokers, dealers or banks during the quarter in which any Securities
were held for the direct or indirect beneficial interest of the Access Person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">Quarterly transaction reports shall be filed no later than 30 days after the end of each calendar quarter.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">The report shall include (a)&nbsp;the date of the transaction, (b)&nbsp;the title of the Reportable Security,
(c)&nbsp;the interest rate and maturity date (if applicable), (d)&nbsp;the number of shares (for equity securities), (e)&nbsp;the principal
amount of each Reportable Security involved; (f)&nbsp;the nature of the transaction (i.e., purchase, sale or any other type of acquisition
or disposition), (g)&nbsp;the price at which the transaction was effected, (h)&nbsp;the name of the broker, dealer or bank with or through
whom the transaction was effected; and (i)&nbsp;the date the report is submitted. In addition, with respect to any account established
by the Access Person in which any Reportable Securities were held during the quarter for the direct or indirect benefit of the Access
Person, the Access Person shall report the following information: (a)&nbsp;the name and address of the broker, dealer or bank with whom
the Access Person established the account; (b)&nbsp;the date the account was established; and (c)&nbsp;the date the report is submitted.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">An Access Person of the Funds need not make a quarterly transaction report with respect to (a)&nbsp;transactions
effected pursuant to an Automatic Investment Plan, (b)&nbsp;a transaction if all of the information required by paragraph (ii)&nbsp;above
is contained in the brokerage confirmations or account statements required to be submitted under paragraph (c)&nbsp;above, and (c)&nbsp;transactions
effected for, and Reportable Securities held in, any account over which the Access Person has no direct or indirect influence or control.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">The report may contain a statement that the report shall not be construed as an admission by the person
making such report that he or she has any direct or indirect beneficial ownership in the Reportable Security to which the report relates.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><B>Identification of Access Persons</B> &ndash; The Chief Compliance Officer or his/her designee of the
Funds shall notify each Access Person of the Funds who may be subject to the pre-clearance requirement or required to make reports pursuant
to this Code of Ethics that such person is subject to the pre-clearance or reporting requirements and shall deliver a copy of this Code
of Ethics to each such person.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><B>Compliance Review</B> &ndash; The Chief Compliance Officer or his/her designee of the Funds shall (i)&nbsp;with
regard to any Access Persons or Investment Personnel reporting directly under this Code of Ethics, review any initial holdings reports,
annual holdings reports, and quarterly transaction reports that are received by the Chief Compliance Officer or his/her designee under
this Code of Ethics, and as appropriate compare the reports with the pre-clearance authorization received; (ii)&nbsp;with regard to any
Excluded Advisory Personnel reporting under a Code of Ethics of the Funds&rsquo; investment adviser, sub-advisers or principal underwriter,
quarterly contact the compliance officer of such investment adviser, sub-advisers or principal underwriter regarding the compliance of
such Access Persons or Investment Personnel with their Code of Ethics and (iii)&nbsp;report to the Funds&rsquo; Board: (a)&nbsp;with respect
to any transaction that appears to evidence a violation of this Code or the investment adviser&rsquo;s, sub-advisers&rsquo; or principal
underwriter&rsquo;s Codes of Ethics; and (b)&nbsp;violations of the reporting requirement stated in such Codes of Ethics.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><B>Board Review</B> &ndash; The Board shall review the operation of this Code of Ethics at least once
a year.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><B>Service Provider Code of Ethics</B> &ndash; The investment adviser, any investment sub-advisers and
the principal underwriter shall adopt, maintain and enforce a separate code of ethics with respect to their personnel in compliance with
Rule&nbsp;17j-1 of the 1940 Act and Rule&nbsp;204A-1 of the Investment Advisers Act of 1940, as applicable. Any material changes to the
investment adviser&rsquo;s, investment sub-adviser&rsquo;s or principal underwriter&rsquo;s code will be approved by the Board no later
than six months after such change.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify"><B>Board Reporting</B> &ndash; At each quarterly Board meeting, the Chief Compliance Officer of the Funds&rsquo;
investment adviser, any investment sub-adviser and the principal underwriter of the Funds shall provide a written report to the Funds&rsquo;
Board stating:</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify">any reported Securities transaction that occurred during the prior quarter that materially violated (either
individually or in the aggregate) the provisions of the code of ethics adopted by the investment adviser, any investment sub-adviser or
principal underwriter; and</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify">all disciplinary actions<SUP>4</SUP> taken in response to such violations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><B>Annual Reports</B> &ndash; At least once a year, the Funds&rsquo; Chief Compliance Officer shall provide
to the Board a written report that contains any previously reported material violations of the code or procedures and sanctions imposed
in response to material violations, any recommended changes in the code or procedures, and a certification that the procedures which have
been adopted are those reasonably necessary to prevent Access Persons (as defined under Rule&nbsp;17j-1) from violating their respective
Codes of Ethics. The written report will also include an assessment of the effectiveness of the Service Providers&rsquo; Codes of Ethics
outlined in Section&nbsp;6 above.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify"><B>Recordkeeping &ndash;</B> This Code, the codes of the investment adviser, any investment sub-adviser and principal underwriter,
a copy of each report by an Access Person, any record of any violation of this Code of Ethics and any action taken as a result thereof,
any written report hereunder by the Chief Compliance Officer of the investment adviser, investment sub-adviser or the principal underwriter,
records of approvals relating to Initial Public Offerings and Limited Offerings, lists of all persons required to make reports and a list
of all persons responsible for reviewing such reports shall be preserved with the Funds&rsquo; records for the period required by Rule&nbsp;17j-1
of the 1940 Act.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>IV.</B></TD><TD STYLE="text-align: justify"><B>Certification</B></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Access Person, including
an Independent Board Member, will be required to certify annually that he or she has read and understood this Code of Ethics, and will
abide by it. Each Access Person, including an Independent Board Member, will further certify that he or she has disclosed or reported
all personal Securities transactions required to be disclosed or reported under the Code of Ethics. Certification of compliance with the
Code of Ethics by an Independent Board Member will occur annually.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">4</TD><TD STYLE="text-align: justify">Disciplinary action includes but is not limited to any action
that has a material financial effect upon the employee, such as fining, suspending, or demoting the employee, imposing a substantial
fine or requiring the disgorgement of profits.</TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Code of Ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;A</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>HOLDINGS REPORT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Year/Period Ended&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 168pt">(Month/day/year)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Check here if this is an Initial Holdings Report</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;______________,
as the Chief Compliance Officer of [Name of Aberdeen Fund]</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;____________________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the calendar year/period
referred to above,&nbsp;I have a direct or indirect beneficial ownership interest in the Securities listed below which are required to
be reported pursuant to the Code of Ethics of the Funds.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 34%; border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of Security</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Shares</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 33%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal Amount</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The name and address of any
broker, dealer or bank with whom I maintain an account in which my Securities are held for my direct or indirect benefit are as follows.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 30%; border: Black 1pt solid; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 70%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Address</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; text-indent: 0.5in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For Initial Holdings Reports:
This report contains information current as of a date no more than 45 days prior to the date of becoming an Access Person.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For Annual Holdings Reports:
This report contains information current as of a date no more than 45 days before the report is submitted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report (i)&nbsp;excludes
transactions with respect to which I had no direct or indirect influence or control, (ii)&nbsp;excludes other transactions not required
to be reported and (iii)&nbsp;is not an admission that I have or had any direct or indirect beneficial ownership in the Securities listed
above.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 8%">Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%">&nbsp;</TD>
    </TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Code of Ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit&nbsp;B</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>QUARTERLY SECURITIES TRANSACTION REPORT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Calendar Quarter Ended&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;_________________________&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 205.5pt">(month/day/year)</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;______________,
Chief Compliance Officer</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;____________________________________</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the quarter referred
to above, the following transactions were effected in Securities of which I had, or by reason of such transaction acquired, direct or
indirect beneficial ownership, and which are required to be reported pursuant to the Code of Ethics of the Funds:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 11%; border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date of<BR>
 Transaction</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number <BR>
of <BR>
Shares</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 10%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 1.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal<BR>
 Amount</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest<BR>
 Rate and<BR>
 Maturity<BR>
 Rate (if<BR>
 applicable)</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nature of<BR>
 Transaction<BR>
 (Purchase,<BR>
 Sale, or<BR>
 Other)</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 9%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0.3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Broker/Dealer<BR>
 or Bank<BR>
 Though Whom<BR>
 Effected</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the quarter referred
to above,&nbsp;I established the following accounts in which Securities were held during the quarter for my direct or indirect benefit:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; width: 52%; border: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name and address of the broker, dealer or bank<BR>
 with which I established the account.</B></FONT></TD>
    <TD STYLE="padding: 2pt 5.4pt; width: 48%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The date the account was established.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding: 2pt 5.4pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report (i)&nbsp;excludes
transactions with respect to which I had no direct or indirect influence or control, (ii)&nbsp;excludes other transactions not required
to be reported, and (iii)&nbsp;is not an admission that I have or had any direct or indirect beneficial ownership in the Securities listed
above.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 8%">Signature:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%">&nbsp;</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.CERT
<SEQUENCE>3
<FILENAME>tm2527059d12_ex99-cert.htm
<DESCRIPTION>EXHIBIT 99.CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_ex99-cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.CERT</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal; text-transform: uppercase">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Certification
Pursuant to Rule 30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)
under the 1940 Act and Section 302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Sharon Ferrari, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this report on Form N-CSR of abrdn Life Sciences Investors (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s) and I have disclosed to the Registrant&rsquo;s auditors
and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 8, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sharon Ferrari</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon
    Ferrari</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Financial Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Certification
Pursuant to Rule 30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>a<FONT STYLE="text-transform: uppercase">)
under the 1940 Act and Section 302 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Alan Goodson, certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD>I have reviewed this report on Form N-CSR of abrdn Life Sciences Investors (the &ldquo;Registrant&rdquo;);</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to
state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report,
fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the
financial statements are required to include a statement of cash flows) of the Registrant as of, and for, the periods presented in this
report;</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial
reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the Registrant and have:</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to
be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries,
is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the Registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to
the filing date of this report based on such evaluation; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the Registrant&rsquo;s internal control over financial reporting
that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the
Registrant&rsquo;s internal control over financial reporting; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s other certifying officer(s) and I have disclosed to the Registrant&rsquo;s auditors
and the audit committee of the Registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the Registrant&rsquo;s ability to record, process, summarize, and
report financial information; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant
role in the Registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: December 8, 2025</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alan Goodson</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Goodson</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    Executive Officer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="margin-top: 0; margin-bottom: 0"></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.906CERT
<SEQUENCE>4
<FILENAME>tm2527059d12_ex99-906cert.htm
<DESCRIPTION>EXHIBIT 99.906CERT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_ex99-906cert.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.906CERT&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Certification
Pursuant to Rule 30</U></B></FONT><B><U>a<FONT STYLE="text-transform: uppercase">-2(</FONT>b<FONT STYLE="text-transform: uppercase">)
under the 1940 Act and Section 906 of the Sarbanes-Oxley Act</FONT></U></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Alan Goodson, Principal Executive Officer, and
Sharon Ferrari, Principal Financial Officer, of abrdn Life Sciences Investors (the &ldquo;Registrant&rdquo;), each certify that:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Registrant&rsquo;s periodic report on Form N-CSR for the period ended September 30, 2025 (the &ldquo;Form
N-CSR&rdquo;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended,
as applicable; and</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Form N-CSR fairly presents, in all material respects, the financial condition
and results of operations of the Registrant.</TD></TR></TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL EXECUTIVE OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Life Sciences Investors</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: italic 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">/s/
    Alan Goodson</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Alan
    Goodson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">Date:
    December 8, 2025</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRINCIPAL FINANCIAL OFFICER</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn Life Sciences Investors</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Sharon Ferrari</FONT></TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sharon
    Ferrari</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    December 8, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification is being furnished solely pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002 and is not being filed as part of Form N-CSR or as a separate disclosure document. A
signed original of this written statement, or other document authenticating, acknowledging, or otherwise adopting the signature that appears
in typed form within the electronic version of this written statement required by Section 906, has been provided to the Registrant and
will be retained by the Registrant and furnished to the Securities and Exchange Commission or its staff upon request.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt"></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(1)
<SEQUENCE>5
<FILENAME>tm2527059d12_ex99-xcx1.htm
<DESCRIPTION>EXHIBIT 99.(C)(1)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_ex99-xcx1.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.(C)(1)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2527059d12_ex99-xcx1img01.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Press
Release</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>For More Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 236pt 0pt 0.25in">Aberdeen Investments U.S. Closed-End Funds<BR>
 Investor Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 276pt 0pt 0.25in">1-800-522-5465<BR>
 Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS</B></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE
DISTRIBUTION PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(Philadelphia, June 30, 2025) - The <U>Aberdeen Investments
U.S. Closed-End Funds</U> (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on June 30, 2025, on a per share basis to all shareholders
of record as of June 23, 2025 (ex-dividend date June 23, 2025). These dates apply to the Funds listed below with the exception of abrdn
Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN)
which paid on June 30, 2025, to all shareholders of record as of May 22, 2025 (ex-dividend date May 22, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 5pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Ticker</TD><TD STYLE="padding-bottom: 1pt; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Exchange</TD><TD STYLE="padding-bottom: 1pt; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap">Fund</TD><TD STYLE="padding-bottom: 1pt; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; text-align: center; white-space: nowrap; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 14%">NYSE</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 61%; text-align: left">abrdn Global Infrastructure Income Fund</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH`</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Healthcare Investors</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right">0.5400</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Life Sciences Investors</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">NYSE American</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Australia Equity Fund, Inc.</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">The India Fund, Inc.</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right">0.4100</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">NYSE</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">abrdn Healthcare Opportunities Fund</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Each Fund has adopted a distribution policy to provide investors
with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">For the abrdn Healthcare Investors (HQH), abrdn Life Sciences
Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN) the stock distributions were automatically paid
in newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in cash. Shares of common stock were issued
at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share with a floor for the NAV of not less than
95% of the market price on June 17, 2025. The reinvestment prices per share for these distributions were as follows: $15.32 for abrdn
Healthcare Investors (HQH); $12.60 for abrdn Life Sciences Investors (HQL); $4.44 for abrdn Australia Equity Fund, Inc. (IAF) and $15.94
for the India Fund, Inc. (IFN). Fractional shares were generally settled in cash, except for registered shareholders with book entry accounts
at Computershare Investor Services who had whole and fractional shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">To have received the abrdn Healthcare Investors (HQH), abrdn
Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN) quarterly distributions payable in
June 2025 in cash instead of shares of common stock, for shareholders who hold shares in &ldquo;street name,&rdquo; the bank, brokerage
or nominee who holds the shares must have advised the Depository Trust Company as to the full and fractional shares for which they want
the distribution paid in cash by June 16, 2025; and for shares that are held in registered form, written notification for the election
of cash by registered shareholders must have been received by Computershare Investor Services prior to June 16, 2025.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 53pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Under applicable U.S. tax rules, the amount and character of distributable
income for each Fund&rsquo;s fiscal year can be finally determined only as of the end of the Fund&rsquo;s fiscal year. However, under
Section 19 of the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;) and related rules, the Funds may be required
to indicate to shareholders the estimated source of certain distributions to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following tables set forth the estimated amounts of
the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed
based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions
paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment
income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions
of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses
on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Funds&rsquo; estimated sources of the current distribution
paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="37" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Current Distribution
    per Share</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>

<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%">ASGI</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.2100</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0252</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">12</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0042</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">2</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0861</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0.0945</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">45</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQH</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5400</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2322</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0486</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2592</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">HQL</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1986</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0916</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1398</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IAF</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0120</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0264</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0816</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">IFN</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">THQ</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0126</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1674</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>










<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Fiscal Year*
    to Date Cumulative Distributions per Share</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1.8100</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2172</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0362</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.7421</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">41</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.8145</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">45</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7439</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">43</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1557</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8304</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">48</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.4000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.6468</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2982</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4550</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">33</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.3700</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0370</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0814</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2516</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">68</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8700</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.8700</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.6200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1134</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.5066</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">93</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">* ASGI, HQH, HQL and THQ have a 9/30 fiscal year end.
IAF has a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">**includes currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Where the estimated amounts above show a portion of the distribution
to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s
investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0">As of June 20, 2025, after giving effect to this payment HQL
estimates it has a net deficit $2,445,453. of A net deficit results when the Fund has net unrealized losses that are in excess of any
net realized gains that have not yet been distributed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for
the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to
report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26pt 0pt 0">The following tables provide the Funds&rsquo; total return
performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution
rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="17" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund Performance and Distribution
    Rate Information</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
05/31/2025<SUP>1</SUP></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
    Total Return <BR>
on NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI<SUP>3</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">9.96</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%<SUP>3</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.35</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">7.93</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">7.54</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.03</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.22</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-16.81</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.15</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 13pt"><SUP>1</SUP></FONT>
<FONT STYLE="font-size: 10pt">Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested
at prices obtained under the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 13pt"><SUP>2</SUP></FONT> <FONT STYLE="font-size: 10pt">Based on the Fund&rsquo;s NAV as of May 31, 2025. </FONT></P>






<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 13pt"><SUP>3</SUP></FONT> <FONT STYLE="font-size: 10pt">The
Fund launched within the past 5 years; the performance and distribution rate information presented reflects data from inception (July
29, 2020) through May 31, 2025. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund Performance and Distribution Rate Information</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
04/30/2025<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Cumulative <BR> Total Return<BR> on
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">4.82</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">13.01</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-5.48</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">6.64</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.78</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">13.45</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-6.93</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">6.83</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.39</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.40</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-0.50</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.31</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">14.16</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.68</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-3.10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.67</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 13pt"><SUP>1</SUP></FONT>
<FONT STYLE="font-size: 10pt">Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested
at prices obtained under the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 13pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 13pt"><SUP>2</SUP></FONT><SUP> <FONT STYLE="font-size: 10pt"></FONT></SUP><FONT STYLE="font-size: 10pt">Based
on the Fund&rsquo;s NAV as of April 30, 2025. </FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 24pt 0pt 0"><B>Shareholders should not draw any conclusions about a
Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution
policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s
investment performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s
investment in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares
in the open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940
Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains,
long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable
at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate
not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution
Policy may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in
the Fund&rsquo;s annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market
price correlates closely to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the
Fund&rsquo;s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would
hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the
distribution. Each Fund&rsquo;s Board has the right to amend, suspend or terminate the Distribution Policy at any time. The
amendment, suspension or termination of the Distribution Policy may affect the Fund&rsquo;s market price per share. Investors should
consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular
circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii)
promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's
investments business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0">Closed-end funds are traded on the secondary market
through one of the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s
shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a
discount) the net asset value (NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment
objective. Past performance does not guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: blue"><FONT STYLE="color: Black"><U>Closed end funds
| Aberdeen</U></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">###</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(C)(2)
<SEQUENCE>6
<FILENAME>tm2527059d12_ex99-xcx2.htm
<DESCRIPTION>EXHIBIT 99.(C)(2)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_ex99-xcx2.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 381pt"><B>Exhibit 99.(c)(2)</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2527059d12_ex99-xcx1img01.jpg" ALT="">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Press Release</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>FOR IMMEDIATE RELEASE</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>For More Information Contact:</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3.25in 0pt 0.25in">Aberdeen Investments U.S. Closed-End Funds<BR>
 Investor Relations</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 274pt 0pt 0.25in">1-800-522-5465 <BR>
Investor.Relations@aberdeenplc.com</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ANNOUNCE DISTRIBUTION PAYMENT DETAILS</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">(Philadelphia, September 30, 2025) - The <U>Aberdeen Investments
U.S. Closed-End Funds</U> (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the &ldquo;Funds&rdquo; or individually the &ldquo;Fund&rdquo;),
today announced that the Funds paid the distributions noted in the table below on September 30, 2025, on a per share basis to all shareholders
of record as of September 23, 2025 (ex-dividend date September 23, 2025). These dates apply to the Funds listed below with the exception
of abrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund
Inc. (IFN) which paid on September 30, 2025, to all shareholders of record as of August 22, 2025 (ex-dividend date August 22, 2025).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">Ticker</TD><TD STYLE="text-align: left; font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Exchange</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Fund</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Amount</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5pt">NYSE</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">abrdn Global Infrastructure Income Fund</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">0.2100</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">abrdn Healthcare Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">abrdn Life Sciences Investors</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">NYSE American</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">abrdn Australia Equity Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">The India Fund, Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5pt">NYSE</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 5pt">abrdn Healthcare Opportunities Fund</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Each Fund has adopted a distribution policy to provide investors
with a stable distribution out of current income, supplemented by realized capital gains and, to the extent necessary, paid-in capital.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">For the abrdn Healthcare Investors (HQH), abrdn Life
Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN) the stock distributions were
automatically paid in newly issued shares of the Fund unless otherwise instructed by the shareholder to be paid in cash. Shares of
common stock were issued at the lower of the net asset value (&ldquo;NAV&rdquo;) per share or the market price per share with a
floor for the NAV of not less than 95% of the market price on September 17, 2025. The reinvestment prices per share for these
distributions were as follows: $16.50 for abrdn Healthcare Investors (HQH); $13.95 for abrdn Life Sciences Investors (HQL); $4.63
for abrdn Australia Equity Fund, Inc. (IAF) and $15.14 for the India Fund, Inc. (IFN). Fractional shares were generally settled in
cash, except for registered shareholders with book entry accounts at Computershare Investor Services who had whole and fractional
shares added to their account.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">To have received the abrdn Healthcare Investors (HQH),
abrdn Life Sciences Investors (HQL), abrdn Australia Equity Fund, Inc. (IAF) and the India Fund Inc. (IFN) quarterly distributions
payable in September 2025 in cash instead of shares of common stock, for shareholders who hold shares in &ldquo;street name,&rdquo;
the bank, brokerage or nominee who holds the shares must have advised the Depository Trust Company as to the full and fractional
shares for which they want the distribution paid in cash by September 16, 2025; and for shares that are held in registered form,
written notification for the election of cash by registered shareholders must have been received by Computershare Investor Services
prior to September 16, 2025.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Under applicable U.S. tax rules, the amount and character of distributable
income for each Fund&rsquo;s fiscal year can be finally determined only as of the end of the Fund&rsquo;s fiscal year. However, under
Section 19 of the Investment Company Act of 1940, as amended (the &ldquo;1940 Act&rdquo;) and related rules, the Funds may be required
to indicate to shareholders the estimated source of certain distributions to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The following tables set forth the estimated amounts of
the sources of the distributions for purposes of Section 19 of the 1940 Act and the rules adopted thereunder. The tables have been computed
based on generally accepted accounting principles. The tables include estimated amounts and percentages for the current distributions
paid this month as well as for the cumulative distributions paid relating to fiscal year to date, from the following sources: net investment
income; net realized short-term capital gains; net realized long-term capital gains; and return of capital. The estimated compositions
of the distributions may vary because the estimated composition may be impacted by future income, expenses and realized gains and losses
on securities and currencies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">The Funds&rsquo; estimated sources of the current distribution
paid this month and for its current fiscal year to date are as follows:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Current Distribution per Share</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2100</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0252</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0063</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0714</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">34</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.1071</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">51</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.5100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1020</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4080</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2461</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1739</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0132</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0348</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0720</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4300</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1800</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0018</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1782</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="36" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Estimated Amounts of Fiscal Year* to Date Cumulative Distributions
    per Share</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Distribution<BR>
 Amount</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Investment<BR>
 Income</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Short-<BR>
Term Gains**</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Net Realized Long-<BR>
Term Gains</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Return of Capital</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">2.4400</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.2928</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">12</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.0732</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">3</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">0.8296</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">34</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">1.2444</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right">51</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.2400</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4480</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.7920</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.8200</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.0665</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.7535</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">41</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.4900</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0539</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.1421</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">29</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.2940</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1.3000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">100</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.1600</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0.0216</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.1384</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">* ASGI, HQH, HQL and THQ have a 9/30 fiscal year end.
IAF has a 10/31 fiscal year end. IFN has a 12/31 fiscal year end.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">**includes currency gains</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in">Where the estimated amounts above show a portion of the distribution
to be a &ldquo;Return of Capital,&rdquo; it means that Fund estimates that it has distributed more than its income and capital gains;
therefore, a portion of your distribution may be a return of capital. A return of capital may occur for example, when some or all the
money that you invested in a Fund is paid back to you. A return of capital distribution does not necessarily reflect the Fund&rsquo;s
investment performance and should not be confused with &ldquo;yield&rdquo; or &ldquo;income.&rdquo;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The amounts and sources of distributions reported in this notice
are only estimates and are not being provided for tax reporting purposes. The final determination of the source of all distributions for
the current year will only be made after year-end. The actual amounts and sources of the amounts for tax reporting purposes will depend
upon the Fund&rsquo;s investment experience during the remainder of the fiscal year and may be subject to change based on tax regulations.
After the end of each calendar year, a Form 1099-DIV will be sent to shareholders for the prior calendar year that will tell you how to
report these distributions for federal income tax purposes.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 26pt 0pt 0">The following tables provide the Funds&rsquo; total return
performance based on net asset value (NAV) over various time periods compared to the Funds&rsquo; annualized and cumulative distribution
rates.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund Performance and Distribution
    Rate Information</B></TD><TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
08/31/2025<SUP>1</SUP></B></TD><TD STYLE="white-space: nowrap; padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
    Total Return on <BR>
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASGI</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">9.97</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">11.61</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.68</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">10.60</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THQ</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4.64</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.21</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-14.06</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11.19</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 13pt"><SUP>1</SUP></FONT>
<FONT STYLE="font-size: 10pt">Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested
at prices obtained under the Fund&rsquo;s dividend reinvestment plan. </FONT><SUP>&nbsp;</SUP></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 13pt"><SUP>2</SUP></FONT> <FONT STYLE="font-size: 10pt">Based on the Fund&rsquo;s NAV as of August 31, 2025. </FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 88%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="16" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Fund Performance and Distribution
    Rate Information</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"><B>Fund</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Average <BR>
Annual Total <BR>
Return on NAV
    <BR>
for the 5 Year <BR>
Period Ending <BR>
07/31/2025<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Current Fiscal<BR>
 Period&rsquo;s <BR>
Annualized
    <BR>
Distribution <BR>
Rate on NAV</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
    Total Return on <BR>
    NAV<SUP>1</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Cumulative <BR>
Distribution <BR>
Rate on NAV<SUP>2</SUP></B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>


<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQH</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">3.44</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">13.11</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">-5.37</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: right">9.99</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HQL</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3.50</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12.55</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-1.18</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.60</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IAF</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.33</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.78</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">8.69</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7.39</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IFN</FONT></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.89</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">10.27</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-5.05</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5.29</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-size: 13pt"><SUP>1</SUP></FONT>
<FONT STYLE="font-size: 10pt">Return data is net of all Fund expenses and fees and assumes the reinvestment of all distributions reinvested
at prices obtained under the Fund&rsquo;s dividend reinvestment plan. </FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-size: 13pt"><SUP>2</SUP></FONT> <FONT STYLE="font-size: 10pt">Based on the Fund&rsquo;s NAV as of July 31, 2025. </FONT></P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 24pt 0pt 0"><B>Shareholders should not draw any conclusions about a
Fund&rsquo;s investment performance from the amount of the Fund&rsquo;s current distributions or from the terms of the distribution
policy (the &ldquo;Distribution Policy&rdquo;).</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3pt 0pt 0"><B>The value at which a closed-end fund stock may trade on
a public exchange is a function of external market factors that are not at the control of the Fund&rsquo;s Board or Investment Advisor.
Closed-end Fund shares may therefore trade at a premium or a discount to net asset value at any given time. Shareholders should be aware
that a fund trading at a premium to net asset value may not be sustainable and a fund&rsquo;s discount to net asset value, can widen as
well as narrow. Shareholders of a fund trading at a premium who participate in that fund&rsquo;s dividend reinvestment plan should note
the reinvestment of distributions may occur at a premium to net asset value.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 7pt 0pt 0">While NAV performance may be indicative of the Fund&rsquo;s
investment performance, it does not measure the value of a shareholder&rsquo;s investment in the Fund. The value of a shareholder&rsquo;s
investment in the Fund is determined by the Fund&rsquo;s market price, which is based on the supply and demand for the Fund&rsquo;s shares
in the open market.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to an exemptive order granted by the Securities and Exchange
Commission, the Funds may distribute any long-term capital gains more frequently than the limits provided in Section 19(b) under the 1940
Act and Rule 19b-1 thereunder. Therefore, distributions paid by the Funds during the year may include net income, short-term capital gains,
long-term capital gains and/or a return of capital. Net income dividends and short-term capital gain dividends, while generally taxable
at ordinary income rates, may be eligible, to the extent of qualified dividend income earned by the Funds, to be taxed at a lower rate
not to exceed the maximum rate applicable to your long-term capital gains. Distributions made in any calendar year in excess of investment
company taxable income and net capital gain are treated as taxable ordinary dividends to the extent of undistributed earnings and profits,
and then as a return of capital that reduces the adjusted basis in the shares held. To the extent return of capital distributions exceed
the adjusted basis in the shares held, capital gain is recognized with a holding period based on the period the shares have been held
at the date such amount is received.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The payment of distributions in accordance with the Distribution
Policy may result in a decrease in the Fund&rsquo;s net assets. A decrease in the Fund&rsquo;s net assets may cause an increase in
the Fund&rsquo;s annual operating expense ratio and a decrease in the Fund&rsquo;s market price per share to the extent the market
price correlates closely to the Fund&rsquo;s net asset value per share. The Distribution Policy may also negatively affect the
Fund&rsquo;s investment activities to the extent that the Fund is required to hold larger cash positions than it typically would
hold or to the extent that the Fund must liquidate securities that it would not have sold, for the purpose of paying the
distribution. Each Fund&rsquo;s Board has the right to amend, suspend or terminate the Distribution Policy at any time. The
amendment, suspension or termination of the Distribution Policy may affect the Fund&rsquo;s market price per share. Investors should
consult their tax advisor regarding federal, state, and local tax considerations that may be applicable in their particular
circumstances.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0"><U>Circular 230 disclosure</U>: To ensure compliance with requirements
imposed by the U.S. Treasury, we inform you that any U.S. tax advice contained in this communication (including any attachments) is not
intended or written to be used, and cannot be used, for the purpose of (i) avoiding penalties under the Internal Revenue Code or (ii)
promoting, marketing or recommending to another party any transaction or matter addressed herein.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0">Aberdeen Investments Global is the trade name of Aberdeen's
investments business, herein referred to as &quot;Aberdeen Investments&quot; or &quot;Aberdeen&quot;. In the United States, Aberdeen Investments
refers to the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, and abrdn Asia Limited.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 12pt 0pt 0">Closed-end funds are traded on the secondary market
through one of the stock exchanges. A Fund&rsquo;s investment return and principal value will fluctuate so that an investor&rsquo;s
shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a
discount) the net asset value (NAV) of the fund&rsquo;s portfolio. There is no assurance that a Fund will achieve its investment
objective. Past performance does not guarantee future results.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; color: blue"><FONT STYLE="color: Black"><U>Closed end funds
| Aberdeen</U></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="color: Black">&nbsp;</FONT></P>


<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="color: Black">###</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(D)
<SEQUENCE>7
<FILENAME>tm2527059d12_ex99-xd.htm
<DESCRIPTION>EXHIBIT 99.(D)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_ex99-xd.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0 0pt 1in"><B>Exhibit 99.(d)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Appendix A - Proxy Voting Policies and Procedures</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><B>Aberdeen Investments U.S. Registered Advisers
(the &ldquo;Advisers&rdquo;)</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: center"><B>Proxy Voting Guidelines<BR>
</B><I>Effective as of March&nbsp;2025</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Rule&nbsp;206(4)-6 under the Investment
Advisers Act of 1940, as amended (the &ldquo;Advisers Act&rdquo;) requires the Advisers to vote proxies in a manner consistent with clients&rsquo;
best interest and must not place its interests above those of its clients when doing so. It requires the Advisers to: (i)&nbsp;adopt and
implement written policies and procedures that are reasonably designed to ensure that the Advisers vote proxies in the best interest of
the clients, and (ii)&nbsp;to disclose to the clients how they may obtain information on how the Advisers voted proxies. In addition,
Rule&nbsp;204-2 requires the Advisers to keep records of proxy voting and client requests for information. As of August&nbsp;31, of each
year, investment managers that are required to file reports under Section&nbsp;13(f)&nbsp;are required to report their proxy voting records
on Form&nbsp;N-PX for the twelve-month period ended June&nbsp;30, with respect to certain shareholder advisory votes on executive compensation
(those required by Section&nbsp;14A of the Exchange Act). As registered investment advisers, the Advisers have an obligation to vote proxies
with respect to securities held in its client portfolios in the best interests of the clients for which it has proxy voting authority.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The Advisers are committed to exercising
responsible ownership with a conviction that companies adopting best practices in corporate governance will be more successful in their
core activities and deliver enhanced returns to shareholders.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The Advisers have adopted a proxy voting
policy. The proxy voting policy is designed and implemented in a way that is reasonably expected to ensure that proxies are voted in the
best interests of clients.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Resolutions are analysed by a member
of our regional investment teams or our Active Ownership Team and votes instructed following consideration of our policies, our views
of the company and our investment insights. To enhance our analysis, we will often engage with a company prior to voting to understand
additional context and explanations, particularly where there is a deviation from what we believe to be best practice.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Where contentious issues arise in relation
to motions put before a shareholders&rsquo; meeting, Advisers will usually contact the management of the company to exchange views and
give management the opportunity to articulate its position. The long-term nature of the relationships that we develop with investee company
boards should enable us to deal with any concerns that we may have over strategy, the management of risk or governance practices directly
with the chairman or senior independent director. In circumstances where this approach is unsuccessful, Advisers are prepared to escalate
their intervention by expressing their concerns through the company&rsquo;s advisers, through interaction with other shareholders or attending
and speaking at General Meetings.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In managing third party money on behalf
of clients, there are a limited number of situations where potential conflicts of interest could arise in the context of proxy voting.
One case is where funds are invested in companies that are either clients or related parties of clients. Another case is where one fund
managed by Aberdeen Investments invests in other funds managed by Aberdeen Investments.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">For cases involving potential conflicts
of interest, Advisers have implemented procedures to ensure the appropriate handling of proxy voting decisions. The guiding principle
of the Advisers&rsquo; conflicts of interest policy is simple &ndash; to exercise our right to vote in the best interests of the clients
on whose behalf we are managing funds.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We employ ISS as a service provider
to facilitate electronic voting. We require ISS to provide recommendations based on our own set of parameters to tailored Aberdeen&rsquo;s
assessment and approach but remain conscious that all voting decisions, where we have been given voting authority, are our own on behalf
of our clients. We consider ISS&rsquo;s recommendations and those based on our custom parameters as input to our voting decisions. We
make use of the ISS standard research and recommendations and those based on our own custom policy as input to our voting decisions. Where
our analysts make a voting decision that is different from the recommendations based on our custom policy they will provide a rationale
for such decisions which will be made available upon request.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In order to make proxy voting decisions,
an Aberdeen Investments analyst will assess the resolutions at general meetings of companies held in our active investment portfolios.
This analysis will be based on our knowledge of the company, but will also make use of the custom and standard recommendations provided
by ISS as described above. The product of this analysis will be a final voting decision instructed through ISS and applied to all funds
for which Aberdeen have been appointed to vote. For funds managed by a sub-adviser, we may delegate to the sub-adviser the authority to
vote proxies; however, the sub-adviser will be required to either follow our policies and procedures or to demonstrate that their policies
and procedures are consistent with ours, or otherwise implemented in the best interest of clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">There may be certain circumstances where
Aberdeen may take a more limited role in voting proxies. We will not vote proxies for client accounts in which the client contract specifies
that Aberdeen will not vote. We may abstain from voting a client proxy if the voting is uneconomic or otherwise not in clients&rsquo;
best interests. For companies held only in passively managed portfolios the Aberdeen custom recommendations provided by ISS will be used
to automatically apply our voting approach; we have scope to intervene to test that this delivers appropriate results and will on occasions
opt to instruct a vote differently from custom recommendations if we consider this to be in clients&rsquo; best interests. If voting securities
are part of a securities lending program, we may be unable to vote while the securities are on loan. However, we have the ability to recall
shares on loan or to restrict lending when required, in order to ensure all shares have voted. In addition, certain jurisdictions may
impose share-blocking restrictions at various times which may prevent Aberdeen from exercising our voting authority.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We recognize that there may be situations
in which we vote at a company meeting where we encounter a conflict of interest. Such situations include:</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">where a portfolio manager owns the holding in a personal account</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An investee company that is also a segregated client</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An investee company where an executive director or officer of our company is also a director of that company</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">An investee company where an employee of Aberdeen is a director of that company</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">A significant distributor of our products</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Any other companies which may be relevant from time to time</TD></TR></TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In order to manage such conflicts of
interests, we have established procedures to escalate decision-making so as to ensure that our voting decisions are based on our clients&rsquo;
best interests and are not impacted by any conflict.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The implementation of this policy, along
with conflicts of interest, will be reviewed periodically by the Active Ownership team. Aberdeen Investments&rsquo; Listed Company Sustainable
Investment Principles and Voting Policies are published on our website.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">To the extent that an Adviser may rely
on sub-advisers, whether affiliated or unaffiliated, to manage any client portfolio on a discretionary basis, the Adviser may delegate
responsibility for voting proxies to the sub-adviser. However, such sub-advisers will be required either to follow these Policies and
Procedures or to demonstrate that their proxy voting policies and procedures are consistent with these Policies and Procedures or otherwise
implemented in the best interests of the Adviser&rsquo;s clients. Clients that have not granted Aberdeen voting authority over securities
held in their accounts will receive their proxies in accordance with the arrangements they have made with their service providers.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">As disclosed in Part&nbsp;2A of each
Adviser&rsquo;s Form&nbsp;ADV, a client may obtain information on how its proxies were voted by requesting such information from its Adviser.
Unless specifically requested by a client in writing, and other than as required for the Funds, the Advisers do not generally disclose
client-specific proxy votes to third parties.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Our proxy voting records are available
per request and on the SEC&rsquo;s website at SEC.gov.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On occasions when it is deemed to be a fiduciary for an ERISA
client&rsquo;s assets, Aberdeen will vote the Plan assets in accordance with Aberdeen Investments&rsquo; Listed Company Sustainable Investment
Principles and Voting Policies and in line with DOL guidance.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Listed Company ESG Principles&nbsp;&amp; Voting Policies
March&nbsp;2024</B></P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Active Ownership and Environmental, Social&nbsp;&amp; Governance
(ESG) considerations are a driver of our investment process, our investment activity, our client journey and our corporate influence.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Through engagement with the companies in which we invest,
and by exercising votes on behalf of our clients, we seek to improve the financial resilience and performance of our clients&rsquo; investments.
Where we believe change is needed, we endeavour to catalyse this through our stewardship capabilities.</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Our expectations</B></P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As global investors, we are particularly aware that ESG structures
and frameworks vary across regions. Furthermore, what we expect of the companies in which we invest varies between different stages of
business development and the underlying history and nature of the company in question. We seek to understand each company&rsquo;s individual
circumstances and so evaluate how it can best be governed and overseen. As such, we strive to apply the principles and policies set out
on these pages&nbsp;in response to the needs of that individual company at that particular time. Our heritage as a predominantly active
fund manager helps drive this bespoke approach to understanding good governance and risk management.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We have a clear perception of what we consider to be best
practice globally &ndash; as set out in this document. However we will reflect the nature of the business, our close understanding of
individual companies and regional considerations, where appropriate, in our approach to applying these policies, which are not exhaustive.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The principles and voting policies noted
herein reflect our current position. We are monitoring and contributing to the many reform agendas and consultations underway in the governance
arena, particularly in the UK, on areas such as market competitiveness, listing rules, the approval of corporate transactions and greater
flexibility in remuneration practices, including wider use of restricted stock. We are actively involved in these discussions, both as
a corporate issuer and an investor, and our position will evolve as rules, guidance and practice develops.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This document has received approval from the Head of Public
Markets and the Chief Sustainability Officer - Investments following consultation with various internal stakeholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Our approach to stewardship</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We seek to integrate and appraise environmental, social and
governance factors in our investment process. Our aim is to generate the best long-term outcomes for our clients, proportionate to the
risk preference they have accepted, and we will actively take steps as stewards and owners to protect and enhance the value of our clients&rsquo;
assets.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Stewardship is a reflection of this bespoke approach to good
governance and risk management. We seek to understand each company&rsquo;s specific approach to governance, how value is created through
business success and how investors&rsquo; interests are protected through the management of risks that materially impact business success.
This requires us to play our part in the governance process by being active stewards of companies, involved in dialogue with management
and non-executive directors where appropriate, understanding the material risks and opportunities &ndash; including those relating to
environmental and social factors and helping to shape the future success of the business.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Take into consideration, in our investment process, the policies and practices on environmental, social and governance matters of
the companies in which we invest.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Seek to enhance long-term shareholder value through constructive engagement with the companies in which we invest.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Actively engage with companies and assets in which we invest where we believe we can influence or gain insight.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Seek to exercise voting rights, where held, in a manner consistent with our clients&rsquo; long-term best interests.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Seek to influence the development of appropriately high standards
of corporate governance and corporate responsibility in relation to environmental and social factors for the benefit of our clients.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Communicate our Listed Company ESG Principles and Voting Policies to clients, companies and other interested parties.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Be accountable to clients within the constraints of professional confidentiality and legislative and regulatory requirements.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Be transparent in reporting our engagement and voting activities.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">abrdn is committed to exercising responsible
ownership with a conviction that companies seeking to upgrade their practices in corporate governance and risk management will be more
successful in their core activities and deliver enhanced long-term returns to shareholders. As owners of companies, the process of stewardship
is a natural part of our investment approach as we seek to benefit from their long-term success on our clients&rsquo; behalf.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><B>Engagement</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">It is a central tenet of our active
investment approach that we strive to meet with the management and directors of our investee companies on a regular basis. We will concentrate
that engagement on investee companies undergoing transformation or facing exceptional challenges or opportunities. The discussions we
have cover a wide range of topics, including: strategic, operational, and ESG issues and consider the long-term drivers of value.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Engagement with
companies on ESG risks an opportunities is a fundamental part of our investment process. It is a process through which we can discuss
how a company identifies, prioritises and mitigates its key risks and optimises outcomes from its most significant opportunities. As such,
we regard engagement as:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Important to understanding investee companies holistically.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Helpful when conducting comprehensive ESG analysis.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Useful to maintaining open dialogue and constructive relationships with companies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>An opportunity to generate positive change on a company&rsquo;s holistic risk management programme&ndash;be active with our holdings
rather than activist.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Proxy Voting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Proxy voting is an integral part of our active stewardship
approach and we seek to exercise voting rights in a manner in line with our clients&rsquo; best interests. We seek to ensure that voting
reflects our understanding of the companies in which we invest on behalf of our clients. We believe that voting is a vital mechanism for
holding boards and management teams to account, and is an important tool for escalation and shareholder action.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This document includes our process and overarching policy
guidelines which we apply when voting at general meetings. These policies are not exhaustive and we evaluate our voting on a case by case
basis. As a global investment firm we recognise the practical necessity of adopting a regional approach, taking into account differing
and developing market practices. Where a policy is specific to one region this is denoted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We endeavour to engage with companies regarding our voting
decisions to maintain a dialogue on matters of concern.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Voting Process</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In line with our active ownership approach, we review the
majority of general meeting agendas convened by companies which are held in our active equity portfolios. Analysis is undertaken by a
member of our regional investment teams or our Active Ownership team and votes instructed following consideration of our policies, our
views of the company and our investment insights. To enhance our analysis we may engage with a company prior to voting to understand additional
context and explanations, particularly where there is deviation from what we believe to be best practice.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">To supplement our own analysis we make use of the benchmark
research and recommendations provided by ISS, a provider of proxy voting services. In the UK we also make use of the Investment Association&rsquo;s
(IA) Institutional Voting Information Service. We have implemented regional voting policy guidelines with ISS which ISS applies to all
meetings in order to produce customised vote recommendations. These custom recommendations help identify resolutions which deviate from
our expectations. They are also used to determine votes where a company is held only in passive funds. Within our custom policies, however,
we do specify numerous resolutions which should be referred to us for active review. For example we will analyse all proposals marked
by ISS as environmental or social proposals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">While it is most common for us to vote in line with a board&rsquo;s
voting recommendation we will vote our clients&rsquo; shares against resolutions which we believe are not consistent with their best interests.
We may also vote against resolutions which conflict with local governance guidelines, such as the IA in the UK. Although we seek to vote
either in favour or against a resolution we do make use of an abstain vote where this is considered appropriate. For example we may use
an abstention to acknowledge some improvement, but as a means to reserve our position in expectation that further improvement is needed
before we can vote in favour. Where we vote against a resolution we endeavour to inform companies of our rationale.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In exceptional circumstances we may attend and speak at a
shareholder meeting to reinforce our views to the company&rsquo;s board.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We endeavour to vote all shares for which we have voting
authority. We may not vote when there are obstacles to do so, for example those impacting liquidity, such as shareblocking, or where there
is a significant conflict of interest. We use the voting platform of ISS to instruct our votes. Where we lend stock on behalf of clients,
and subject to the terms of client agreements, we hold the right to recall shares where it is in clients&rsquo; interests to do so and
where we take the view that to maintain full voting weight on a particular meeting or resolution may impact the final vote.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our votes are disclosed publicly on our website one day after
a general meeting has taken place.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Strategy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We invest in companies that will create the best outcome
for our clients in line with their investment mandates. Companies must be clear about the drivers of their business success and their
strategy for maintaining and enhancing it. Investment is a forward-looking process; we seek to understand the opportunity for a business
and its scope for future value-creation over the long term. In order to do this, we need clarity on past business delivery and its drivers,
and on the effective track record of management; we require honest and open reporting to build confidence in that track record. We seek
confidence that companies and their management can maintain their competitive positioning and operational performance and subsequently
enhance returns for investors. A clear strategy and clarity about the drivers of operational success provides the lens through which we
will consider most corporate issues, not least assessing performance and risk management.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against executive or non-executive directors if we have serious concerns regarding the oversight or implementation
of strategy.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Board of Directors</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We believe effective board governance promotes the long-term
success and value creation of the company. The board should be responsible for establishing the company&rsquo;s purpose and strategy,
overseeing management in their implementation of strategy and performance against objectives. The board should ensure a strong framework
of control and risk oversight, including material ESG risks. The board should assess and monitor culture and be engaged with the workforce,
shareholders and wider society.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Board Composition</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Effective decision making requires a mix of skills around
the table and constructive debate between diverse and different-minded individuals. A range of skills, experience and perspectives should
be drawn together on the board. These include industry knowledge, experience from other sectors and relevant geographical knowledge. Independence
of thought plays a crucial role in the ability of a board to generate the debate and discussion that will challenge management, help enhance
business performance and improve decision-making. Board assessments will help the board ensure it has the necessary mix of skills, diversity
and quality of individuals to address the risks and opportunities the company faces. Unitary boards should comprise an appropriate combination
of executive and non-executive directors such that no group of individuals dominates decision-making. We expect the size of the board
to reflect the size, nature and complexity of the business. We also expect regular internal and external board evaluations which include
an assessment of board composition and effectiveness.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Leadership</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Running businesses effectively for the long term requires
effective collaboration and cooperation, with no individual or small group having unfettered powers. Nor should any individual or small
group have dominant influence over the way a business is run or over major decisions about its operations or future. There should be a
division of responsibility between board leadership and executive leadership of the business. We believe that there should be a division
of roles at the top of the organisation, typically between a Chief Executive Officer (CEO) and an independent Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider supporting the re-election of an existing Chair&nbsp;&amp; CEO role combination, recognising that this remains common
in certain geographies. In reviewing this on a case by case basis we will take account of the particular circumstances of the company
and consider what checks and balances are in place, such as the presence of a strong Senior Independent Director with a clear scope of
responsibility.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose any re-combination of the roles of CEO and Chair, unless the move is on a temporary basis due to exceptional
circumstances or other mitigating factors.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose any move of a retiring CEO to the role of Chair.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Independence</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies should be led and overseen by genuinely independent
boards. When looking at board composition we generally expect to see a majority of independent directors, with boards identifying their
independence classifications in the Annual Report. It is preferable to see an identified Senior Independent Director (SID) on the board,
who will lead the appraisal of and succession planning for the Chair. We expect SIDs to meet with investors and be a point of contact
for escalating concerns if required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In assessing a director&rsquo;s independence we will have
due regard for whether a director:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">i.</TD><TD>Has been an employee of the company within the last five years.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">ii.</TD><TD>Has had within the last three years a material business relationship with the company.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">iii.</TD><TD>Has received remuneration in addition to director fees or participates in the company&rsquo;s option or variable incentive schemes,
or is a member of the company&rsquo;s pension scheme.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">iv.</TD><TD>Has close family ties with any of the company&rsquo;s advisers, directors or senior employees.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">v.</TD><TD>Holds cross-directorships or has significant links with other directors through involvement in other companies or bodies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">vi.</TD><TD>Represents a significant shareholder.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">vii.</TD><TD>Has served on the board for more than 12 years (or 9 for UK companies).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against the re-election of non-independent directors if the board is not majority independent (excluding employee
representatives). In doing so we will have regard for whether a company is controlled and the nature of the non-independence &ndash; for
example, we are unlikely to vote against shareholder representatives unless their representation is disproportionate to their shareholding</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Succession Planning&nbsp;&amp; Refreshment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Regular refreshment of the non-executive portion of a board
helps draw in fresh perspectives, not least in the context of changes to business and emerging opportunities and risks. It also helps
limit the danger of group-think. Thoughtful and proactive succession planning is therefore needed for board continuity, to ensure that
a board is populated by individuals with an appropriate mix of skills, experience and perspective. We expect the board to implement a
formal process for the recruitment and appointment of new directors, and to provide transparency of this in the Annual Report.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against non-executive directors where there are concerns regarding board refreshment or excessive tenure. Where there
are directors who have served for over 12 years on a board which has seen no refreshment in 3 years (2 in UK), we will generally vote
against their re-election. If a director has served for over 15 years we will generally vote against their re-election. We will, however,
consider the impact on board continuity and the company&rsquo;s succession planning efforts prior to doing so. We may also not apply the
tenure limit to directors who are founders or shareholder representatives where we believe this is appropriate.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Diversity</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We
believe that companies that make progress in diversity, equity and inclusion (DEI) are better positioned for long-term sustainability
and outperformance. Diversity of thought, paired with a culture of inclusion, can help companies to tackle increasingly complex challenges
and markets. We expect boards to report on how they promote DEI throughout the business and believe that setting targets is important
to addressing imbalances. We recognise the necessity of adopting a regional approach to diversity, equity and inclusion, allowing us to
press for progress with appropriate consideration for the starting point. We have for several years, actively encouraged progress in gender
diversity at all levels, and have expanded our scope in relation to diversity, equity and inclusion across geographies. In respect of
ethnic diversity, this is coming increasingly into focus as we encourage boards to progress in ensuring that their composition reflects
their employee and customer bases. Our regional specific policies are below. In determining our votes we will take account of mitigating
factors, such as the sudden departure of a female board member. We will also consider any clear progress being made by the company on
diversity and any assurance that diversity shortfalls will soon be addressed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Gender Diversity.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B></B>&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>UK: We will generally vote against the Nomination Committee Chair of FTSE 350 companies if the board is not comprised of at least
one third female directors. We expect companies to seek to comply with the FCA&rsquo;s diversity targets and may vote against the Chair
of the Nomination Committee if we have concerns regarding the Committee&rsquo;s efforts in succession planning to achieve the gender diversity
target of 40% female members. For smaller companies, we will take action if the board does not include at least one female director.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Europe: We will generally vote against the Nomination Committee Chair of LargeCap companies if the supervisory board is not comprised
of at least 30% female directors, or is not in line with the local standard if higher. For smaller companies, we will take this action
if the supervisory board does not include at least one female director.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Australia: We will generally vote against the Nomination Committee Chair of ASX300 companies if the board is not comprised of at least
30% female directors.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>North America: We will generally vote against the Nomination Committee Chair of LargeCap companies if the board is not comprised of
at least 30% female directors. For smaller companies, we will take this action if the board does not include at least one female director</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Ethnic Diversity</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>UK: We will generally vote against the Nomination Committee Chair at the boards of FTSE 100 companies, if the board does not include
at least one member from an ethnic minority background. This is in line with targets set up by the Parker Review.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>US: We will generally vote against the Nomination Committee Chair at the boards of S&amp;P 1500&nbsp;&amp; Russell 3000 companies
if the board does not include at least one member from a racial or ethnic minority background.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Directors&rsquo; Time Commitment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Individual directors need sufficient time to carry out their
role effectively and therefore we seek to ensure that all directors maintain an appropriate level of overall commitments such that allows
them to be properly diligent.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider opposing the election or re-election of any director where there is a concern regarding their ability to dedicate
sufficient time to the role. In making this assessment we will have regard to the ISS classification of &lsquo;overboarding&rsquo;.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose the re-election of any director who has attended fewer than 75% of board meetings in two consecutive years.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B>Board Committees</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Boards should establish committees, populated by independent
and appropriately skilled non-executive directors, to oversee (as a minimum) the nomination, audit and remuneration processes. It may
also be appropriate for additional committees to be established, such as a risk or sustainability committee. These committees should report
openly on an annual basis about their activities and key decisions taken.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will consider voting against committee members if we have
concerns regarding the composition of a committee in relation to independence or skills.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Nomination Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This committee has responsibility for leading the process
for orderly non-executive and senior management succession planning and recruitment, and for overseeing the composition of the board including
skillset, experience and diversity. We expect the committee to be comprised of a majority of independent directors with an independent
Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against the re-election of the Nomination Committee Chair if we have concerns regarding the composition of
the board or concerns regarding poor succession planning.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Audit Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This committee has responsibility for monitoring the integrity
of the financial statements, reviewing the company&rsquo;s internal financial controls and risk management systems, reviewing the effectiveness
of the company&rsquo;s internal audit function and appointing and overseeing the quality of the work done by external auditors. We prefer
the committee to be wholly independent, and expect this at UK and US companies in view of general market practice and board composition.
In other regions, as a minimum, we expect the committee to be comprised of a majority of independent directors with an independent Chair.
Furthermore we expect at least one member of the committee to have recent and relevant financial experience.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>UK&nbsp;&amp; US: We will generally vote against the re-election of non-independent members of the Audit Committee..</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Europe: We will generally vote against the re-election of non-independent members of the Audit Committee if the Committee is not majority
independent. We will also generally vote against a non-independent Chair of the Audit Committee.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against the re-election of the Audit Committee Chair if at least one member of the Committee does not have
recent and relevant financial experience.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Remuneration Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The
committee is responsible for determining the policy and setting remuneration levels for executive and nonexecutive directors. The committee
should ensure that directors&rsquo; remuneration is aligned with strategy and company performance and should clearly demonstrate that
outcomes have had regard to the experience of the company&rsquo;s employees and wider society. Remuneration policy should be cognisant
of the company&rsquo;s licence to operate and the potential overall level of remuneration. We expect remuneration committees to be robust
in their approach to developing and implementing remuneration policies, with formal and transparent procedures for developing policies
and for determining remuneration packages. Remuneration committees should be comprised of a majority of independent directors with an
independent Chair and we expect members to have appropriate experience and knowledge of the business and remuneration practices in the
jurisdiction in which they operate. No executive should be involved in setting their own remuneration..</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left">Where we have significant concerns regarding the company&rsquo;s remuneration policy or reward outcomes we may escalate these concerns
through a vote against the Chair or members of the Remuneration Committee.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Director Accountability</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect to be able to hold boards to account through engagement
and regular director re-elections and directors should feel that they are accountable to investors. We encourage individual, rather than
bundled, director elections. While our preference is for directors to be subject to re- election annually, we expect re-elections to take
place at least every three years. Lengthier board mandates, while not uncommon in some markets, risk divorcing directors from an appropriate
sense of accountability. Directors and management should make themselves available for discussions with major shareholders as we expect
to have open dialogue to share our perspectives and gain confidence that the individuals are carrying out their roles with appropriate
vigour and diligence. A further important element of director accountability to shareholders is that investors should have the right,
both formal and informal, to propose and promote individual directors to be considered for election to the board by all shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally oppose the re-election of nonindependent NEDs who are proposed for a term exceeding three years. We may not apply
this to directors who are shareholder representatives.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where we have significant concerns regarding a board member&rsquo;s performance, actions or inaction to address issues raised we may
vote against their re-election.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may vote against directors who decline appropriate requests for
meetings without a clear justification.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where a director has held a position of responsibility at a company which has suffered a material governance failure, we will consider
whether we are comfortable to support their re-election at other listed companies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support resolutions to discharge the supervisory board or management board members from legal liability unless we
have serious concerns regarding actions taken during the year under review. Where there is insufficient information regarding allegations
of misconduct, we may prefer to abstain. In exceptional circumstances we may vote against the discharge resolution to reflect serious
ESG concerns if there is not another appropriate resolution.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will not support the election of directors who are not personally identified but are proposed as corporations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Reporting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A company&rsquo;s board should present a fair, balanced and
understandable assessment of the company&rsquo;s position and prospects &ndash; financial and non- financial &ndash; and of how it has
fulfilled its responsibilities. We support the principle of full disclosure of relevant and useful information, subject to issues of commercial
confidentiality and prejudice. Boilerplate disclosure should be avoided. We encourage companies to consider using the appropriate globally
developed standards and would particularly encourage the use of those created by the Taskforce for Climate related Financial Disclosures
(TCFD), the International Integrated Reporting Council (IIRC), the Sustainability Accounting Standards Board (SASB) and the Global Reporting
Initiative (GRI).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Audited reporting and financial numbers should be published
ahead of any relevant shareholder meetings. We continue to monitor the evolving reporting landscape and consider new reporting developments
as they emerge, either voluntary or regulatory.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We may consider voting against a company&rsquo;s Annual Report&nbsp;&amp; Accounts if we have concerns regarding timely provision
or adequacy of disclosure.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Political Donations&nbsp;&amp; Lobbying</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies should be consistent in their public statements
and not undermine these in private commentary to market participants or to politicians and regulators. We welcome transparency from companies
about their lobbying activities and believe that good companies have nothing to hide in this respect. Similarly we encourage transparency
of any political donations that companies deem appropriate &ndash; and we expect a clear explanation of why such donations are an appropriate
use of corporate funds.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Risk&nbsp;&amp; Audit</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The board is responsible for determining the company&rsquo;s
risk appetite, establishing procedures to manage risk and for monitoring the company&rsquo;s internal controls. We expect boards to conduct
robust assessments of the company&rsquo;s material risks and report to shareholders on risks, controls and effectiveness. The introduction
of global accounting standards has led to much greater investor confidence in the accounts produced by companies around the world. It
has also assisted in creating consistency of reporting across companies, enabling fairer comparisons between different operating businesses.
We therefore encourage companies seeking international investment to report under International Financial Reporting Standards (IFRS) or
US GAAP. As a firm abrdn supports the continued development of high quality global accounting standards.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">An independent audit, delivered by a respected audit firm,
is a required element for investor confidence in reporting by companies. We strongly favour meaningful, transparent and informative auditor
reports, giving us additional insights into the audit process and accounting outcomes. Audit fees must be sufficient to pay for an appropriately
in-depth assurance process. We would be concerned if a company sought to make unjustified savings in this respect as the cost in terms
of damage to audit effectiveness and confidence in the company&rsquo;s accounts would be much more substantial.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The independence of the auditor and the standard of their
work, particularly in challenging management, should be subject to regular assessment that is appropriately disclosed. Even when individuals
carrying out the audit are refreshed, we believe that the independence of the audit firm erodes over time and we will encourage a tender
process and change of audit firm where an engagement has lasted for an extended period. In order to demonstrate the level of independence,
companies should not have the same audit firm in place for more than 20 years.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The relationship with the auditor should be mediated through
the audit committee. Where we are significant shareholders, we expect to be consulted on plans to tender and replace auditors.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against the re-election of an auditor which has a tenure of 20 years or over, if there are no plans for rotation
in the near term.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against the auditors if we have concerns regarding the accounts presented or the audit procedures used.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against the approval of auditor fees if we have concerns regarding the level of fees or the balance of non-audit and
audit fees.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Remuneration</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Remuneration policies and the overall levels of pay should
be aligned with strategy, attracting and retaining talent and incentivising the decisions and behaviours needed to create long-term value.
The component parts of remuneration should be structured so as to link rewards to corporate and individual performance and they should
be considered in the context of the remuneration policies when taken as a whole. We recognise the benefits of simplicity in forming the
policy, which should clearly link outcomes and expectations for those receiving the remuneration, as well as external stakeholders. The
structure should be transparent and understandable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A company&rsquo;s annual report should contain an informative
statement of remuneration policy which communicates clearly to stakeholders how it has developed and evolved. This should include details
of any stress testing that may have been undertaken to understand the policy outcomes for different business scenarios. The remuneration
committee should provide a clear description of the application of policy and the outcomes achieved.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Base
salary should be set at a level appropriate for the role and responsibility of the executive. We discourage increases which are driven
solely by peer benchmarking, and expect increases to be aligned with the wider workforce. Consideration should also be given to the knock-on
impact to variable remuneration potential. Pension arrangements and benefits should be clearly disclosed. We generally expect pension
structures to be aligned with the wider workforce.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A company should structure variable, performancerelated pay
to incentivise and reward management in a manner that is aligned with the company&rsquo;s sustainable performance and risk appetite over
the long term. We expect all variable pay to be capped, preferably with reference to base salary. In the UK we expect variable pay to
be capped with reference to base salary. In other markets, if variable pay is capped at a number of shares, we expect the value of grants
to be kept under review annually to ensure the value remains appropriate and is not excessive.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Performance metrics used to determine variable pay should
be clearly disclosed and aligned with the company&rsquo;s strategy. A significant portion of performance metrics should seek to measure
significant improvements in the underlying financial performance of the company. We also encourage the inclusion of non-financial metrics
linked to targets which are aligned with the company&rsquo;s progress on its ESG strategy. Where possible we expect these targets to be
quantifiable and disclosed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Variable
pay arrangements should incentivise participants to achieve above-average performance through the use of challenging targets. We encourage
sliding-scale performance measures and expect performance target ranges to be disclosed to enable shareholders to assess the level of
challenge and pay for performance alignment. We expect annual bonus targets to be disclosed retrospectively and encourage the disclosure
of long term incentive (LTI) targets at the beginning of the performance period, but at minimum we expect retrospective disclosure. Where
bonus or LTI targets are not disclosed due to commercial sensitivity we expect an explanation of why the targets continue to be considered
sensitive retrospectively and expect some detail regarding the level of achievement vs target. Where a share price metric is being used,
we expect this to be underpinned by a challenging measure of underlying performance. We encourage settlement of a portion of the annual
bonus in shares which are deferred for at least one year. We expect settlement of long term incentives to be in shares, with rationale
provided for any awards settled in cash. Long term incentives should have a performance period of no less than three years. In the UK
we expect a further holding period of two years to be applied, and we encourage this in other markets. We do not generally support value
creation plans. We will consider supporting the use of restricted share plans in the UK which have been structured consistent with the
guidelines of the Investment Association. We expect appropriate malus and clawback provisions to be applied to variable remuneration plans.
We expect shareholding guidelines to be adopted for executive directors and encourage the adoption of postdeparture shareholding guidelines.
We expect details of any use of discretion to be disclosed and its use should be justifiable, appropriate and clearly explained. We would
expect policies to be sufficiently robust so that discretion is only necessary in exceptional circumstances. We do not generally support
exceptional awards, and are particularly sensitive to such awards being granted to reward a corporate transaction. We expect executive
service contracts to provide for a maximum notice period of 12 months. We will consider local best practice provisions related to severance
arrangements when voting. Non-executive fees should reflect the role&rsquo;s level of responsibility and time commitment. We do not support
NED&rsquo;s participation in option or performance-related arrangements. However we do support the payment of fees in shares, particularly
where conservation of cash is an issue. In the UK our expectations of companies are aligned with the Investment Association&rsquo;s Principles
of Remuneration. Where significant changes to remuneration arrangements are being considered, we would expect remuneration committees
to consult with their largest shareholders prior to finalising any changes. Where any increase to variable remuneration is proposed, we
would expect this to be accompanied by a demonstrable increase in the stretch of the targets. Furthermore we expect any increases to remuneration
to be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In response to the issues arising from the cost of living
crisis being experienced by many people in the UK, we expect companies to focus additional capacity towards those members of the workforce
who need it most. We expect Remuneration Committees to take into account factors arising from the cost of living crisis when deliberating
over executive pay outcomes. We would be concerned by reputational issues arising from decisions made in these unusual circumstances and
may make this a factor in our voting decisions at relevant AGMs.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In line with the expectations set out above we will generally
vote against the appropriate resolution(s)&nbsp;where:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We consider the overall reward potential or outcome to be excessive.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A significant increase to salary has been granted which is not aligned with the workforce or is not sufficiently justified.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A significant increase to performance-related pay has been granted which is not sufficiently justified, is not accompanied by an increase
in the level of stretch required for achievement or results in the potential for excessive reward.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>There is no appropriate cap on variable incentive schemes.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performance targets for annual bonus awards are not disclosed retrospectively and the absence of disclosure is not explained.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performance targets for long term incentive awards are not disclosed up front and there is no compelling explanation regarding the
absence of disclosure or a commitment to disclose retrospectively.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Performance targets are not considered sufficiently challenging, either at threshold, target or maximum.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Relative performance targets allow vesting of awards for below median performance.. Retesting provisions apply.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Incentives that have been conditionally awarded have been repriced or performance conditions changed part way through a performance
period.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We have concerns regarding the use of discretion or the grant of exceptional awards.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Pension arrangements are excessive.. Pension arrangements are not aligned with the wider workforce (UK).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Investor Rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The interests of minority shareholders must be protected
and any major, or majority, investor should not enjoy preferential treatment. The structure of ownership or control should minimise the
potential for abuse of public shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Corporate Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies should not make significant changes to their structure
or nature without being fully transparent to their investors. Shareholders should have the opportunity to vote on significant corporate
activity, such as mergers and acquisitions. Where a transaction is with a related party, only independent shareholders should have a vote.
Even in markets where no vote is given to shareholders in these circumstances, investors need transparent disclosure of the reasons for
any such major change. Companies should expect that shareholders may want to discuss and debate proposed developments</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Diversification beyond the core skills of the business needs
to be justified as it is more often than not a distraction from operational performance. All major deals need to be clearly explained
and justified in the context of the preexisting strategy and be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote on corporate transactions on a case by case basis.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Dividends</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will generally support the payment of dividends but will
scrutinise the proposed level where it appears excessive given the company&rsquo;s financial position.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Share Capital</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The board carries responsibility for prudent capital management
and allocation.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Share Issuance</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will consider capital raises which are proposed for a specific
purpose on a case by case basis but recognise that it can be beneficial for companies to have some general flexibility to issue shares
to raise capital. However we expect issuances to be limited to the needs of the business and companies should not issue significant portions
of shares unless offering these on a pro-rata basis to existing shareholders to protect against inappropriate dilution of investments.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where a company seeks a general authority to issue shares we generally expect this to be limited to 25% of the company&rsquo;s share
capital for pre- emptive issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management
Guidelines.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Where a company seeks a general authority to issue shares we generally expect this to be limited to 10% of the company&rsquo;s share
capital for non- pre-emptive issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management
Guidelines and those of the Pre-Emption Group.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will not generally support share issuances at investment trusts unless there is a commitment that shares would only be issued at
a price at or above net asset value.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">When considering our votes we will, however, take account
of the company&rsquo;s circumstances and any further detail regarding proposed capital issuance authorities prior to voting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Following changes to the UK&rsquo;s Pre-Emption Group Guidelines
in November&nbsp;2022, which reflect an increase on previous limits, we will hold the Chair of the company accountable for any perceived
misuse of the increased flexibility through a vote against their re-election.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Buyback</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We recognise that share buybacks can be a flexible means
of returning cash to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support buyback authorities of up to 10% of the issued share capital. In the UK we will generally support authorities
which are in line with the levels permitted under the Listing Rules.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Related Party Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The nature of relations &ndash; particularly any related
party transactions (RPTs) &ndash; with parent or related companies, or other major investors, must be disclosed fully. Related party transactions
must be agreed on arm&rsquo;s length terms and be made fully transparent. Where they are material, they should be subject to the approval
of independent shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against RPTs where there is insufficient transparency of the nature of the transaction, the rationale, the terms or the
views and assessment of directors and advisors.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Article/Bylaw amendments</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">While it is standard to see proposals from companies to amend
their articles of association or bylaws, we will review these on a case by case basis. When doing so we expect full transparency of the
proposed changes to be disclosed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will vote against amendments which will reduce shareholder rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Anti-Takeover Defences</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">There should be no artificial structures put in place to
entrench management and protect companies from takeover. The best defence from hostile takeover is strong operational delivery.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against anti-takeover/&lsquo;poison pill&rsquo; proposals.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Voting Rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are strong supporters of the principle of &lsquo;one share,
one vote&rsquo; and therefore favour equal voting rights for all shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally vote against proposals which seek to introduce or continue capital structures with multiple voting rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will consider voting against proposals to raise new capital at companies with multiple share classes and voting rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>General Meetings</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Shareholder meetings provide an important
opportunity to hold boards to account not only through voting on the proposed resolutions but also by enabling investors the opportunity
to raise questions, express views and emphasise concerns to the entire board. We may make a statement at a company&rsquo;s AGM as a means
of escalation to reinforce our views to a company&rsquo;s board.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We welcome the opportunity to attend meetings virtually,
being of the view that this can increase participation given obstacles such as location or meeting concentration. However we are not supportive
of companies adopting virtual-only meetings as we believe this format reduces accountability. Our preference is for a hybrid meeting format
to balance the flexibility of remote attendance with the accountability of an in-person meeting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support resolutions seeking approval to shorten the EGM notice period to minimum 14 days, unless we have concerns
regarding previous inappropriate use of this flexibility.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>We will generally support proposals to enable virtual meetings to take place as long as there is confirmation that the format will
be hybrid, with physical meetings continuing to take place (unless prohibited by law). We expect virtual attendees to have the same rights
to speak and raise questions as those attending in-person. We will generally vote against proposals which permit wholly virtual general
meetings.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>As part of strategic planning, boards need to have oversight
of, and clearly articulate, the key opportunities and risks affecting the sustainability of the business model. This includes having a
process for, and transparent disclosure of, potential and emerging opportunities and risks and the actions being taken to address them.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The effective management of risks extends to long-term issues
that are hard to measure and whose timeframe is uncertain and will include the management of environmental and social issues. We use the
UN Global Compact&rsquo;s four areas of focus in assessing how companies are performing in this area.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Specifically we expect companies to be able to demonstrate
how they manage their exposures under the following headings.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>The Environment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">It is generally accepted that companies are responsible for
the effects of their operations and products on the environment. The steps they take to assess and reduce those impacts can lead to cost
savings and reduce potential reputational damage. Companies are held responsible for their impact on the climate and they face increased
regulation from world governments on activities that contribute to climate change.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect that companies will</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Identify, manage and reduce their environmental impacts.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Understand the impact of climate change along the company value chain.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Develop group-level climate policies and, where relevant, set targets to manage the impact, report on policies, practices and actions
taken to reduce carbon and other environmental risks within their operations.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Comply with all environmental laws and regulations, or recognised international best practice as a minimum.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, in relation to the environment we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will use the indicators within the Carbon Disclosure Project
to identify companies which are not fulfilling their climate commitments. Where appropriate we will take voting action to encourage better
practice among companies which we deem to be laggards.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Labour and employment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Companies that respect internationally recognised labour
rights and provide safe and healthy working environments for employees are likely to reap the benefits. This approach is likely to foster
a more committed and productive workforce, and help reduce damage to reputation and a company&rsquo;s license to operate. We expect companies
to comply with all employment laws and regulations and adopt practices in line with the International Labour Organization&rsquo;s core
labour standards. a minimum.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In particular, companies will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Take affirmative steps to ensure that they uphold decent labour standards.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt strong health and safety policies and programmes to implement such policies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt equal employment opportunity and diversity policies and a programme for ensuring compliance with such policies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt policies and programmes for investing in employee training and development.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Adopt initiatives to attract and retain talented employees, foster higher productivity and quality, and encourage in their workforce
a commitment to achieving the company&rsquo;s purpose.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ensure policies are in place for a company&rsquo;s suppliers that promote decent labour standards, and programmes are in place to
ensure high standards of labour along supply chains.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Report regularly on its policy and implementation of managing human capital.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, in relation to labour and employment we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We recognise the impact that human-rights issues can have
on our investments and the role we can play in stimulating progress. We draw upon a number of international, legal and voluntary agreements
for guidance on human-rights responsibilities and compliance. Our primary sources are the International Bill of Rights and the core conventions
of the International Labour Organisation (ILO), which form the list of internationally agreed human rights, and the UN Guiding Principles
on Business and Human Rights (UNGPs), which clarifies the roles of states and businesses. We encourage companies to use the UNGPs Reporting
Framework and encourage disclosure in line with this guidance.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Continually work to understand their actual and potential impacts on human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Establish systems that actively ensure respect for human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Take appropriate action to remedy any infringements on human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, in relation to human rights we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Business ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As institutions of wealth and influence, companies have a
significant impact on the prosperity of their local communities and the wider world. Having a robust code of ethics and ensuring professional
conduct mean companies operate more effectively, particularly when it comes to ethical principles governing decision- making. A company&rsquo;s
failure to conform to internationally recognised standards of business ethics on matters such as bribery and corruption, can increase
its risk of facing investigation, litigation and fines. This could undermine its license to operate, and affect its reputation and image.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect companies to have policies in place to support
the following:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ethics at the heart of the organisation&rsquo;s governance.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>A zero-tolerance policy on bribery and corruption.. How people are rewarded, as pay can influence behaviour.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Respect for human rights.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Tax transparency.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Ethical training for employees.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Where we have serious concerns regarding a board&rsquo;s
actions, or inaction, related to business ethics we will consider taking voting action on an appropriate resolution.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>We will review any resolution at company meetings we have
identified as covering environmental and social factors. The following will detail our overarching approach and expectations.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our approach to vote analysis is consistent across active
and quantitative investment strategies <B>Review </B>the resolution, proponent and board statements, existing disclosures, and external
research. <B>Engage </B>with the company, proponents, and other stakeholders as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Involve </B>thematic experts, regional specialists, and
investment analysts in decision-making to harness a wide range of expertise and include all material factors in our analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Ensure </B>consistency by using our own in-house guidance
to frame case-by-case analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Monitor </B>the outcomes of votes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Follow-up </B>with on-going engagement as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Given the nature of the topics covered by these resolutions
we do not apply binary voting policies. We adopt a nuanced approach to our voting research and outcomes and will consider the specific
circumstances of the company concerned. Our objective is not to vote in favour of all shareholder resolutions but to determine the best
outcome for the company in the context of the best outcome for our clients. There are instances where we are supportive of the spirit
of a resolution however there may be a reason which prevents our support for the proposal. For example, where the purpose of the resolution
is unclear, where the wording is overly prescriptive, when suggested implementation is overly burdensome or where the proposal strays
too closely to the board&rsquo;s responsibility for setting the company&rsquo;s strategy.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Management Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We
are supportive of the steps being taken by companies to provide transparent, detailed reporting of their ESG strategies and targets. While
shareholder proposals on environmental and social topics have been common on AGM agendas for several years, an increasing number of companies
are presenting management proposals, such as so called &lsquo;say on climate&rsquo; votes, for shareholder approval. While we welcome
the intention of accountability behind these votes, we have reservations about the potential for them to limit the scope for subsequent
investor challenge and diminish the direct responsibility and accountability of the board and individual directors. We believe it is the
role of the board and the executive to develop and apply strategy, including ESG strategies, and we will continue to use existing voting
items to hold boards to account on the implementation of these strategies. As active investors we also regularly engage with investee
companies on ESG topics and find this dialogue to be the best opportunity to provide feedback.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will review the appropriateness of &lsquo;say on climate&rsquo;
votes and consider if other voting mechanisms should be applied to ensure both Boards and Executives apply the appropriate rigour to initiate
and deliver strategies to support the climate transition.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Shareholder Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The number of resolutions focused on environmental and social
(E&amp;S) issues filed by shareholders continues to grow rapidly. The following provides an overview of some of the factors we consider
when assessing the most prevalent themes for shareholder proposals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Climate Change</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are members of the Net Zero Asset Managers Initiatives
and this is reflected in our Active Ownership approach. We encourage the companies in which we invest to demonstrate a robust methodology
underpinning Paris aligned goals and targets and are supportive of resolutions that will help companies to achieve this. Once a credible
climate strategy is in place, we prioritise evidence of implementation over requests to re-draft strategies and targets after only a year
or two.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A growing number of resolutions call on companies to increase
the transparency of their reporting on climaterelated lobbying. These proposals typically encompass direct lobbying undertaken by the
company and indirect lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Lobbying
contrary to the objectives of the Paris Agreement is effective in creating climate policy inertia and impeding the transition to net zero
economies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We do not evaluate resolutions in isolation. Our approach
recognises the links between corporate governance, strategy and climate approach. Where a company&rsquo;s operational response to climate
change is inadequate, the effectiveness of board oversight and corporate governance may also be called into question.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Demonstrate that a robust methodology underpins Paris aligned, net zero goals and targets.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Set targets for absolute emission reduction, not just carbon intensity, to show a clear pathway to net zero.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Report in alignment with the TCFD framework.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Link targets to remuneration and ensure they are reflected in capital expenditure and R&amp;D plans.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Carefully manage climate-related lobbying by ensuring appropriate oversight, transparent disclosure of activities, and alignment of
activities with the company&rsquo;s strategy and publicly stated positions.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Diversity&nbsp;&amp; Inclusion</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Diversity, Equity&nbsp;&amp; Inclusion (DEI) is an important
and growing theme for shareholder resolutions. In recent years resolutions have focussed on racial equity audits, pay gap reporting, transparent
disclosure of DEI metrics and assessments of the efficacy of DEI programmes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A racial equity audit is an independent analysis of a company&rsquo;s
business practices designed to identify practices that may have a discriminatory effect. We are supportive of racial equity audits in
relation to internal and external DEI programmes. It is appropriate that these programmes should have KPIs and audit mechanisms in place
to measure and evaluate outcomes. Some proposals request racial equity audits of provision of services. We are aware that measuring provision
of service is challenging and gathering racial data on customers can be difficult and inappropriate. There are also multiple different
factors that can influence service provision and which could be misconstrued as being racially motivated. We will however, support resolutions
which are not unduly prescriptive and allow companies to carry out audits within a reasonable timeframe, at a reasonable cost, and excluding
confidential or proprietary information.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We consider standardised gender pay gap disclosure to be
an important tool for assessing how companies are addressing gender inequality. Reporting on gender pay gaps across global operations
can help companies to remain ahead of the regulatory curve. It also enables them to offer better opportunities and remuneration for women
around the world. We are therefore supportive of resolutions which are likely to deliver these benefits.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Proposals must be carefully drafted
to achieve these outcomes. For instance, in the past we have been unable to support resolutions which called for global median gender
and racial pay gap reporting as it was unclear how this would reveal potential pay disparities at a local level and how it could be implemented
by companies with operations in jurisdictions where collection of racial identity data is illegal.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the US market we support public disclosure of EEO-1 forms
by companies. The EEO-1 form details a comprehensive breakdown of workforce by race and gender according to ten employment categories.
The form is submitted privately to the US Equal Employment Opportunity Commission on an annual basis. When publicly disclosed, it offers
investors and other stakeholders data in a standardised and comparable form. We have used our engagement programme to ask the companies
in which we invest to disclose this form for their US operations while making it central to our D&amp;I voting approach and supporting
resolutions that request it.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As a supporter of the UN Guiding Principles on Business and
Human Rights (UNGPs), we expect companies to demonstrate how human rights due diligence is conducted across operations, services, product
use and the supply chain. Companies can have a significant impact on human rights directly through operations and provision of services,
and indirectly through product use and the supply chain. In recent years the sale and end-use of controversial technologies, such as facial
recognition software, has emerged as a prominent theme.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Have robust due diligence processes to assess the actual and potential human rights impacts of their operations, services, product
use and supply chain.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Conduct customer and supplier vetting processes commensurate with the risk of human rights abuse.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Publicly disclose information about the operation of these processes and utilise the UNGPs&rsquo; Reporting Framework. This will improve
the standard and consistency of human rights reporting and enable more informed investment decision making.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Corporate Lobbying&nbsp;&amp; Political Contributions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Corporate lobbying and political contributions are a recurrent
theme of shareholder resolutions, particularly in the US. These proposals typically encompass direct lobbying undertaken by the company
and indirect lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Proposals may also
request the disclosure of more information regarding the process and rationale for political contributions. We expect companies to make
transparent, consolidated disclosures of direct and indirect lobbying and political expenditure. This disclosure should be underpinned
by a coherent policy that: explains public policy priorities and the rationale for associated expenditure, identifies the management positions
responsible for public policy engagement, and provides appropriate mechanisms for board oversight. These measures should mitigate the
risks associated with corporate lobbying and political contributions, protecting the interest of shareholders and other stakeholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Nuclear Energy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the Japanese market nuclear energy is a recurrent theme
of shareholder resolutions. The Japanese government is seeking to reduce the nation&rsquo;s reliance on coal and its energy strategy presents
safe nuclear power generation as an important source of base-load power. In this context, resolutions which seek to limit or cease the
nuclear operations of an individual company do not appear to be in the best interests of shareholders and other stakeholders. The health&nbsp;&amp;
safety risks associated with nuclear energy are high, must be managed carefully across the industry, and are an important consideration
in our voting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><B>Important Information</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This document is strictly for information purposes only and
should not be considered as an offer, investment recommendation, or solicitation, to deal in any of the investments or funds mentioned
herein and does not constitute investment research. abrdn does not warrant the accuracy, adequacy or completeness of the information and
materials contained in this document and expressly disclaims liability for errors or omissions in such information and materials.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Any research or analysis used in the preparation of this
document has been procured by abrdn for its own use and may have been acted on for its own purpose. The results thus obtained are made
available only coincidentally and the information is not guaranteed as to its accuracy. Some of the information in this document may contain
projections or other forward looking statements regarding future events or future financial performance of countries, markets or companies.
These statements are only predictions and actual events or results may differ materially. The reader must make their own assessment of
the relevance, accuracy and adequacy of the information contained in this document and make such independent investigations, as they may
consider necessary or appropriate for the purpose of such assessment. This material serves to provide general information and is not meant
to be investment, legal or tax advice for any particular investor. No warranty whatsoever is given and no liability whatsoever is accepted
for any loss arising whether directly or indirectly as a result of the reader, any person or group of persons acting on any information,
opinion or estimate contained in this document. abrdn reserves the right to make changes and corrections to any information in this document
at any time, without notice. This material is not to be reproduced in whole or in part without the prior written consent of abrdn.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Applying ESG and sustainability criteria in the investment
process may result in the exclusion of securities within the universe of potential investments. The interpretation of ESG and sustainability
criteria is subjective meaning that products may invest in companies which similar products do not (and thus perform differently) and
which do not align with the personal views of any individual investor. Furthermore, the lack of common or harmonized definitions and labels
regarding ESG and sustainability criteria may result in different approaches by managers when integrating ESG and sustainability criteria
into investment decisions. This means that it may be difficult to compare strategies within ostensibly similar objectives and that these
strategies will employ different security selection and exclusion criteria. Consequently, the performance profile of otherwise similar
vehicles may deviate more substantially than might otherwise be expected. Additionally, in the absence of common or harmonized definitions
and labels, a degree of subjectivity is required and this will mean that a product may invest in a security that another manager or an
investor would not.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">abrdn plc is registered in Scotland (SC286832) at 1 George
Street, Edinburgh EH2 2LL.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.(E)
<SEQUENCE>8
<FILENAME>tm2527059d12_ex99-xe.htm
<DESCRIPTION>EXHIBIT 99.(E)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif"><!-- BannerFile="tm2527059d12_ex99-xe.htm"   BannerFilePath="/apps/files/files/jms2files/gofiler/tm2527059-12/tm2527059-12_ncsrseq1/users" -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.(e)</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>U.S. Registered Advisers</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Summary of Proxy Voting Guidelines</B>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>as of October 26, 2022</I></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where clients appoint abrdn Inc. to vote proxies on their behalf, policies
have been established to vote these proxies in the best interests of our clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We employ
ISS as a service provider to facilitate electronic voting. We require ISS to provide recommendations based on our own set of parameters
tailored to abrdn</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s assessment and approach, but remain conscious
that all voting decisions are our own on behalf of our clients. We consider ISS</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
recommendations and those based on our custom parameters as input to our voting decisions. We make use of the ISS standard research and
recommendations and those based on our own custom policy as input to our voting decisions. Where our analysts make a voting decision that
is different from the recommendations based on our custom policy they will provide a rationale for such a decisions which will be made
publicly available in our voting disclosures.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to make proxy voting decisions, an abrdn analyst assesses
the resolutions at general meetings in our active investment portfolios. This analysis will be based on our knowledge of the company,
but will also make use of the custom and standard recommendations provided by ISS as described above. The product of this analysis will
be a final voting decision instructed through ISS and applied to all funds for which abrdn have been appointed to vote. For funds managed
by a sub-adviser, we may delegate to the sub-adviser the authority to vote proxies; however, the sub-adviser will be required to either
follow our policies and procedures or to demonstrate that their policies and procedures are consistent with ours, or otherwise implemented
in the best interest of clients.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">There may
be certain circumstances where abrdn Inc. may take a more limited role in voting proxies. We will not vote proxies for client accounts
in which the client contract specifies that abrdn Inc. will not vote. We may abstain from voting a client proxy if the voting is uneconomic
or otherwise not in clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">best interests. For companies held
only in passively managed portfolios, abrdn Inc. custom recommendations provided by ISS will be used to automatically apply our voting
approach; we have scope to intervene to test that this delivers appropriate results, and will on occasions intrude to apply a vote more
fully in clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">best interests. If voting securities are part
of a securities lending program, we may be unable to vote while the securities are on loan. However, we have the ability to recall shares
on loan or to restrict lending when required, in order to ensure all shares have voted. In addition, certain jurisdictions may impose
share-blocking restrictions at various times which may prevent abrdn Inc. from exercising our voting authority.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognize that there may be situations in which we vote at a company
meeting where we encounter a conflict of interest. Such situations include:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a portfolio manager owns the holding in a personal account.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An investee company that is also a segregated client.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An investee company where an Executive Director or Officer of our company
or that of abrdn plc or another affiliate is also a Director of that company.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An investee company where an employee of abrdn plc or an affiliate or subsidiary
is a Director of that company.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant distributor of our products.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Any other companies which may be relevant from time to time.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have adopted
procedures within our proxy voting process to identify where a conflict exists. These procedures are designed to ensure that our voting
decisions are based on our client</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s best interests and are not impacted
by any conflict.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The implementation
of this policy, along with conflicts of interest, will be reviewed periodically by the Active Ownership team. abrdn</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Global ESG Principles &amp; Voting Policies are published on our website.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Clients may
obtain a free copy of abrdn Inc.</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s proxy voting policies and procedures
and/or proxy voting records for their account by contacting us at (215) 405-5700. abrdn publishes ESG Principles &amp; Voting Policies,
which describe our approach to investment analysis, shareholder engagement and proxy voting across companies worldwide. There are published
on our website.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Clients that have not granted abrdn Inc. voting authority over securities
held in their accounts will receive their proxies in accordance with the arrangements they have made with their service providers.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listed Company ESG Principles &amp; Voting Policies</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>February 2023</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Introduction</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Active Ownership and Environmental, Social &amp; Governance (ESG) considerations
are a driver of our investment process, our investment activity, our client journey and our corporate influence.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Through engagement
with the companies in which we invest, and by exercising votes on behalf of our clients, we seek to improve the financial resilience and
performance of our clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">investments. Where we believe change
is needed, we endeavour to catalyse this through our stewardship capabilities.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our expectations</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As global
investors, we are particularly aware that ESG structures and frameworks vary across regions. Furthermore, what we expect of the companies
in which we invest varies between different stages of business development and the underlying history and nature of the company in question.
We seek to understand each company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s individual circumstances and
so evaluate how it can best be governed and overseen. As such, we strive to apply the principles and policies set out on these pages in
response to the needs of that individual company at that particular time. Our heritage as a predominantly active fund manager helps drive
this bespoke approach to understanding good governance and risk management.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We have a
clear perception of what we consider to be best practice globally </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">as
set out in this document. However we will reflect the nature of the business, our close understanding of individual companies and regional
considerations, where appropriate, in our approach to applying these policies, which are not exhaustive.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This document
has received approval from the Head of Public Markets and the Investment Vector</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Chief Sustainability Officer following consultation with various internal stakeholders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Our approach to stewardship</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We seek to
integrate and appraise environmental, social and governance factors in our investment process. Our aim is to generate the best long-term
outcomes for our clients and we will actively take steps as stewards and owners to protect and enhance the value of our clients</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">assets.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stewardship
is a reflection of this bespoke approach to good governance and risk management. We seek to understand each company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
specific approach to governance, how value is created through business success and how investors</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">interests
are protected through the management of risks that materially impact business success. This requires us to play our part in the governance
process by being active stewards of companies, involved in dialogue with management and non-executive directors where appropriate, understanding
the material risks and opportunities </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">including those relating
to environmental and social factors and helping to shape the future success of the business.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take into consideration, in our investment process, the policies and practices
on environmental, social and governance matters of the companies in which we invest.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Seek to enhance long-term shareholder value through constructive engagement
with the companies in which we invest.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Actively engage with the companies and assets in which we invest where we
believe we can influence or gain insight.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Seek to exercise voting rights, where held, in a manner consistent with our
clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">long-term best interests.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Seek to influence the development of high standards of corporate governance
and corporate responsibility in relation to environmental and social factors for the benefit of our clients.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Communicate our Listed Company ESG Principles and Voting Policies to clients,
companies and other interested parties.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Be accountable to clients within the constraints of professional confidentiality
and legislative and regulatory requirements.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Be transparent in reporting our engagement and voting activities.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">abrdn is committed
to exercising responsible ownership with a conviction that companies adopting improving practices in corporate governance and risk management
will be more successful in their core activities and deliver enhanced returns to shareholders. As owners of companies, the process of
stewardship is a natural part of our investment approach as we seek to benefit from their long-term success on our clients</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">behalf.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Engagement</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is a central tenet of our active investment approach that we strive
to meet with the management and directors of our investee companies on a regular basis. The discussions we have cover a wide range of
topics, including: strategic, operational, and ESG issues and consider the long-term drivers of value. Engagement with companies on ESG
risks and opportunities is a fundamental part of our investment process. It is a process by which we can discuss how a company identifies,
prioritises and mitigates its key risks and optimises its most significant opportunities. As such, we regard engagement as:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Important to understanding investee companies as a whole.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Helpful when conducting proper ESG analysis.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Useful to maintaining open dialogue and solid relationships with companies.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">An opportunity to inflect positive change on a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
holistic risk management programme </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">be active with our holdings
rather than activist.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Proxy Voting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proxy voting
is an integral part of our active stewardship approach and we seek to exercise voting rights in a manner in line with our clients</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">best interests. We seek to ensure that voting reflects our understanding of the
companies in which we invest on behalf of our clients. We believe that voting is a vital mechanism for holding boards and management teams
to account, and is an important tool for escalation and shareholder action.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This document includes our process and overarching policy guidelines
which we apply when voting at general meetings. These policies are not exhaustive and we evaluate our voting on a case by case basis.
As a global investment firm we recognise the importance of adopting a regional approach, taking into account differing and developing
market practices. Where a policy is specific to one region this is denoted.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We endeavour to engage with companies regarding our voting decisions
to maintain a dialogue on matters of concern.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Voting Process</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In line with our active ownership approach, we review the majority
of general meeting agendas convened by companies which are held in our active equity portfolios. Analysis is undertaken by a member of
our regional investment teams or our Active Ownership team and votes instructed following consideration of our policies, our views of
the company and our investment insights. To enhance our analysis we may engage with a company prior to voting to understand additional
context and explanations, particularly where there is deviation from what we believe to be best practice.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">To supplement
our own analysis we make use of the benchmark research and recommendations provided by ISS, a provider of proxy voting services. In the
UK we also make use of the Investment Association</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s (IA) Institutional
Voting Information Service. We have implemented regional voting policy guidelines with ISS which ISS applies to all meetings in order
to produce customised vote recommendations. These custom recommendations help identify resolutions which deviate from our expectations.
They are also used to determine votes where a company is held only in passive funds. Within our custom policies, however, we do specify
numerous resolutions which should be referred to us for active review. For example we will analyse all proposals marked by ISS as environmental
or social proposals.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">While it is
most common for us to vote in line with a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s voting recommendation
we will vote our clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">shares against resolutions which are not
consistent with their best interests. We may also vote against resolutions which conflict with local governance guidelines, such as the
IA in the UK. Although we seek to vote either in favour or against a resolution we do make use of an abstain vote where this is considered
appropriate. For example we may use an abstention to acknowledge some improvement, but as a means to reserve our position in expectation
that further improvement is needed before we can vote in favour. Where we vote against a resolution we endeavour to inform companies of
our rationale.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In exceptional
circumstances we may attend and speak at a shareholder meeting to reinforce our views to the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
board.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We endeavour
to vote all shares for which we have voting authority. We may not vote when there are obstacles to do so, for example those impacting
liquidity, such as share- blocking, or where there is a significant conflict of interest. We use the voting platform of ISS to instruct
our votes. Where we lend stock on behalf of clients, and subject to the terms of client agreements, we hold the right to recall shares
where it is in clients</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">interests and we take the view that it will
impact the final vote to maintain full voting weight on a particular meeting or resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our votes are disclosed publicly on our website one day after a general
meeting has taken place.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Strategy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We invest in companies to create the best outcome for our clients.
Companies must be clear about the drivers of their business success and their strategy for maintaining and enhancing it. Investment is
a forward-looking process; we seek to understand the opportunity for a business and its scope for future value-creation over the long
term. In order to do this, we need clarity on past business delivery and its drivers, and on the effective track record of management;
we require honest and open reporting to build confidence in that track record. We seek confidence that companies and their management
can maintain their competitive positioning and operational performance and subsequently enhance returns for investors. A clear strategy
and clarity about the drivers of operational success provides the lens through which we will consider most corporate issues, not least
assessing performance and risk management.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against executive or non-executive directors if we
have serious concerns regarding the oversight or implementation of strategy.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board of Directors</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We believe
effective board governance promotes the long-term success and value creation of the company. The board should be responsible for establishing
the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s purpose and strategy, overseeing management in their
implementation of strategy and performance against objectives. The board should ensure a strong framework of control and risk oversight,
including material ESG risks. The board should assess and monitor culture and be engaged with the workforce, shareholders and wider society.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Composition</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Effective decision making requires a mix of skills around the table
and constructive debate between diverse and different-minded individuals. A range of skills, experience and perspectives should be drawn
together on the board. These include industry knowledge, experience from other sectors and relevant geographical knowledge. Independence
of thought plays a crucial role in the ability of a board to generate the debate and discussion that will challenge management, help enhance
business performance and improve decision-making. Board assessments will help the board ensure it has the necessary mix of skills, diversity
and quality of individuals to address the current risks and opportunities the company faces. Unitary boards should comprise an appropriate
combination of executive and non- executive directors such that no group of individuals dominates decision-making. We expect the size
of the board to reflect the size, nature and complexity of the business. We also expect regular internal and external board evaluations
which include an assessment of board composition and effectiveness.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Leadership</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Running businesses effectively for the long term requires effective
collaboration and cooperation, with no individual or small group having unfettered powers. Nor should they have dominant influence over
the way a business is run or over major decisions about its operations or future. There should be a division of responsibility between
board leadership and executive leadership of the business. We believe that there should be a division of roles at the top of the organisation,
typically between a Chief Executive Officer (CEO) and an independent Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider supporting the re-election of an existing Chair &amp; CEO
role combination, recognising that this remains common in certain geographies. In reviewing on a case by case basis we will take account
of the particular circumstances of the company and consider what checks and balances are in place, such as the presence of a strong Senior
Independent Director with a clear scope of responsibility.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose any re-combination of the roles of CEO and Chair,
unless the move is on a temporary basis due to exceptional circumstances or other mitigating factors.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose any move of a retiring CEO to the role of Chair.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Independence</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies should be led and overseen by genuinely independent boards.
When looking at board composition we generally expect to see a majority of independent directors, with boards identifying their independence
classifications in the Annual Report. It is preferable to see an identified Senior Independent Director (SID) on the board, who will lead
the appraisal of and succession planning for the Chair. We expect SIDs to meet with investors and be a point of contact for escalating
concerns if required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In assessing
a director</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s independence we will have due regard for whether a
director:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in">(I)</TD><TD>Has been an employee of the company within the last five years.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in">(II)</TD><TD>Has had within the last three years a material business relationship with the company.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(III)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Has received remuneration in addition to director fees or participates in
the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s option or variable incentive schemes, or is a member
of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s pension scheme.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(IV)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Has close family ties with any of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
advisers, directors or senior employees.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in">(V)</TD><TD>Holds cross-directorships or has significant links with other directors through involvement in other companies or bodies.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in">(VI)</TD><TD>Represents a significant shareholder.</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in">(VII)</TD><TD>Has served on the board for more than 12 years (or 9 for UK companies).</TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against the re-election of non-independent directors
if the board is not majority independent (excluding employee representatives). In doing so we will have regard for whether a company is
controlled and the nature of the non-independence </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">for example,
we are unlikely to vote against shareholder representatives unless their representation is disproportionate to their shareholding.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Succession Planning &amp; Refreshment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regular refreshment of the non-executive portion of a board helps draw
in fresh perspectives, not least in the context of changes to business and emerging opportunities and risks. It also helps limit the danger
of group-think. Thoughtful and proactive succession planning is therefore needed for board continuity, to ensure that a board is populated
by individuals with an appropriate mix of skills, experience and perspective. We expect the board to implement a formal process for the
recruitment and appointment of new directors, and to provide transparency of this in the Annual Report.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against non-executive directors where there are concerns regarding
board refreshment or excessive tenure. Where there are directors who have served for over 12 years on a board which has seen no refreshment
in 3 years (2 in UK), we will generally vote against their re-election. If a director has served for over 15 years we will generally vote
against their re-election. We will, however, consider the impact on board continuity and the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
succession planning efforts prior to doing so. We may not apply the tenure limit to directors who are founders or shareholder representatives.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Diversity</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that companies that make progress in diversity and inclusion
(D&amp;I) are better positioned for long-term sustainability and outperformance. Diversity of thought, paired with a culture of inclusion,
can help companies to tackle increasingly complex challenges and markets. We expect boards to report on how they promote D&amp;I throughout
the business and believe that setting targets is important to addressing imbalances. We recognise the importance of adopting a regional
approach to diversity and inclusion, allowing us to press for progress with appropriate consideration for the starting point. We have
for several years, actively encouraged progress in gender diversity at all levels, and have expanded our scope in relation to diversity
and inclusion across geographies. In respect of ethnic diversity, this is coming increasingly into focus as we encourage boards to progress
in ensuring that their composition reflects their employee and customer bases.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our regional specific policies are below. In determining our votes
we will take account of mitigating factors, such as the sudden departure of a female board member. We will also consider any clear progress
being made by the company on diversity and any assurance that diversity shortfalls will soon be addressed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gender Diversity</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">UK: We will generally vote against the Nomination Committee Chair of FTSE
350 companies if the board is not comprised of at least one third female directors. For smaller companies, we will take this action if
the board does not include at least one female director.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Europe: We will generally vote against the Nomination Committee Chair of
LargeCap companies if the supervisory board is not comprised of at least 30% female directors, or is not in line with the local standard
if higher. For smaller companies, we will take this action if the supervisory board does not include at least one female director.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Australia: We will generally vote against the Nomination Committee Chair
of ASX300 companies if the board is not comprised of at least 30% female directors.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">North America: We will generally vote against the Nomination Committee Chair
of LargeCap companies if the board is not comprised of at least 30% female directors. For smaller companies, we will take this action
if the board does not include at least one female director</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ethnic Diversity</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">UK: We will generally vote against the Nomination Committee Chair at the
boards of FTSE 100 companies, if the board does not include at least one member from an ethnic minority background. This is in line with
targets set up by the Parker Review.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">US: We will generally vote against the Nomination Committee Chair at the
boards of S&amp;P 1500 &amp; Russell 3000 companies if the board does not include at least one member from a racial or ethnic minority
background.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Directors</B></FONT><B>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">Time Commitment</FONT></B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Individual directors need sufficient time to carry out their role effectively
and therefore we seek to ensure that all directors maintain an appropriate level of overall commitments such that allows them to be properly
diligent.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider opposing the election or re-election of any director where
there is a concern regarding their ability to dedicate sufficient time to the role. In making this assessment we will have regard for
the ISS classification of </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">overboarding</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose the re-election of any director who has attended
fewer than 75% of board meetings in two consecutive years.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Board Committees</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boards should establish committees, populated by independent and appropriately
skilled non-executive directors, to oversee (as a minimum) the nomination, audit and remuneration processes. It may also be appropriate
for additional committees to be established, such as a risk or sustainability committee. These committees should report openly on an annual
basis about their activities and key decisions taken.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against committee members if we have concerns regarding
the composition of a committee.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nomination Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This committee has responsibility for leading the process for orderly
non-executive and senior management succession planning and recruitment, and for overseeing the composition of the board including skillset,
experience and diversity. We expect the committee to be comprised of a majority of independent directors with an independent Chair.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against the re-election of the Nomination Committee
Chair if we have concerns regarding the composition of the board or concerns regarding poor succession planning.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Audit Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This committee
has responsibility for monitoring the integrity of the financial statements, reviewing the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
internal financial controls and risk management systems, reviewing the effectiveness of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
internal audit function and appointing auditors. While we prefer the committee to be wholly independent, at minimum we expect the committee
to be comprised of a majority of independent directors with an independent Chair and at least one member having recent and relevant financial
experience.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against the re-election of the Audit Committee Chair
if at least one member of the Committee does not have recent and relevant financial experience.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration Committee</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">This committee
is responsible for determining the policy and setting remuneration for executive and non-executive directors. The committee should ensure
that remuneration is aligned with strategy and company performance and should clearly demonstrate regard for the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
employees, for wider society and be cognisant of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s licence
to operate when considering policy and the overall level of remuneration. We expect remuneration committees to be robust in their approach
to developing and implementing remuneration policies, with formal and transparent procedures for developing policies and for determining
remuneration packages. Remuneration committees should be comprised of a majority of independent directors with an independent Chair and
we expect members to have appropriate experience and knowledge of the business. No executive should be involved in setting their own remuneration.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have significant concerns regarding the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
remuneration policy or reward outcomes we may escalate these concerns through a vote against the Chair or members of the Remuneration
Committee.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Director Accountability</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to be able to hold boards to account through engagement and
regular director re-elections and directors should feel that they are accountable to investors. We encourage individual, rather than bundled,
director elections. While our preference is for directors to be subject to re-election annually, we expect re-elections to take place
at least every three years. Lengthier board mandates, while not uncommon in some markets, risk divorcing directors from an appropriate
sense of accountability. Directors and management should make themselves available for discussions with major shareholders as we expect
to have open dialogue to share our perspectives and gain confidence that the individuals are carrying out their roles with appropriate
vigour and diligence. A further important element of director accountability to shareholders is that investors should have the right,
both formal and informal, to propose and promote individual directors to be considered for election to the board by all shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally oppose the re-election of non- independent NEDs who are
proposed for a term exceeding three years. We may not apply this to directors who are shareholder representatives.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have significant concerns regarding a board member</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
performance, actions or inaction to address issues raised we may vote against their re-election.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We may vote against directors who decline appropriate requests for meeting
without a clear justification.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a director has held a position of responsibility at a company which
has suffered a material governance failure, we will consider whether we are comfortable to support their re-election at other listed companies.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support resolutions to discharge the supervisory board
or management board members unless we have serious concerns regarding actions taken during the year under review. Where there is insufficient
information regarding allegations of misconduct, we may prefer to abstain. In exceptional circumstances we may vote against the discharge
resolution to reflect serious ESG concerns if there is not another appropriate resolution.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will not support the election of directors who are not personally identified
but are proposed as corporations.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reporting</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
board should present a fair, balanced and understandable assessment of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
position and prospects </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">financial and non-financial </FONT>&ndash;
<FONT STYLE="font-family: Times New Roman, Times, Serif">and of how it has fulfilled its responsibilities. We support the principle of
full disclosure of relevant and useful information, subject to issues of commercial confidentiality and prejudice. Boilerplate disclosure
should be avoided. We encourage companies to consider using the appropriate globally developed standards and would particularly encourage
the use of those created by the Taskforce for Climate related Financial Disclosure (TCFD), the International Integrated Reporting Council
(IIRC), the Sustainability Accounting Standards Board (SASB) and the Global Reporting Initiative (GRI). Audited reporting and financial
numbers should be published ahead of any relevant shareholder meetings. We continue to monitor the evolving reporting landscape and consider
new reporting developments as they emerge, either voluntary or regulatory.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We may consider voting against a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Annual Report &amp; Accounts if we have concerns regarding timely provision or disclosure.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Political Donations &amp; Lobbying</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Companies
should be consistent in their public statements and not undermine these in private commentary to market participants or to politicians
and regulators. We welcome transparency from companies about their lobbying activities and believe that good companies have nothing to
hide in this respect. Similarly we encourage transparency of any political donations that companies deem appropriate </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">and
we expect a clear explanation of why such donations are an appropriate use of corporate funds.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risk &amp; Audit</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The board
is responsible for determining the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s risk appetite, establishing
procedures to manage risk and for monitoring the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s internal
controls. We expect boards to conduct robust assessments of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
material risks and report to shareholders on risks, controls and effectiveness. The introduction of global accounting standards has led
to much greater investor confidence in the accounts produced by companies around the world. It has also assisted in creating consistency
of reporting across companies, enabling fairer comparisons between different operating businesses. We therefore encourage companies seeking
international investment to report under International Financial Reporting Standards (IFRS) or US GAAP. As a firm abrdn supports the continued
development of high quality global accounting standards.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">An independent
audit, delivered by a respected audit firm, is a required element for investor confidence in reporting by companies. We strongly favour
meaningful, transparent and informative auditor reports, giving us additional insights into the audit process and accounting outcomes.
Audit fees must be sufficient to pay for an appropriately in-depth assurance process. We would be concerned if a company sought to make
savings in this respect as the cost in terms of damage to audit effectiveness and confidence in the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
accounts would be much more substantial.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The independence of the auditor and the standard of their work, particularly
in challenging management, should be subject to regular assessment that is appropriately disclosed. Even when individuals carrying out
the audit are refreshed, we believe that the independence of the audit firm erodes over time and we will encourage a tender process and
change of audit firm where an engagement has lasted for an extended period. In order to demonstrate the level of independence, companies
should not have the same audit firm in place for more than 20 years.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The relationship with the auditor should be mediated through the audit
committee. Where we are significant shareholders, we expect to be consulted on plans to tender and replace auditors.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against the re-election of an auditor which has a
tenure of 20 years or over, if there are no plans for rotation in the near term.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against the auditors if we have concerns regarding
the accounts presented or the audit procedures used.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against the approval of auditor fees if we have concerns regarding
the level of fees or the balance of non-audit and audit fees.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Remuneration</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Remuneration policies and the overall levels of pay should be aligned
with strategy, attracting and retaining talent and incentivising the decisions and behaviours needed to create long-term value. The component
parts of remuneration should be structured so as to link rewards to corporate and individual performance and they should be considered
in the context of the remuneration policies when taken as a whole. We recognise the benefits of simplicity in forming the policy, which
should clearly link outcomes and expectations for those receiving the remuneration, as well as external stakeholders. The structure should
be transparent and understandable.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
annual report should contain an informative statement of remuneration policy which communicates clearly to stakeholders how it has developed
and evolved. This should include details of any stress testing that may have been undertaken to understand the policy outcomes for different
business scenarios. The remuneration committee should provide a clear description of the application of policy and the outcomes achieved.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Base salary should be set at a level appropriate for the role and responsibility
of the executive. We discourage increases which are driven by peer benchmarking, and expect increases to be aligned with the wider workforce.
Consideration should also be given to the knock on impact to variable remuneration potential. Pension arrangements and benefits should
be clearly disclosed. We generally expect pension structures to be aligned with the wider workforce.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A company
should structure variable, performance- related pay to incentivise and reward management in a manner that is aligned with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
sustainable performance and risk appetite over the long term. We expect all variable pay to be capped, preferably as a proportion of base
salary. In the UK we expect variable pay to be capped as a proportion of salary. In other markets, if variable pay is capped at a number
of shares, we expect the value of grants to be kept under review annually to ensure the value remains appropriate and is not excessive.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance
metrics used to determine variable pay should be clearly disclosed and aligned with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
strategy. A significant portion of performance metrics should seek to measure significant improvements in the underlying financial performance
of the company. We also encourage the inclusion of non-financial metrics linked to targets which are aligned with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
progress on its ESG strategy. Where possible we expect these targets to be quantifiable and disclosed.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Variable pay arrangements should incentivise participants to achieve
above-average performance through the use of challenging targets. We encourage sliding-scale performance measures and expect performance
target ranges to be disclosed to enable shareholders to assess the level of challenge and pay for performance alignment. We expect annual
bonus targets to be disclosed retrospectively and encourage the disclosure of long term incentive (LTI) targets at the beginning of the
performance period, but at minimum we expect retrospective disclosure. Where bonus or LTI targets are not disclosed due to commercial
sensitivity we expect an explanation of why the targets continue to be considered sensitive retrospectively and expect some detail regarding
the level of achievement vs target. Where a share price metric is being used, we expect this to be underpinned by a challenging measure
of underlying performance.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We encourage settlement of a portion of the annual bonus in shares
which are deferred for at least one year.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect settlement of long term incentives to be in shares, with
rationale provided for any awards settled in cash. Long term incentives should have a performance period of no less than three years.
In the UK we expect a further holding period of two years to be applied, and we encourage this in other markets.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We do not generally support restricted share schemes or value creation
plans. We will consider supporting the use of restricted share plans which have been structured consistent with the guidelines of the
Investment Association.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect appropriate malus and clawback provisions to be applied to
variable remuneration plans.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect shareholding guidelines to be adopted for executive directors
and encourage the adoption of post- departure shareholding guidelines.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect details of any use of discretion to be disclosed and its
use should be justifiable, appropriate and clearly explained. We would expect policies to be sufficiently robust so that discretion is
only necessary in exceptional circumstances. We do not generally support exceptional awards, and are particularly sensitive to such awards
being granted to reward a corporate transaction.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect executive service contracts to provide for a maximum notice
period of 12 months. We will consider local best practice provisions related to severance arrangements when voting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-executive
fees should reflect the role</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s level of responsibility and time
commitment. We do not support NED</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s participation in option or performance-related
arrangements. However we do support the payment of fees in shares, particularly where conservation of cash is an issue.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the UK
our expectations of companies are aligned with the Investment Association</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
Principles of Remuneration.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where significant changes to remuneration arrangements are being considered,
we would expect remuneration committees to consult with their largest shareholders prior to finalising any changes. Where any increase
to variable remuneration is proposed, we would expect this to be accompanied by a demonstrable increase in the stretch of the targets.
Furthermore we expect any increases to remuneration to be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In response to the issues arising from the cost of living crisis being
experienced by many people in the UK, we expect companies to focus any additional help towards those members of the workforce who need
it most. We expect Remuneration Committees to take into account factors arising from the cost of living crisis when deliberating over
executive pay outcomes. We would be concerned by reputational issues arising from decisions made in these unusual circumstances and may
make this a factor in our voting decisions at relevant AGMs.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In line with the expectations set out above we will generally vote
against the appropriate resolution(s) where:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We consider the overall reward potential or outcome to be excessive.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant increase to salary has been granted which is not aligned with
the workforce or is not sufficiently justified.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A significant increase to performance-related pay has been granted which
is not sufficiently justified, is not accompanied by an increase in the level of stretch required for achievement or results in the potential
for excessive reward.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">There is no appropriate cap on variable incentive schemes.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance targets for annual bonus awards are not disclosed retrospectively
and the absence of disclosure is not explained.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance targets for long term incentive awards are not disclosed up front
and there is no compelling explanation regarding the absence of disclosure or a commitment to disclose retrospectively.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Performance targets are not considered sufficiently challenging, either at
threshold, target or maximum.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Relative performance targets allow vesting of awards for below median performance.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Retesting provisions apply.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Incentives that have been conditionally awarded have been repriced or performance
conditions changed part way through a performance period.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We have concerns regarding the use of discretion or the grant of exceptional
awards.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pension arrangements are excessive.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Pension arrangements are not aligned with the wider workforce (UK).</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The interests of minority shareholders must be protected and any major,
or majority, investor should not enjoy preferential treatment. The structure of ownership or control should minimise the potential for
abuse of public shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Companies should not make significant changes to their structure or
nature without being fully transparent to their investors. Shareholders should have the opportunity to vote on significant corporate activity,
such as mergers and acquisitions. Where a transaction is with a related party, only independent shareholders should have a vote. Even
in markets where no vote is given to shareholders in these circumstances, investors need transparent disclosure of the reasons for any
such major change. Companies should expect that shareholders may want to discuss and debate proposed developments</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diversification beyond the core skills of the business needs to be
justified as it is more often than not a distraction from operational performance. All major deals need to be clearly explained and justified
in the context of the pre- existing strategy and be subject to shareholder approval.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will vote on corporate transactions on a case by case basis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally
support the payment of dividends but will scrutinise the proposed level where it appears excessive given the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
financial position.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share Capital</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The board carries responsibility for prudent capital management and
allocation.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Share Issuance</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will consider capital raises which are proposed for a specific purpose
on a case by case basis but recognise that it can be beneficial for companies to have some general flexibility to issue shares to raise
capital. However we expect issuances to be limited to the needs of the business and companies should not issue significant portions of
shares unless offering these on a pro-rata basis to existing shareholders to protect against inappropriate dilution of investments.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a company seeks a general authority to issue shares we generally expect
this to be limited to 25% of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s share capital for pre-
emptive issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management Guidelines.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Where a company seeks a general authority to issue shares we generally expect
this to be limited to 10% of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s share capital for non-pre-emptive
issuances. In the UK we are aligned with the guidance of the Investment Association Share Capital Management Guidelines and those of the
Pre-Emption Group.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will not generally support share issuances at investment trusts unless
there is a commitment that shares would only be issued at a price at or above net asset value.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">When considering
our votes we will, however, take account of the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s circumstances
and any further detail regarding proposed capital issuance authorities prior to voting.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Following
changes to the UK</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s Pre-Emption Group Guidelines in November 2022,
which reflect an increase on previous limits, we will hold the Chair of the company accountable for any perceived misuse of the increased
flexibility through a vote against their re-election.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Buyback</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognise that share buybacks can be a flexible means of returning
cash to shareholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support buyback authorities of up to 10% of the issued
share capital.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Related Party Transactions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The nature
of relations </FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">particularly any related party transactions (RPTs)
</FONT>&ndash; <FONT STYLE="font-family: Times New Roman, Times, Serif">with parent or related companies, or other major investors, must
be disclosed fully. Related party transactions must be agreed on arm</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
length terms and be made fully transparent. Where they are material, they should be subject to the approval of independent shareholders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against RPTs where there is insufficient transparency of the
nature of the transaction, the rationale, the terms or the views and assessment of directors and advisors.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Article/Bylaw amendments</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While it is standard to see proposals from companies to amend their
articles of association or bylaws, we will review these on a case by case basis. When doing so we expect full transparency of the proposed
changes to be disclosed.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will vote against amendments which will reduce shareholder rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Defences</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There should be no artificial structures put in place to entrench management
and protect companies from takeover. The best defence from hostile takeover is strong operational delivery.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against anti-takeover/</FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">poison
pill</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">proposals.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Voting Rights</U></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are strong
supporters of the principle of </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">one share, one vote</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">and therefore favour equal voting rights for all shareholders.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally vote against proposals which seek to introduce or continue
capital structures with multiple voting rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will consider voting against proposals to raise new capital at companies
with multiple share classes and voting rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Meetings</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholder
meetings provide an important opportunity to hold boards to account not only through voting on the proposed resolutions but also by enabling
investors the opportunity to raise questions, express views and emphasise concerns to the entire board. We may make a statement at a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
AGM as a means of escalation to reinforce our views to a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
board.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We welcome the opportunity to attend meetings virtually, being of the
view that this can increase participation given obstacles such as location or meeting concentration. However we are not supportive of
companies adopting virtual-only meetings as we believe this format reduces accountability. Our preference is for a hybrid meeting format
to balance the flexibility of remote attendance with the accountability of an in-person meeting.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support resolutions seeking approval to shorten the EGM
notice period to minimum 14 days, unless we have concerns regarding previous inappropriate use of this flexibility.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">We will generally support proposals to enable virtual meetings to take place
as long as there is confirmation that the format will be hybrid, with physical meetings continuing to take place (unless prohibited by
law). We expect virtual attendees to have the same rights to speak and raise questions as those attending in-person.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>As part of strategic planning, boards need to have oversight of,
and clearly articulate, the key opportunities and risks affecting the sustainability of the business model. This includes having a process
for, and transparent disclosure of, potential and emerging opportunities and risks and the actions being taken to address them.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The effective
management of risks extends to long-term issues that are hard to measure and whose timeframe is uncertain and will include the management
of environmental and social issues. We use the UN Global Compact</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
four areas of focus in assessing how companies are performing in this area.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Specifically we expect companies to be able to demonstrate how they
manage their exposures under the following headings.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Environment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is generally accepted that companies are responsible for the effects
of their operations and products on the environment. The steps they take to assess and reduce those impacts can lead to cost savings and
reduce potential reputational damage. Companies are responsible for their impact on the climate and they face increased regulation from
world governments on activities that contribute to climate change.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect that companies will</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Identify, manage and reduce their environmental impacts.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Understand the impact of climate change along the company value chain.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Develop group-level climate policies and, where relevant, set targets to
manage the impact, report on policies, practices and actions taken to reduce carbon and other environmental risks within their operations.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Comply with all environmental laws and regulations, or recognised international
best practice as a minimum.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, in relation
to the environment we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will use the indicators within the Carbon Disclosure Project to
identify companies which are not fulfilling their climate commitments. Where appropriate we will take voting action to encourage better
practice among companies which we deem to be laggards.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Labour and employment</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Companies
that respect internationally recognised labour rights and provide safe and healthy working environments for employees are likely to reap
the benefits. This approach is likely to foster a more committed and productive workforce, and help reduce damage to reputation and a
company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s license to operate. We expect companies to comply with
all employment laws and regulations and adopt practices in line with the International Labour Organization</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
core labour standards. a minimum.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In particular, companies will:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take affirmative steps to ensure that they uphold decent labour standards.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt strong health and safety policies and programmes to implement such
policies.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt equal employment opportunity and diversity policies and a programme
for ensuring compliance with such policies.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt policies and programmes for investing in employee training and development.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Adopt initiatives to attract and retain talented employees, foster higher
productivity and quality, and encourage in their workforce a commitment to achieving the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
purpose.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ensure policies are in place for a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
suppliers that promote decent labour standards, and programmes are in place to ensure high standards of labour along supply chains.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report regularly on its policy and implementation of managing human capital.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, in relation
to labour and employment we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We recognise the impact that human-rights issues can have on our investments
and the role we can play in stimulating progress. We draw upon a number of international, legal and voluntary agreements for guidance
on human-rights responsibilities and compliance. Our primary sources are the International Bill of Rights and the core conventions of
the International Labour Organisation (ILO), which form the list of internationally agreed human rights, and the UN Guiding Principles
on Business and Human Rights (UNGPs), which clarifies the roles of states and businesses. We encourage companies to use the UNGPs Reporting
Framework and encourage disclosure in line with this guidance.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Continually work to understand their actual and potential impacts on human
rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Establish systems that actively ensure respect for human rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Take appropriate action to remedy any infringements on human rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, in relation
to human rights we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Business ethics</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As institutions
of wealth and influence, companies have a significant impact on the prosperity of their local communities and the wider world. Having
a robust code of ethics and ensuring professional conduct mean companies operate more effectively, particularly when it comes to ethical
principles governing decision- making. A company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s failure to conform
to internationally recognised standards of business ethics on matters such as bribery and corruption, can increase its risk of facing
investigation, litigation and fines. This could undermine its license to operate, and affect its reputation and image.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect companies to have policies in place to support the following:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ethics at the heart of the organisation</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
governance.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">A zero-tolerance policy on bribery and corruption.. How people are rewarded,
as pay can influence behaviour.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Respect for human rights.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax transparency.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ethical training for employees.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Where we have
serious concerns regarding a board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s actions, or inaction, related
to business ethics we will consider taking voting action on an appropriate resolution.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We will review any resolution at company meetings which ISS has
identified as covering environmental and social factors. The following will detail our overarching approach and expectations.</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our approach to vote analysis is consistent across active and quantitative
investment strategies</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Review</B> the resolution, proponent and board statements, existing
disclosures, and external research.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Engage</B> with the company, proponents, and other stakeholders
as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Involve</B> thematic experts, regional specialists, and investment
analysts in decision-making to harness a wide range of expertise and include all material factors in our analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Ensure</B> consistency by using our own in-house guidance to frame
case-by-case analysis.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Monitor</B> the outcomes of votes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Follow-up</B> with on-going engagement as required.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Given the
nature of the topics covered by these resolutions we do not apply binary voting policies. We adopt a nuanced approach to our voting research
and outcomes and will consider the specific circumstances of the company concerned. Our objective is not to vote in favour of all shareholder
resolutions but to determine the best outcome for the company in the context of the best outcome for our clients. There are instances
where we are supportive of the spirit of a resolution however there may be a reason which prevents our support for the proposal. For example,
where the purpose of the resolution is unclear, where the wording is overly prescriptive, when suggested implementation is overly burdensome
or where the proposal strays too closely to the board</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s responsibility
for setting the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s strategy.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Management Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We are supportive
of the steps being taken by companies to provide transparent, detailed reporting of their ESG strategies and targets. While shareholder
proposals on environmental and social topics have been common on AGM agenda for several years, an increasing number of companies are presenting
management proposals, such as so called </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">say on climate</FONT>&rsquo;
<FONT STYLE="font-family: Times New Roman, Times, Serif">votes, for shareholder approval. While we welcome the intention of accountability
behind these votes, we have reservations about the potential for them to limit the scope for subsequent investor challenge and diminish
the direct responsibility and accountability of the board and individual directors. We believe it is the role of the board and the executive
to develop and apply strategy, including ESG strategies, and we will continue to use existing voting items to hold boards to account on
the implementation of these strategies. As active investors we also regularly engage with investee companies on ESG topics and find this
dialogue to be the best opportunity to provide feedback.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We will review
the appropriateness of </FONT>&lsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">say on climate</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">votes
and consider if other voting mechanisms should be applied to ensure both Boards and Executives apply the appropriate rigour to initiate
and deliver strategies to support the climate transition.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Proposals</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The number of resolutions focused on environmental and social (E&amp;S)
issues filed by shareholders continues to grow rapidly. The following provides an overview of some of the factors we consider when assessing
the most prevalent themes for shareholder proposals.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Climate Change</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are members of the Net Zero Asset Manager Initiatives and this is
reflected in our Active Ownership approach. We encourage the companies in which we invest to demonstrate a robust methodology underpinning
Paris aligned goals and targets and are supportive of resolutions that will help companies to achieve this. Once a credible climate strategy
is in place, we prioritise evidence of implementation over requests to re-draft strategies and targets after only a year or two.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A growing number of resolutions call on companies to increase the transparency
of their reporting on climate- related lobbying. These proposals typically encompass direct lobbying undertaken by the company and indirect
lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Lobbying contrary to the objectives
of the Paris Agreement is effective in creating climate policy inertia and impeding the transition to net zero economies.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">We do not
evaluate resolutions in isolation. Our approach recognises the links between corporate governance, strategy and climate approach. Where
a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s operational response to climate change is inadequate,
the effectiveness of board oversight and corporate governance may also be called into question.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Demonstrate that a robust methodology underpins Paris aligned, net zero goals
and targets.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Set targets for absolute emission reduction, not just carbon intensity, to
show a clear pathway to net zero.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Report in alignment with the TCFD</FONT>&thinsp;&hairsp;<FONT STYLE="font-family: Times New Roman, Times, Serif">framework.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Link targets to remuneration and ensure they are reflected in capital expenditure
and R&amp;D plans.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Carefully manage climate-related lobbying by ensuring appropriate oversight,
transparent disclosure of activities, and alignment of activities with the company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
strategy and publicly stated positions.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Diversity &amp; Inclusion</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Diversity &amp; Inclusion (D&amp;I) is an important and growing theme
for shareholder resolutions. In recent years resolutions have focussed on racial equity audits, pay gap reporting, transparent disclosure
of D&amp;I metrics and assessments of the efficacy of D&amp;I programmes.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">A racial equity
audit is an independent analysis of a company</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s business practices
designed to identify practices that may have a discriminatory effect. We are supportive of racial equity audits in relation to internal
and external D&amp;I programmes. It is appropriate that these programmes should have KPIs and audit mechanisms in place to measure and
</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">evaluate outcomes. Some proposals request racial equity audits of provision
of services. We are aware that measuring provision of service is challenging and gathering racial data on customers can be difficult and
inappropriate. There are also multiple different factors that can influence service provision and which could be misconstrued as being
racially motivated. We will however, support resolutions which are not unduly prescriptive and allow companies to carry out audits within
a reasonable timeframe, at a reasonable cost, and excluding confidential or proprietary information.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consider standardised gender pay gap disclosure to be an important
tool for assessing how companies are addressing gender inequality. Reporting on gender pay gaps across global operations can help companies
to remain ahead of the regulatory curve. It also enables them to offer better opportunities and remuneration for women around the world.
We are therefore supportive of resolutions which are likely to deliver these benefits. Proposals must be carefully drafted to achieve
these outcomes. For instance, in the past we have been unable to support resolutions which called for global median gender and racial
pay gap reporting as it was unclear how this would reveal potential pay disparities at a local level and how it could be implemented by
companies with operations in jurisdictions where collection of racial identity data is illegal.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the US market we support public disclosure of EEO-1 forms by companies.
The EEO-1 form details a comprehensive breakdown of workforce by race and gender according to ten employment categories. The form is submitted
privately to the US Equal Employment Opportunity Commission on an annual basis. When publicly disclosed, it offers investors and other
stakeholders data in a standardised and comparable form. We have used our engagement programme to ask the companies in which we invest
to disclose this form for their US operations while making it central to our D&amp;I voting approach and supporting resolutions that request
it.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Human rights</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a supporter of the UN Guiding Principles on Business and Human Rights
(UNGPs), we expect companies to demonstrate how human rights due diligence is conducted across operations, services, product use and the
supply chain. Companies can have a significant impact on human rights directly through operations and provision of services, and indirectly
through product use and the supply chain. In recent years the sale and end-use of controversial technologies, such as facial recognition
software, has emerged as a prominent theme.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect and encourage companies to:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Have robust due diligence processes to assess the actual and potential human
rights impacts of their operations, services, product use and supply chain.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Conduct customer and supplier vetting processes commensurate with the risk
of human rights abuse.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Publicly disclose information about the operation of these processes and
utilise the UNGPs</FONT>&rsquo; <FONT STYLE="font-family: Times New Roman, Times, Serif">Reporting Framework. This will improve the standard
and consistency of human rights reporting and enable more informed investment decision making.</FONT></TD></TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Lobbying &amp; Political Contributions</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Corporate lobbying and political contributions are a recurrent theme
of shareholder resolutions, particularly in the US. These proposals typically encompass direct lobbying undertaken by the company and
indirect lobbying undertaken by trade associations and other organisations of which it is a member or supporter. Proposals may also request
the disclosure of more information regarding the process and rationale for political contributions. We expect companies to make transparent,
consolidated disclosures of direct and indirect lobbying and political expenditure. This disclosure should be underpinned by a coherent
policy that: explains public policy priorities and the rationale for associated expenditure, identifies the management positions responsible
for public policy engagement, and provides appropriate mechanisms for board oversight. These measures should mitigate the risks associated
with corporate lobbying and political contributions, protecting the interest of shareholders and other stakeholders.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nuclear Energy</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">In the Japanese
market nuclear energy is a recurrent theme of shareholder resolutions. The Japanese government is seeking to reduce the nation</FONT>&rsquo;<FONT STYLE="font-family: Times New Roman, Times, Serif">s
reliance on coal and its energy strategy presents safe nuclear power generation as an important source of base-load power. In this context,
resolutions which seek to limit or cease the nuclear operations of an individual company do not appear to be in the best interests of
shareholders and other stakeholders. The health &amp; safety risks associated with nuclear energy are high, must be managed carefully
across the industry, and are an important consideration in our voting.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Important Information</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This document is strictly for information purposes only and should
not be considered as an offer, investment recommendation, or solicitation, to deal in any of the investments or funds mentioned herein
and does not constitute investment research. abrdn does not warrant the accuracy, adequacy or completeness of the information and materials
contained in this document and expressly disclaims liability for errors or omissions in such information and materials.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any research or analysis used in the preparation of this document
has been procured by abrdn for its own use and may have been acted on for its own purpose. The results thus obtained are made
available only coincidentally and the information is not guaranteed as to its accuracy. Some of the information in this document may
contain projections or other forward looking statements regarding future events or future financial performance of countries,
markets or companies. These statements are only predictions and actual events or results may differ materially. The reader must make
their own assessment of the relevance, accuracy and adequacy of the information contained in this document and make such independent
investigations, as they may consider necessary or appropriate for the purpose of such assessment. This material serves to provide
general information and is not meant to be investment, legal or tax advice for any particular investor. No warranty whatsoever is
given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the reader, any
person or group of persons acting on any information, opinion or estimate contained in this document. abrdn reserves the right to
make changes and corrections to any information in this document at any time, without notice. This material is not to be reproduced
in whole or in part without the prior written consent of abrdn.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Applying ESG and sustainability criteria in the investment process
may result in the exclusion of securities within the universe of potential investments. The interpretation of ESG and sustainability criteria
is subjective meaning that products may invest in companies which similar products do not (and thus perform differently) and which do
not align with the personal views of any individual investor. Furthermore, the lack of common or harmonized definitions and labels regarding
ESG and sustainability criteria may result in different approaches by managers when integrating ESG and sustainability criteria into investment
decisions. This means that it may be difficult to compare strategies within ostensibly similar objectives and that these strategies will
employ different security selection and exclusion criteria. Consequently, the performance profile of otherwise similar vehicles may deviate
more substantially than might otherwise be expected. Additionally, in the absence of common or harmonized definitions and labels, a degree
of subjectivity is required and this will mean that a product may invest in a security that another manager or an investor would not.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">abrdn plc is registered in Scotland (SC286832) at 1 George Street,
Edinburgh EH2 2LL.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 14; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2527059d12hqlreporti001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d12hqlreporti001.gif
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MX-_@X>/DY>;GZ.?HZ>OK[._O\._P\/+R\_?W^/?X^/S\_
M
M
M                                                 "'Y!
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M !.-,<LTUE@TMU XX3C3V%5782!ZH\TU#CTDF%\HND,0#D+<@T\0^O"S0Q
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MP;4 /#ZGJE?0,%$$'%%?6UU1AR%V>'N^MPT/#,'%UP^.-03)%Q=F$;="*C8
M%8#9!'W%&$/EQQ8L\V?8YY79IZ/HZEG3.J+^67)<4481CRO#'0&7*!S-8V$D
M_==GF96)PWR5@PFO1'Q<B&(RD\470D0W\<:9MUII]PG/[=,^6(L,VJ//3FM6
MF@JI&Y6^Y65>I(9AG!(;CG0>Q..0@D<L'2N;R5M3+J6\(FN#<TI'TEM'+3N<
M\T&00MB:VB&SK)%(SU8>%"9XVY%4W2$"-PL>*3T[X\L=M\N1Z0MNX=BPR7,@
MU/,>F]-M!Z+)O>"IG(D@NM"&0S9CR9 ]<H@WU)57ITI=Y$,H.Q91^PO)JQ"U
M7AN4CA8Q<S,7P2=\&=.KCM6VD]@3/'=#V%19$=I\/)I >2)]R_J7WNR7S"S7
M6=;,7VF6A\F6GEC^PV*AP][L,C@B%ACJ?\BL933$HU4VM\@HM\=XHGMMKVCC
M%PQ<J^K)Q;L7MM(U5Q@"/DP\U)_GF:4IM"46@E^%M*8""8VTNQ/['MWB7IVC
M.\MQ*\,[O!"-722+@[J-T1@='7;,*@#)+,.98")-'B.-TA'&O3IK>"/0W(1<
M2#']'<PV ALF:@*-OM\HR:^@P)@L(*OB+? ""RM&5GNS@!<2N_*6M05CJG1E
MM=#0NG<C#66SD[(W#(>SNJUL1"<B(D(93+Z'MB_BE(NXRSM@7'XF*,35-6D-
MM\H,*,[WUEBIE2DS<31'PB]#X0NDB2RSH7--E1,! ^T$0WK9X1KZ,GG^RQ'6
ME[=^PGQ? X#"_+9>(RB<RW.JZ'.4S<!,E,\?0BCK0C+Z.7M(5PR+L2%)C9Y3
M%TJ3RJCZX8']BKO5MD7B4A^[&RMD#%.=$[Q?EUV= Q\B"1SWZ+%OQ]L9W9LL
M>T<<W3K'&7BK)G@C+6$5J=R*.CNU0\C-+9$W*P)XGN<A,(+C=;O9+77CYBZB
MR0JI<F*?MIK'LZG_P0MJ.'JM=[KO78>MI)/XW-ZKVA  S,JJM[_]YAFR0IX3
M@DN]E [5Z-\_X@Y??0^)*.#,U#\6+')A S8!6)@W='/+UR<.)W%GL:[<9.'I
M.N$;7N(<3N(>KB/+Z.M7TULL8]=84R0ICLS^_J3,P9XU"E>).K=\[<26BNES
M/_>?1_0A^<TPA36>_4$RKQPBH@R[5JJT6MKGYAMJUUW)D31MIHF:O8O0\8@K
M/T6S4S31;7>/_OXIYT*GR3'FJ7'PRU*]?620@?0X@,SF;Y[<@HS(#B8"S1T"
M(R "(:#Q([#Q&A\"(!\"'S#RC8S3'9GDI8G9X?U=W8UBU]4K_YK)"U+>VG,]
MKYNOX?-NG(V_,SGD.-E# %PP>$,PDX!?HD*UKZK?@65[D&;JJ,Z4+B+!BUC!
M:5:LQ=5S \6Y<TN)"U=97>-G5S;.B<U9&OY;E"M#NGY WN36;LW#,A?9( [B
M@WWV)?Z+O,[V>\+^S,D*Q+C^]=5NE1PLXT&B0X5FKY-YSU&=U7QXC8Z<]"'2
MJIC.(4;-2O+R@4DNT/-RW^8;\Z&R>=-&"";('A2KT#$E'%"5+>UU+B&+7;E)
M\'/\VZQCIRU+;,;V=X,ZA,EV2!5)81'OG#$]W2%O\2 _\B(__!_@ <C/ 1F0
M 1B  25/>56'\N %Z&4E;O&+5K5P79ID_8P^/5$[L.UVU%4KR^]=MIEM2T,6
MQ7TE8_)>:X4 Z@O<8T4TJX!QZI'Y]*J>H(S8ZFS[ZN3G,X P0S,X(SA(6#-3
MDWC8>%CSJ A)8S.X: FYJ*EIL]CI^=DI"FI366KZN;E)4Y.JNEG*&1K^>RIJ
M"UD( S,C8]@:^@O:.@SL23S\:MQ*B4HY6,IZZ<@Z3:,H*5AH7<C=S2T#+A,3
M T.N>_YRKCM./BX>#LX>(RY/_N+2DI_ODJ[N#Y/NQ3V +G2YX'=/8,*##!LV
M;.$0HCZ)^"9:E'@QXT06+3AVY,@B),B1^5:(Y&B2A<D5*U6J9 DSY@H5-%.@
M.''S9@J:*E2JF-D3* N>1(L:/8IT9XJ=-54H=:ITJ=2H2U&@F'K5ZE6;6U.<
MP'F"JU6<6K^:O6G6K(FO)DR0<$N"Q(BY(T2$N/OAPUV[>3U\X, A0P8,%BI,
MD( 8@H.,%?4UQG=0H[X7$RGO@PAY8F3,G#/^1Z[H,+3#D#)-[N,'4>!!U?P0
MHJ:,D&#K@@@5IFL(@_; W+=S&_1=T"#MWPSSB20*,R1%AO_.M5O'KEST>O/&
MP9!QG5XX&T&$#/'^/<B/'CQX]/A!I @/0H)P9>-F+;ZA:]6J99KT"%.T2_>3
MO4H5"B7$Q#(,-?WY!\M]HQ1#BS&U;#.#=#&TI\PH#J;"C#*:"/B*@8U4X@Q^
M^8'HS#3S;2.?-]_T$LX__31'CSOPN%,=.S/86 ]!^GCT(D ^]J,0<0[=<Q!O
MHHFV7'$:@2299!YUM)%Q'XF4TD<MK,322R>5QN5,0*F %EAA(5?4ET,-1=.7
M/'W)5%%+$86"4W'^3D4G5&_2V16>6E5%EE=A>9755SF=E=8):[55P@EOQ<5H
M""/<%8)>>4TZJ0<<;##8!148EIAB$CB F 035-#D18U=9E%FJ3[DV6>>8>8J
MJT,V1*22'7E)$X\+L290"[O65NMMP@++&W"\W19<0 7U]IM P%44TE%9=A1:
M0#W^\YQUTDE8(XW5Q?,.+S=X!]YW0HS7 WGH$<$#B.VQ-Y\A\2727C;U-8)-
MB=-TB* J  [8H"O2].LO+*[<XF#"J7!3HS8'$\Q??]3L=R UT,A[KXF'8 RA
MBMVPZ&)S[;P#3\GOS$/RA+M0)Z&.4T+4'$"V&9E;;38?N9FK%.UL:JG^4#*V
MHY4C,7EET2FM8+1++V79Y4] X4J3H&*V:92::"*%=9Q8,_44G5+E:1-67U>E
M5=EF ^IGF&&N=4())+@=EPAR0XJ77I%2:NFEF7(J 01^.^ W!*)N:@$&@FVP
M 0=-@H;18Z==!%OCEVT&JV.0S8;S:ID_9)R9RL%*I$+ VM:;Z*0O]*S,,R?D
M['"K"0<M3U+QI!S.Z,2\K3K/;9LM==:!NYT0Y YA+KKI_E $$3NP9TF*\6I3
M"",9.Y*(-/8U3S'$_AT"HH413XS?@1*/G[V&!W>R33T4:K]*Q*IXF DA)$X?
MGR/VOH=_+X7$*+,NUTI',I,),&7@\E:.M&7^#LM,B06Z45U 9.8:(J4&9[#2
M&48N6*HGG2IH46+2T!8H$J%AB30ND<G28O*3%++$36'Z"M5F<C6LR9!J1-F)
MUE1P JC8Z4Y>P]/8]F2VLOG)3X5*2PF.&)>ZV(5NE&JB!RR%*0Q@8%.="IS@
M!E>!"T@Q XCCP!/],JD0. 95FF$,XY)D.<ZL2E:;P\="VNB0FNWH3+GB"$-4
MP[K5F(YT1=+-0)9E&WX AUDOBHA/@-*F$%90D,$Y1R-QI[M(8H<<D_2==L*!
M,AL(CWB<%$^ZRN,#(K"K&R6Z'[RZ0:_W$ (1K) 7O394O?Q,PGVKJ,3X((:^
M^LRR$;.<A"W=5S[^[0F"?Q-:GX%6<4Q>8F^7^:'?QN2S,>AY Q[E4,?_=!%
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M3>@E__$12]%[S.A62L;5*\?#C9N.?KT5%O'^2]K3ESX+R%F^U.GIS#EDI[S
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M56D84,QE9B4R0'U%J53AF&8->W/)=-8P[-7DJ4JIQ6;2;8%YLDL+-OPV!!'
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M,] BG1(76T)"G1-\9H9FNR=QOH=FR_$4X;8S&5=\$S,U'9<.H&99,<$Z<'-
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MP>)YJ\F/%7 !%] *BW8L&')W]%N>V8=SW-B[P $<0O!#A_ #P%&\$&QF)\/
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MS$ #-CCDP$,W/?@0SH5!@*/..>D T0XZ[X088A ^Q#"//?7(Q@] ++;H&&&
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M<!+N+URLLD6H>$\7V1<GV^H+&NNC!3I8&,-X7([SK0/(ZQNRD(^\NN4P*\E
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ML?<"CQJ=*:52PV18%1?A\>M]&-U1RMD:L6++2?LJJ3' 2ZN<4.C**#(;^=O
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MX0A".':RNR,M*_-4%/R!Y"QA$&VCXA$REW/P9!PLP[T$ 0@_Z+P/?-"#'OP
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M4T@0!#?E@S_V2O^R4]Z#<.UR"=%V1WG$&-961WO!>3_@ W18AYTG;M+^=AA
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MBN*2+),N200MS@$%OLEA[=;Q ,J,.$CFEKW@<"#'31$]#B^YQ"C?(V2K*=B
M+3!UFKYT!1]9WB;GM:OF@J7L9>JP]O#0(:K^\J-V(66XJ!@VHI"<RVA_4*$4
M8U8P8 ZS:4:FX.*F22'KC^V1K[;FM.:_/J%GXSP:MHF-(%*HJ%,:#;MGO/WG
MP$D@!?,BD$KH7VZI<<ETQ[7<)AA0):C#4&*)DDZWC\[0VSG$9<5DU5-8[G$)
MFG0GA@,#GG[1FM<#?B+J2W':[OGJZDV?(AT6*RVYC8L5:Q[2'86LLXX5''X9
MN)[K5;C?+)D91: 7H:<#/5WLNH;->A(#.I W&AI%*[&M3PA3#)H$/J#MM;Q3
MWFX8-7#5BBS'CWSB*B[6ZQ[6+%D$,# !&T #/<W6_ZD#+<!.5H6]Z*:C#TNV
M12+U#5==7L_*GHC^I8$=R^.1(*QIRP/7"0#C6<&J)FEGK&%6%H"C+#$;%:TF
M2C,+$(Q%A!4?7V"!"!&1(]=5F(*P6V:F4B)?ZCMH/C?63%3Q=BVO]_OIGE#J
M+T.I"#4/VZ5AYVUF<ZZ%FSH*""4D)R8E)2>')XB*C(PHBBB1)RDHE)4I*I>:
M*9R=*BJ8H)^AGY\KIJ>I*ZJKK:ZM+"NQL[(LMK>V+;>ZN;RY++RZP;_ LL+'
MP, MR\S,+BW/T='0T"[6R];7UB\NW-G=X-[;W3U"0^=#0D) /3P[.SU$0CPR
M,# O,#+Z]O7Y]C$P8@#D]R^@O8," R9<:% @P(4/'2IT2+%BQ(H38]3^JX=#
MB)$B1Y D2;*DI,F32Y(H0<+2B$MS/]CMT''#A@R!W5ZPB/'B18T9,W30V!%D
MAY C09 L0?($BI,H4*-";;)$B(T9 []I?=&QB%<B-3 D6" "2!&7+D,>6<M6
M+<N02.#&9?GVK1$8%#C0P($#9,L=+$ ]:F2"D(G#)!"32,QX<>))I5:I:#6Y
M5K)DS9Q1TPING+AOWEKTS 8CF[>>J%-SNY?Z7FG7KUUOPW>P]D"#M7,_+(B[
M]\&>T%!;\\T[8>Y_MW_K&E5*A6C>O8T?USV16XOFGW(-1YZ0FRUC/6\#W"<]
M7[_2V[<?[+<1QHQ\ -\3G$Z_]NC[R[BIAE'^R 0)08(XMM@( XX@PH$B&$@"
M@0(VR-AAABAR2(2-5!C)(Y)$8@DGDUS2"2>B>!(B<]B94MDI)[X"BRRK?&>,
M99C%N(LOS/PBC#+'+-.+CCIBEMF/FC4CS6;95,-93N.8EE-//*"#SCH]O+,#
M#T00L<-Y&OEC'D)9"M3/1<E)9!%#"O&S&YB[E9F1F!7=-%Y -Q!Q5D@CD412
M2B6)--)*<:%591!"^. ##SKD )0,+L00#0LNP+#3#"_<@ ,-[/!0A#E++1%%
M$U!(%=432%@U$#Z?67.#$%YY90,&"RPP A!IL65$2+/..I=<=.6J:TLRY+57
M7W,9D4-@E!!VV+'^QRZ&K++^#4)*B:C $@N/V#@SC32SA9/M,_HU^LT]W;"&
MFKBTD<H:;.BFUY-N Y7'4)H1%20>;]'LUU!RU!'7VW+,A<(H;?8 S%/  ;>F
M9D3>W?))->M.5-UH.5VDI4'LU=;H:Q>S^V9\7M;WV[D D[N5<"''4$@)B 'H
M&(,$CN!R@B*0$+.#_C5;V'^%(%*8A(DT,M@)%P:M2 J3<*)A)9F  B(F2S^+
M72J5G9AB+2O"B,O56.^"XXTX=@VDU\$ *;:UUQ YY)&FW:<MR=8TZ60ZE4X9
MCQ!7 GQ3>P%]V=!Z[W(7[[OQDG<OF&6.:;B7-\$70YQIZ5EG$GK2!1?^6BX5
M,001003QPP^$ZC##3QHQ&I@M*K@ #%:+SX###SG\4,0/2"AQA!-0,.$I5$\8
M(40. '5K&@Y#@.35#1DDX$ )0: EJQ%SU>76K9+O>H01,UC 00TYW. 7$D4
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ML3-  UI; SN0!$ZAGM!E V(K2S60%'$&!#JP V;16B5!%4W0!$J@ ^9F1_@
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MKE2]H;J)F^JZKE0=@;\7+@ D.!2C+V,IU9]\E&32.PYF?(,,M>%&>OKTB?8
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MB P[JG@2FBT5.DQS@<X7D9\YJA5ID6/"21R##> XJ,U0.!84J'XR"7!HEA\
M B8@HBVXHA^0@[XGDSDHHSEZ9F;E91H@ AKP554G5CR(15:$@QJP ;LX B5@
M"MM  ]B4 SN :NJG?CNQB:.')CI!#D.!M5:;M>]@M45 !$1PA5_KM3G^<84&
M!T=3$U@@(C:%!5'"E"+X^(8M8GP@P9:JXRN$)DF;P#*F<*=Y2J>*9EE\N%F
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M5QL$X24$9T<.8/L.7PNV.7' O:9$:5MLZ99N^*@H;PNP8^%S8YDHBHPK<*M
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M\N8E<((BQ DAU/!##D&\DM<0L\3&""X.DJ8H::5!!MDQQTQ9IG!H0B)>-3+
MF*F..@Y(#H$(*J@@##/ > TUGL:CCSSXZ-/.#.NP.L\]^XBS@@<.88!!3154
M,$$%%$PP@00358B1 PTLH,"R(86$D88+).MALM&BE"R'*VW4T@,2R233KQ0
MVZL%%Y![P;GG/G1!!AMDX"Z[/Y6X08GT>B"(("#DFZ]4!XV@+P@?? !""$LQ
M-<(AAI0Y' S2H:EI6#C<8$,..J3EPP\]].#^@P_SS47$7$4@$7)>FN19YU^6
M,(:RG7H=08000OBPPPW<O)"""?[Z LPOB!2#668_3T99BIXU154)J24-(83(
M-/+:T[O-9MO4S 27&W'-6'TUUKUEW?5O*_Q&W-C,/6>VV=9)HG9VW8&'733B
M;<?VW R/-U[=[.5MS7M\PP??"S3 #'-]]^6W'P\^^ =@I]]< ZLW"$8N>3D-
MGG;HH8W<8LP(&1AKH84:AFXA!!-T<% (';C;@2%$LUX0(2A8(X.,M-OX3CG8
MR&/##3',4 033CQ1Y)%)*HF$$4/\@ .4+*06F@HM*,@"+R9@&8*]0I6@@@@"
M<W95::[YYM4,0%C^(J<HHOB%_LGFFQ]+$$0, >@KF,CR#^81ZBP,HXY2)C1D
M93+3(Z2!IFFH)U.:*@?C/@6K>-1 ' I*$#G4(2IVY(,&8K''K.0Q#@5=4%;X
M"$<,2C"!F&BD(B1)X4FB):V0)" !S%) 2$*G(61I:'3%BHD$?"6L<(DK7#[L
MU;C2=2YW86 #&&"7N]J%1*#\1 -;FI>6!#$(IHB !(5@D54.@24L71$1*3A$
M@QR1 A8P#%88M $.9H0#BOF !S] '%R$X+&/T:4(>,D+R42!B3<E(2]',$+\
M@O #F?F(!C%HG@E ((A= >LB'4E)#!6P"]+H+S(]P\QE,$,91W%Q12C^"HTN
M%K4TS26B3 &$S3( 4K56&DIKPLD-;XS3->#\(VMA:P9RCI-+Y"SGE\^@3C34
M-AVU&5-N;OM.,>L6M_ PTYEW>X$YSI.W]Z0#57N;IGSL(SC\9&P_\/O/WD05
MP<?%2G+HA""#$E7*"!E$ Y[[G#P?, $*2*!<%1C$0:(( M>Q;HM8C)TZ:D2C
M#.:H4WN31PQ:P ,C*$$P34B2^P(Y!$(Z"08L:% PJ#2[&62E>EXZB@=.A)P0
MB.B*EP$?(P1HJ1CDH A+0,+ZUN>7]J7,?("QZ1%\((0CZ%$(-?C-,DX3&E(V
MBG_\BTRD@L&+1E"J@.#!%*;<PREU4+""Y03^1P8?",$.,C""K<H'"%?U*@U>
M,(2TFD$,2" !C8@DA7!]ZPP[%!(94HM;$XE !+PU$WL&:R85L("P?!5$(1HV
ML.,RE[O6E8$+)/%=3/R)9(G2 <H.K"F$D! )>)'19BQ**[J\97I:P+!7U:B-
M.=B!#M02A(WQ- CS$4(1YG,7NQR!+K>]"QZ+\#(@_$ '.;A!#6#P&YRAK@,:
M@$A$*N(A22[KN3!4  RG^T+IOO"%C7I,4I5:F:!)II, Y!\O!L*T!QV*J:.!
M6FM>N=Y5WJ9JL91E;G8)B:L)IVO%V24O@?D(%T#B;-J!QG2Z8YT"UTV8VRGF
MVIIIGJBF)ST,4P_^A-EC352Y!S[6-$?@!$<X('PS8_,19T(/U,!SNB.="(*!
M43<:1A(0%6<4VNM%7A)/;IV+ H[L$B$8^0$1$ .@!3$$[*B!H[#4R';=.%5"
M29LX(]#OCWHI0GWPPX,<V& &+V"$,!PAS1K03*/%L![ ^LF"&*0@8)PAP3%8
M(YO^?@4(FYA337&Z,I3EU*;M4T(1>A $G_YQ"#2@Q5!1 \:F'G6[F 0OBU=Y
M)@=/^%-5A32"'OC M(:J@6/]H%C$<E:QNJ/3K"K0"-M*DI.L\ %O?4!;<ZC7
M5GMK6,)ZM02&Y5<*V/K6ONH5$ ^+6'*92U?K<BQD?P(OR6Y)(49!2%/^3+ "
M$^B"-RS(3JE0!0EJ%!"C,HB>J-B(P;7PH <ZN%A^"/F#CH63D!O3 0[6:(XJ
MH: I6]) 38BE+><^5[K6C>YU]\WO!"!@W_\VP+\#KBA%\.S@/DOXSQ0-&5X8
M/*GMM!RB5I/*IQEJ-ZR4&BSE>]_CC&ULL7P$V43N#&#^=Y@(MHYTO'(=8LI-
M$G,3,-SB]LP&.UAOU\2FW[+)<_1L<W P\[!^P"F$(-@@&UF-8%9K]2IXH!A6
ME2--52J#I1$0M2H;D "Y(G"1&C] 0WKE%CT]T"]";+)Z__SGD*TQ ]MA\'&G
M@J8*9L #(,0%9%/.SPZ"VP[B:C017";5C!C^]!B0+F5@)%@!-TAP4JH<PVG'
M\8I+88KGFU:^\G4:A>:)4#$BZ'$(-1"T:7(A&ITIJE']\UG_G!I: SXZ@9#F
M5#G+^?:V:_#I9LV'[2K=:4]GNNGBN,8+V-J2"EE$(L/JEDP@H%<)N)JOL)[U
MK(4%ZWK>VM; ^A5BA5A8<Y7K(4G456/AM9 .$&*D(TV(OJHR F-4Z055,D>G
M>C<C -$@@?28! S"<H,;Z$ '-:!:.< 6J44Q:G1_Q*5(6/(![6(!%4 L&+$2
M,G1="U!=_)9O_09PU_5O_C9P_M:!"!""'^B! I< J.<@/*,:2N5=X.5PON +
M2S,:$><\E40FZN7^7AI'-1M'&_4E<LP!"61#7Y12<B9G<G#S'6^C8.@!<^;Q
M'.@Q8-708%'X8 Q3'M,D8=(T83AW*GV331HF.-SD31G#9T1@=.[1.VJ%:4M7
M(&5U8NBT3A&2201Q%;PP(1$0+A$P3S3T(2G1 !&@3R)P19KD.EHT9.K0=K8C
M0>\!?\[ "&JR W*T,6F1 VOT0.6!'(SB;(O  I+0=L+5 JGQ&)=Q.DRA C%@
M RY@4DR14J;1&I'W N1S>;*(9YFG>9Q !!'S R,#>F"#/Z@!@XER5,/ <&"T
M"/=%<^LA>PK$0)BF55J%06[G=)'3:9R&0=#8>VTH0=?A;B: 11^P)8W^)5C$
MLGSDJ$/C:(XR$0'#\BW3-WT]9'T]='WC8E@.V"L7$%B[XECIH@&Z(ED_X0$B
MT %?4@@H4!7$H C3TR"TL% R@ XQ0 ,18V0QL&Y'AR,Y,@-A 2.:4B4L< )4
M\8T@(&\0 8&15($OY($H.8(=>)(LR8$@"((A&),R*9/4-9,R:0 )(' ZB0 Z
MR2BGMS./PH+$" RC]' SN%*8XQ@R6'&JU$I2XUY6(VC L1Q$6(2_5)5A8Y7!
MU$SGL$PJUW+5P3#H8'-IXVC2]$P[%X75M#=^PX79@&$P\'.$4SA#QP/P8X;8
MT"DD9@]<E8W3R$'!%W6:XR\D@(*"2 )+ 4_^>*6'S=5<*_&'@9AFEJ%%*B)D
M(8 "TJ$@1P:8" 5_^J4+,2 CZ]8CE0@KV]@\U&,,M_ (;.=E@39QFW,Z(X"9
M,W)F!.-X8/1*_<5R+S6+LG@R[&,^28"+,_!2@Q)Z +$(2YD,2(5HF+14I<%F
MM 1_!B15L0<YH"(.FWF-'\1!M&*-NG>-&?0X#)-14G=^'- 0CA1K?-6>WC(1
MYXB.[;E7[BE][?@M]61]%G!]0%2/%8 !^+B/.-&/&W!<)B(B2N%L)I 5 0$]
MMD +T&%5TJ$.I/(.H3E-+K 5M[" /)$!&@"!&+$L)VF3,0F3)'JB*)JB):JB
M*+J3.QF".IF3"!#^(:?G<*E7&=T%G:O15# X&D6U-/C#""JXE$ZS2A;G2CO(
M<?5%7\JQ'/[E7UH9I4_*-DBX<N?P8"NW<L:T3"YG-Q&&-Q+VI6N981:&87RC
M#7$)AMUD."!6AD?G.,V(A@8"?"'DA@@2 X*9 HQG(BA8"!)""!<P+3<$.J&S
M$H(: 0(9F5ET)4&6(BA"D-5@>UR59-.Q2ZWA;*0EI[""H6#C/#@*/M$&(] H
M [:@@H;'&2?0 C6@ S+0+P=3#&SV<=#0.T(@9^:3>7E64[@J9TJ BS)@ Z[
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M02H 8T/&78AS-R.*AR1!#J"1  0@F$424<!$%ESGB5#<Q@DZ4 $+7& #&^"
MC:+&#)Y%8T<\ZFK/@K01:8DC%H90@0R$X 0DM( 9@NF6',GESWOP  G\H!L?
MH>"$/^9-3'SM&YK^?A$X-K4@!1A RN8N1TJ<16ZQC#TES3J!N4M>,K&6<RS-
M%$ *56KV4U(!%:J0YSM8 4^9N43F+9793&K.<K32/"U8=$E:W?V2FFVIW6S!
M,LQ>?H68=SD5 6PIS=WJ=BRQ14!JIVG;7 +WEM>TICC &49O-@-8W31JD41#
MFD.L$)W=.^?W..,CP%2C?/%D'D?B,<<YOL]]KT$7;5XSO_JM2W_ZBY= "VA
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M)]W@H1U1#,^& C6 DT>  YJ1-FX%5T!) SOP T;0!'TD$&X&9S7*-TNYA3#
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M*4Q;3IE2<>-$QB4XQF'\$S0Y%#9I $NA .W$M2(GCN+HQM;#TU7D,L)8K[9
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M%C\/A7-O^VJ][CX))6,591VJW6,[()QEO[\3/&(H0 3F%H5!D#X[EL,XP(:
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M!B#PFP(*,-! <!!$()T$$TQ 09/./?ED<U!*V=P%%T39G 5:5F"!!BHP>(2
M11019A%#C&GF$&J*)80F0G"C"3N*^- #(C\H<F</.]300@H=8 "H=3I<4X0Y
MV]A@0@XFP#"+#([TZ<)X+O 00@HYT##"#BC@< (.*.PP@@PDL-"#-]\ P4D/
M-* @2@;=";,,,ZZT\HH3.?0 1 ZWJK($#3L,P4@- B:!A#4T (',K,[^.+-$
M$D&@$*H.AI$ !+&%=F)J.-VXL^TY[^#90[ATGJ6#63KH:HP-\]@S#SX7[=./
M/XX%E!Y!!0VD4$(9&<301A,!5!%#^VK$$4@BD12222F!MI)++[544PPPV"0Q
MQ3GUQ!-.064\ PT>?_RQ44QIU553)9<L%<I;886RRBN_O%0--R0U@PYLO@E$
M#V695:H0^U'U%EUVZ46T7#@83?13-+#@P07=L>#"8#FY(-IHG#'&&67U$F3"
M"961@)AB69NP0M0PN&!"!A-8L$%J'W3@P0>HA4"W:R>P,(,/8?JP00-""MD;
MD CTQH #$$A @7-;0I=DD@\@3@';(&37007^TFF0@@MXZ^###C; D()D 1&T
MT$,1D= >:2BH8!(,--PJ3@\Z=#64#"=LL$$'(L 08($%'IC@@D6$X$ "%1Y/
M88\;9IBA <UC.***TLMX(HXRUAACC-2[&*.-.XJH_(]_,T#D T<B"3F4BG,I
M)9<56'GEDQ>T;V65\%]Y__L7,*?E_H"N, 0DU&8(84$$JA1QB'#="4]W>@<Y
M%NB#%##E!7;JP0O:T0,^A0!0RP%!$;"A#6X! 04Q" (.2(""%9#@!2V  =0R
M=8(9?, '0)"!"W)0 B"(8 8AD($*9""!%J *59LXQ Q*L %7:2 $14"%K&3%
M"E<XH1%-L $1>*#^IB8(@0=-(,('U92$)C0Q"<N(8C.6E80AT" %0FA6H<X&
MA&PT4!R(F%.X=*8S1IP+!VJI2U)JT#'"2$PE!_-7NQ#BKHJ\*U[T HB]]-&0
MAD 2(_>(Q\#B,P^+1(0?*9#(12R)R?AT!"0)4YCFH&9*AK'$831II4XHMA.,
M98QC0"%*QS[V$Z+\T61#<TO+H**RH)GLEW!YBU."F;2A[05F0P.DS6Z6L[*<
M!2P^BYG,;H #H?DRF]A$6EV0QA>YS" %&HC<!R)C A;$P"<S*(QH1C :>(HM
M:Y?Q6F80@\^K@0T^+=@)# SC 0@\X $8B)O;6E.WUKQ&!2^X 6V*T(+^!RA@
M >1C &\@9( ##&Y(1'* ^3XJ4 B(] $>?0 %,M !U&R  H?#P E@@C<>_* '
MD^BDO+:F28^49 4H0)U[/".?&-S /CNPCS1GAQ,4'.<#))C!#X+ANP$5@0<)
MJD$<0<  XQW/>1[:ZO.8)Z'JY2A'-QJK6;TGO0]%:' )()\#C'0XR"4N<>_3
M7_S89X']Y2^O\,O2_?"7O[_6%0/SXZN5W@>H+ %J!$*0*C<ZAX,Z*2)<.8@!
MN.IX@QC,- <_V $V?1""N'PE!BRH 0=T<(X=Q, $@<* "8Z0!"+$:;8FP,$/
M<&B"M4"+!RWQ0$YV( )NE, L)M#A#% PB!G^G( $.8 3$3L+@Q!L0 /3Z$ /
M8A7%[,I*"<J 12I> <5F2%&\X&4&*I PA!NPH(W$&I 08( "&L@E*54!) UN
M(@.8M.24*ZB(O/(Y@KJQ9L#8@6<C*9F/=S4R/0Q^)+\FF9!US6,CEJPD0"*\
MKX\4C"0*.QC#3,D2%T"LE32I&"QOTLZ+^82=&@L*6SI62[;0]YC G(LVAUE,
M7AH3+L?,\8Z[4A=ATCC'=Q$RCV]0LYN]R1'DHJ8.C,++;,:%F]P$<CB+]I0:
MP. $'=A?:J8A@A6\8)T>RV^?$"//S4SF,O<,FSY-L#H7K),G9XO("#(@T =8
MP -S$W!"L7.WKQC^X0@\Z(! (Q !D39@ ;[Y$5M[DX %-$"D G6 I1W@UND8
M1P,6$*@$-' "LX6D!F6Y 0P,XDCUU.,AI31)?WTZ A.D@ 4OF$$.&B$.'N"
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M E95&SA0 G33&M)X$5XS JF: 9;34AF .QI 71PPE=F1'?HW&#_A$S"A.3'
M1QO8)X"G:O8@JIL!9V+&0L^GI!98 SM )]+D1RRG&B3@ IH9)L5V;#, J!E
MFCX8/LP#5ER% ,T#(:S)/E$2FW;%5_)6/\[!;EMH6(1EA<#I/\OQK[J)F[^9
MF[_I/^JV;VA(6 L;AJWE6M>@#=S0 S<0 HRB C90 M=) RL@ G6"0SZP0BWT
M O91GBT =BPK CRG62V@ Z8"=-IY C>0 PHJ ]:",P5*1 &*+<]E*';^H@@[
MLX*WQD=R00,NL (EL *G0$96AP0^0#4M<(U+00.#\4],VU\5H7@I-&N."0,=
M4P-\Q .X$J%",";>^(W<M00N:HZ_:*.X"(Y+$%52VU[@B+<\:G5PB[=!2G(2
MIFKJ<1CZ-*GLT1YBYT@"<1X%P1!4JJ7Q8:455DF-QZ6DU&%>>I -$Z8)J7D_
MP7GME*83^1. 9+JCUZ8X=C1PBJAX^GJK2V7$EY&O2[L:2;M"@Y%T"A=)%J@[
M$WR%RA2)BJC#*Y,T&3,OP'!OMACN."\"H1$F(1-SEJD@HZP2$Q,B,:1>LQGQ
MY)0!6*IW&;'4P0&VBATF\$,Z\)5!T *JD5+^/(EFHW$:X NLN?,VOG9_QFJL
M3CNV.)%?,.&7MJ@6,=!?\"*MVFNLC)%"%_<"/64:8M<",X #WLJ*D 5(V@D"
MB\)90S!H D1L%DI55HLJ&-"NT3:$/O@\\II1!M B!# =8HB;^ 98\*,_ GLE
MM4F<_ZI7[F9O5ZA7_;.PX?O#\,:P6BC$11S$K44<)/!!2W8(-H!</D!Q374"
MA3 3TN(#B@@#JN(KS76VBG #*6 .WN">/' #+B "+="B J0#*]![;\) @D .
M>&06^I$#.B"37<$6ML03+H$2CI=X35D".!"US6)U=CL$OW 1,2$#'B,79C$(
M83$F1L"VS>*+*OK^MH0LMW [CIOLC)PLM3-JMS.JM^0(MVE,<GZ[HWQ;CDE
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MIF"A(@4*>.E"?-BPH8.'#RA1ABB!(H5+%"5&D !Q4L0(EAM5M*#!+$8+%2B
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M&08CHY;!R*6%!EIJ)B^TP0E$D =;OT?PH *NW'#C@0<A)+</"D/&0 D//_P
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MH%DVV94#:W #&;A@.-!R45&,DY&,U"-;+VB!1UK @G2PJQ3(V,$S"L$"$9P
M!C;8@0^"0(0BZ.N(1S""#P#V@QP,S"YS\4O""G PA-7E  F(6 (RYC&2/8:+
M7:Q8&%-V,LY<)C$&01D9$Q+ S"!& RS;S&A2,T?.:  @,B/)!D10@[#^]2LV
M_4J"$&SP&^WUX <^^$$1BU"$\O0+/6SKVM4FM)W /2UMZ1$;W"R4-0*!;4"
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M A*D (B>*-0/>J##:Y@5B/<J(A+-4H0?L$4&/\ !! @V%[ODQ8IY(<#!J&@
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M4JNB#N=S9+2P:,V09(E&*39Q9]I 0.XP F.',I*%=FC768]A61X3$)P%9MS
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M9 TLG#"E5[B8$*4)N1#BU2&'7"(("'+.V4E22R&%E)R:9/*!!W*^R:8A(8A
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MFM4COQ,$%;BU&KRU$.)]^I*G/]*F6'D0 )$0.7&Z?@A=@P0WSJS>[XUN-/A
MQL&:EM"LN#LE(+#7'3"7^VUQ_KU=W,5*JR49!&[@!;Z$5R.J@CDS#+ !-%!?
M\3S/CW&]77C/8LB]41.9 +9?_TR^2VFVZ<N9, \LBI6^?&/I'^I'#@UA+-Y,
ML=E5H!9J4C4*44$>1:]U(K9'!/RM6T?2"-SC;KS8Q+F)!-*N*\6>6=V,-6QE
M 2OE&NSD&]SD&=QC^#KE.]UC U51>,>=IB,\41W5_/++#2M"B$<$/H 57Q*>
M\[KFH!<^A, ""W+^YOK)95\V DN!"\, 4\G$9O1K)DK,LJ:WL0J*9WU&LX0
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MUP] 9#8$$40,X0,-(M4P 0,((%"  3ON:,"// 990(\_$F! C@0,X$ 0'B
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M%2K$. I:< -3=R@) )R$$303K\(T<"Z,P1M\X18^0"B($"B^URB.$%<042E
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M$%P$+EQ$#O;F10<Q#Q7 :T\8A51X1AF1 Q3Q(A91!/X4,-9EDEI#"J+&=K1
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M-F;R5#&@/YJ11I/ :B_R(;8I")\A=R)%&WVA%H#22YW1")2P+ONW+D*P S*
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MH%!,._PP70_.1>>+$$.PDH,+(RQ6V5YSZ44"E)C)59J3%&)8'E]7AC#""""
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M+*81B64,;5MQRL(N><B/*3(C.)#!R5#F(0^9QF4PBUE;VE*SFKG%+2JHVF<
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MFR$"*."6;N,#OL).6S$XVZ "LL&+'!<C+H)/-< ")K !CR>-S1@?ED>- 64
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MO#>=X[6$Z\)BY&*G+K "W@>SX(EC"Z%C:G,NA$,>*"6P0 *,?48#+5 "&M
MH].,D7>?F.-/Z5%0\+EE_AFR/RQZ FH!+B C*5MWH\:R"_8!&OFR7Q+ WN.R
M=J%+L0..Y1%5+I #*!$$S[&AHW(50QL1^U@0RU<0:$,N.L*X?P,C)\%2,1*/
MM1@#+AN1W#?!6_O^OXKA)946CDL5=2]KMAS0?FEK 100?V^KC=IHR'M%0$\Z
MN 6D;/TW"@P0 R1@DZB@*,"6DY$ N) ,IBX)R5):08!5E*M 63Q5$.3"J2<F
MD*4*),;##2VP+-!0,^+ZOC@S&&EA-D PNDZ@!$.@ \M**]& J.( #T^$EORF
MEE*D#I*Z#;1;N]Y2<'.)<+I[EV_'+FBT$6MT8E(87A5'$X%IA=(!)(.)O%>X
MO"H1$\WKF"6A1R8AAN]L%9F$0D<6'11CONFUF904K%DAK-LU2-X5%#<7ONA+
MT,M3$'9ZFH$1-1>VAZ(AG O\:4/SOQ-=-XVAFPV&KGPQFU_S LK0T<#^*1BQ
MM&E")V% LQA_^(=IX0(Q\(%$<7.G>)T9K'#9T+%Y>$P>@-,AH ++,62D@@24
M]2(@ZF.[1P/E!!+\ HS3$P,(E $3:[&29\/+B)\4:V4WL (?6SD@*SK8B,@6
M  -!8!1@@7YBPWT:\JXXW0$X[;_L0S=WG#)9A4LU!L4F<#9:/ M'D!2_8(\B
M@:EFA T'\=?544Y]O17/9TXG\2LF9$().<E^O!B.",+%\;_L4XXB,!>5$1G_
MVP'@] $<0*1A-\B$?#\EV6HG>9+]([<M"<K*MBF0W  S$ *5W$"8O B-HLF0
M@KBY#5C+EFO^Q\F40(%%@!1(8&Z<56ZC]5G^3^ $RDVZR^T$YI ,2W0,?>JY
M;+$S+4 #0K $/[0$0Y #P'S T- LS.(.KZN6KIO,LP4#'8O>0:A%0^A%TRPX
M"E?->*F7N,&F<$B&W:P3<92\XSP=Y<R\=%2%'K<3_\*8+S$3 W-='0?/"7.&
M-U!>2?$=)_$1;@AQ4<A>->?/WE6] DTOEE30!9VR]H6_FXN:1B=@Q:DA<S-J
M%6T<H6;1MB2)L7D"!BP.LFPS*W!TMM.:@.$SM1DS\VK4USL4;:?!.373--"Q
M+_#![J/6*! #(XPV=]04NC$#+' "T"B+,3=(\C(#"$0"&,  -#QY9VXY68TY
M&&ME.I ""B506OW^>23+)A@0NCE @W47?IN151R%TW^.=^[#H.'W>AS%)1<B
M-MY#%R@P QIA(C@$E<"0D M3M!+QUT5; P=Q#8"]*^(924B%"^X9'JL0!+\,
MP74#&W1Q:=O'K>78G4\%?F3K <;1 1V) :!- 2%YI!%PR&05:PX [ J4VA!(
MMY,05V/: #:@M[*=I07X* X  8A"5[?VR0#DVV4*@(@[RL(G!#W$0TK0!,6M
M0YN5!)LU+.>.(D7PRLX@W7@ZW7V:##"@ T<@J$Z0!$)PN@CLN= P#HF:EMJ2
M-S^(+=?RENY=<)1:A-B0N[]EE_1-1F;4A, +A>I;%23W7,A+F %>F +^[B]V
MI*K3Y<YY)%T>)S"/*8:R.KY"<6<LEX*:"00S-)IKBDG8-;[^///@9;WA*W$C
MG@.#5W0OHV&N>1DL?HBO2*,-.33GZB$<4L#A ,L(W PV\S.SI'M/4QA4(QC,
M4M3,X=)%D6*=NBX(,3A(V[$>7 )0#AM2;M02@T-"\$;963B_B6_VU@*DH54>
M( (70)\6>^:4EY\^/'D%M0,G@-6 #Z! C "L!@%V#FDSX (L4XX6?:ZSYP%I
M#1M.7+9C>_3=29&) 4XSZS5%O0,L-8\<:(\O <;;1!#5D>DVL.F_H5(D0TE-
M.SWC^2+K!B.XWP,NP%6S7ARKKA=DO:T=Q9O^X*B;L[[$[W/KH!V2:C*2I4V2
M$*17J3V4/)DGA@L*@#((-A#;-8E7S?Y .0GL$$"W/7GMUO[)O@V3HW !1W*4
M31 \OY"4&4AMPB/_1% .'EV6X^ ->=H",  (-#]+4%!.2#\W,"^,+RZ/D(R+
MD"XPEC(Q,YDSF#(SG)PRHIZ?I:4T-#.HJ:HT-:\VL#6Q-K4WMS<XNC@Y.3HX
M.CJ^OL'!.\?'/#O*RSS.SCW//#W4U3X^/]G:/T#<0-W@V=W;Y#_8V-D]/]3F
MZ^H]Y]COYM37/M7P^-;ZU=/^-CR$"!R8S9D.'C^$  '6K)FS'=&F\>-QSP>T
M>O@N^I/8$)E'92#^0>Z(H2*%29,H4IXPP=($"9<N2<B<.5-$B)LX<8K8*8*F
M3)8K@YY0T<@1I!8L6*Q <6)EB1) 3Z!(H:*JBA5)7=#(X5#:LXC2H@7K):Q7
M#ARO/LF X8)%BA,C0'CXX $$BADV@.GH(1#(-;$W9JC@:3,G70L2($2 ("&$
M!08)#!@@,+FR@0*7)U.6C!DS 027"23H44*RZ=.H,9L&C?HT L80+-3X@4/P
MB1(A1HRX"0+$31&Z;WJ8._=#B.$?0/ $\2%Y;IRZ=T.73L+%#!P\@A39/F2[
M0K\\<-P(%BN7#1IY7]W(<<.&+UW+@&%#Z%?(D"!!B-P/PF-PB.;,&??^WTT?
MV%277"$PEV (A8G@G'',@=!!!AA<8$$%%4Q  0433""!! ] (&*(#Y3X@ ,-
M-,"  @FTF "+"L#(X@(Q)K#  B_F&",##=@  @,K @EDBD.FF*(#)R)IX@,Q
MXCBCC2Z^"*.+3[:(HY0ZZABC @Q<($0102#1Q'9$;%=$F6=N9X29W97971$Q
M,-)""T451<F=+\B00Q%.%-*$$3W44.>@EA2ZB"0OP)#)HJ:,$H,GCX)BRJ2I
MK()*#:Z@4@LLMN""RRZ\F%7,J!XA\Y!78$G$SS7D?"..-N&X6DXYZ-2ZC3KK
MF&////-45(^O]^23$3736!3-#M@-!,1 %AG^],,0"^F0C%?^K(H11<2"-2PT
M%Z7Z4#+@+K-##B2=A%)*)C"U4DLL,96N"4W%*V]35%FUPKU)L3#GOBZT<(),
M0^G;0K^.()64"NY"!6]34]6;+PLP</75Q!%%0^PSQY1EUEDSN*#"O\=QP($'
M'6S P08FFP ##0PE),0/.PB#%B<HE(SRS3=CX  ""0 )@0B/1289941K=EH!
M2)NFVF4#*/"#"*PIS5EFK56]&@(?0I"!#4'D( ,+)D@W@DW-&0><='1UT)S:
M<OG&TW\"YA0""6/_%AQP)K@@ PX^"$&$0&8*<<Y9R^10 R\WH)?#>37D<O@O
M$O-"C0[I//NR?2[^YS!8<_]Y0*!Q9G,NX-H"^M;;<;ZI[<$&%%IHP845<.CA
M!"2*"(&)1*H898Y8LOCBE5O6&&./(J@HY/%&)N_ \DF:*&/POS- 8XL*X A9
MDTW>&/SV00*)09EA+G&$F63B4"81.OA-)OG='?I""W$.^HA1D,100Q"$%**$
M$%X/FFBBAK)$# *HJ$C%X%&9\,0H-,' 27V"%1!<!:8NA2E9U,(6-O!4+G0A
MLU^0*F:F:@BU-(*/O[!J5N#XAJM4.*L6:D,=\FC'.63HCG34PQTFS!4_^I$M
MBX5G!WTAR ^D\:QH=84BU5*5/D:(JHU4S(FJ"LL(1[*"JMRKBO<RR17^L2*P
M1UC"*(QP 0 )* H'SJ &K9@!#$B0@0QXH"<+L^)5E'*ODJ0K)2F82DFHPD6(
MY8!:%?/AQ!XB#&&,:QB"(L$&)M" X5'@ I"$9 9,<)V#]" _8/J&118G@YIU
M0&0<Z$ '2-8!#4   0@ D@1(4 '(#*TR1?/,TCK#&004@  #6$ 00B TI2&-
M  1 6M*L5C78:" '_(,!"W!CM\+0Q3<XD8LHU58VSCFS;*=C$-VDDQO=G,T$
M+;B.R[[D'2 $ 6;P,1POT)*7P-2 /2Q;G'MTD(MI_-$=]@D"YK23B!6@CBX$
M(I!O(.2< !$TH  :)<DV@(&&NNY"LO/08F[^1Z(') ](O9.1E#3J)!TQX $Y
M^%'WAB2DW!U)229RP/:RMZ.-L@A(6]+>CE:T4NY= 'Q(6(*9B'"^$Z )!^KC
MZ?K:=\!%'/" \A/C"S+1 R3T"0I-.((/;! #I=:I4(DZX%J.>E1%0:J!I BK
M)KYJQ@>FL5*6FJ"E6,&)HLKI!8\;53%*=:H1]G ?)]Q&.+S!C;ZRL%4MS"L-
M9TC8=N J'^NH2+#VL4,>.N,&0!R(0-+QC&<%@2& U(=B@U61C3#QLQ:[&+>R
MA3$;%.JH!<O7G++Z*$QTU1*/0$I5WM(4%<#@C*^816YW&P,V8F N_X%F3D8
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M3K"5:20$"4@80CI^40,8H$ N .J-SCL@ 9[^ 8D")+ O?F-Y&<]LIK^VY,P
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M 2K "[D&0@@8$J-E+>S0@,4F9.!0;!/H5WO%E.TP*QRH*Y7SBJS"#E5Y6/M
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M#::E K@Q:V+G8=&XA*3D@_Z9=I_$@R:;A SR'\#AELV! MN[ SQ*L"X&,\J
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M#9#3'JA $F-# E-!)U[U AS (G&V 2L  0O K?EUT/N%T)<1&0,P !A@!!(
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M.E'2X$H_1)*#+#/$P,(H++R04R^NX!", @] X($*R#@SSC+,D ..-=&D(^H
M WA 1 /A;%/..:Z*LTXTZ[PC 0A"T+,""?ETD(\^_AP44C\@](I00A1)%%%&
M#X$%T5<C:=216 ?MXX%()]0P9(4LN:2;I#_U8@,--^!@7K@V_733)3C$9 ,L
M0/[6X@]#.-64ACC^H$"51_E\A5$&&6#ET+(-.920/KLJI$%9:%7 , 442"!!
M!'$]X$#%=266F69^6<;Q8!3@<$%BB(G,6&-T038Q999QQG'&G86FUVB?A699
M8ABX%L012=QV&VX^YIA;CDQAB)YVRQE7G O4.<>T<LMYAUUVTTV=7=7>20U>
M##*0MW5YYZ$G@PL=,&!??&;'5[:GGG9J@ ,D\-=?@ *6"::5"Y((U89+64AA
MWB_E_:'>'#XH8HF&O[@BBB\FJ7B2)SJNI"47NA0B(R?YB(.!/@SI.".,RPCC
MD43.J"6<3;ZI)IQ7KA[EZF2^;J:79YIIB)EICHDZZTNV'J6 KE@2+@S^'B0P
M@  *A,!"\BNH<((*J/@RB4N+"/*?#3,TFH+2,]2PKG\YF"#,I1]HJH![GS)S
MC:S0K#_J  2 D&HXY+@_OZOHG'V?6Q*,<.L,N7XP$8, RQ_"^M5(#O:5AV"D
M(1&Y" <2<A$&\@I:'1%@P:SR@19DC@<J@4UL@&")'-2 %S;X%@YH0!/K;<\\
MZZJ!4$ZXKE7T($A :!"&;@@$&DR%'Q_@0 ^Q\J\,8  C1&R@!IBU*V,A3(@,
M:]A:)#"QR-P%,7^IHF8ZQA<&5" '%5#,8A@CLI.=[#%DA M>LJ@7RM#L,BY;
M&6#6N,;!E&8E0?#!MGRP@U^4T'H_V<4IG)/^M!9D;3I7(V1WL,,T[ES-:ED[
MA0S"L[5!=NUKXS%/>;@6-CR%BE/HPQ\[[(. <;B/DYU:P ATXHJB%.4_03(0
MEVIGB.F!KD$C&ER()(02'''H0D_94-YN*3C#"7.8)GI<Z&+4(,@UHA$]L,30
MGKD()OD -_X9Q.9DQ#D7,4YTCT-2-R&GS>FU3DAQRE(A&+0C+.E.G;"+A.W>
M>3LQ>0F6;$I=/=^$3Q[ICDETFA0F0J  /3& !"U@04'_M (92"H''/S!?X W
M0AFT( 4J@!1-4BF)$X1/ A]( 004P,EFH(,:HTK'J R0#5.%('[A$(?]SD$J
M_$$ 8B70C?]T11'^8/V#6/T B3\T@A"%\"LB&F!@LAZHD"%VA5<<Z=7!#C8"
M&-P@!],D@DM>4Y2@I(*/,4GA#'HRBYNX,"@WT($,!W&H'C3%!SBJD!!Z< ,4
M3*M76&F($/U%1(<<D0-[G: 2$8:!"U2  DZ$F,0F=C(O5A$S5^188K:(@9&1
MK&1B1%G*!H/9P;01BYUY(V@\D\;!8* U0YF!"U20@A.DUD^L35YRE..T%XRG
M:^%I)-02R32C:><[67ND;[76M>!ZC9*4W-IL&96!4-K/5*#B%-I N0SZ>6J4
M#!@!]U*IRO_(27:[<UR))C2A#6E(0A*:4$LL%%Y@AFA"?6LO,0^'HM#^H>2<
MQS3F.8G4(M+!@EZZA)&"K(FY("U32:,SYGR/A& %<5.9#.Z<(]*)B .O3IP[
MVA$\Q80F-)%SPQJ.9X;99 A8ZA-*^'7=G!XZDQ$HH'C5A:T+6( +[E7S!T<P
M GOQV-6)/@H&-(#>G$[P@ 5(8 (? '+Y0OD,9LCOI+(BE38&,((@,*"ETG@I
M.<+A26<D0'\DZ%^N+((1'L[5( 3L1P<("$"A3H0#_P+85X1:1(7P8UB\VE=&
M+/) $O1D!T& 39^)$!57_&0FW+->+[XZ Y[<1!6";N%1"#6(I[051X7 P0GT
M!<&(!'&(&&A(43'2 082K,Z\>N &F#A8ASW^$0)OD0Q<$HLQF&U&UAVSF0TJ
M(%G%B+%D923C6U2F +\L8-B;7>QFV!B8F&6Q-+:9QPZNF:1?ZC(W/F*-$<!V
M7-L><FG/40YU=@N>J@T2DL 5[M>&2]SSL""Y]", <]V]C2S3!Z7*@/<Y!N ,
M!HA *-B5&]U<229'0*Z64-&0AE)27O+N32DOH9Q3QBM>7[;WX.^%+^+0F4P#
MT_+ 2LJCP_OK)$50,T@$:C#C[AM?6J)\P<IDN8H0-"*5LTZ<5KHPAFVGX9RC
MR4"H(Z?JJG0EFN]SNY,*3C!,I0 2(/(%,%Y!3GS"B@*]PA*_H,%I<Q$I( DH
M!0Y@  4N  (3/ #^I,[M%#FRD0WUJ:]4!#"!#Q0@OTZUZE4GQ9\R($:!$P1A
M!_XK 9@)5A5JC61:^RA(0I:JUX$ERR'-"EA$Y@R"#CP0S,MZR =*(%6V!J'/
M+#G4#L*U+A3.1%PHI %/8G"#$@[E%:H8A X*]'JHZ+*M*-%A"#2"YXO@]=1%
M[;VHN2+Y)$[^U()-]00>YA8IPEIE<>1LS3!P PQXL62Z'J.KH_@ 8%?FLQWK
MOO<%LS'&XH7911@"#Y+@!"= 0?WJ7[_[T_^$],N_"4U80B4M&<E!2BUJ2^-V
M=Z@V;K55;L*5'L1E7,-E$S"P;J%$/Z;B@&QC-O4A*NYV/N9@  L0 CW^UF_5
M)"=U(W#;Y"#@-5X&5U[CA5Z;AW#C!2%ZDU[M!3@@0CCP%5_HE#B*0TLLDB#^
M)0E#4R&]D0@G47X<J$SAA#@&]B*,T#@,YG+@)&$5EDX8MT[GU'/OE'.S(R0=
M5CNN=SI7F&$39C>(('0A1G2^( O@XVY)!RG-T0(JX *#0@@Y8V/1%!02I0(M
MD!V\T#V4D */80$:  (E,'8'$%)RAV7@P&2E4@ GP ,)$'=6=F77$('TYA9Y
M!Q,QL (E\$-%Q50&-'C_,"R&MRMYM4"BF$!<H4 2T0\646K.$GQA!P,XX /F
M!1M0T4S796@J] N[8#T*-6AF!20Q\5 G\7K^# ($\\(4$/)Y+$ MR](O0Y0!
M1857S^A 8%$1JF@16F$!JO8P;?$6C^%JRY<Q+&-%@Z$!-X!KTT=98209UW=9
MWC=LWM=]&Z,9:R1LH*$8HU4$0% $3K $2) $_G@$2!"0 HD$1G $-59C1J"0
M*P$>OP5N4Z-_A]0<$ F X_9( TB !8ANZ38>+: !"/!N#V@JY9!E].8,[]8J
M^$8 "0 "&JA*JU0F=',Z/#(Z>(,2*#B"(B@A#5<A*<%+#[<4X96"'@(XA5-Q
MQ&1?,5)A*L<BB[!?;M56T<0Y0;@;OJ&$*G),"'8WH/--7>E-+!<O\?*$1R*%
M+9(@9KDD[61SM_/^8;DS)B!F3OGTA>(T.F>I)7-"AC5@A@1078>TAH+$"S=0
M5B<R); 0'"ZP G:X"^OR"O^QAPR0 1T0 B,P=O7V*9Y"4H789(BH CJ0 .!@
M#NY3#BVUF?<1'ULV4R?@ S8  Y=(>7=F08774YQH+(<'9[W79DJU>([W0+\B
M9Z;80'56$B>1$J_1$E$!/>22"J970C9A+C0P"ZN@"H8Y*:U$"#O@5D$P+[PQ
M0SB@ I$'%KGI+\^(5P.S5P%39TJD:1B0:D/V,*S6:\MW&0S ,FW$ !U  Q/@
M19)568[!CMVH??'86)?!?>,(6J"Q  R0H#>3CTC0!$=@&[;Q&JW!&JS^<1KE
M-P0Q "F&M'3_)S7BMFU8$X 7V9 9.5OH<7_%A7_$\9$A^8"/N#[R89+1-4KG
M<($MV3W9%9-J,I,#]R+@Y4LZ*8(&MWD.=XSFE4LB@H(P2#@Q6'$&ADZ+8TP:
MEV""@ .YE"/^997E]PK6]#E(HI7QU4UB.J7>-:;>U A+F4XX"&&'L)12&'.F
MLX7W="95Z)8=5J=K(H91F" EYCJ(0G4G!&3C,%"00AUKV(93I3F4]E"R(!PO
MIARZR)A%P74-L $A$0)C%U(B57<D50W5D%(%P (XD'9K\U*;5)((@'<IL)HP
MD (C('F2%YQ E6;_,!"8EIZVV14)HQ6]5T3^"917I,8/DC<P;Z8/)V #A* M
MYQ4$OV 4B883T+DU*L0+HJ=Z5&<) )(4A7",\[(4AH #+4 "5^%IY.DO&/ O
MGY:N R-GO?(0'J 5%^ P$,,6R5=&E35^L@9'C76?-7".^VDR_LF.<0$!P*9L
MHK%]C.59^IILH2&/HD%^0) $35"AK%$;IX&Q*S$$$7H::9A(Q)$TV&%;A!0U
M#UE;^6<TU5%NEI2B''ENZL8!"7!O#CB2):D.HE2C%I@ 'Z"!<3,W'D@C9FJ3
M&4*D15JT1NM6(8BD*8&TY:44(.(@?5.4Q'2#\B4Z&#=?+((2>72,?Y.U #8$
M1?%?#3:#8YI,BB/^7P/'36C[E7"Z<5&Z<6AIEVVR83='IUEHIU@88GLKEP\&
MAC09M&UZEX%J X/*EU$5-2V0F-O3/6SU$M,C"<$!'185F-V3 Y6Z 3[5  E0
M;VJC9$L6*J6I#07P C?0#HUX/YWTJ9Z4 *Q6 2JPFBUP I%'KJ &5/J@$)Y(
M$,5B,+:Y$ O!J^-91*;($*!F+,/B :080"HP"1Q4&]S" XQI/3AP Y%2>L*Q
M/:)W":N0"C'!4+]Q*#H0(C["%'A4BS* 4[SWC ES5[S*OL7;$+TB9QN0$%K1
MGH;5C==W,8GQ?=Z7&![@KQ>#&(G5GY9E1ATCC^,8CE:$L XK&K*FH)#^24>J
ML1(0JK%%X ,XH&$ZD KEAQNOX;$>FS3&(;*&=#7\UULDFK(AJPL'2!XN:X!?
MU0(Q&YHT>S\QNG;KX&Z=\%()X % T6\#0COZI)1X4W D2*1,6Z0E:+0OH10N
M\<0BB#="";5'B94U6+8K4L2%D$=)JR,,PCD]$K8"!FTM%Z8(AL9*>7%<N;:?
MHW(KPI3^Y;<,,CU/*+<\FB9VZG-Z^G,>")>Y\X6 *W"><Y9D0G6I9[@*, (>
M6U ML N"N2Z FBBJ\!//<0IXR)@YH"D-X 'W\ &:6G:8:8B?6IK150 \=KJA
MDKJ'J#[P80VM"P$4L (]4 .R"YX,,:M,)7C^G@@0OD) R8MX184!Z#K,Q?J,
MB7>>#[0/IY97S)A!0/(#?J9+OP-#.[%H-($N+H1ZRJE'(504&EP@\P4T0  )
MJN"J(;! [$O,YSJ>Y/EIP2>_"+,![#FO$-.-4;2_]&F@_OL!,S !4Q1&ZEA9
MV,=J >I&;;0Q!4HS!^O $8R/0."@1W"A%?H#,# $28#111 #0& $%JK1NK5T
MS5$<(OJA'QMNO;7"(XP=!=BR,&Q<E20V,LM<-,M<FYG#\?&B-NK#-Q'$.UJG
MGJ/&41NUZY6"1FO41<N#?#,XX,6T0RTB(6*4,IB5-#BE< O&5PJ5CSNV8EP4
MA.!=5WO%,TC55KO^8%D)ID5XA/,5MP>&M1_XIFAIA3ZWIUE"U^ID.H_ IT3<
M.;/4IR.&)H=L RCP (2ZR"G[*.(R"3;TN$XI0C/P'#&P/;U@N2L  0X0=OCP
M  D@B!7XN=#@J:N[# )0 ..1#3A,#H084ZSK%A70 CY0 RQP I1'C6!A,-3"
M*\&"O+RL1!F1%9TF1,/<+\#Z::8(9I\VBD0D CWAO%>E&Y/28R?48R.D"LSY
M$S5P XPK"T/A/=?9(D_A(RPB:-1A LG+ONW\V^8=003S+/.; 6H!,6YQSP([
M,I6AS_V;&" P __Z10 M1J^&?=D'C]V'T 3ZP,$6&,0V;#:S$A"]&A3^6J%!
M4 -%H 1&0 -"D+'E]]&%]+$@RJ&*%(#@@30CK#3 -5O8*QRF=^(O.UMATP$R
M3;.=X(!J1\KQ\62B28'CD  <P--Q(S=6^+>/\[;$I%X/=]1&2UY'CN2^!$Q"
M'8/LQ5[#='%I6X-=&;U>K-5NPM4Z4,97:2)6NSAD:M9EJ[5>J=9:F91LBI9[
MG4Y[C+=WRX5\ZR2O!.=>&&%R"X;X)4LT B=&X0LU@ (00-B']&)VF&BJ "2P
M\#M!P1,CC@J232<L $4A<&D<L+G9 "J7:7:=!('HXVX&4 ,PT Z<O@SI@#XW
M?38*X!86  ,]0 ,M@(G!"F>Y.A8]52P!,2W^L9HL[*L5Q=QIGU:NHBA4G9;.
M>>4!F >+]?(:?^T+1B'9J4 N-'$#YX+8UVT44P4+0<)0:?42/K)YS21"V"&[
M)@ "#(&NXUGNY7X!O?>[!O&;"]'>;6'/ET(Q%4/O\SV@QI88(2 #^KD8B)%]
MV<<8_RWO!9M9!AW@H7%&!]U9] V9'4UC36 $1!#QK5$;+$$#K*X2$ZKQ%/E_
M2Z<U6F,U$ND=*/U(U!'BS+'2Z;$U*+0+QH6]*KXU+N !"T#3,%[3HH+S=2<-
MQ3/3Q3,."+ !,C!5/2V30 ?4:4V#1\G$1;[$FZ?D2KZ"O]0A42U,45Z$9I[&
MFV,#/9FE1,(YI]'^U6%<U5!:IE-=Q&/_35%:U6A<(FI,.D"M367).VOBYK4C
M3G4=EW:=]WYMYV&Y(WFNYTO"Y[*@*8&^'4C38]44BS!")E4W'"O-N(PI"9#^
M "&@ B) Z9QK#:[BN<\0RM%E #CP C>+Z2(%VJ?/#BCENC/P S:P B, KXJG
M9N_:NW46$KS[*VEF9[TWS+WO>T?4+VW69EGA:<9-1!Y@ C$@OBCA&DX<O64%
M0]"M"JAPW==\"3PM%$:![5XR(D.@G?/P&XZ]ABN  B4@ J$VS[T?6!=0S.SJ
M5[&J5^U= ? .GU%4,=/W6?N*&?D. _HY,OX." P,#PV"A ^($ ^*$(+^"@H,
MCY*3E)6/"0J8E)J0@AE$14!'34:@I46HH$$X,4%%1$-%L42P,C Q,+FY+S O
MO#$RN+:ZN[HQ+S')P,FV+R[/S\XO,M0S,C/8U#3;U]?8V=;6+A\+ ^8$ @/I
MZ00%!N\%[@;R\?/SZNSF P0$"!LQ-W+@T)%#AXX="'?P6,BPAT.'/B+Z^.'P
MAT6*%S-J!!*DH\>/'3F*!$(2B)"2)7^05*D2B,65+EUJG#G18LT?$W-&Q*E3
M(@\;0D[^$&+3!P^C/F+MT'%4(DZ>.VU*S2GUHE.J/:/JY#EUYU:O5RE&[ %V
M[,2'/1:F=<AC;=NV.]RNE=MV;H^X<>NB?>C^@^_>OSTH5JS8EZQ8M(73ZL#!
MV(:*" 4(, A!K 4+%]=JW!A(EB$/@C9H'(,A@T8-&SARY-B1PX6$!R-4B-C0
M(($] @;XY<:=^]WN=[R!"S"@0P5PWLC=R?/-_!V"Y@@00(!@888/&RU,>-"0
M0<,&#ALZ=-@0GD,'#^+%>P 1 H1[#QX^O/=@O@-X#=PS8-B/(8/_#-^!UQV
M )*W@7_>_;<!?N1U<$(-1PU%!%$4J<9:#:EM<X,-,]AP S:FS7###31L=II
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M-WL37N21).^5'N&Q'J:3-O3$@N/U'1L0@QD7)#7X(SD(<G&#DSC9'WOC 2I
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M>5H$D1HW4+(5E  >H++;YI 8PAD TQ:@$4C^+]5;+\L8=XBS+! ".QL=W)N
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M.+^(G2V7RP%T#>B6;CCP A: LSK+LQ0HHY(DDC8J 4=P 9U4;U&3M$W\Q!W
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MD>+$B.7+0XPH$<*$">4=Z,[5@-WM!0L4)DB \.!!@P8,RILWKR"] @;IRSN
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MTFPJ6,$*T(:=PVC@,(>I# 4H\!T!T8<!L=2;@@JDMP?P;0*[;,!\[+,?"4@
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MHQ*CHJ!,(3#\N!4'B4,=VP#UAW\1F7\BFVW^_\<6:1%')6HR?F1N=X2 '*F
M&]. +PIO,6H9@\$9:52!I-! *ZF!&]AO\O0SA90D!+<:F:0;T5BD)GBD3[.D
M/@F4?_HW#D:&78H@LE07NI2F6#I?3>F4V3&#^T6#&=$@7QJ6!+81/D"F==.5
M8E--]>%*T/&5-)<W( >G: IR0.=>#_:V*;8Y-;(<<2DX5+=S*F:H+NB6WU1,
M54=.ANLY&=8A;BB8(=  "#!C*L 8B:FBOY6!\2!=_Y"I">B'K16(&F "&,
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M \I(>]2U*[0W):6A&SGJW<3"#B4V'1@A!/4<(+ZA&C%  N4,$/'0C>@,0#2
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MBXPC\_ D,M#HE9P"M65;B9%'6,)<IE$[HHV'LT/*& !KH0Y1A]!1I$F[BC@
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M_\_'/W\""0H\Z..'PH4"%2;\ 00(Q(@4*U*<./%B1B$_.';\$:1B1I'^0(*
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M\!&1,)<(SCUI$@H8736O>4T&)( !"D@ -K?936UB<YS6/.814J&Z3W3)2Z8
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MG+V+C$FSR]:)G:\%K4!S'N:1'76T:\OK'1]@ BD@ ^B';=-<C_1L=;_B$D0
M$SUE;X]W22G2#.F'2S'2<](5#P/B#]=%"@&2OC'1-]< ,#5 O=)MSRW^ +^K
M#!A".DD[4 ,(BR,+"@-BA- 0V; 2> @/2TVD(\$8&. #'L$1C7 E<#<^8 1/
MX 1-T 1,L 00W@1.,.%,@.%+(.%+P.$<K@0V.CNSD]+ D#LLS=(SR4]_$J,W
M">(U30X\R0P*A=,ZC"@_/5%!9^->HSW<DY2G1*9&[%%)C+0AQ2GC A=.9Q5C
MH1'ZPU)LS4!N9W>HLBMO5ROW Q5@)Z8208;UX+5.'BO'<A1"9=5NV=9\-BQM
MEQ1 @12,24%L'L=R)K=P@:=;=<?ITRUT/E(9!'>+686+61:',1?O; &,P*B*
M##",+ P*DHC8H(]F0J,JP!X:8,F5QKF@V#'^I;B*K:D"-Y"ZHJVJIKRJI]Q%
M"%#:KNL;#+  JET)LCO+K]T<,',!L3W;-!.\O7IK2,,>Q3>\&] !/L/K')!(
MRF?,PVM:T'I:#*D",G!MU]9=W8I=H'!.&UR?'UP_,1%)B)&(/R<AX- ..&">
M \(N&SP$__,0.0 P%;*_-@ $%\V?BKL"*^"J_;EON911@%8!5/( ^8T!$&HE
M$YHY^?7?B%#!&VK! PZ2%1N2%]L )G W/2#A=^-*KK0ZJZ,E%'_2+2DG;:+2
MNC,-+*W"N^/"MA"C,VBC- PA-4>SS4!BG(1SB+&S1>F.0+P],H:DTS9MX%-C
M2+QT3(>TXF)X;$'^*F>WYDT.*U9.M?"S=6SYI<@B$O HMA(!/AL<UE&;9 HD
MIFSH/F&[=E#^MVJ[UC!%$E6H%( [=W8<QV*%F'LW0HU)F#XV>-:"96G:9'X-
M$X!N#8/-"(;]3SND3X-Q#=N6&"[7#)!> 9(>R@R#R:!*6*"J::W) C3@Z2$3
MVJ+.1:M*Z@_0 B;0RHN@ZJO-ZK/LB[3L'+$NG,TQ?,&+-,*ZJ[4F'<:I'=UA
M[->'']:9,SNC'1XP BPP#<G=7082(_RP[IQP-T4P_*_D*NT0CWLC2=X^7?_H
MCF'X->NJ%/%C"BV5OCU0 [-0 RZPOSD 3T&  P##TOQG BS0 BR@/.;^%H8P
M@# **G RT $4,)$'!Y&0(X$5"N 8.=$%/O 4>[$5# @,@H(-(TA%/4Y)1$6-
MC$6,0T1$0D)#DI*31$,SG9XS,C*@,C&EI3 P,:@P+ZLNKRZHL:NHIJ6DHJ4S
M,9TQHI\UG34TQ,/#Q#8T-LG+S<LW-S;0TS@Y-S@WUMDY.=4XU=SA.3KC.N8[
M.N@[ZSL\[3SP\3P]\?0]]O<^^3WZ]_S]/@(*]/$CX(^"! T&^0&D(9"#$(4P
M?+@P2,4?%H,\Q AQHD.,$BT>;"A2I,.-/7(T%*+Q(3UYE>!!?'@22,F,-BV2
M;%GSX\:%'&F._#FSX]")# \";3B3:5*C!Q/^_NAAE.!!JE [&C08=:I7A 41
M#MPJ%6)&I6@YIKT(,26V9"HJ,&A X82H4#)@Y%VUMY4H9=^>V:AQUQ,Q%1<J
M8'B@P( ! HX?0R8 67(! Y<C:QY P,4,! 8.:,8,>G3IR*!+GT: X$$$&" J
M2'C 8,&"VH(<.&#@X &$WQ,D3*@P?(+Q"LB3#T^._()SQ1@P5+B @?H%"]4M
M7,^@(0.&#1PVB._0@0/Y#1HX<-# OKUX#>@S9-@@?X.(%BL\P["!8UF.&CGX
M4XD01QR1!!)))'%$$4(P* 01\$C$PP_<K*//.M_TAXX./NC 0X<.25*$11))
M!,0.,\ P PTLN$#^PPX,_E!#"RVPP,()**#  GXOS-#-#C[DT (($.@VB" /
MS-#!!@TT<*23O#4IY0,-.##E UABR8 "6W+II2 *?-DEF%N6J<!M"YQ)YB +
M.'""$48DDD0CD!0Q!(,VG.##$#?,8(,.ED"BR2>@C(*7+:?0 D,LL,SBRBJV
MX')HH;P4:A@QF!93PS#)**/,,ILV$XTTTT#SS3;BB ,...F08TZKK[+3SJSP
MV%/////XH^NN^WCUSU@"A=651S0!8:*Q$X6$444Y+0L2LB>QI%8E28F$T48?
MY4#L0_&TX\.#/DS8U$Y*5<0L3B<]Y516[ [;;D<4J87M4]6F!5%95%G^]=55
M'6&E;U3\!$S0K\%&Q96^07!E%E ,+YO16<YV",U@<0DB@5UXA<(7I*:$XN<S
M@5G:R6$6*/9  HY1IC)ECQ50 &0N7Q8S9I@-8$ JIZ&F66J.I:9:SP:P!EH"
M6,+0@6\0U&:;;;GIAC1PPBVWG'+$35WR=,XY)UT%VG4MW748>%<?>.!UX %Y
M'H1G'GKMP;=!=/3--UY^+>PG2G\VA%,0#\8V6,012 1>(!$%%K@0)03!LQ!+
M/J"4PPX]0 XD$#UH% 0CE%1B[$(YY)57"R_8$,010NSPP@HLI)#"""244,()
M)[P0P^,?XI#"T;L=R4"2&UQ R%QS56FEE5+^%D]EEEJ2Z:68RR]O9IFW"<+T
MF4RW:8(1B#B!Q)V-W"D$"A2@P C?;EFBB1">9&PH*:JHHJ@KL,CR/J(9D[)+
M_2+3L&(Q^V/*S*>#<<8S2H6-4W7C@*GBAC?*$0YS/.X<ZF"'.^1Q*USA8U?]
MV,>NI@*L#@K+(TF1R ],5"]S+>QAXV**LD3X$8?YY"':LHD,IT+!( @A7/ B
M25 H\K"'S>M=0(3*1I RE)H 15U#Q)82#::P?'U06 :YAU@.QD2K%&PL3/S@
M$9UUDX4Y2RT6Z1 V;E"#BC%@ A@[E,84U;$5\6<9U;"!^E8T \10  ,-0-EC
M)+,R L3,92V366;^"F"S&+@@-:+AF6E&$[35-+*16)(!!G(CO:5%KS=/^TW4
MJD8U3DZM.=-13"BKDS7G6$ [8<. V]3F@;.9K3SAH0]\-*#*[G#G;>+90 @6
ME1\Y^BD8W+A!0ZC"$K\!KG &.M""@L"@QDV($I0 0B.H=1#(?2@(/+#(G29A
MN67Q0(ZHR,_L'@0$&JS@!"8@P0E&(((1C, $)VA!#+PE(Q1DP$BZ>T --% !
M* T"2DXB7O&:=+PL^3-,@VA>F19J)BZ-*7JXB2AOWH2()QQB$MT; @U"P -)
M9+,'0M#!#3;Q("(0JA-W89\M4D&+%S J?HYB:2H0Y0M?>*Q2'B.4_C+^18-C
M]-13 '1&J:AQ*FQTPZC>^$8"876.=*S#J>N8X#LH:"M=Y4I7^AC8!K'(U8%L
M2RC%L@E'& 8QCASK6#Q<G$=*LJV#Q! G-)2'#7VP@Z*0ZR8]-$E/BD4OL :Q
M76&-UT*<0MB.;%$K6'%78A/[+GV 18K!2@A7JV(5$UKVL&@YHAA!Q0*Y,.!B
M*,4+7_;B"YU*HQQR_,7(ZG@!"ES@9"ECF<KX&)G)#-(QA#3 #%K FJ MTI&/
M]&UO5<.:!T@@!A586NX< %&G_>:Y$H! <*1&M:D=!Y3)20QRL".=DIU2.[<T
MCWHV\$H.G&T]ZTD/VV:IRKC!AP2H:($+4FO^@TZ, P<$T0%#B&E#!A'.0$=X
M1(-N*$(Z06)!#V+)8'&8S4PHF"D+D2,+9' ZV>V $CA@P0I,P$X.BR $K#N!
M9]P1$!B0H *[R=T@(( #53[I=P,-WI601QN$=DE,#053F!QJXS0I[<=,<Q/V
MY(2Y[@&!;^8C'^4"Y."3_N)0II#IHQH54X[1U*:ZN.DH#-._&?CTIS\%E5!)
M14 #7@.!J5J@.,A1CJ?*2AT3I* \7G)!?V108) -",&RZA4K5I98'2'A"!W&
M18@Y12,@*=%8R;I#$,90ABZ11^-N."%]0=AA>,TK3UKXU[\.L8@Z5)<0?0*5
MK7Q%*OSH<UNT0A;^L9Q:*K N6,(XHA NVAJ,%Q%)AYI11L]*P 0I5:E>5/$"
MOZBV!N!0( T*0\<58,"U#6A,RB2S1\K(#&9^I!EN;6:#%?P,:#SK+;@5.=R@
M)< !$H#!!&R3 (A&KTV]>2X$)!!=>A_'.,7)=]4^R9SD5*>[6*N.W,A;'H(O
MR6SH48_;9+E>6LZ' RB(Q0KL)HK!C.-Q/?#0#V32$")8Q+\C>M (0U),1@0X
MP V:A!#$:M9+$.'0"^E!BDX  QO!@ 8C[ $,4G!.$KR3G1\>0<1M(!,>N( $
M$E#QD1YP ^F\&* #C3J5&I"E->W8H0UM'D)[C"8T2:]I*$ "$>3D"(S^ZJ"<
MJ3!'#S9U Q_<H,GI"VTH:KK21<%O4?%[WTQO@>7UH?2D(R-&_Y"QJ1H$4( 3
M&^HUC&J-5245S0XL1SH>V*JH6IZJN+(@G:\:L'WH66# >G7! *UHI*CUBPVS
M%LP#C>O,ILNM#-'(RC=.06/1U=(Z9$L/<[+I=/$57DF!\+QJ\M777_J'P[]6
M5Z+8Z6$I[(,"H4JJI^A5??D@C&-=UO6[",9;%T0';ZD!"R;Y66 ;:N^B;85>
M/&7X:I"C/X7ZRPQ6T-H+-* TD^%C'_V8&=Q&YF4&@ ,HX#/@QDC!)30%*#0(
MX  0H&X)P!KMIAL0Q1L,F$F:-%W451Q58V_^&AA*_:9=I!0=<J,>Y&%>YV4V
MX:%>\+$DL\0>Z/$='Y ?,% W@R$#H)(#/-!4^N4.R3(5E&!#)$(00I!-BV,1
MT&0GC5 @DL 2'A<$0P!I0'!]!7$#,+ "*= "*: "+X!S/T #*6 "Z<1A[ 0"
M(> !(! [&$<A+? !1J)T#,!BU-$D_P0\=!AU!$5U6!)M5[=U>S@F7[*'7&))
MEH0;;8(" =8#3S G=3()-C $-U<#,, #7L8#-0 $,: ))A5WP29LBO)2C6)W
M5=8^'6-3]9-2)Z4_@5<,898,H8)XBE= &7)4V9!L1\4-KM)4&Q(KLB)GF)<K
MFL<K6)4/T==!U5?^:]>"+(.V$H/6>FRU.+.'+"MG(C:TC&P%:!0R0CH1:7)U
M0W4%?'G%>[M'$N*X5SK4$^?2>^1H1".!%'Q%%)]V+_SR#T\4%E:16/\B6=%W
M%7Q&?88EA;-6$-68:XN660LA,:"B N07 250/WJ!"G?!"L7F"SVU#$\U#O65
M4YW@;!-@ ?>G?Y4Q&3!S&02  ("D;04@  B0 R80;N$V;CU#7 18&D1# 3$@
M 0H@-.U&@;F1)="E2?/&@5*#;\3!@<1! ?W&'->A-=0!'VI3@J]4'@4G7N.!
M'N)Q2_5Q'Z 3"\O@98-Q ^CP..,0.=TX:%0!% 21,-]B14!13)5 )X#^PR"7
M4TQ0V#@_L ,T\ *P8P*OPP(PT ,WD (^YW- !P(?$ (?\ $F$ /5$!!E= 'X
MI#L1D ,7H %T2 AR*&,#-74%56-^F'4WUH=;]V->\F[2XP!AESV+L(A%\'8P
M<)@X0 ZD4(DSL F30"A/!F519G>@2&6Z60M[US%J=)M;IE.I"&;'$$"&-V;4
M8"H&I&;A\'BV&)T[ )8;\F821%6;YXMUYGG!.(Q=18]6P13(UT*Y1VC,\FF%
MI6B75A*^1R$]0!*S]Q+P((1UF4/64B[@:"Z6PQ,ML6FQ]T*-1D3B*6JKEWR_
M=Q3.EQ4# Q7VN'S+-S"2545E 14)4Y"7E7W^S:@642%2_5%&"4D"FY@HZ5=L
M,O I2O6:.X #RZ9:\]=:<H%_'CE;+P,SF'%;!C  "; #(U!NP@4TJ%%N/#I<
MYV8!-:D #X@ "9  E,0;/"EO/0F40FD<]#:ETR4!R6&EV44=_\8=ZA$>YV$V
M9T->;"->KY1+M 0?\S$"+K "\F6#.! J*T(.?\(-]\ A&[<W6E%I$3HAYM(W
M)G=,'K=R#=$X-!$0E"@#+4 "(1 "(J!.+Z #,N!A0/<!2[(!A!D"=L$-%"(#
M2.>&92(!DDD!+V:9EVF'5^(DSG-UG^F9@&@;@1B(U5.(AX"(<X)1D\ /J< "
M1]8#/54#[D )0X#^/K99BAN#"L7V EGI4BYPK&QT99)2BGCQ=X%'1ZK8JZ%2
M>*(2#:\(BP>4;*N20)+W*KKH(>G BYBWG9R'9\(X$+^R9Z;F>WO%CN0HD.*Y
M$SIQC.-(?!NA7PZ!:+8"#\@REF:Q5SKQC=V4:ST4?/32?'9%:F E%""TCJPV
MCXS%6*L&:_>"CV2QH$[45^M2+3+$GC\A?/0B4M!@3AC 7!!0 I7"=Z? "[F9
M"CV5#5])#L& D1J)8KV5?_N7&=DV,X!$2 G@ R,@&D;KHRT9DT#J&"B#  Q
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MKXYR=S@,:)=[%U\'$L32,N#PN1>Q1'/H 2=P BK@ B>@ 93&&KK;&@P  B]
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MMQNZN+H:&QR\P[S^&L8;M+2WR< @+#0R+3 PSSHW.CLY.SX[VSP\W#T_/#]
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M&0ZAZ1 ;.0XNYZD0EZ:3G(XYV- \C?C4$-6JK1;D.JT&D?B K CI"LL&'I!
M@@8/F%2133 Q\! H^H-6228R0)5,Y";50F!-<)) F6SD)#-  A%^\*W^JH2K
M*$4H0A"D,985N 4$4ZE*O (W+[7D2RSZ>EY97N25PJ5E+3!<B\'F0L,:-NR&
M-_3+7P1#L1X>QF**N5'&+F.9CD4F,R'SS&=$8S+2./$TJE$9:U;&,IA9D4'S
MR1IVWM,?FVGO-]6!FWVH([<,X<9H1&M;:\##- IE"#W'D9O.ZK,?L-W'.G6[
MFAUI!A^P-8<=$_K/R]"FF][@AFT!*F2"%K1(0U8MB\W!4(: IB$>+ 8P(8(
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M1Y-&N&5LD,2++M/^#J]%2+P86P)25["1&LUWBXSI:L<HBFED?7[AC-*6 2T
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M%A.,44 "(-L?;D VD\A(C&+Y.PW^?H5$EK ,.<K901&$(#/I6(<(.4""$)!
M1B$D85U&N $1?O9%P,0'/,P;3WONZ#SU8.J.])"/?*)&M:G%(#_[X0]_O/8?
MK]$@06$3&X,<5#8&20AM&KK0VC34H7*Q+9,B,E%>Y+8B&+5(;SW 6REKA,K)
MY>UV>PM<X/JT.B5]3DBX !/I@)064BR)2:9;Y24JUZ1A=,D6BR.%*:0Q2\\Q
M3AJP&)/N3#>E4:BN3VA2'2]<R:9 #2-VR4"&[P '*&9$PT='0M*@DG%.0OG'
M&R:@P (80($4##+^/_AYE#R2ID<\'LT>TU,!]?*A G<&!'P'\9[X1N60AQ"
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M 8PU52-.U\SF-E_WIMKY"!N DQTZ@V0-WM7N&'0JL.U\H(.MF0,&)W G/$]
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M^%SIS@L)9>;RF>$U$S5XP3LXR4G@^R7&G;I9)Q[A21G<_/:Y=7F+YB(\$IW
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M,> .<Q@# !+2-,#^=S40 V1A%O"B(<^677W1(5!6 W 1TV51B#?\%VE& AV
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M[WJ@M9UP]<H#ONT-!_M.$*#-R:/'9GUA<)C<$"OK^;L"(?  _8N3,N=RO3[
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M0 BD#\QH4SHU#P\D-CZE*V F/=WQB#U59F8&>)08$;=RFLS"FR"$>")D3C3
M>%:%0E#RB=Y"BCP@&JV2<B:WBK'#0,GB"2"1$E#23CK0&$<@+\?90ZC^]WK/
M&6E,8"_(JB_*^IQ15%>]2'MM93!)P!IW02N!@5C,* 2]9T221B_3^!>P9HW+
MYVIQ]S//YS,G$S7FFAK<Z%F#]#/#!FWY"%NO16S"L2YAU'W["FSE.)]*<35.
M@UK'EA0N%W,ID* )L* &^8/7\Z!MTPA=^C8.R6$66CPA  'OMS>MM$J%NFX@
M*J($T %"\  N=6\(L&_CE4MQN%'HH0'4)*,T6CG(U($S:;,-]TP/-X(59SI
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M7C);HY6S3!HH7SJ:7SQ*(Q$78/REPST+M-:$ 2!@M*L @SP7)K)S S3@"9V
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M [/P/HCRMYIB*9QRUH")LO@CJ XBD@$R(/J! 7#! TGPN/H0#SMP!-^I T'
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MPX<)%5RHH8B"OXL8,_ICD)'COH )#PXT8,"@0(0'#I1$L+*D2Y8N#10H0*"
M@0U%AO!(LD1($"% A?3@,4/)DB- DO@ HJ1'D)\_A32;ZJSJBZM8L;IP@17&
M5J];OX*E2K8LU1AHT<I8*V-&V[=K:<R8*Y>&W;N_BMG8JZ,'D*=_?_3^T)'C
MQEX;.7K\"/)C<>,?/A8+*4*$R! AD'EH5NR#1PY?=N?.)4:CAFBT=.W^0ORC
M"!*>2Y8H,1J[MNW;3&(SR9U[R>[;P&OW!DZ[=G'92Y+P7*X\MO+G28+T 'H9
MJ. >/K)/+N+Z]?/9X,$G-PH;?!(CE'T"^0%D_>/VC=M'=N_^<>/(]B'?AQP9
MOW[!V?D78'\]%&B@#]@9J" /!6[F8(-#03@4@Q%.&"&#&%*HX(8%(N@AAQMF
MJ!D/R,  #0LJ;,! 2124H,*+,$J#@CDTTFC"C21H XXNU:#@8P<."&03 008
M4&21,\DD4Y)**EG   2<D(,"(E7)TI4B&9#^D)8EI70 2PEP.5 #-:"@P06'
M+ ))(VLBX@@ED32RB2:>=&)G**20XLHK>H;"2BNCP.(!-QYT8*@'NH"P@F$T
MX+!,,C?DH ,.>]$  S/0K/".CRF4(,())73#30@AC# -CB2<H$X[,83U(@LL
ME%"H!AJ 8.@%_.2JCT,(G2020P\-!)&P$#GD3P8T*"(!1@EHY.Q% /W#@*\#
M'1"2EE]6F=)!+W&+)4Q$$GE3$4+P,!MUUOE ! Y)*!$$$4$@Z-,.0?TDPU0O
M>-5,5EFUL%56804<<#,NF#55#&4AG%8,;#4\EPPTK"4:73/<5=IAD>[P@Q"7
M,;9##I3F94-?C.7^]Y001!1Q!!(L'W$$=S#GQ-B(Q]0\XH@Z^%*#,J8A?-6E
M.0AA1+O!%<V;;K$UX5MOO!W-M&W#Q7:<U%+3!AMSR4$'7;P<#V&9$.X%*#1W
MWK&L]6S*B?==>$FPC!X10 &VWMSQ_9???O_AYY]] =K=7]_]\9<=B!(:B"&$
M#VYFH8,97M@XA1HBJ"""&'JHX>$WUUP#.RANL !)+<*H@HP^UEA"/#>:0(+J
MJZN>>H\H;! D2^(>V>1,-I'$I$TT$;EH2%E:N=)(VPY_T)=AGO2 #29P@&8$
M;CZ2""1N2K*)]==G_TF==X;"9YZFO$)!*JV 8@$(GGI :P<?B+ +"R#^S[#7
M##7D8#\/P2SSP@PQI)!I"O% 0:AN! )=?  $(0!!/%*5*A2H8"LKB,$+7+ "
M%+3C!+;:  9J=:M^\,,?#0&)27I5I844JUC"(E:S-""#!C3@ 2!LUK.<Q1%H
M<:0A" &3M:R$ "\9CR3<(@E)PA6N<1%A!SRYC!*%D)TCS 9>1]#!#HX F2 ,
M 2HPN!>^\L6OJQ0L+,Z8H,# 6# N&NPLS5#8PASVL#9.[(T00PR#V!,4^/Q@
M!R&K6*,2<[>-;6=E6FM;R] #MO88TB=Q&X+74H:9Q_  !S-HQPK0<2D<^& (
MKS'*<:96-.'81FE.\$TGH]9)Y!@'.>0AC];^6!:ORKCRBOD9 B&-0$LCK(QE
MN/1.V\YF'NC@TF7HR4EU@F#'/O+MF/K)SC&5J;=F_BTRA%N0A'C0&<P]:'&(
M>YSC)M<A!E%N*(/3T#1%1*(=Y(QS*5!1223@HA?YZ)WCJ$;J4E<";=BSGJ\[
M@8\V $,$)(EWN?LG0'6G)")!B04U\!6U@@<3+'$I3& R /(2\  <G* #SXN
M(C3JB$:PR4V5""DFZ-0)3&P/3RA-J2I2,3Y3!&H"&'"?K32P@5N, %0MT($.
M@&&#BNDT!SNX 0V$V@)GI, =^A3'"5(P@FR 8 0D:-\(1+! <QS57^B(@;]<
M8$$5S$.#%]C /3;^4($&>- CS H)KW*80F#A4*TG))8_-A #!D!@ A=IE@Q!
M."V-H/6L(CS)0KU%V(8*\;"X"Y=-.&"$<CTQ*/7:@1&40 09J P)1Z#73X
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M  90 RSP+<.SGH<G45SR4+\R$!1@ R0@C)0'9F:6C)>WC)O09FS6GZ$@ :J
M)WSR/=1X4AFP5"+ ?!NT 2*P C 0*9X!7/<C5$2E72@@#@XD0#-2*B?05""
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MJ*6V<#LEM+:#$TA08U\MM(R'<2T4UT)##1X_9\,--^! \B0X6==#*]=Y^0J
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M->5RP ((*(#90?0YG8(X&M_3R>?PF$ 1+C"\0>%P^?A(;KG49<\2G"4D$JC
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MKM,Y_>VADN"Q+Q*F<M/<%Q$13@(')@+HX\@;QG BH (U((2X8@,S4._"X17
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MTJ7'ES=SZMRH::>.GCF!!N6)*<?,FT6-LIR)Z6?,G20+<G"0 ($! E>S8B7
M5>O5K0:N#AA P(0/!@G")DB+H*W;MW#?5JV*8"T"!C5DF BQ <,%"Q4""[9
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M< .W, DXD!=;0X\EEAHZUC 4<P(B8$/>T7+^ 6D"+)!S*R ='L,").9CO"&
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MA\4DOY?3.6="OH6X:[JT.>4KOS[JOHS(>E^I.47:.K&<I/_KORV[I/M;B9.
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M"2)^'C$? +&,/O2167]8E#.:T6QG"4+1SZXH-*(M38L8(EJ&O+@A#4'^9T-
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M#QYD@?.0+_[24!H(<KVQ:A$0!$3 4RDW@@ZC',O!<M=Q#$^1'2MX0R$C<^@
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M>JW(7*]G*1P!;)<R79W)>\"C*ELA%R3P ?44 B- /_6V?"V0C,H(!*#%7C
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M N$84)O:?K\9 ]>G%^69;_:X4>VH -[2G*$!*-&)CRJ&@0F1GAA(&?=8&!
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M.C*_N""_D36DTLQH4D*7=DE:CJ2D>K.R69(#-F !X-R7FIAY<")R]8   5$
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M09^ _0%HH,\!$NWS@D(/J#32Y:77],L/4BB=RE-/':$/.\BP(HJ"/$)BB(:
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M 0C2R<$,9$ #FBPE5JO:2?" DCV@F" G(BE!^%9@OAF8K@53B4%4MKF4$$3
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M3K.T)0=>]X_8^0DAO81(1&QW.Q*H("F\_8G^JT0P*Q20  0+\4 +;/";@_$
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M%@U  V\BPD#Q:44KIOE IF2*2P:1W@GQ)PJ]$-]W;4_Q2B+0;$8!*1L *"1
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MP-%Q6J""%:1 ,<XQ 0J8")N800P9R5#&&AO^,I$7I* $&H" >1P0M/0LH(Z
MN2,"_(-'_"1U7DB[C[L4-,@ ,?6SF]7CT=A%(:L5R ,OR H#*% A2(:-/1K*
M[= PM-L'><@N!T"JB?PRHD[*C:>A+-$H?5 $@C2W"*<22$"F:X3J5K>Y0\AN
MX%;UNTG84I>V#.\U&5$YR%'BO*"8YI2:Y,SV'M,5T71O?)%YBBQUB9J>PR\L
MK!D+8XX""$9XG8 =Y<TW=;,((HC !"J0 0Z(8 0IP ZA.$:XP.6-G=RML."
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M4BC%4J^BIV5G0,@2F( :0(6I%(.:=@]40";PAV+Q069F%I_DJ$!U+@20 #W
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MPAHH_TA)L^4H<(EL9-K$]M@&O4T0CF01)A4+ZDJ:=I,=6FTG<^3G ZUVM8Q
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M6M90HOV2I$0 #!S! KWNO>40S(L)@"#NPUV!\5& ;.2*0)C.]09SG=\Z$L#
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MV^[.^[OIE^,K 6S^WLH0/PFP 3)0*PM*8AVI[A J%2Q&DBDWL2AE0;1500A
M AF; X1QU/:H&<*AO5_W R=$A@'?HCU)\!W-PDW)PA2>\#3:\!E^\ H#"#N"
M@X(\A(,\/4)&1DA(C8^,19-'C(Y(1TF9EY=)G$E*2*&C2Z5*E9.-I:!)K:RM
M1IE*2TJSMK6SIKA*241 0$&_041'N:7'O$+!.C@Y.3Q 0D5(Q]7&U]6TRD5'
MDT5&1+%'X^1)V;2V/!H1#^WN[^[L[1'L]!$2$Q<9'" D*2XR</08ELG<N6I-
MF#!9HE#ADB8)(9:"2'&A0H@7*5;4Z*24$X4?-3)Q\G%D2"=-4):$2%+^H\N(
M&)G$3+C0E*-N0X3HW#F$"+<C2%S1.DC4VJICYFH-7=)*R8X*#!(8($"U0 &J
M5:]JW8J5P  ! PB<X,$ @5D#"-">-9N6K=NW<-\F,+L@@=T$"D((0>'B 8,&
M(6 P8+!@P6 &&S)LD$"A @8.'_J=6,%"!0L8,52H@-&"1>46+U*PD %#!HT;
M.9K]\.%#)VME/'[\V)&#=6T?@H 8^M%#A^T=.F;$:!$B0X0&R),W^#M8P=RX
MT*-+1S#WN5GK!PY,9YL=@7;OW]UJ1VL@?'CJ'&0P4*#@PGKG\-G'ET]?_OOZ
M!O+G3ZN_O_^K!A20GX !!DB @ 2B14).0MC^0%H+)Y 0PH0CD%!""2>D8!D+
M+90V@PTUW(!:#H0X(X@.P*&HPXHIKNABBRZJ&..,--9HXXTQ G=(BH.HN.,A
M/,3VC2.6<$)D+-XD^<TX1C8YBBBY8&+$-TM2@XLKU#P2%"VBH*.4E[:@PU0W
M1(33)3;'(!'$FKSY\$,0BW2Y5%'G\ )4-SF<-L,-1/PP#3D'*=$$+3YP((\[
M#<"CZ*+M0/" HQ! 8,\$CFW@P0@GM!###3L 08R<!RTTZ* R31230PU1]-!&
M'+'44$D7E20K1R-=)!-,J=HJ4D.KTC3JJM5X@LH00:S60P]N M,3DULJ%::S
MK.BR"RXY5+! 6@?^6M555EEIM:U7!JS @P+[1:<66^?&E2Y<U=FE0&8.-%"!
M"YKY\($$&5A 00,0:*:# X0M4!][@SGP  447& I""&<<,((('C0 3\A>* !
M!AAHH'$''7A  @DGH-#"R#.43$-J./SB0YF>%N%F$,S<P,(('62 <0442"#/
M<NS915UU[+IEG75"__P<T4=?5W1TV777W73?G9= !R]$E4 $\>'E;L\#=[W>
M?6WY1Y[8"!9H58!6G8W@V0B40(00.0$A6P\\X'"#@S"\T((**%PX@@@?1.:!
M!R!\,*&)M-%&(HF#Y("CC#P^+OF,CM,(HX\G L<#BYC_2$@B0@"EI>C^37;R
M23?C*)E*+% &!8HIDGC#NCFN-)7$-+L,=<NT2M$>K"ETAB*$,&L*08Q!QB!#
M)SKD=!,$:SL$(0@CHA\TJ!) ='#H.XDRVCVC\&P?3Z00X%.!/AZ$8,(*+]A0
MFS1!&3/J_ D!NVI#^*?J$DHIR?K1_[&J54HRXI);T817_&/52V;RD ;6I";9
M<,0DB 4$NM$M$6[Z@4Y^XHC:78D7M6B%#290%@.$)6W?XLI5#L1"K!2 !3M0
MP'9F"!T9RH4ZU%$ #5"0 AA\2 @S0)8*CN"#'GR@!GKC 0E T(\*;  #$R!8
MP K#->?<Y2Z&090$*H S+E:  R,8@0D>5K'^#6S  ER, *4L@($-=. #%3)!
M9UH@'!C<8 8!L<$,<$"##^EM9B( @1DQ8($+4& "$7#4 Y:SGBM:T6=7C"0D
M(XG#2K9+:33,Y'5"P *K5:!G=ZEBU[Q&,/;P1VRH+-" RF:VM*T-+2=X6T[>
M1LNWZ426.H&3W(ZUN1S8H(\P:-R/'->CR.EH1BVZ7.4F=Z-E(O.8/=+!Y@R!
M.13]2$CC$ ?I/-%!;GKBFZ[[INUN,J4I== 8CUB=)%11.U<T@G>YNX7NCB*4
M;(0)>&F:DD]D093D+25YM;@))C#1/&TZ I_(P)X(Q+>H[\'#H>![A_@4^:A&
M18H>$Z" !?8!@A+^_(,& B$(E!@R$8OD+W\+),D29 42_+$4(PG$R$OPEY*5
MNJ17.'W@H!SXP 8NCRFA(),RBMA+QP6I!V\R'B6 0@,28JN%W^K6"JM"U0*T
M( <V!-K2MEI)31[M72SX !!TD /A@'0&0@A!$$A01!D@@0<IP,T+D."#$4*@
M!AMP00AB  ((A( #^8B 5ME"-'8QX $2:.,&0#"""ZU@!2A000OZAH(0&"Y?
M&,B9!!KE#DEI- -O%($)_/%8T+ @!C&  1)I8(--T: TFCG!A"3V1 S@S!Z,
M;*36KH@ &=[%:)),&F$U*;01J  ^G\3+*)?+7*FH96S0)9M^"*0VLZG^$@$H
M&()V>W++[C)H)^ %+YR4(3U!+(YQB],1XW(D(\E=[D7,Q%$RJ_E,'6WN<XHH
M4B5*Q]]PBK.= (;2ZY8@I51\PQ(&H88YM'3/?WX)GKZKDS\!*B9__C10D6C>
MG31<O4 I(0@B\-[W1@S1AT;TQ(Q29*0>=5'&G,]2(CC!:&X C4\=XZ3Z,^!,
M*B(3_L%J@2(YH$Q \I".O,14)+5( TE5"H?XM",75MXL6G&3(NAD-<"Q@99K
M@ ()7,N$4'6AMK*EK:E2YT MJ,$%;MN.YCRRL)#$9&%O^!8%;, ',=A!#&;
M%QOP0 8\R$ 03L :&32!7D3@@0N&D $(,$#^ B#V 0YF8 (8I,P%1V#!G,F#
M  %E9VR$W4 +)CD!#PSF 1/ @,TT  (1A$!#<OP,92W[ 8Q1()&+;( "OG88
MY#PJHPH#H_I.(,<5:(J.,9!!#?8T@QK8X 5(;$$*/C:X#6A@S17 AR(9R;7@
M_A:X,TS "%(0%05@;6OP42YS2[GK70_FE/J!=RI5R<I7H@TM*M"N$'8 C6/Q
M1C8_$$9X;1E>92#.FHP[D34Y5Z/WQO?A-DKFB38G3?BB:)K6Y+>?F$0]TO6W
MF]X$L"NN],U:,"$4ZRSG)*A!3T\8(2GP=!8NYCEEIE18RLM#TSR5UT^"&Z],
M/CFP. Y:%"*,@*'^B?*UTI/>CA$O\L0:S2R*44Q1%I./?/A(F!O5MP+5OF\:
M!E$RCW5LP%>57<>[RHA'D$R_):.*I$PF:90OG(O>[:)VXW"!H],2EJA&U5LK
M3$ ##O2"'N# 03'0FPH<)B&)9<"0$G 4ST#I;:5=TF@*H$ '+!"!OGT@;QZ8
M@01F,(1$R,!/-="!"$3P@\@O8 ) &$$/1B $$VS.!P&) +KXTY9.Y^< \=9/
M D)@ \%#( $2T $0&I" !;0 !S* @!49\ $(-& #DFJC!CK@QC"2(+8M6(%E
M3E ""8'@8A>@A_5SZQR!U><P\T!8Q@@WQA3L#08NP P,:!"#UK)VCS'^4 ,P
M  ,ID )_\P'<IVKZ(@&;M4B#X7Z_-4D*,$;R@0'TH6ZCA('W81_OMA_1)6^M
M9%UH<S;WMA\KH%T\$ 0D\02J @J84 0,4BR\@53(<BQ%)$S0E#B)8W&7<TP6
M!W% "#G51''W57'35 A!P A*J"67@ I$$(.Y) 1-(G*@$$(C9PJH0"5*& NK
ML& $]G)UYV#!\F D!SS.LG/R5"=%86$-I@165CQP4CQ1:#R0T$]%, *(Q#U-
MUSU,EVN(DG1\N(?N(&JHP0,Y4 (H5F(&\P"+N"@J5E$K=G4,. %L!!DD(#)[
MU"G'DPLXAE('="IGIV.]<F0^E61RQQ 0-'?^:_A@JW!W ,8"$/!E53$57>$M
M9#9F5*$ #W @,I ZV:1R;_,\AGA'^+<W?4,"'_!$"^@H  -*;R9) F,7 M-K
M"^  %V !UM8!(^ !+D #(2!Z-! I*=,#)N "SG "W/@"UA%\G88N'AAO"# "
M,[  '*!I$M "/L!\$  $&] #'7 7&E $*# !/S !(! <0! #&W!:(! 5"]
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M0P 4G AWTBD1H_@K&I$-J5B6JHB&8E)A)&>%((0$*.  UT)5M.AWW&)F"3
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M!$%P=&O] _B8&FO% "Y0-2,@"(9)>\B& Q\ 'R_@ JJV9@UP AO   [0,PR
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M*!K5Z%'(H%P1@("M'(!M!C%X@0ILTYNA;4 #P9% (G U$*K(2U[M2@ #!,$
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M,U5V^Q-FHV)3:^<R.;5.J5(:6;@J=:>%/31 >/>%7#@5,R- ,W-W=+9#K/$
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MB:=2#T;53AUX8@":)R-X/:[0<EZR8B_7"FCRD3BHH F*H$P%8@X@ 2&ECM.
M#<AT'4+0 B:0 BM0 R;P B10 Q@!HNYA=25*!#B HE'8#A)[DS7EHD4*E%:H
M#VQD9G-7=V)H=T@YB5)QA4/*E$U9GOA IZK5HV"H*DY10,7!$%3Y 'WV"QT@
M B5 >,1B+.YU:,MRARYQ.EF:3=20!)1C$]ER'S9  S'@ E@1%+V!B.8R :-7
M'.P"HREK@;1'I+UV;-"!I[[GB0ZP($&P ]NQ;;$8BZ_H'IZTF= WK$'^T&WW
M 5UT2[>T&)H\L(N1VHO;AUVJJ6[]L2 ;$CL=H@.:J:GDMR(K@GXJ<B(G9%4D
M,JHD6JJ)!YQ*$"/86"2>\R$/<A-:$T5  #@&QR&1TE_L)6&JLXX?%"(IR1Z(
MZC=!0K1+4 0DL&6I@88?M@@6H (A\ %]) (>L L7<*84P*!U%6>IL6&UMV'@
MBKM%]4"SPH$6F6(K1X(:58(P-PHF1KTBYKTGN'0=&:_V2J\+:KX-2I+0\%[%
M=")9MUM @%@Z(8@OP ,PL+#CU[#N2P0W\ TIBG84JS^D,BH]>7(=>RI*V;%#
M.7<:BV9.V;(T*J-C"*<RHUE-.<&'.6P4_)3^1MF%,-N/*:<(1&>5'! ,6FE&
M/%!H J=XRX(26(JE8[FE D:AW)$M;3F_FY<;4GN7&7 !1N,("I$9DB@SL\>)
MQJ:83,,T?=H=@S9=2E1<,D ##08V\&%6AW=XV**V04!I>%NW7*RH>],?IK2W
M<N.+Z_9*KK0@*4(IY(2V6NP#;XPMVZ:IRM2X&Q<95E5,G-.E /<WJUJ<U)!X
M/**E!Y<YR7BIQK<=$()PFR.,T7"="1@B%K>Z[3C(,B&/#=* +%$$(R !F6&0
MI,$:>B59)* "1N0!0C0!P7 !'@ ")= !-2L"&) NN,)7:*B\WFJ&T'NM"$%Z
MJR&]S\IB8.((WX/^3\IC8C1HO?)*8LJ<9*),KSAXKQL@!.^U.255=4,(-;^E
M;=O,L [[2-=! PW!A**RHBHZ  5P .]06F98E#8:AN^LE"*[E!)LP!!\9B1[
MLA3,E+AG6@%$ABG;P O<9@P$O;Q,LQ$@ :\A6R.  BP  YNT$1V1#$"[>"\\
MNZB3I1G'#8^$0M.5'BRD>2F  D8T-&FJB$N!-!4,;*>%F$:L#M.!  _0 Y]4
M S#P F4Z%&W55B$ +"/0>2>@ BO  CY1;32@1.-V'XJ*U-:'2M,E2JI$J>BV
MFI.*('<3'PR2.+W$QNIW(>_[ U?\ ^OQ./6V6_>VC12Z=;K$.3'!KR7^*3K0
M\BQ)<(I:]YU8=IWS%U:1' WJ2V42ELDQ?)9#"R1&@ ()0V=O-JY-!P$7L- G
M8 $2T $EH $4\"LE<,J&R*:+4 $BD#"JE@$/ $!F.&H+T4[.^F&]W$88*$ 0
MY'07=;U)QZX6&:_Y.;[/G(/,3!RYS8%=DJ^2&W&28GS>D<VHF&W;[!TF%(37
ML5OA7!P #(5H1\[J;"KX?,_^?,]A:')4D=W:?689.Y_>+<0K7:3YO%G"AAS_
M$Y7_W-T\*HEG"! [A')(JG)X-$%\- (F,-0T@ />A2R+-A)AB1*'!MC/PBC;
M@'4XT0-+6],O8%@H(!1M=9>?9C3#(<Z 26S^& Q\$##3RH5"V)+@Y$%%,, "
M+/ S)5"7(/ !'J#BOUM]S_5<=$M=_.'4<G-N9IQ]56W5JAE=KP,B-&%2/YX-
M' =]*"1.<@PB>WUPO!EPTIA?).76UB1EHA.K0$#EG"DVCS.B?DTI[].J3=(^
M0F)Q!CC@M7,$*6 T2=4/2G6ON:(4N^ 5)5 !&I "LM4!(* "(+#9(_#8'>!S
M$T "%68H'O !Q7$K!_$->M8E$7C:,]L0[-H0I@>0\;DTA2E MH(K3D9/_)ED
M_EDGRRRO3N?,N6VON=+H%I6^D6.Z5??5V!+65&[<W$SE_B?K0_BOW3$##7$<
M [RB+R5F4GB!*+O^P23KL6"8W>[,P,5.[. -T.3]S\<AE<#FM:I59OH<H\5N
MW0Z,[!SLRP?$RZ3-$*;=<A)  1<P$;(Q> ]M ][%((EBAXFV3?CE: 7N.-!W
MJSJPH<7U+27.TQ[  4=Q2(/0OZ:1;!"PL,**BMJ6;<5-Y7=Q'S=@ X/VXJ1T
M-C"N(--G-E3,M^S6MZTTJ=$%!(3K( LX*7O=?B4O*::;C**Z#!0*DX8S.J.S
M#0.'.2-D?+LUY%6.\QSA.=1@?-((<9 \+=@4YLYRT<8JM(O6+%F:!"V % C-
M/5VRYKK25KP V26@1P/;[QI0EQ4  B:0 2*0 1A K7[> 38D 101=HO^;BL.
M0'3Y,@**GJ#18R@SN.C]D&&YQYAANW9W9BNX[??*;+[N=+XYN*#5^F%=\A9Y
M7/*18@1EI;=.34J/7\6')\?Z:_.O&P/B; #G_"D4:PY16  U=<ZUE[52&= 9
M.\\)W(4SNMW77=VOYW;BW48F^S+ !J<7[K7,GK6A;6;X()37O=U%Z86EIGIW
M1= $<:WG294(+1%8*7@IT (Q8 ,Z *(LLL(5_<)?E3YZF(W.D(WH%]Q T /V
M?@,T, -/JP(],P*<1BX>8"RL'JPA^DG<3/]L*[=+?;<4CXL6[Q_?]A]C# @Z
M@CDZA(6#A3F*A(N$0$9'D4=&1DB6EYB924G^EIQ(G)N@GYN=GTI+2DA&1460
M1T62ITNS2K612:BYJ*>UM+NUGI.K141"QD)$1[6IQ4'.0<9#K)2N2+*SV-G:
MV]S:3=[;WTM'-R\I(QX:%Q43$A(0[Q /\P\7&A@8%1X6$B4@&NQ B)C0 04*
M#?P<.( 0(H2$!Q TD)C H*)%!PP</*B@P0,+%1D>,&@ <1X$>1$D;/# (<-#
MA1H=-%B0H":" P@,(,BYLV=. T"#%@!:H*B!H02"'CB00($"BPVB2IW:0*;"
MJE2G5HRZ=:17KA4Q7LPHX<8H4IX\$>G!@X>@MXP2-=(1A(A=(D.&"-%[S)F+
MBCF+$AA,F$!1P07^D@X67'C 4)T]$R"0/'DGY9HV,TO>/'DSYLJ=.W\.'=IS
M99NG+7.NK,!G3YV0=P*5[3IR;9^P<_.\;9NWZ\M,5W/6[+DX<=&8DRM?GEQ!
M3>>8H3MURJ#I].M.%S#0/I+D@P@3*F#H &+$"18P:.3@ 43:J29-G,AW I\)
M$UVZEBW!Q3^4_TW[6?)*$7KYX$,B-]A  PTU,%B##3C@H,,./!CH0Q! /*.A
M,T  L<.'.7PHHHB%[/#6B6^9B.**)ZJXHB&''!(77(PX0HDDDV2B8RF7H.7?
M6:&4@LM^ [)BY"O*8+.,$D<@\8LOO$2YY)*_+).)DD4(L:&&&6HY1)+^O70C
MYICB8%,F.-DLD\0K0?!P PPLF !"2^RX T\\[TA@@09\ZC-!!B1D( (($(B%
M 0G\2'"!"!4LT$!&%F5T00<>A,"!"AU ,-))$$3@J3LA@! ""2BDX$$$\&3P
M@0<;4 0=:CY11EMN00D5E&&*&6#844#AA,!T4%65T:-9$2O55\=ZU1VDD"I4
M0A&?C++C*G@9 \0//; EUPW<XN##77A5VQ>'?U6G*V&)H6L88XLAEI0!CAEP
M@$ZR6F:OO</=FYESIYD&6KZ9]2NP<:G5BYMO""?\$T^S[:;PO?B"UINLE_W;
M&;T6#\?<QLN]&IUR'E<'LG0UT=3<=-9=M]7^/!)0@($&'81@0@HMQ&"##CT(
M <M[\='GA'WW9=-??_L-#:!_ :Y)C)8^\+!#A W2,,/4,S@8H0YM?9CBA!.Z
MZ"+68(<M=HN"?'TBC"\B4J-<.OC@"HX[8B(**=&"@E8G=(,RB]*M3(.DD[FH
MV>0N^STI"S"K0)+)E(0?;B42D1@AKH9"&#$D?KXH.>829WYS)N?AS%+FY]JD
M<H000.A @PLHH).!!12X(_N=$%!0 00O%ZH=!29HL $(MD<J_ 0GG-!!!R>0
M((%,)WF:DCL?F(I!I2B00,$'(VSP00@GA/! 5#(M('[)W%5W6ZWHIZ_^^K^)
M7SY76AE+;%>/1BK^E@,9 !&D*)<T";DJU!@&@8P1!&QE*PA#L$L"CZ$E#EVK
M!15)P%$*DRY<K>LP&"P* J*"@,?,)C8/*XW&DM.OXN!+,ZH)&&HT)K&*O2:$
M,*3-3R #&]Z D#<&JXFO?@.KR<2&A1;[%PHY]ADB&O&(2-R8=++CJ$<]0 (3
ML  &.("]$ZS@!3.XP0[: ZTD &T^]OG<T896M/_\R!.0HY:6?N"6'-R,1%LK
MFQS=PB)!N$5%6EN1V<ZFMA@M0FTY\$$KX):CN.DH+3P"TMP^@0K(&6D:1C(%
ME-;DI%Z<(@F'*YP2A$"#%^R &D8*("8LF29++DE DVC2-;JQRFZ0;G/^\#%3
M+N#CN5INCA9L<E,,5. /#N2C'?#@E#Q.<H$+4( "#]".6""E@ 5<( 0EL*(*
M2""23DG >>[@P I L*H3M  %&?! "CA0 >U%$U7OH,<R3](1!Y@L 2:;U0QK
MM91Y+24HKEE?K7;S'/$%2UGPZXI",K*0&4@+D9B(Q"4".,A'LB(O"LP+7PCX
MC&NQ ",2),P$$\/1#&;P* EH602<<A2C?+1A"C/8;U03F=$$K(1"E%A,5=JP
M&LKPA9$Q@ 0?AM*$Y; V*A68;2ZS0IB:L(@<0\['DJ@<I3;5.#U$SL!2HZ_E
MT,1]&JE=!3+ @?*<)STX8,^7AM0S6FYC?V;^I%LM+)$*:YAH1"'2FM=01"&P
M[9&N>:PCBN*BB$3("&M$N%&3)%$)_UFB$IK@D=V"%*W&#LF1?8NL*G.Q"26L
M"9.!TV3CQC$#%]"@<I1HA0"G00G,KI6M4](/E%AY2S21B1NQ!)WH4%&F^SAA
M"?3A7&QG6SK(#>$'.[#!"U2 #H3$+D_Q*,D#8N).A4"@ N:YP 06(H$,N,1Y
M&4@!"SY0@NVM8 ,;8$$(/.!=%>##!"0@9P=> H$)<),#)[" .Q<PT'BZ9E[R
MPDE3ZK6<?,YP8?IL:3.U4S[[*80$B-U?8P641F& TJ$/O4M>&-A #%WK!RO
M:$DOV%'$=!B#"/C^!S(C,(_I\(I=A1G,N0H@PZ!"K(4R)5A+>\/2U?A&-Q]$
MF$YCN%(8]I"%1-673&$L0N&(L,A./6*2F5/CB>V8QB_F,92'6K**0"2*,(,F
M"EH @YOQ (%'V 0MS5JFM3+6$B0:D8N<=B*WT+'-<NR:7EFT-AFMK1$\&,+;
MX/:_P:JB?SO*VT'1:%K(^@T6E4A3(P>GVDLV#AC&0#01V',$O$"+&J900I:$
MD,9!&C:UVVAE:UWI6G%XSDRGYNUMLW&?T8T.=-^X#Q/.M-;3^0 ',6B!"4+0
M@0S4*4\G@<A)5'*!Y2W$ KM.YP1,@-X-3(\%'<" =ANRJN]6H'4C*,'^!DRP
M@2>.X ,;>)T).N#.!P!3)#29S/@\ULP&0&")PHLJ;992FQH&&#)5S@@&?G 6
M0S8)L0%\L)'L0@R\3+3"'?J!PGV@ @U[].%(.2E0GL* IU!'92*3# AU-8".
M=YP CDF*!_%)0]_8^(0HEW>L<$-#>^/XIE*^H8]Y[&*63MDT2 7R44LCFA)N
M3*H]5WG-%7;#C?N$Q3$7H?@4 L4]Q6P$6[89UH+ BLO%YQMJYMJ(WG)'%;4E
M17C4.EWC#)<8^?7.; N"8'&D4#\#VG^&E9O<%Q>@1R9ND("K$N0P:<J];=:R
M:81$$7;@-B/HH 9"</ RA%"AQ%,+7$1@Q:?^,S?JT&7CU987G1*:L/G+BR-H
MLP"];<$1R])SKM6@D_42@@;X(@#!33"8YISR<=QX<$I/$Y#' R@P@O'ZL@0>
MF  )3# "#OP)!1\0OK:3EP'C,60%O.R]"3ZP^PN<@/@?@, "U#T3]]%$ 1"P
MQPDD0/$(.-L"$R QOR933WKW_,8,0]]/$K 0&1QT6@$'Y3!&2R "V64OX](A
M%[9P*: 0DJ%1'J51BJ%BA_%!-F49TS$9V.$4CU)$#&-! Y!B*G8N\K<P".-"
M-%9S#CA/.&9OO+%#4_8P$C1T4F9S$1,Q2K9?/^<O%0-5_85S(-B"#B-/\J0;
M#$."^B1_^^1RZ6/^&1D!#U)$'B6P95JG9GGD-7F%-6_%9EQ#-G.F1WS5"#:R
M9_]S6%UH2& 8:+Q@:) $"4,2)9P09K1PA@ ")985.9!@!#T !/YS(Y1@#;R@
M%\EPAY.0#)$@>9$@:M? "Y17>:37.;2E6XHH2[.P:K@%>K %:Z86:V'T>;,&
M-*''6Y!#!*E3 \/U;1M@3.WP#J@"'K:S#A4 />C@2Z(B 1YP AF0;;$H A(
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M(K&08$! 4&!?CU_/SW_O;R"! @4&"A0(B "!@8('$R XJ. A@@0'&20LD-"
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MN9@+6G ;'-IPAB_0X0Y[V$,<Z( XX&!.RISHLB,RD3O.<!/,G+@<+J(GC$D
M(\^4 807I" '1UP;><HS-)\A[6BW3*-_GL;&#KEQ:?<QD"0".:"LV5%&!E*1
M--+3UT!^C;!_%:3^B81THD)FHS- 0"02)$E*&I6U.45(3Y!TQ$D=Y6A'D_21
MWTQK""+Y[6\_DF2)SF8@'3'C"$KR@0YHX((4D&!Q&;! "[PV5^XDX8CC\08Z
M=LFOU>P@",TYY)[,X2?2^1('DR'4 G#7.YGL0S"*(DE6%  4GQA**R+1YN]
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MUP$GU\J(QG9$9*E%\R&)QN$.Q"$[.O !\Y  *GL6P8E]K$@2Y(,K04&S/=$
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MFW-Z*&*[F(H2ERG'M>KMPT';T5I,PCY;T#M,IS)<%5?J"Q6@ 1WP 5>M6R5
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MN/58CP8O9#S7\,'A\![8CS0@\1/OXB<H SP VUSGGT(>AV:]R,_P RI@ C
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M!C#E\@IFD$6:<AD@7/@KB[^"@8P+5&D$)E!!"UX0 QG,X 4O:$$*2@ "#VC
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M&I !%1!##  W>39]O/A=2F*&69&&6;$:WH)0Z<8<SD$=XC=N))50ZO(6_"5
M!00O:>%N=A$^H<%?^)=/&(9 !<=_\79@U5AQ]F51]4<N_=9_ '@9R )2%+5Q
M$^0_9\%A]*=_Z#AB\40N)19B&\<9HV@\( >0.#0R&H@=+#-C0104()B0ZJ%R
M)=@?$'D?0? S494$1'8B0!<B3R9,5L5S&$($/1&2JR J5F-66I1%3 -55I1'
MGA!7K/8U4.>2H8#^!"M0%%&2A#B9DSD))<=0 0U0 6DV 1E 2%2X4AZ0 <=1
M9G'#2(KE9WX6C&F(  LP:%""-\=P#(5&,!P@ B=@63M05I/ .*BD>*WD6A3A
M#?-@.:>&)Z 6#X3H!&]Y)Y7G#W'9EI>F#X4B6V6)2K2E.IS@ R9@ CZPDCWP
M 1:  3)P-8703)=8"#OR1I\8BC0TBM_Q7&_D1I]XF3<A \@'BRF  KY! B$
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M)< ",: E(=(13NK^6GT(.87HEC0[EW.)I?CPEG9Y)UTZ6K 5IFDB*3UP0BL
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M,L!7@+6^2@A8[?O,T1R_(-NB5C>_> 9)AZ64><8 U%S-_SM)=P,E1:( ;.@
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M-JU:76S;YOH%UY>O P;H&KAKH$!=O7<+^,WKUR\! H()##B,>(#AQ(<%-!8
MF;'DR9075Y9L&7%FQ8<7%^!,.;1HT00<#S!MV?!FQ@)*NVX->[#IQHEGTW:,
M^_3IT@,85JS(46%%AL1=%O_-X[?QBBU=-M<!/3K%Z1 C6H^X$H<.[3N&'/E^
M! GX\.'%FR=/+1^2>_KPJ5_O/OZ]>>[I+U%B;_Y])??W\_>/7W\""LA?@/7
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M.+G ),#*%BX'?ILS?DV0!'NFATBP!-S )NA7CH@%1DGPG:@#'D2P3N+I.C\
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M3!A03%MX.3W73",F12@V32SD3PH050TG#&RA "8H5RG(*!7'<;!C.^1D.];
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MJB@,4 $GXB*4HY92R*,R\C -!0%TNR>!0M#^)W@H0!17X)R";>PD+/@D43(
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MPOSY7!P:72[MTK-$73)-TS;0 S_0;#.  @!I74"-@$*-2T<M2A<BT_B7Q"D
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MJ#=APC#._C*MVU.;7Q6"9%45[7SO^#X6@" 1$5%Q\="PL""14L$ 05(2HL%
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M"B2,((()EJ:PPD,9620K1;).!%&PN**S:3<@92,""2*D^,!5*7E5VDH$%,!
M!2->8$$%%D@PP00\3? 3!$&I6U2/H%#2@"@@_N448 ;DU5=J-6K[55AQ;>89
M6I^E]=EF;AU,EDLM#8 53/?NI=<!^ (&5;U.+468AD!.-@AD1$%VI)&&*7#
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M:DCSN1Q%BGZKY#06=4GGR5OHB7[NITG1D1W^\=E]V*D;\5I<D91S=B-O[+:
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M,R #,1 #=XH"#X&&)_ ".= #6+[6D6)!?-[G?SKH?@Z('I2'NK(1:"AX3%9
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MUGLM] 1-P)\VP!0SP'\JH% 7P $]DE0$/#C95U@U@1,,:FL*8Q1=)!81^@)
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MX@-F./@S B<0& G8HX;1LV6YX^EN<AL043[.DVS*ID&);D5^YL$9QEW,'9#
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M PPLJ+!"#*2 D@DE>IZR"2BEV%G*#(**,DJ996;B@BJLJ,#H*R<\*@L))9C
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M,PD_P/*.> 0#ITZV59>UX*FJ46,/D( %JXCI"V*@XQV+-$MA K)C?' #&,@
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M/\ P>MW #==@>L!7-[#6>HMV52140J\'5O=0%-IG15:T0LI"3)M631A ;!I
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M7.@17])7%$$A$TL0<G>#7] DA$TP!!$7(/_1'AHG((JS!$* 8"V7("E0"AT
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MPK7G@<-$('UZ51-)"=3,U$M"0,->6V!-+2#^4!RVV20],0!S6%@*/KRV'_
MT-$ ;4HJ%#!ZMHP/;'P"<PEC-A(D,? 4"L("+U"YK4L#C<("*P53D; ^=)VX
M=BB*AGP#2]?(L(J(?GPHJ8.JH;P)GO _B) (LQMFGWG8A]W,ZM/,4H;7C%()
M\<1WDI"IFOH^<XUX2K9X9EHI9/IX(0)GIE=Z/I?+]@!GPZFL=C)P?#)E9[B)
M+)(B%]4H>Z<BI3O*G>P)J!@^BD=WQ$LAK' IMYFVOO  )+$UVK$-V]FNX:N^
MZ"( H7:>+('=X+R>XUM7 \T8+*/.+=-\[FR4\%R_\2*E^E+/W=>__)O/D#7
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MNE&<;G6.\"\C8H=-0P"X"*&(DND6L20GG%,(Z32>.TU @@Y,@# 7UD4'%&"
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M')A-L0-@3T $F'"1&:=PDJ,*3: $0;""Q^-@.I 5($<"$M !)'<4';  <[(
MJ,$Q<N)R#>!/R1 QKE=0..1VZH ^99&)D<<7)W!E(O 5+T88)1 3)9 ^Q^)S
M\( J*.4"&(%1Z8!D*\522V8H9P@6WQ"'4=9#2F@/\$,6<RB'*($2/;$3=%@2
M&F0K?IAF@9$HU"+^55U!=H9X0>B#B(G8,(U(F .% 1KP@YTF+A]0+C*80XUW
M*^MBE(*68X;669EWF4\D0*.H#F0X::B8BH"A=K9@3U=!6$]1>!(S,1;#FA'C
M,'C6&*M9 6.$#+TH1XE5>RP#1Q+  ^U4C,&7+S@P?$&0,WF$:\51'+R&6M)1
M!,^W6H'46M=G2-AA2$R32%&36UCS2//!2.0'CN((?A6X'P R-_V1!,PQ?JFD
M;:GT2N3V(/0'CWP32ROBC^+U-R<"(H=02^$57O](@#%B@#QR3+Z$;SQ"DN@E
M()JT'OFR ]<Q Q0G(.9I)/Q58"387YN0D=H$@IJ 3>=ID2:X7U&R"AK^!P5+
M4 0-5CS'HP,T8 $=X)("54471@' <),IPP (D  ?UD\B%C$S-PTC$!,QL ,&
MX0(A@ )F,1$Q0$3J,"C=D)>)(H,A8 (QL3Z5&!2/5PT.00-"L"HJ)3 #T5*?
M:1)V^%0O$8=CT4#WP Z%0A;PXX9FE8IEZ0UQ&65EM9;#PH;.4G<,9:51%56#
M6!2$\9=6% *!^3"!IR>KYYH24YA;=7B**0V-*5&0668X(9GP<Y27@A#Y0D1.
MI'GVDP[QT)D084![<59-)E,JI&F!-2X>,!5 &!6P-YB.43&283$_N56A)C&Y
M.'NTUS(AYD5H1$8K4P1!<#Q(A WVXBFU9A_^MW9\HK4<S,AKJM6<KU6M0N-K
MU$B=WC%;V)A;O\5LC?2=Y7=)Y>H?:"-*]U4@C;0<5;,@[4@WX59N#Z)=&;*?
M^9=_W44X]TF/D1,Y 5@XQ 20BQ-,_&9,!+EO,Y(@0Y($1% #V@$$/A!? I),
M%M<)%7J1HI"ABK"Q#K>A4R($*U(Z'WJA%BH\*)FBL- "C7%!&P !5B0"'=
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MP%'V\$3;D*8R\ (I8(:5"'0 T4$[E2[EHQ+N<$"7&Z;W0!%+:%-]2A,;\3^
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M#D@$5Y!"QU@+A0IIK#6E?U;IIT:%9"<[V7QTJF$JJ $-9>QUP3U='T,4]H'
M!E:P5-R 2NAB0BUJ,0,M^4O'0*:+'A!I,#9HTPPJRVK,'N8PE\T!'%<&F,4Q
M;C)%$.W,1ELSTWJF-#OK66IE$QO<Y(:UN3DD(HE#'.. TK:1Q.UNN]8U3P+7
M.\(5;G&]QASED.?^.@."S]GTAA]>)G=NU<5;=^O#GE92-Y>ZU.XN)P1O5I)(
M/]H)CA$>-R+]S-??+\)<Y2RW.?H2O+XV$L(M+S>Z9FK.1TTH@C=WP+IPID73
M3'(I/SQ 80H_X.,/: #((P#1#&@8R,!0A8=C,(-^AMB?+U !#&; E)8+0\4X
M7$'"/-".4U1 QA/P %6FDE9^[9AVOG*B0ABBD($\*N66B,:1006J?RWC4:J*
MU9(5U=)?P&J&"]8)3V^5*Z57D%==7ABEU>X!Q"+U@^!;%D>Z>(%FW:4D%S%L
MM:[%0JUNE:M<Q14)^A6J4T2J&49>:Z@\17666AVC^%!+K<1NJX04Q"'^N/)
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M"ZA@ S78"=!@I2'0#RCP#2  /_42"T!!4:=2##*W @"A%N>##$M: LS0+Y9
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MH LE2*H&<@\E#.--2/!&/T#Z*O6!1%05R4C[6N6.@$3$(QXYZ4=!>C^.HA2
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M0'AO\8@=0 +[LF44X &"T0(Q8 /Z(C # T$*(A1L%0-#T 1(P (,<XKJ$GI
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M\X(*!H/(L$X[68,3%D\XZ).$0J0TURA#B0X@)G0O06)'V*10FH3H W20@F(
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MP(F]51:XIXJS,2]YMAN>>GH-VEM59-S?B8ND;!QLQ*TYL]AJQ '-F'?$)J'
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MBB8>Q%9.2'C"<Z3#'"SDA6- 2H]YG"H9&(,*#6LH%7G5<*QEV>$0[[66MH#
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MSL8VM+5RV_4)]X#^ G2W4>[M_.E.?X7^9B%@@M=PB(O_O8^YWL7%^W+--";
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M0W-\8R841E5Z"[:P%OQCLR*=DU$15ACS%3 @,2XP RM]9C.0V4. !$00!#E
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MP0.@9@_7\%G"4!,1KPX/->-([&,I]&E-;!7^9H&(%IY$_J,L*@?D1/ZU6!A
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M9\)+WJ,A36E)2Z4$+  "%<S %C^&C<5G><OYUK>^7?L:G8G#;F#V]SG)-!N
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MEB$9Z> !X"(")8!6XP9]"J-;B"4"Q%A'1:0P%I%;ZD9((Z-N(I<<_C<VQC6
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M/*U!9GWX)HIF51W1,*W@BN^3%<)0* -4 B8 F( Y*>\U"H*F*6X608YV>HL
M+ATQC*RG?Y666R(A K.%&-UPCN<8+-S80D,40N$ ?MJP0OS ;]G9C:]VC^$H
M?L('6,="%AE0:^68 =>Y>\XXD'14;HEE1),F?_&(5@'IG B#C3*40@S^(1:1
MD8^2T9[H,!&%Y6W<=BVH0I")Q0S))J&YQ7_ -9$ J*&)1!?(E9'SYER0- @H
M4!AHE1C% HX* 1D =Y)KH9(:.%[C930PR7 UVG!.$7$ -!NN(5^"UZ,<IQL[
MH).W\65^EPE%61=DHY3*=$P\6& KMTQ(('-3*G-W4Z5#:)7KT6!'^!Y:N4T7
MAF%/Z$UB6854:)97F$Y(=SD:<CEBN)9,!R,7<CH:$G4P$J=L>G4"%:<U<B%X
M"21!<B3DXY<M< %F@B8@  '_(U5*$@,9@* :\ $F@ (5(%(,8 $>4 (L  ,
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M./L13A:681KF.!MVIHV#IA\6IV(H8B\R(FSJ="<BIR&"3U''A7YJ4+FC.TY
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M=]U3V\5A(S8HSI1HC1U Z-;2-)5T0^98^F!S;==H*V%A*I:.$TZ.$[>54Y:
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MPH6*!R%DR*#16VB.%QDX8NA@@H4*" 8&"!B@G?L  ^##.T@@8'N \@'.;Q>
MH$%,!PT8*% P03X&$A&T18 0GP$! N"Q\(,//O2@ C0V.: @!!3T8LPP&*!
M@PPQ./10"Q.VT$(,--R0 P\]%/0#$$ 01""!/?"@(@\ZX-!;<T3AT*)ORLD
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M!E3G AB$  (N8$[^NXX"G5MH( 0I<($'$K   G1G/6!+CRC')DKMA&T #(#
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:W"R'.0>R67+^R+.>#2<EA*09;V16@4   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2527059d12hqlreporti002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d12hqlreporti002.gif
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<TPNW7+.-32[!L=>RUIG476;OC&S2U5+Z0 $ .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2527059d12hqlreporti003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d12hqlreporti003.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( .\!8@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M2^X_Z%+Q%_WXB_\ CM'_  E]Q_T*7B+_ +\1?_':Z>B@#F/^$ON/^A2\1?\
M?B+_ ..T?\)?<?\ 0I>(O^_$7_QVNGHH YC_ (2^X_Z%+Q%_WXB_^.T?\)?<
M?]"EXB_[\1?_ !VNGHH YC_A+[C_ *%+Q%_WXB_^.T?\)?<?]"EXB_[\1?\
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MA<UG_OB+_P".5<T_4Y;Z1U?2[ZS"C.ZY5 &]AM8UH44 %%%% !1110 4444
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MX5KX1_Z!/_DS+_\ %4 =717*?\*U\(_] G_R9E_^*H_X5KX1_P"@3_Y,R_\
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M+>0 "1GW.U@/7!]*AM_'FEW<Z6]O:ZC+<;W2:&.V+/;[9!&Q< G@,>V>Y[4
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M19KC[,PDG*C&YV"_,QZDGN36G_PF6@?\_P#_ .09/_B:!&[16%_PF6@?\_\
M_P"09/\ XFC_ (3+0/\ G_\ _(,G_P 30!NT5A?\)EH'_/\ _P#D&3_XFC_A
M,M _Y_\ _P @R?\ Q- &[5>^LK;4K">RNXA+;3QF.1#T92,$5E?\)EH'_/\
M_P#D&3_XFC_A,M _Y_\ _P @R?\ Q- '(6OP]\4:!HO]E^'?%_V> 73RJLUN
M"50@87//?).  2<U/?\ A/X@75E81Q>-ECFAC99V6#9YC%B0<@<_*0/P]ZZC
M_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\ XF@#F-1\(^/;F^MY;;QP(8TA
MB1P+?'SJH#MM'!R06Y]<=!5S3? 5ROC^;Q3K&L/?R1[EL8MFP0JV1@\XX#$?
MKUK;_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\ _P#D&3_XF@#=HK"_X3+0/^?_
M /\ (,G_ ,31_P )EH'_ #__ /D&3_XF@#=HK"_X3+0/^?\ _P#(,G_Q-'_"
M9:!_S_\ _D&3_P")H W:*PO^$RT#_G__ /(,G_Q-7-.US3=6D>.QN?-9!EAL
M9<#\0* -&BBB@ HHHH **** "BBB@ HHHH Q+CPGHUUXBBUV6U+7\>"&\QMA
M8<*Q3.TLHZ''?V&(I_!/AZYLS:26!\DS2SD+<2*=\@(D^8,#A@2"N<$=JZ"B
M@#G&\#:#+<FXN+:2>3S?,7?,P4 %"$VJ0"@,:$*P(!&:4>!?#@\[;I[*965]
MRW,H:,JY<>60V8P&9CA,#)-=%10!GQ:%I46E0:6-/MWL;=0L4$D8=5 _WL\^
M]9%Q\._!]RSF3P[8 N"I\N+9U]-N,'W%=/10!Y]<_!;P7/#+''97-NTF,217
M+%H_]W=D?F#6+<? '0V@5+;5;^.02;F>0*^4_NX &#[_ *5ZW10!C^'_  OI
M/AG3H++3K556$$"5P&D;)R26Q[UL444 %%%% !1110 4444 ,EACGB>*:-)(
MW&&1U!##T(-);V\%I L%M#'#"G"QQJ%5?H!4E% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%,EEC
MAB>65U2-%+,[' 4#DDFN<C^('AB6V6==3!5I6A4")RQ8#/W0"<$<@^E '345
ME7OB71]-FM(;R^CADNE#0JP/()"@GCY1E@,G')JK_P )MX<VW##58CY#A' 5
MB22Q0;1CY_F!'RYY!H WZ*@LKVVU&RAO+.99K:90\<B'A@>]3T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK/\ WW%_\;H_X1ZX_P"ACUG_ +[B_P#C=;E% &'_ ,(]<?\ 0QZS_P!]Q?\
MQNC_ (1ZX_Z&/6?^^XO_ (W7FRWFM3ZI,H\>_:+&QF>6\N;2:(-#"H;.8C'D
MX.T9!<'V.*]EH P_^$>N/^ACUG_ON+_XW5S3],EL9'9]4OKP,,;;ED(7W&U1
M6A7C$>M:WJ=IJ<A\0K#/H]GA3:ZFA5I%D.Z25/+)9=I7@9'R8ZMP >ST444
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M)%)=7-VDD2GHH6-PN!T&,9%=]I=K-8Z196EQ<-<S00)%).W61E4 L?J1G\:
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MF0*,J&^903GC(!-1W_@7Q1/HE@+6*2+5%O+R665[I6*HRN(\'=QD$#Y>1G-
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M1G\*YV?X<:)/>ZQ=>9>(^K6@M;@)(H 4;?F7Y>&^4>HZ\4 .M?B)HEY=6]K
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2527059d12hqlreporti004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d12hqlreporti004.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( !T D@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M^&V@MEVP0QQ+@#"*%''3I4M 'F7Q'F_X3#P!:#2XKH1W&IP0YFMWB.&.T'#
M'&YEYZ9K3A^%NFS11QZUK.N:U&A#"&]OF,61_LC'\Z[EE5QAE!&0<$=QR*6@
;"I#IEA;P1P0V5ND4:A$18@ H P **MT4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2527059d12hqlreporti005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d12hqlreporti005.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_X@H@24-#7U!23T9)3$4  0$   H0
M  (0  !M;G1R4D="(%A96B                !A8W-P05!03
M                        ]M4  0    #3+
M                                              ID97-C    _
M 'QC<')T   !>    "AW='!T   !H    !1B:W!T   !M    !1R6%E:   !
MR    !1G6%E:   !W    !1B6%E:   !\    !1R5%)#   "!   " QG5%)#
M   "!   " QB5%)#   "!   " QD97-C         ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4              ")!<G1I9F5X(%-O9G1W
M87)E('-21T(@24-#(%!R;V9I;&4
M            =&5X=     !#;W!Y<FEG:'0@07)T:69E>"!3;V9T=V%R92 R
M,#$Q %A96B        #S40 !     1;,6%E:(                     !8
M65H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M,C(R,C(R,O_  !$( '$ L0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MILH_>1?\NTN/^/AAU\SC_([9H ^K:***!!1110 4444 %%%% !1110 4444
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M\C:-.J121F0G48#@"9G_ +O. 0?\>@ /H2BBB@04444 %%%% !1110 4444
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MI UT',Y.06\G"KN^N<_49J+PM\49O"NAP:;I_A!<*H,DWFL&F?'+GY>_Z=*
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M3_\ "J]4?Q3*6NGLYC$LB8E6/RSCS#W/Z^O/3FOV>_\ D'Z]_P!=8?Y/7LY
M8$$ @\$'O3(X(H<^5$B9Z[5 S0(Y+XE>$7\8>$Y+2VVB^MW$]MNXW, 05SVR
M"1]<5Y9X4^*VI>![/_A'?$&D32BTRD>6\N6,?W2".1Z'T]17T)5:ZT^ROBIN
M[.WN"OW?-B5\?3(H ^;/'_C76/'EBMW'ITEIH%G,%&3G=*P."S<9.,\#H"?6
MN\M?"3^,/@-I%G;$"]@5KBVSP&8.XVY]P2/KBO6Q;6X@6 01>4OW8]@VCZ"G
MHBQH$10JCH%& * /!/"OQ:O/!M@OAWQ)I%P[67[J-E.V1%'165N#CH#GICKU
MJ6]^)OBKQOK]E8^#;.:S2*0,S'#;L\9E.-H0#/'/KUQCVZ\TRPU#;]ML;:YV
M_=\Z)7Q],BI+:SM;*+R[2VA@C_NQ(%'Y"@9Q'Q+\&7GB[P?#%$T<FKV6)4*C
M8LIVX=1G.,]1SU YKA/#/QFN/#>FQ:)XCT>Z>>R40B13MDV@8 =6QR!@9SS_
M #]XJI=Z5IVH,K7MA:W)7H9H5?'YB@1XF/B)XQ\>>*K*#PE;/86T!S)N^=,'
MJTIQC '0=?3)Q4W[0@8)X:#L&<"YW$# )_==NU>V6]K;V<0BMH(H(QR$B0*/
MR%-N;&TO-OVJU@GV9V^;&&QGKC/TH I>&?\ D5-'_P"O&'_T 5YC^T%_R!-&
M_P"OE_\ T&O8418T5$4*JC 4#  ]*BN;.UO%5;JVAG53D"5 P'YT ?$U%?:'
M]B:3_P! NR_\!T_PHH'<OT444""N#\,ZN;75O'=W?W,S6EA>&3YF+B.-8]QV
MCZ#H*[RO*H?^0?\ %?\ [;_^B&H WA\6?"1DCQ=W!MWV@W7V9_*0MCAFQP1D
M9]*Z-_$.FIKEII!G_P!+O(#/;X4E)$'7#="<<X]*YNRLK8_!&&W\A/*?00[+
MC@L8=Q/UW'.?6N<U"">'X5^$?$]J&>]T**"X]VA*A9%^F,?@* /2?[=L#XA.
MA"5FOUM_M+($)"QYQDMT'/;K7/3_ !3\*P74D7VJXE@B?RY+N&V=X$;T+@8_
M$9K T*SOO$/A7QAXGMT=;_75FCL@?O"!%*1J/0GG]#7.:#>RP^!XE'Q-L].M
M88#'-IDNDP&2,X.Y-I.YSG/./FZ^M 'KNK>*='T71X=5N[Q3:SE1 8@9#,6Y
M4(!][-4-/\?:'J,=]Y;7<4]E"9Y[::U=)0G]X+CG\*X>/3=$LOA_X5M-1\17
MFFW(F:?3+^>W\IHB26PZY90,$=6].V:W?!_B+4YO&5WH-YJ6GZXD=F)_[3LX
MPA7YL".3:=N>2<#U^N ";P-X_3Q&^HPW9D%Q%<S-$%MG1%@7 4$D?>[D$YJ3
M_A;7A-D62.YNY8, R31VDC)#_OG'%9O@#4K-++Q/H[W$::BFI7LIMF.'V9'S
M8]*N?#6T@C^$%DBQKMFMYWD! ^<EGSGUXP/H* +=Y\4O"MI<M%]LFN(H\"2Y
MMH&DACSSRX&._;-=%=Z]I5CHO]LW-]#'IVP2"X)RI4],8ZYSP!7)?#>U@7X/
MV48B4K-;SM("/ODL^<^O''TK@)8[RX^#?@N[-RT%G:W[M<SB 3B$"614=HSP
MP'3!]: /4=)^(WA[5]0AL8YKBWGN/^/?[7;M$)O]PD8)]JFUKQ]X?T'49=.O
M;F7[;&JL((X6=WW=-N!ST_"O-_$$<VKKIEC<_$N'6)9[J-K6"PTF"217!X?Y
M'!4#G/([UV&FV\4GQMUJ=XU:2+3(0C$<KD\X_*@#:T[QUH6JZ5>ZA:SS,MC_
M ,?,)@831YZ93&3^&:ROA_XZ'BB*[BNV87B2RR#%NR1K"K!5&XC&>1P3GK4-
MIB+X\7Z( JRZ$LD@ ^\PE4 GWQQ5+X=:GI<7AS7-)O;A%N+:ZO)+JVY\Q8MV
M&;:.2.<<4 ;2_%'PNUP%^T77V9I?*6]^RO\ 9V;.,!\8Z]^E=E7B2Z[_ ,(G
MX>M[OPYXML=:TA9$$.BWD2_:!EA\JD?-N&<\@8QFO;%)*@E2I(Y![4 +1110
M 4444 %%%% !7 1?\>GQ _[:_P#HIJ** -RU_P"2;0?]@A?_ $352V_Y)*W_
M &"'_P#11HHH T/!?_(F:5_UP%>&>./^2U1?]=XO_0J**!GJWQ?_ .2>WG^\
M/Y&L'X"?\BO?_P#7<?R-%% &HO\ R5G5/^P>W_H*UN>#?^2>67_7O)_Z$U%%
M @\&_P#)/++_ *]Y/_0FK/\ #'_)(E_Z]KG_ -#>BB@#S3X(_P#(\ZC_ -<V
M_F:]9L/^2F:O_P!>,/\ .BB@8R'_ )*U<?\ 8('_ *-6L[1?^2OZS_UYG_T*
?.BB@1Y3X6_Y+:G_7T?Z5]*T44#84444""BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2527059d12_ex99-xcx1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2527059d12_ex99-xcx1img01.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !! .$# 2(  A$! Q$!_\0
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MOCUH'PM^)^MKXC^#=W=3V3_8XO$5CI45M<:U>V-DE@+XVQ2SC/FEF=I40[9
M#]E[?_@XG_X)FW.FC5(O''Q7^S&&.<!_@WXOC<QS7EW8Q??A$0+W-E<1KF4
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M98G)5)$9@"2JNK, #C)"DG&3UQ[=:/-4],GDKTP=XYV8;#;L9/(Q@$DCC/\
M%C\#O^#R[]G#Q)XWT_PO^T?^RY\6O@;I6JW4,8\4VNH6/B/3M&MF=5-[JNGS
M2:1K0ME@::YEFTS3]0VK"L0C>6>('^POX9_%+P)\8_A_X,^*GPU\16'BKP)\
M0/#&F>+/!OB337-Q8:OH&M6AO;"]AF3<&9XHI/.MAFYM)5:"[BAG/ET >B[@
M-N006. .O."V"1D#@'G..,9R0"@D! R&4L&(4C+84@$G86&.1W[COD#^<_\
MX*=_\')7[%'_  3E\?ZA\#[/3_$O[0GQ]TF9;/Q1\/\ X9RZ>T'@G4I+;[2E
MAXO\17NH6EI:ZEMELV;2-.-_=JEV9)/)>WDA;\Q/A!_P>=_ +4?&FGZ#^T+^
MR?\ %?X/^&-2NHHO^$ITF_M?$YTZVFFC3[==Z1<7>F:I+;1QF9YY])MK\QL(
MT6.19]X /[;%=7SM.<$@\$$$=B#A@?3C'%*S;1GJ>@&0"3Z#<0,_B*\<^ WQ
MW^%O[2WPH\!_'/X*^*+'QQ\+_B3X?MO$7@[Q5II+0:EI=R[Q@R!COMKB&:">
M&[LYPEU:7%O+!<Q1R[$?\NO^"H?_  79_8G_ ."6ALO"WQ9U?7_B%\9=3MO[
M0T_X-_#>.POO%D.G.C_9M3UN?4=0TW2-'L;J0*MN=0OXC*@E8A)$BBF /VFW
M@8W*X)SQM+=/4IO7/MG.,GL:575\[3G!P>""#Z$'!!_"OXF/A5_P>F_LJ^)?
M&MII/Q1_9B^,?P^\&7MVD<GBW3;_ $7Q7-I5D]W% U_J.C66LQW20VL+RW%V
MVFB]F58_*MX+AI<#^N_]FW]I7X,?M:_!_P '?'KX ^,].\?_  O\=65Q<^&_
M$>GDHUR;&X-GJ5G=6LY2YLK[3[U)+6\M;E$D26+S5\RVEMIY@#WJBF;F_P">
M;_G'_P#'** /\X[_ (.3O"/B&Y_X*+?$W5M,TH26\G@WP,D]W'\/-&UBXNY4
M^#:-!+/XACU+2[G*QRW@-JUC(J%HW:2=T#C^\7]ARU-I^R#^S%$T;V[1_ 3X
M7(\+6266Z1O".E,SR0_9U,<@Q@(ES*C*Y=E)VR'^++_@YF_9#^.EO^U'J7[3
MD/@R35?A!XZ\-Z'HFF>)--^'B>+KFVU'P_\ "R\TB\LM>U32-2M9M#CN;_3)
M);6*ZT.1Y+9[:9[B-R+>7Z]^ '_!Q_/\(?@9\-_AI+^Q3\2=5G^%_P ._A%X
M.N]7MDN-%CN)K[08]-LY'TQ+"YG5)9+!KEC!-*BVX+&-YVV  _KH^.H:3X*_
M%N)8WDDF^&GCN*.-+07Q9Y/"NK",-:E'29"^ R2M%&X^1I4W#/\ F[_\$2_#
MOB"P_P""JW[)UW>:7!;6,GC/XNQ17</P_P!+\/++)%:ZZ6A?4H_%-Y#<*R[F
M\A;2.XE,8F"J('5OZ(_AW_P7S^+/[:.@^,_A9\)/^"?_ ,4+W6?$OP]\7"?4
M]2OE70_#6F3Z7KVFW.K^(+C4;>WT[3[:U-I)E]0O;.%WN[&$3F>X$%?SN?\
M!$GPAXATO_@JK^R9?:EHLFF0W'C+XMJA;X<CPY'#*UIK)U*V75[K76@U:UCO
M BK+IMG.MUM6Y@E:*)PP!_;9_P %R_VD_$W[*G_!+S]JGXI^!M1FTCQK+X!N
M_!GA75+63R6L-8\7I_90N8I 2\5RED]ZMBUN7F%TT 7"EY(_PU_X-A?^"/\
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MVUNQT"UU>P0-_:EG91ZU=)'?VZ3+"IA_!#_@R19C\>?VU0Z2;U^$OA %V!C
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M]7/.4%0RNA9F5=R\$K(L8.X$J-^X.BL0[1AF"_(P$0NX=PC) D9%D6+?$TC
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M[:36Z2LN&)5&D#' ) !(#$ $ _@R?XA_%OX;?\&TFJZ[\#_BAXQ^#WQ#U/\
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$B@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
